sign in sign up
<<
Home , Amifampridine, Apomorphine, Bimatoprost, Carboprost, Casimersen, Clidinium bromide

CUMULATIVE SUPPLEMENT 8 AUGUST 2021

APPROVED PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

41st EDITION

Department of Health and Human Services Food and Drug Administration Office of Medical Products and Center for Drug Evaluation and Research Office of Generic Office of

2021

Prepared By Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

41th EDITION

Cumulative Supplement 8 August 2021

CONTENTS

PAGE

Contents 1.0 INTRODUCTION ...... v 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT ...... vi 1.2 CUMULATIVE SUPPLEMENT CONTENT ...... vi 1.3 APPLICANT NAME CHANGES ...... vii 1.4 LEVOTHYROXINE SODIUM ...... viii 1.5 AVAILABILITY OF THE EDITION ...... ix 1.6 REPORT OF COUNTS FOR THE PRODUCT LIST ...... x 1.7 CUMULATIVE SUPPLEMENT LEGEND ...... xi

DRUG PRODUCT LISTS Prescription Drug Product List …………………………………………………………………….. 1-1 OTC Drug Product List ...... 2-1 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ……………………………………………………… 3-1 Orphan Product Designations and Approvals List ……………………………………………… 4-1 Drug Products Which Must Demonstrate in vivo Only if Product Fails to Achieve Adequate Dissolution …………………………………………………………………. 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Patent and Exclusivity Lists ...... A-1 B. Patent and Exclusivity Terms …………………………………………………………………. B-1

iv

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

41st EDITION

CUMULATIVE SUPPLEMENT 8 AUGUST 2021

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons. The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists. Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.) v

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item. New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item. The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

• Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

vi

• All product changes received and processed as of the date of publication. o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

• New Drug Application (NDA) approvals appear in the CS month they were approved.

• Patent information, also updated daily in the EOB, is current to the date of publication.

• Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at [email protected].

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME NEW APPLICANT NAME (FORMER ABBREVIATED NAME) (NEW ABBREVIATED NAME) AKORN INC AKORN OPERATING CO LLC (AKORN) (AKORN)

AKORN INC AKORN OPERATING CO LLC (AKORN INC) (AKORN)

PADDOCK LABORATORIES LLC PADAGIS US LLC (PADDOCK LABS LLC) (PADAGIS US)

vii

PADDOCK LABORATORIES LLC PADAGIS US LLC (PADDOCK LLC) (PADAGIS US)

PERRIGO CO OF TENESSEE INC PADAGIS US LLC (PERRIGO CO) (PADAGIS US)

PERRIGO CO TENNESSEE INC PADAGIS US LLC (PERRIGO CO TENNESSEE) (PADAGIS US)

PERRIGO NEW YORK INC PADAGIS US LLC (PERRIGO NEW YORK) (PADAGIS US)

PERRIGO PHARMA INTERNATIONAL PADAGIS US LLC DAC (PADAGIS US) (PERRIGO PHARMA INTL)

PERRIGO UK FINCO LTD PADAGIS ISRAEL PHARMACEUTICALS PARTNERSHIP LTD (PERRIGO UK FINCO) (PADAGIS ISRAEL)

PERRIGO ISRAEL PHARMACEUTICALS PADAGIS ISRAEL PHARMACEUTICALS LTD LTD (PERRIGO ISRAEL) (PADAGIS ISRAEL)

WEST-WARD PHARMACEUTICALS HIKMA PHARMACEUTICALS USA INC INTERNATIONAL LTD (HIKMA PHARMS) (WEST-WARD PHARMS INT)

1.4 LEVOTHYROXINE SODIUM1

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.2

1 In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths. 2 Please consult the Active Section of the Orange Book for information on other strengths.

viii

• Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

• More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

Appl TE Code Proprietary Name Applicant Strength RLD RS No AB1 UNITHROID STEVENS J 0.3MG N021210 RLD RS

AB2 SYNTHROID ABBVIE 0.3MG N021402 RLD RS

KING AB3 LEVOXYL 0.2MG N021301 RLD RS PHARMS

ALVOGEN GROUP AB4 THYRO-TABS 0.3MG N021116 RLD − HOLDINGS 4 LLC AB4 LEVOTHYROXINE SODIUM3 MYLAN 0.3MG A076187 − RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

3 Lloyd’s Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan’s levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan’s levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016). ix

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare- diseases-conditions/designating-orphan-product-drugs-and-biological- products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, x

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES DEC MAR JUN SEP DEC COUNTED 2020 2021 2021 2021 2021

DRUG PRODUCTS 20478 20726 20916

LISTED SINGLE 2659 2671 2675

SOURCE (13.0%) (12.9%) (12.8%)

MULTISOURCE 17819 18055 18241

(87.0%) (87.1%) (87.2%)

THERAPEUTICALLY 17746 17990 18175 EQUIVALENT (86.7%) (86.8%) (86.9%) NOT 73 65 66 THERAPEUTICALLY (0.4%) (0.3%) (0.3%) EQUIVALENT EXCEPTIONS4 54 54 54 (0.3%) (0.3%) (0.3%) NEW MOLECULAR ENTITIES 22 29 33 APPROVED NUMBER OF 1185 1184 1182 APPLICANTS

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the

4 containing products of varying composition (see Introduction, page xx of the List). xi

action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description: NEWA New drug product approval NFTG New first-time generic approval CAHN5 Applicant holder firm name has changed CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. CDFR Change. Dosage Form; Route of Administration CFTG Change. A TE Code is added when a first time generic for an innovator is approved. CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status. CMKT Change. RX to OTC marketing status switch. CMS1 Change. Miscellaneous addition to list. CMS2 Change. Miscellaneous deletion from list. CPOT Change. Potency amount/unit. CRLD Change. Reference Listed Drug CHRS Change. Reference Standard CTEC Change. Therapeutic Equivalence Code. CTNA Change. Trade Name. DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

5 The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

xii

PRESCRIPTION DRUG PRODUCT LIST - 41ST EDITION RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -1

ABIRATERONE ;ORAL ABIRATERONE ACETATE AB AMNEAL PHARMS 500MG A 208327 002 Dec 23, 2020 Apr NEWA AB QILU 500MG A 212462 002 Jun 25, 2021 Jun NEWA

ACARBOSE TABLET;ORAL ACARBOSE AB EMCURE PHARMS LTD 25MG A 202271 001 Feb 07, 2012 Apr CMFD AB 50MG A 202271 002 Feb 07, 2012 Apr CMFD AB 100MG A 202271 003 Feb 07, 2012 Apr CMFD >D> AB HANGZHOU ZHONGMEI 25MG A 213821 001 Aug 18, 2020 Aug DISC >A> @ 25MG A 213821 001 Aug 18, 2020 Aug DISC >D> AB 50MG A 213821 002 Aug 18, 2020 Aug DISC >A> @ 50MG A 213821 002 Aug 18, 2020 Aug DISC >D> AB 100MG A 213821 003 Aug 18, 2020 Aug DISC >A> @ 100MG A 213821 003 Aug 18, 2020 Aug DISC

ACETAMINOPHEN POWDER;INTRAVENOUS ACETAMINOPHEN + @ MYLAN LABS LTD 1GM/VIAL N 206610 001 Jan 15, 2021 Jan NEWA ;INTRAVENOUS ACETAMINOPHEN +! B BRAUN MEDICAL INC 500MG/50ML (10MG/ML) N 204957 001 Feb 18, 2021 Feb NEWA +! 1GM/100ML (10MG/ML) N 204957 002 Feb 18, 2021 Feb NEWA

ACETAMINOPHEN; ; CAPSULE;ORAL CODEINE, ASPIRIN, APAP FORMULA NO. 2 >D> @ SCHERER LABS 150MG;180MG;15MG A 085640 001 Aug CRLD >A> + @ 150MG;180MG;15MG A 085640 001 Aug CRLD CODEINE, ASPIRIN, APAP FORMULA NO. 3 >D> @ SCHERER LABS 150MG;180MG;30MG A 085639 001 Aug CRLD >A> + @ 150MG;180MG;30MG A 085639 001 Aug CRLD

ACETAMINOPHEN; BUTALBITAL TABLET;ORAL BUTALBITAL AND ACETAMINOPHEN AA ALVOGEN 300MG;50MG A 207635 001 Jun 05, 2017 Jun CAHN AA 325MG;50MG A 205120 001 Oct 30, 2015 Jun CAHN >D> @ WATSON LABS 325MG;50MG A 087550 001 Oct 19, 1984 Aug CRLD >A> + @ 325MG;50MG A 087550 001 Oct 19, 1984 Aug CRLD PHRENILIN >D> @ VALEANT 325MG;50MG A 087811 001 Jun 19, 1985 Aug CRLD >A> + @ 325MG;50MG A 087811 001 Jun 19, 1985 Aug CRLD

ACETAMINOPHEN; BUTALBITAL; CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >D> @ GILBERT LABS 325MG;50MG;40MG A 088825 001 Dec 05, 1984 Aug CRLD >A> + @ 325MG;50MG;40MG A 088825 001 Dec 05, 1984 Aug CRLD >A> AA SENORES PHARMS 300MG;50MG;40MG A 214087 001 Aug 13, 2021 Aug CAHN >A> AA 325MG;50MG;40MG A 214087 002 Aug 13, 2021 Aug CAHN AA XSPIRE PHARMA 300MG;50MG;40MG A 206615 001 Aug 04, 2017 Feb CAHN TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >D> AA ACTAVIS LABS UT INC 325MG;50MG;40MG A 088616 001 Nov 09, 1984 Aug CRLD >A> AA + 325MG;50MG;40MG A 088616 001 Nov 09, 1984 Aug CRLD AA ALVOGEN 325MG;50MG;40MG A 204984 001 Jan 10, 2017 Jun CAHN @ GRANULES 325MG;50MG;40MG A 040864 001 Dec 01, 2008 Apr CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE AB NOSTRUM LABS INC 325MG;50MG;40MG;30MG A 075929 001 Apr 22, 2002 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -2

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE CAPSULE;ORAL TREZIX XSPIRE PHARMA 320.5MG;30MG;16MG A 204785 001 Nov 26, 2014 Jul CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> @ ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML A 085861 001 Aug CRLD >A> + @ 120MG/5ML;12MG/5ML A 085861 001 Aug CRLD W/ CODEINE >D> @ ORTHO MCNEIL PHARM 120MG/5ML;12MG/5ML A 085057 001 Aug CRLD >A> + @ 120MG/5ML;12MG/5ML A 085057 001 Aug CRLD TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088629 002 Mar 06, 1985 Aug CMS1 >A> AA 300MG;30MG A 088629 003 Mar 06, 1985 Aug CMS1 >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Aug CRLD >A> AA +! 300MG;60MG A 088629 001 Mar 06, 1985 Aug CRLD >D> @ PUREPAC PHARM 300MG;30MG A 086681 001 Aug CRLD >A> + @ 300MG;30MG A 086681 001 Aug CRLD >D> @ SANDOZ 300MG;15MG A 087433 001 Aug CRLD >A> + @ 300MG;15MG A 087433 001 Aug CRLD >D> @ 300MG;30MG A 085917 001 Aug CRLD >A> + @ 300MG;30MG A 085917 001 Aug CRLD @ VINTAGE 300MG;15MG A 089990 001 Sep 30, 1988 Apr DISC @ 300MG;30MG A 089805 001 Sep 30, 1988 Apr DISC @ 300MG;60MG A 089828 001 Sep 30, 1988 Apr DISC AA 300MG;60MG A 089828 001 Sep 30, 1988 Apr CAHN TYLENOL W/ CODEINE NO. 2 >D> @ JANSSEN PHARMS 300MG;15MG A 085055 002 Aug CRLD >A> + @ 300MG;15MG A 085055 002 Aug CRLD TYLENOL W/ CODEINE NO. 3 >D> @ JANSSEN PHARMS 300MG;30MG A 085055 003 Aug CRLD >A> + @ 300MG;30MG A 085055 003 Aug CRLD TYLENOL W/ CODEINE NO. 4 >D> @ JANSSEN PHARMS 300MG;60MG A 085055 004 Aug CRLD >A> + @ 300MG;60MG A 085055 004 Aug CRLD

ACETAMINOPHEN; BITARTRATE TABLET;ORAL ANEXSIA 5/325 AA ! SPECGX LLC 325MG;5MG A 040409 001 Oct 20, 2000 Apr CHRS ANEXSIA 7.5/325 AA ! SPECGX LLC 325MG;7.5MG A 040405 001 Sep 08, 2000 Apr CHRS HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ ALVOGEN 300MG;5MG A 208540 001 Nov 08, 2018 Aug CAHN >A> @ 300MG;7.5MG A 208540 002 Nov 08, 2018 Aug CAHN >A> @ 300MG;10MG A 208540 003 Nov 08, 2018 Aug CAHN >A> @ 325MG;2.5MG A 209958 001 Oct 24, 2018 Aug CAHN >A> @ 325MG;5MG A 209958 002 Oct 24, 2018 Aug CAHN >A> @ 325MG;7.5MG A 209958 003 Oct 24, 2018 Aug CAHN >A> @ 325MG;10MG A 209958 004 Oct 24, 2018 Aug CAHN >D> @ ALVOGEN PINE BROOK 300MG;5MG A 208540 001 Nov 08, 2018 Aug CAHN >D> @ 300MG;7.5MG A 208540 002 Nov 08, 2018 Aug CAHN >D> @ 300MG;10MG A 208540 003 Nov 08, 2018 Aug CAHN >D> @ 325MG;2.5MG A 209958 001 Oct 24, 2018 Aug CAHN >D> @ 325MG;5MG A 209958 002 Oct 24, 2018 Aug CAHN >D> @ 325MG;7.5MG A 209958 003 Oct 24, 2018 Aug CAHN >D> @ 325MG;10MG A 209958 004 Oct 24, 2018 Aug CAHN AA ! SPECGX LLC 325MG;10MG A 040400 001 Jul 26, 2000 Apr CHRS NORCO AP IL@ APIL@ 325MG;2.5MG A 040148 004 Jul 07, 2014 Apr DISC @ 325MG;5MG A 040099 001 Jun 25, 1997 Apr DISC @ 325MG;5MG A 040148 005 Jul 07, 2014 Apr DISC @ 325MG;7.5MG A 040148 003 Sep 12, 2000 Apr DISC @ 325MG;10MG A 040148 001 Feb 14, 1997 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -3

ACETAMINOPHEN; HYDROCHLORIDE SOLUTION;ORAL OXYCODONE AND ACETAMINOPHEN >D> ! ABHAI LLC 325MG/5ML;5MG/5ML A 211499 001 Dec 31, 2018 Aug CTEC >A> AA ! 325MG/5ML;5MG/5ML A 211499 001 Dec 31, 2018 Aug CTEC >A> AA NOSTRUM LABS INC 325MG/5ML;5MG/5ML A 201448 001 Aug 26, 2021 Aug NEWA TABLET;ORAL OXYCODONE 5/APAP 500 >D> @ BRISTOL MYERS SQUIBB 500MG;5MG A 085911 001 Aug CRLD >A> + @ 500MG;5MG A 085911 001 Aug CRLD OXYCODONE AND ACETAMINOPHEN AA CHARTWELL 325MG;5MG A 207834 001 Aug 15, 2019 Jan CAHN AA 325MG;7.5MG A 207834 002 Aug 15, 2019 Jan CAHN AA 325MG;10MG A 207834 003 Aug 15, 2019 Jan CAHN PERCOCET >D> @ VINTAGE PHARMS LLC 325MG;5MG A 085106 002 Aug CRLD >A> + @ 325MG;5MG A 085106 002 Aug CRLD ROXICET >D> @ HIKMA PHARMS 325MG;5MG A 087003 001 Aug CRLD >A> + @ 325MG;5MG A 087003 001 Aug CRLD @ 325MG;5MG A 087003 001 Jan DISC

ACETAZOLAMIDE CAPSULE, EXTENDED ;ORAL AB ACCORD HLTHCARE 500MG A 207659 001 Oct 18, 2018 Apr CMFD AB ! INDICUS PHARMA 500MG A 090779 001 Jul 14, 2011 Jun CAHN TABLET;ORAL ACETAZOLAMIDE AB APPCO 125MG A 211372 001 Feb 22, 2021 Feb NEWA AB 250MG A 211372 002 Feb 22, 2021 Feb NEWA >A> AB RUBICON 125MG A 215101 001 Aug 19, 2021 Aug NEWA >A> AB 250MG A 215101 002 Aug 19, 2021 Aug NEWA

ACETIC ACID, GLACIAL; ALUMINUM ACETATE SOLUTION/DROPS;OTIC DOMEBORO >D> @ PHARMS 2%;0.79% A 084476 001 Aug CRLD >A> + @ 2%;0.79% A 084476 001 Aug CRLD

ACETYLCYSTEINE INJECTABLE;INTRAVENOUS AP EXELA PHARMA 6GM/30ML (200MG/ML) A 204797 001 Apr 15, 2021 Apr NEWA

ACLIDINIUM POWDER, METERED;INHALATION TUDORZA PRESSAIR +! ASTRAZENECA 0.4MG/INH N 202450 001 Jul 23, 2012 Feb CAHN

ACLIDINIUM BROMIDE; FUMARATE POWDER, METERED;INHALATION DUAKLIR PRESSAIR +! ASTRAZENECA 0.4MG/INH;0.012MG/INH N 210595 001 Mar 29, 2019 Jun CHRS + 0.4MG/INH;0.012MG/INH N 210595 001 Mar 29, 2019 Jun CRLD 0.4MG/INH;0.012MG/INH N 210595 001 Mar 29, 2019 Feb CAHN

ACYCLOVIR OINTMENT;TOPICAL ACYCLOVIR @ ANDA REPOSITORY 5% A 206437 001 Jul 31, 2017 Jun DISC AB MACLEODS PHARMS LTD 5% A 212444 001 May 19, 2021 May NEWA SUSPENSION;ORAL ACYCLOVIR @ VISTAPHARM 200MG/5ML A 213951 001 Jan 11, 2021 Jul DISC AB 200MG/5ML A 213951 001 Jan 11, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -4

ACYCLOVIR SODIUM INJECTABLE; ACYCLOVIR SODIUM AP NAMIGEN LLC EQ 50MG BASE/ML A 207919 001 Jun 17, 2020 Jun CAHN AP ZYDUS PHARMS EQ 50MG BASE/ML A 206535 001 Aug 31, 2018 Jan CHRS AP ! EQ 50MG BASE/ML A 206535 001 Aug 31, 2018 Jan CPOT

ADAPALENE; GEL;TOPICAL EPIDUO FORTE +! GALDERMA LABS 0.3%;2.5% N 207917 001 Jul 15, 2015 Feb CTEC

ADENOSINE SOLUTION;INTRAVENOUS AP EMCURE PHARMS LTD 60MG/20ML (3MG/ML) A 202313 001 Sep 15, 2014 Feb CMFD AP 90MG/30ML (3MG/ML) A 202313 002 Sep 15, 2014 Feb CMFD

AIR POLYMER-TYPE A FOAM;INTRAUTERINE EXEM FOAM KIT >D> +! GISKIT 10ML N 212279 001 Nov 07, 2019 Aug CAHN >A> +! 10ML N 212279 001 Nov 07, 2019 Aug CAHN

ALBENDAZOLE TABLET;ORAL ALBENDAZOLE AB DR REDDYS 200MG A 211034 001 Jan 26, 2021 Jan NEWA @ LUPIN LTD 200MG A 211636 001 Jun 10, 2020 Jan DISC AB MSN 200MG A 213435 001 Jan 21, 2021 Jan NEWA

ALBUTEROL SULFATE AEROSOL, METERED;INHALATION ALBUTEROL SULFATE @ PADAGIS US EQ 0.09MG BASE/INH A 203760 001 Feb 24, 2020 Jul CAHN AB1 SANDOZ INC EQ 0.09MG BASE/INH A 207085 001 Jun 01, 2021 May NEWA SOLUTION;INHALATION ALBUTEROL SULFATE >D> @ AUROBINDO PHARMA LTD EQ 0.021% BASE A 211888 001 Apr 20, 2020 Aug CAHN >D> @ EQ 0.042% BASE A 211888 002 Apr 20, 2020 Aug CAHN >D> AN EQ 0.083% BASE A 206224 001 Oct 17, 2017 Aug CAHN >A> @ LUOXIN AUROVITAS EQ 0.021% BASE A 211888 001 Apr 20, 2020 Aug CAHN >A> @ EQ 0.042% BASE A 211888 002 Apr 20, 2020 Aug CAHN >A> AN EQ 0.083% BASE A 206224 001 Oct 17, 2017 Aug CAHN TABLET;ORAL ALBUTEROL SULFATE AB AIZANT EQ 2MG BASE A 210948 001 Mar 15, 2019 Feb CMFD AB EQ 4MG BASE A 210948 002 Mar 15, 2019 Feb CMFD @ EYWA EQ 2MG BASE A 213524 001 Oct 08, 2020 Apr DISC @ EQ 4MG BASE A 213524 002 Oct 08, 2020 Apr DISC

ALBUTEROL SULFATE; SOLUTION;INHALATION ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE >D> @ AUROBINDO PHARMA LTD EQ 0.083% BASE;0.017% A 206532 001 Jul 08, 2020 Aug CAHN @ EQ 0.083% BASE;0.017% A 206532 001 Jul 08, 2020 Jan DISC >A> @ LUOXIN AUROVITAS EQ 0.083% BASE;0.017% A 206532 001 Jul 08, 2020 Aug CAHN

ALENDRONATE SODIUM TABLET;ORAL ALENDRONATE SODIUM @ JUBILANT CADISTA EQ 5MG BASE A 090557 001 Feb 18, 2010 Jun DISC @ EQ 10MG BASE A 090557 002 Feb 18, 2010 Jun DISC @ EQ 35MG BASE A 090557 003 Feb 18, 2010 Jun DISC @ EQ 70MG BASE A 090557 004 Feb 18, 2010 Jun DISC @ US EQ 5MG BASE A 079049 003 Aug 04, 2008 May CAHN @ EQ 10MG BASE A 079049 004 Aug 04, 2008 May CAHN @ EQ 35MG BASE A 079049 001 Aug 04, 2008 May CAHN @ EQ 70MG BASE A 079049 002 Aug 04, 2008 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -5

ALENDRONATE SODIUM; CHOLECALCIFEROL TABLET;ORAL FOSAMAX PLUS D + ORGANON EQ 70MG BASE;2,800 IU N 021762 001 Apr 07, 2005 Jun CAHN +! EQ 70MG BASE;5,600 IU N 021762 002 Apr 26, 2007 Jun CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE TABLET;ORAL TEKTURNA HCT + @ NODEN PHARMA EQ 150MG BASE;12.5MG N 022107 001 Jan 18, 2008 May DISC + @ EQ 150MG BASE;25MG N 022107 002 Jan 18, 2008 May DISC

ALLOPURINOL TABLET;ORAL AB CHARTWELL 100MG A 077353 001 Sep 08, 2005 Jun CAHN AB 300MG A 077353 002 Sep 08, 2005 Jun CAHN

ALPRAZOLAM TABLET;ORAL ALPRAZOLAM @ MYLAN 0.25MG A 074215 001 Jan 27, 1994 Jun DISC @ 0.5MG A 074215 002 Jan 27, 1994 Jun DISC @ 1MG A 074215 003 Jan 27, 1994 Jun DISC @ 2MG A 074215 004 Jan 27, 1994 Jun DISC AB NOVITIUM PHARMA 0.25MG A 074174 001 Oct 19, 1993 Apr CMFD AB 0.5MG A 074174 002 Oct 19, 1993 Apr CMFD AB 1MG A 074174 003 Oct 19, 1993 Apr CMFD AB 2MG A 074174 004 Oct 19, 1993 Apr CMFD

ALPROSTADIL INJECTABLE;INJECTION CAVERJECT + @ 0.005MG/VIAL N 020379 003 Jun 27, 1996 Jan CAHN AP + 0.01MG/VIAL N 020379 001 Jul 06, 1995 Jan CAHN AP +! 0.02MG/VIAL N 020379 002 Jul 06, 1995 Jan CAHN AP +! 0.04MG/VIAL N 020379 004 May 19, 1997 Jan CAHN CAVERJECT PFIZER 0.01MG/VIAL N 021212 001 Jun 11, 2002 Jan CAHN 0.02MG/VIAL N 021212 002 Jun 11, 2002 Jan CAHN PROSTIN VR PEDIATRIC AP +! PFIZER 0.5MG/ML N 018484 001 Jan CAHN

AMANTADINE HYDROCHLORIDE SYRUP;ORAL HYDROCHLORIDE >A> AA INVATECH 50MG/5ML A 214178 001 Aug 20, 2021 Aug NEWA @ WOCKHARDT BIO AG 50MG/5ML A 075060 001 Dec 24, 1998 Jan DISC TABLET;ORAL AMANTADINE HYDROCHLORIDE @ INVAGEN PHARMS 100MG A 207571 001 Jan 31, 2017 Jan DISC TABLET, EXTENDED RELEASE;ORAL OSMOLEX ER + ADAMAS PHARMA EQ 129MG BASE N 209410 001 Feb 16, 2018 Jan CAHN + @ EQ 161MG BASE N 209410 004 Apr 22, 2020 Jan CAHN + EQ 193MG BASE N 209410 002 Feb 16, 2018 Jan CAHN + @ EQ 258MG BASE N 209410 003 Feb 16, 2018 May DISC +! EQ 258MG BASE N 209410 003 Feb 16, 2018 Jan CAHN + ADAMAS PHARMS EQ 129MG BASE N 209410 001 Feb 16, 2018 Jan CAHN + @ EQ 161MG BASE N 209410 004 Apr 22, 2020 Jan CAHN + EQ 193MG BASE N 209410 002 Feb 16, 2018 Jan CAHN +! EQ 258MG BASE N 209410 003 Feb 16, 2018 Jan CAHN

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE >A> @ CHARTWELL RX EQ 5MG ANHYDROUS;50MG A 073357 001 Nov 27, 1991 Aug CAHN >D> @ YAOPHARMA CO LTD EQ 5MG ANHYDROUS;50MG A 073357 001 Nov 27, 1991 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -6

AMINOCAPROIC ACID SOLUTION;ORAL AMICAR AA +! AKORN 0.25GM/ML N 015230 002 Feb CPOT AA +! 1.25GM/5ML N 015230 002 Feb CDFR AA AIRIS PHARMA PVT LTD 0.25GM/ML A 213825 001 Apr 08, 2021 Apr NEWA AA AMNEAL 0.25GM/ML A 212780 001 Aug 23, 2019 Feb CPOT AA 1.25GM/5ML A 212780 001 Aug 23, 2019 Feb CDFR AA BELCHER 0.25GM/ML A 213825 001 Apr 08, 2021 Jul CAHN AA LEADING PHARMA LLC 0.25GM/ML A 214140 001 Jan 26, 2021 Feb CPOT AA 1.25GM/5ML A 214140 001 Jan 26, 2021 Feb CDFR AA TULEX PHARMS INC 0.25GM/ML A 212494 001 Aug 11, 2020 Feb CPOT AA 1.25GM/5ML A 212494 001 Aug 11, 2020 Feb CDFR AA VISTAPHARM 0.25GM/ML A 212814 001 Feb 26, 2020 Feb CPOT AA 1.25GM/5ML A 212814 001 Feb 26, 2020 Feb CDFR SYRUP;ORAL AMINOCAPROIC ACID AA LEADING PHARMA LLC 1.25GM/5ML A 214140 001 Jan 26, 2021 Jan NEWA TABLET;ORAL AMINOCAPROIC ACID AB EDENBRIDGE PHARMS 500MG A 212110 001 Jun 14, 2021 Jun NEWA AB LEADING PHARMA LLC 500MG A 213928 001 Feb 12, 2021 Feb NEWA AB 1GM A 213928 002 Feb 12, 2021 Feb NEWA

AMINOPHYLLINE INJECTABLE;INJECTION AMINOPHYLLIN >D> @ GD SEARLE LLC 25MG/ML A 087243 001 May 24, 1982 Aug CRLD >A> + @ 25MG/ML A 087243 001 May 24, 1982 Aug CRLD >D> @ 25MG/ML A 087621 001 May 24, 1982 Aug CRLD >A> + @ 25MG/ML A 087621 001 May 24, 1982 Aug CRLD

AMIODARONE HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE >A> AP ACELLA 50MG/ML A 077610 001 Oct 30, 2008 Aug CAHN >A> AP 50MG/ML A 077834 001 Oct 30, 2008 Aug CAHN >D> AP WOCKHARDT 50MG/ML A 077610 001 Oct 30, 2008 Aug CAHN >D> AP 50MG/ML A 077834 001 Oct 30, 2008 Aug CAHN TABLET;ORAL AMIODARONE HYDROCHLORIDE AB RUBICON 100MG A 078578 002 Feb 26, 2021 Feb NEWA AB 400MG A 078578 003 Feb 26, 2021 Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB MANKIND PHARMA 10MG A 213999 001 Feb 19, 2021 Feb NEWA AB 25MG A 213999 002 Feb 19, 2021 Feb NEWA AB 50MG A 213999 003 Feb 19, 2021 Feb NEWA AB 75MG A 213999 004 Feb 19, 2021 Feb NEWA AB 100MG A 213999 005 Feb 19, 2021 Feb NEWA AB 150MG A 213999 006 Feb 19, 2021 Feb NEWA @ MYLAN 10MG A 086009 002 Jun DISC @ 25MG A 086009 003 Jun DISC @ 50MG A 086009 001 Jun DISC @ 75MG A 086009 004 Jun DISC @ 100MG A 086009 005 Jun DISC @ 150MG A 086009 006 Jun DISC >D> AB SANDOZ 10MG A 085968 004 Aug CRLD >A> AB + 10MG A 085968 004 Aug CRLD >D> AB 50MG A 085968 001 Aug CRLD >A> AB + 50MG A 085968 001 Aug CRLD >D> AB 75MG A 085968 006 Aug CRLD >A> AB + 75MG A 085968 006 Aug CRLD >D> AB 100MG A 085968 003 Aug CRLD >A> AB + 100MG A 085968 003 Aug CRLD >D> AB 150MG A 085968 005 Aug CRLD >A> AB + 150MG A 085968 005 Aug CRLD AB UNICHEM 10MG A 214548 001 May 19, 2021 May NEWA AB 25MG A 214548 002 May 19, 2021 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -7

TABLET;ORAL AMITRIPTYLINE HYDROCHLORIDE AB 50MG A 214548 003 May 19, 2021 May NEWA AB 75MG A 214548 004 May 19, 2021 May NEWA AB 100MG A 214548 005 May 19, 2021 May NEWA AB 150MG A 214548 006 May 19, 2021 May NEWA

AMLODIPINE BESYLATE TABLET;ORAL BESYLATE @ WOCKHARDT EQ 2.5MG BASE A 078500 001 Sep 06, 2007 Jan DISC @ EQ 5MG BASE A 078500 002 Sep 06, 2007 Jan DISC @ EQ 10MG BASE A 078500 003 Sep 06, 2007 Jan DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL TABLET;ORAL AMLODIPINE AND OLMESARTAN MEDOXOMIL @ JUBILANT GENERICS EQ 5MG BASE;20MG A 207450 001 May 15, 2017 Jun DISC @ EQ 5MG BASE;40MG A 207450 002 May 15, 2017 Jun DISC @ EQ 10MG BASE;20MG A 207450 003 May 15, 2017 Jun DISC @ EQ 10MG BASE;40MG A 207450 004 May 15, 2017 Jun DISC

AMMONIA N-13 INJECTABLE;INTRAVENOUS AMMONIA N 13 AP METHODIST 3.75mCi-260mCi/ML A 215083 001 Jul 09, 2021 Jul NEWA AP NUKEMED 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A 204455 001 Apr 23, 2015 Jan CAHN

AMOXICILLIN CAPSULE;ORAL AMOXICILLIN AB CHARTWELL 250MG A 062058 001 Jun CAHN AB 500MG A 062058 002 Jun CAHN AMOXIL AB US ANTIBIOTICS 250MG A 062216 001 May CAHN AB 500MG A 062216 004 May CAHN FOR SUSPENSION;ORAL AMOXIL AB US ANTIBIOTICS 50MG/ML A 062226 005 May CAHN AB 125MG/5ML A 062226 001 May CAHN + @ 200MG/5ML N 050760 001 Apr 15, 1999 May CAHN AB 250MG/5ML A 062226 002 May CAHN + @ 400MG/5ML N 050760 002 Apr 15, 1999 May CAHN LAROTID AB US ANTIBIOTICS 125MG/5ML A 062226 003 May CAHN AB 250MG/5ML A 062226 004 May CAHN TABLET;ORAL AMOXIL + @ US ANTIBIOTICS 500MG N 050754 002 Jul 10, 1998 May CAHN + @ 875MG N 050754 001 Jul 10, 1998 May CAHN TABLET, CHEWABLE;ORAL AMOXIL + @ US ANTIBIOTICS 125MG N 050542 002 May CAHN @ 200MG N 050761 001 Apr 15, 1999 May CAHN + @ 250MG N 050542 001 May CAHN @ 400MG N 050761 002 Apr 15, 1999 May CAHN

AMOXICILLIN; ; LANSOPRAZOLE CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) @ ANI PHARMS 500MG;500MG;30MG A 200218 001 Aug 30, 2013 Jul CTNA @ 500MG;500MG;30MG A 200218 001 Aug 30, 2013 Jul CPOT @ 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A 200218 001 Aug 30, 2013 Jul CDFR A,30MG AB ! RISING 500MG;500MG;30MG A 206006 001 Oct 07, 2016 Jul CTNA AB ! 500MG;500MG;30MG A 206006 001 Oct 07, 2016 Jul CPOT AB ! 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A 206006 001 Oct 07, 2016 Jul CDFR A,30MG AB SANDOZ INC 500MG;500MG;30MG A 202588 001 Mar 04, 2014 Jul CTNA AB 500MG;500MG;30MG A 202588 001 Mar 04, 2014 Jul CPOT AB 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A 202588 001 Mar 04, 2014 Jul CDFR A,30MG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -8

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL PREVPAC (COPACKAGED) + @ TAKEDA PHARMS USA 500MG;500MG;30MG N 050757 001 Dec 02, 1997 Jul CTNA + @ 500MG;500MG;30MG N 050757 001 Dec 02, 1997 Jul CPOT + @ 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ N 050757 001 Dec 02, 1997 Jul CDFR A,30MG

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN + @ CUMBERLAND PHARMS 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ N 050824 001 Feb 08, 2011 May DISC A,20MG

AMOXICILLIN; CLAVULANATE POTASSIUM FOR SUSPENSION;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM AB MICRO LABS LTD INDIA 200MG/5ML;EQ 28.5MG BASE/5ML A 205187 001 May 21, 2021 May NEWA AB 400MG/5ML;EQ 57MG BASE/5ML A 205187 002 May 21, 2021 May NEWA AUGMENTIN '125' AB + US ANTIBIOTICS 125MG/5ML;EQ 31.25MG BASE/5ML N 050575 001 Aug 06, 1984 May CAHN AUGMENTIN '200' + @ US ANTIBIOTICS 200MG/5ML;EQ 28.5MG BASE/5ML N 050725 001 May 31, 1996 May CAHN AUGMENTIN '250' AB +! US ANTIBIOTICS 250MG/5ML;EQ 62.5MG BASE/5ML N 050575 002 Aug 06, 1984 May CAHN AUGMENTIN '400' + @ US ANTIBIOTICS 400MG/5ML;EQ 57MG BASE/5ML N 050725 002 May 31, 1996 May CAHN AUGMENTIN ES-600 AB + US ANTIBIOTICS 600MG/5ML;EQ 42.9MG BASE/5ML N 050755 001 Jun 22, 2001 May CAHN TABLET;ORAL AUGMENTIN '250' + @ US ANTIBIOTICS 250MG;EQ 125MG BASE N 050564 001 Aug 06, 1984 May CAHN AUGMENTIN '500' + @ US ANTIBIOTICS 500MG;EQ 125MG BASE N 050564 002 Aug 06, 1984 May CAHN AUGMENTIN '875' AB + US ANTIBIOTICS 875MG;EQ 125MG BASE N 050720 001 Feb 13, 1996 May CAHN TABLET, CHEWABLE;ORAL AUGMENTIN '125' + @ US ANTIBIOTICS 125MG;EQ 31.25MG BASE N 050597 001 Jul 22, 1985 May CAHN AUGMENTIN '200' + @ US ANTIBIOTICS 200MG;EQ 28.5MG BASE N 050726 001 May 31, 1996 May CAHN AUGMENTIN '250' + @ US ANTIBIOTICS 250MG;EQ 62.5MG BASE N 050597 002 Jul 22, 1985 May CAHN AUGMENTIN '400' + @ US ANTIBIOTICS 400MG;EQ 57MG BASE N 050726 002 May 31, 1996 May CAHN TABLET, EXTENDED RELEASE;ORAL AUGMENTIN XR + @ US ANTIBIOTICS 1GM;EQ 62.5MG BASE N 050785 001 Sep 25, 2002 May CAHN

AMPHETAMINE ASPARTATE ; SULFATE; SACCHARATE; DEXTROAMPHETAMINE SULFATE TABLET;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB RHODES PHARMS 2.5MG;2.5MG;2.5MG;2.5MG A 213111 003 Jan 13, 2021 Jan NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 213111 005 Jan 13, 2021 Jan NEWA AB 5MG;5MG;5MG;5MG A 213111 006 Jan 13, 2021 Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE TABLET;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB ASCENT PHARMS INC 1.25MG;1.25MG;1.25MG;1.25MG A 213709 001 Apr 22, 2021 Apr NEWA AB 1.875MG;1.875MG;1.875MG;1.875MG A 213709 002 Apr 22, 2021 Apr NEWA AB 2.5MG;2.5MG;2.5MG;2.5MG A 213709 003 Apr 22, 2021 Apr NEWA AB 3.125MG;3.125MG;3.125MG;3.125MG A 213709 004 Apr 22, 2021 Apr NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 213709 005 Apr 22, 2021 Apr NEWA AB 5MG;5MG;5MG;5MG A 213709 006 Apr 22, 2021 Apr NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 213709 007 Apr 22, 2021 Apr NEWA >A> AB LIBERTY PHARMA INC 1.25MG;1.25MG;1.25MG;1.25MG A 210293 001 Apr 03, 2020 Aug CAHN >A> AB 1.875MG;1.875MG;1.875MG;1.875MG A 210293 002 Apr 03, 2020 Aug CAHN >A> AB 2.5MG;2.5MG;2.5MG;2.5MG A 210293 003 Apr 03, 2020 Aug CAHN >A> AB 3.75MG;3.75MG;3.75MG;3.75MG A 210293 004 Apr 03, 2020 Aug CAHN >A> AB 5MG;5MG;5MG;5MG A 210293 005 Apr 03, 2020 Aug CAHN >A> AB 7.5MG;7.5MG;7.5MG;7.5MG A 210293 006 Apr 03, 2020 Aug CAHN >D> AB MYLAN 1.25MG;1.25MG;1.25MG;1.25MG A 206721 001 Nov 10, 2015 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -9

TABLET;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE >A> @ 1.25MG;1.25MG;1.25MG;1.25MG A 206721 001 Nov 10, 2015 Aug CAHN >D> AB 1.875MG;1.875MG;1.875MG;1.875MG A 206721 002 Nov 10, 2015 Aug CAHN >A> @ 1.875MG;1.875MG;1.875MG;1.875MG A 206721 002 Nov 10, 2015 Aug CAHN >D> AB 2.5MG;2.5MG;2.5MG;2.5MG A 206721 003 Nov 10, 2015 Aug CAHN >A> @ 2.5MG;2.5MG;2.5MG;2.5MG A 206721 003 Nov 10, 2015 Aug CAHN >D> AB 3.125MG;3.125MG;3.125MG;3.125MG A 206721 004 Nov 10, 2015 Aug CAHN >A> @ 3.125MG;3.125MG;3.125MG;3.125MG A 206721 004 Nov 10, 2015 Aug CAHN >D> AB 3.75MG;3.75MG;3.75MG;3.75MG A 206721 005 Nov 10, 2015 Aug CAHN >A> @ 3.75MG;3.75MG;3.75MG;3.75MG A 206721 005 Nov 10, 2015 Aug CAHN >D> AB 5MG;5MG;5MG;5MG A 206721 006 Nov 10, 2015 Aug CAHN >A> @ 5MG;5MG;5MG;5MG A 206721 006 Nov 10, 2015 Aug CAHN >D> AB 7.5MG;7.5MG;7.5MG;7.5MG A 206721 007 Nov 10, 2015 Aug CAHN >A> @ 7.5MG;7.5MG;7.5MG;7.5MG A 206721 007 Nov 10, 2015 Aug CAHN AB RHODES PHARMS 1.25MG;1.25MG;1.25MG;1.25MG A 213111 001 Jan 13, 2021 Jan NEWA AB 1.875MG;1.875MG;1.875MG;1.875MG A 213111 002 Jan 13, 2021 Jan NEWA AB 3.125MG;3.125MG;3.125MG;3.125MG A 213111 004 Jan 13, 2021 Jan NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 213111 007 Jan 13, 2021 Jan NEWA >D> AB USPHARMA 1.25MG;1.25MG;1.25MG;1.25MG A 210293 001 Apr 03, 2020 Aug CAHN >D> AB 1.875MG;1.875MG;1.875MG;1.875MG A 210293 002 Apr 03, 2020 Aug CAHN >D> AB 2.5MG;2.5MG;2.5MG;2.5MG A 210293 003 Apr 03, 2020 Aug CAHN >D> AB 3.75MG;3.75MG;3.75MG;3.75MG A 210293 004 Apr 03, 2020 Aug CAHN >D> AB 5MG;5MG;5MG;5MG A 210293 005 Apr 03, 2020 Aug CAHN >D> AB 7.5MG;7.5MG;7.5MG;7.5MG A 210293 006 Apr 03, 2020 Aug CAHN

AMPHETAMINE SULFATE TABLET;ORAL AMPHETAMINE SULFATE @ GLENMARK PHARMS LTD 5MG A 212186 001 Jan 27, 2021 Jun DISC AA 5MG A 212186 001 Jan 27, 2021 Jan NEWA @ 10MG A 212186 002 Jan 27, 2021 Jun DISC AA 10MG A 212186 002 Jan 27, 2021 Jan NEWA >D> AA HAVIX 5MG A 212901 001 May 22, 2020 Aug CAHN >D> AA 10MG A 212901 002 May 22, 2020 Aug CAHN >D> @ LANNETT 5MG A 083901 001 Aug 31, 1984 Aug CRLD >A> + @ 5MG A 083901 001 Aug 31, 1984 Aug CRLD >D> @ 10MG A 083901 002 Aug 31, 1984 Aug CRLD >A> + @ 10MG A 083901 002 Aug 31, 1984 Aug CRLD @ MAYNE PHARMA 5MG A 213898 001 Jul 14, 2020 Jan DISC @ 10MG A 213898 002 Jul 14, 2020 Jan DISC @ NOVAST LABS 5MG A 213763 001 Aug 24, 2020 Mar DISC @ 10MG A 213763 002 Aug 24, 2020 Mar DISC >A> AA RHODES PHARMS 5MG A 213852 001 Sep 07, 2021 Aug NEWA >A> AA 10MG A 213852 002 Sep 07, 2021 Aug NEWA >A> AA SENORES PHARMS 5MG A 212901 001 May 22, 2020 Aug CAHN >A> AA 10MG A 212901 002 May 22, 2020 Aug CAHN AA SPECGX LLC 5MG A 213583 001 Jan 22, 2021 Jan NEWA AA 10MG A 213583 002 Jan 22, 2021 Jan NEWA AA SUN PHARM INDS INC 5MG A 214574 001 Jan 27, 2021 Jan NEWA AA 10MG A 214574 002 Jan 27, 2021 Jan NEWA TABLET, ORALLY DISINTEGRATING;ORAL EVEKEO ODT + @ ARBOR PHARMS LLC 2.5MG N 209905 005 Apr 16, 2021 Jul DISC + 2.5MG N 209905 005 Apr 16, 2021 Apr NEWA +! 20MG N 209905 004 Jan 30, 2019 Apr CHRS

AMPICILLIN SODIUM INJECTABLE;INJECTION AMPICILLIN SODIUM @ HQ SPECLT PHARMA EQ 125MG BASE/VIAL A 062772 005 Apr 15, 1993 Mar CAHN AP EQ 250MG BASE/VIAL A 062772 006 Apr 15, 1993 Mar CAHN AP EQ 500MG BASE/VIAL A 062772 007 Apr 15, 1993 Mar CAHN @ EQ 500MG BASE/VIAL A 062772 008 Apr 15, 1993 Mar CAHN AP EQ 1GM BASE/VIAL A 062772 001 Apr 15, 1993 Mar CAHN @ EQ 1GM BASE/VIAL A 062772 002 Apr 15, 1993 Mar CAHN AP EQ 2GM BASE/VIAL A 062772 003 Apr 15, 1993 Mar CAHN @ EQ 2GM BASE/VIAL A 062772 004 Apr 15, 1993 Mar CAHN AP EQ 10GM BASE/VIAL A 063142 001 Apr 15, 1993 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -10

AMPICILLIN SODIUM; SULBACTAM SODIUM INJECTABLE;INJECTION AMPICILLIN AND SULBACTAM AP HQ SPECLT PHARMA EQ 1GM BASE/VIAL;EQ 500MG A 065176 001 Nov 30, 2005 Mar CAHN BASE/VIAL AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A 065176 002 Nov 30, 2005 Mar CAHN AP EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL A 065188 001 Nov 25, 2005 Mar CAHN

ANAGRELIDE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE >A> @ CHARTWELL RX EQ 0.5MG BASE A 076683 001 Apr 18, 2005 Aug CAHN >A> @ EQ 1MG BASE A 076683 002 Apr 18, 2005 Aug CAHN >D> @ UPSHER SMITH LABS EQ 0.5MG BASE A 076683 001 Apr 18, 2005 Aug CAHN >D> @ EQ 1MG BASE A 076683 002 Apr 18, 2005 Aug CAHN

ANASTROZOLE TABLET;ORAL >D> AB FRESENIUS KABI USA 1MG A 090088 001 Jun 28, 2010 Aug DISC >A> @ 1MG A 090088 001 Jun 28, 2010 Aug DISC @ US ANTIBIOTICS 1MG A 090732 001 Jun 28, 2010 May CAHN

ANIDULAFUNGIN POWDER;INTRAVENOUS ERAXIS +! VICURON HOLDINGS 50MG/VIAL N 021632 001 Feb 17, 2006 Jul CAHN +! 100MG/VIAL N 021632 002 Nov 14, 2006 Jul CAHN

APIXABAN TABLET;ORAL APIXABAN AB BRECKENRIDGE 2.5MG A 209845 001 Jul 26, 2021 Jul NEWA AB 5MG A 209845 002 Jul 26, 2021 Jul NEWA

APREMILAST TABLET;ORAL AB AMNEAL 10MG A 211782 001 Jun 30, 2021 Jun NEWA AB 20MG A 211782 002 Jun 30, 2021 Jun NEWA AB 30MG A 211782 003 Jun 30, 2021 Jun NEWA >D> AB UNICHEM 10MG A 211819 001 Feb 17, 2021 Aug DISC >A> @ 10MG A 211819 001 Feb 17, 2021 Aug DISC AB 10MG A 211819 001 Feb 17, 2021 Feb NFTG >D> AB 20MG A 211819 002 Feb 17, 2021 Aug DISC >A> @ 20MG A 211819 002 Feb 17, 2021 Aug DISC AB 20MG A 211819 002 Feb 17, 2021 Feb NFTG >D> AB 30MG A 211819 003 Feb 17, 2021 Aug DISC >A> @ 30MG A 211819 003 Feb 17, 2021 Aug DISC AB 30MG A 211819 003 Feb 17, 2021 Feb NFTG

ARFORMOTEROL SOLUTION;INHALATION TARTRATE AN AXAR PHARMS INC EQ 0.015MG BASE/2ML A 213762 001 Jun 22, 2021 Jun NFTG AN CIPLA EQ 0.015MG BASE/2ML A 207306 001 Jun 22, 2021 Jun NFTG AN GLENMARK PHARMS LTD EQ 0.015MG BASE/2ML A 213132 001 Jun 22, 2021 Jun NFTG

ARGATROBAN INJECTABLE;INJECTION AP CAPLIN 50MG/50ML (1MG/ML) A 214235 001 Jan 21, 2021 Jan NFTG INJECTABLE;INTRAVENOUS ARGATROBAN IN + @ EAGLE PHARMS 50MG/50ML (1MG/ML) N 022434 001 Jun 29, 2011 May DISC SOLUTION;INTRAVENOUS ARGATROBAN IN SODIUM CHLORIDE +! ACCORD HLTHCARE 50MG/50ML (1MG/ML) N 212035 001 Jun 07, 2021 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -11

ARSENIC TRIOXIDE INJECTABLE;INJECTION >D> @ AMNEAL 1MG/ML A 210739 001 Jan 25, 2021 Aug CMFD >A> AP 1MG/ML A 210739 001 Jan 25, 2021 Aug CMFD @ 1MG/ML A 210739 001 Jan 25, 2021 May DISC AP 1MG/ML A 210739 001 Jan 25, 2021 Jan NEWA >A> AP 2MG/ML A 210739 002 Aug 19, 2021 Aug NEWA @ INGENUS PHARMS LLC 2MG/ML A 209315 002 Jan 14, 2021 Feb DISC AP 2MG/ML A 209315 002 Jan 14, 2021 Jan NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; INJECTABLE;INTRAVENOUS INFUVITE PEDIATRIC ( BULK PACKAGE) +! SANDOZ INC 80MG/VIAL;0.02MG/VIAL;400 N 021265 002 Jan 29, 2004 Feb CAIN IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL

ASENAPINE MALEATE TABLET;SUBLINGUAL MALEATE AB ALEMBIC PHARMS LTD EQ 2.5MG BASE A 206098 003 Jul 19, 2021 Jul NEWA AB BRECKENRIDGE EQ 5MG BASE A 205960 003 Mar 08, 2021 Feb NEWA

ASPIRIN; CAFFEINE; CITRATE TABLET;ORAL NORGESIC + @ BAUSCH 385MG;30MG;25MG N 013416 003 Oct 27, 1982 May CAHN NORGESIC FORTE + @ BAUSCH 770MG;60MG;50MG N 013416 004 Oct 27, 1982 May CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE CAPSULE;ORAL PROPOXYPHENE COMPOUND 65 >D> @ SANDOZ 389MG;32.4MG;65MG A 080044 002 Sep 16, 1983 Aug CRLD >A> + @ 389MG;32.4MG;65MG A 080044 002 Sep 16, 1983 Aug CRLD

ASPIRIN; ; CODEINE PHOSPHATE TABLET;ORAL CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE ! INGENUS PHARMS NJ 325MG;200MG;16MG A 040860 001 Jan 07, 2010 Jul CHRS 325MG;200MG;16MG A 040860 001 Jan 07, 2010 Jul CTEC @ SANDOZ 325MG;200MG;16MG A 040118 001 Apr 16, 1996 Jul DISC

ASPIRIN; CAPSULE, EXTENDED RELEASE;ORAL ASPIRIN AND DIPYRIDAMOLE @ LANNETT CO INC 25MG;200MG A 204552 001 Mar 20, 2019 Apr DISC AB MICRO LABS 25MG;200MG A 209929 001 Aug 11, 2021 Jul NEWA >D> AB SUN PHARM 25MG;200MG A 208572 001 Aug 21, 2018 Aug DISC >A> @ 25MG;200MG A 208572 001 Aug 21, 2018 Aug DISC

ASPIRIN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ASPIRIN LGM PHARMA 500MG;5MG A 205479 001 May 28, 2021 May NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE AND ASPIRIN @ MAYNE PHARMA INC 325MG;4.8355MG A 091670 001 Mar 16, 2011 Jul DISC

ATAZANAVIR SULFATE CAPSULE;ORAL ATAZANAVIR SULFATE AB LAURUS LABS LTD EQ 150MG BASE A 212579 001 Apr 30, 2021 Apr NEWA AB EQ 200MG BASE A 212579 002 Apr 30, 2021 Apr NEWA AB EQ 300MG BASE A 212579 003 Apr 30, 2021 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -12

ATOMOXETINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB HETERO LABS LTD V 10MG A 202682 001 Mar 11, 2021 Mar NEWA AB 18MG A 202682 002 Mar 11, 2021 Mar NEWA AB 25MG A 202682 003 Mar 11, 2021 Mar NEWA AB 40MG A 202682 004 Mar 11, 2021 Mar NEWA AB 60MG A 202682 005 Mar 11, 2021 Mar NEWA AB 80MG A 202682 006 Mar 11, 2021 Mar NEWA AB 100MG A 202682 007 Mar 11, 2021 Mar NEWA @ MYLAN 10MG A 079021 001 Feb 18, 2021 Feb DISC AB 10MG A 079021 001 Feb 18, 2021 Feb NEWA @ 18MG A 079021 002 Feb 18, 2021 Feb DISC AB 18MG A 079021 002 Feb 18, 2021 Feb NEWA @ 25MG A 079021 003 Feb 18, 2021 Feb DISC AB 25MG A 079021 003 Feb 18, 2021 Feb NEWA @ 40MG A 079021 004 Feb 18, 2021 Feb DISC AB 40MG A 079021 004 Feb 18, 2021 Feb NEWA @ 60MG A 079021 005 Feb 18, 2021 Feb DISC AB 60MG A 079021 005 Feb 18, 2021 Feb NEWA @ 80MG A 079021 006 Feb 18, 2021 Feb DISC AB 80MG A 079021 006 Feb 18, 2021 Feb NEWA @ 100MG A 079021 007 Feb 18, 2021 Feb DISC AB 100MG A 079021 007 Feb 18, 2021 Feb NEWA

ATORVASTATIN TABLET;ORAL ATORVASTATIN CALCIUM AB ALKEM LABS LTD EQ 10MG BASE A 209288 001 Dec 21, 2018 Jan CAHN AB EQ 20MG BASE A 209288 002 Dec 21, 2018 Jan CAHN AB EQ 40MG BASE A 209288 003 Dec 21, 2018 Jan CAHN AB EQ 80MG BASE A 209288 004 Dec 21, 2018 Jan CAHN >A> AB AUGUST EQ 10MG BASE A 214969 001 Sep 02, 2021 Aug NEWA >A> AB EQ 20MG BASE A 214969 002 Sep 02, 2021 Aug NEWA >A> AB EQ 40MG BASE A 214969 003 Sep 02, 2021 Aug NEWA >A> AB EQ 80MG BASE A 214969 004 Sep 02, 2021 Aug NEWA AB DR REDDYS LABS LTD EQ 10MG BASE A 214659 001 Jul 14, 2021 Jul NEWA AB EQ 20MG BASE A 214659 002 Jul 14, 2021 Jul NEWA AB EQ 40MG BASE A 214659 003 Jul 14, 2021 Jul NEWA AB EQ 80MG BASE A 214659 004 Jul 14, 2021 Jul NEWA

ATORVASTATIN CALCIUM; EZETIMIBE TABLET;ORAL EZETIMIBE AND ATORVASTATIN CALCIUM @ SCOV3 EQ 10MG BASE;10MG A 206084 001 Apr 26, 2017 Jul CAHN @ EQ 20MG BASE;10MG A 206084 002 Apr 26, 2017 Jul CAHN @ EQ 40MG BASE;10MG A 206084 003 Apr 26, 2017 Jul CAHN @ EQ 80MG BASE;10MG A 206084 004 Apr 26, 2017 Jul CAHN LIPTRUZET + @ ORGANON EQ 10MG BASE;10MG N 200153 001 May 03, 2013 Feb CAHN + @ EQ 20MG BASE;10MG N 200153 002 May 03, 2013 Feb CAHN + @ EQ 40MG BASE;10MG N 200153 003 May 03, 2013 Feb CAHN + @ EQ 80MG BASE;10MG N 200153 004 May 03, 2013 Feb CAHN

ATOVAQUONE SUSPENSION;ORAL AB BIONPHARMA INC 750MG/5ML A 212918 001 Mar 30, 2021 Mar NEWA

ATROPINE SULFATE SOLUTION;INTRAVENOUS SULFATE AP ACCORD HLTHCARE 0.25MG/5ML (0.05MG/ML) A 212868 001 Jul 26, 2021 Jul NFTG AP 0.5MG/5ML (0.1MG/ML) A 212868 002 Jul 26, 2021 Jul NFTG AP 1MG/10ML (0.1MG/ML) A 212868 003 Jul 26, 2021 Jul NEWA AP +! HOSPIRA 1MG/10ML (0.1MG/ML) N 021146 003 Jul 09, 2001 Jul CTEC AP +! 1MG/10ML (0.1MG/ML) N 021146 005 Aug 17, 2017 Mar CTEC AP INTL SYS 1MG/10ML (0.1MG/ML) A 212461 001 Oct 05, 2020 Mar CTEC SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL ATROPINE SULFATE AP ACCORD HLTHCARE 8MG/20ML (0.4MG/ML) A 213424 001 Mar 19, 2021 Mar NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -13

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE TABLET;ORAL DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE AA WINDER LABS LLC 0.025MG;2.5MG A 211362 001 Jan 27, 2021 Jan NEWA

ATROPINE SULFATE; EDROPHONIUM CHLORIDE INJECTABLE;INJECTION ENLON-PLUS + @ MYLAN 0.14MG/ML;10MG/ML N 019678 001 Nov 06, 1991 Jan CAHN

AVAPRITINIB TABLET;ORAL AYVAKIT + BLUEPRINT MEDICINES 25MG N 212608 004 Jun 16, 2021 Jun NEWA + 50MG N 212608 005 Jun 16, 2021 Jun NEWA

AVIBACTAM SODIUM; CEFTAZIDIME POWDER;INTRAVENOUS AVYCAZ +! ALLERGAN EQ 0.5GM BASE;2GM/VIAL N 206494 001 Feb 25, 2015 Jan CDFR

AZELASTINE HYDROCHLORIDE SPRAY, METERED;NASAL ASTELIN >D> AB +! MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY N 020114 001 Nov 01, 1996 Aug CPOT >A> AB +! 0.137MG/SPRAY N 020114 001 Nov 01, 1996 Aug CPOT ASTEPRO >D> @ MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY N 022203 001 Oct 15, 2008 Aug CPOT >A> @ 0.137MG/SPRAY N 022203 001 Oct 15, 2008 Aug CPOT + @ 0.2055MG/SPRAY N 022203 002 Aug 31, 2009 Jul DISC AB +! 0.2055MG/SPRAY N 022203 002 Aug 31, 2009 Jul CPOT HYDROCHLORIDE >D> AB AKORN EQ 0.125MG BASE/SPRAY A 207610 001 May 17, 2019 Aug CPOT >A> AB 0.137MG/SPRAY A 207610 001 May 17, 2019 Aug CPOT >D> AB EQ 0.1876MG BASE/SPRAY A 210032 001 Aug 23, 2019 Aug CPOT >A> AB 0.2055MG/SPRAY A 210032 001 Aug 23, 2019 Aug CPOT >D> AB ALKEM LABS LTD EQ 0.125MG BASE/SPRAY A 208156 001 Aug 18, 2017 Aug CPOT >A> AB 0.137MG/SPRAY A 208156 001 Aug 18, 2017 Aug CPOT >D> AB AMNEAL EQ 0.125MG BASE/SPRAY A 204660 001 Aug 28, 2017 Aug CPOT >A> AB 0.137MG/SPRAY A 204660 001 Aug 28, 2017 Aug CPOT >D> AB EQ 0.1876MG BASE/SPRAY A 208199 001 Dec 15, 2017 Aug CPOT >A> AB 0.2055MG/SPRAY A 208199 001 Dec 15, 2017 Aug CPOT >D> AB APOTEX INC EQ 0.125MG BASE/SPRAY A 077954 001 Apr 30, 2009 Aug CPOT >A> AB 0.137MG/SPRAY A 077954 001 Apr 30, 2009 Aug CPOT >D> AB EQ 0.1876MG BASE/SPRAY A 201846 001 Aug 31, 2012 Aug CPOT >A> AB 0.2055MG/SPRAY A 201846 001 Aug 31, 2012 Aug CPOT >D> AB AUROBINDO PHARMA LTD EQ 0.125MG BASE/SPRAY A 212289 001 May 08, 2020 Aug CPOT >A> AB 0.137MG/SPRAY A 212289 001 May 08, 2020 Aug CPOT >D> AB EQ 0.1876MG BASE/SPRAY A 212775 001 Nov 12, 2020 Aug CPOT >A> AB 0.2055MG/SPRAY A 212775 001 Nov 12, 2020 Aug CPOT >A> AB BRECKENRIDGE 0.137MG/SPRAY A 090176 001 Jul 28, 2015 Aug CPOT >D> AB EQ 0.125MG BASE/SPRAY A 090176 001 Jul 28, 2015 Aug CPOT >D> AB HIKMA EQ 0.125MG BASE/SPRAY A 091444 001 Oct 24, 2014 Aug CPOT >D> AB EQ 0.1876MG BASE/SPRAY A 207243 001 Sep 22, 2017 Aug CPOT >A> AB HIKMA PHARMS 0.137MG/SPRAY A 091444 001 Oct 24, 2014 Aug CPOT >A> AB 0.2055MG/SPRAY A 207243 001 Sep 22, 2017 Aug CPOT >D> AB SUN PHARM EQ 0.125MG BASE/SPRAY A 090423 001 May 23, 2012 Aug CPOT >A> AB 0.137MG/SPRAY A 090423 001 May 23, 2012 Aug CPOT >A> AB UPSHER SMITH LABS 0.137MG/SPRAY A 202609 001 Mar 17, 2017 Aug CPOT >D> AB EQ 0.125MG BASE/SPRAY A 202609 001 Mar 17, 2017 Aug CPOT >D> AB ZYDUS PHARMS EQ 0.125MG BASE/SPRAY A 091409 001 Aug 14, 2017 Aug CPOT >A> AB 0.137MG/SPRAY A 091409 001 Aug 14, 2017 Aug CPOT

AZELASTINE HYDROCHLORIDE; SPRAY, METERED;NASAL AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE >A> AB APOTEX 0.137MG/SPRAY;0.05MG/SPRAY A 207712 001 Apr 28, 2017 Aug CPOT >D> AB EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A 207712 001 Apr 28, 2017 Aug CPOT >D> AB PADAGIS ISRAEL EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A 208111 001 Feb 18, 2021 Aug CPOT >A> AB 0.137MG/SPRAY;0.05MG/SPRAY A 208111 001 Feb 18, 2021 Aug CPOT AB PERRIGO UK FINCO EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A 208111 001 Feb 18, 2021 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -14

SPRAY, METERED;NASAL DYMISTA >D> AB +! MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY N 202236 001 May 01, 2012 Aug CPOT >A> AB +! 0.137MG/SPRAY;0.05MG/SPRAY N 202236 001 May 01, 2012 Aug CPOT

AZITHROMYCIN FOR SUSPENSION;ORAL AZITHROMYCIN AB TARO EQ 200MG BASE/5ML A 211521 001 Dec 11, 2019 Feb CMFD INJECTABLE;INJECTION AZITHROMYCIN @ MYLAN ASI EQ 500MG BASE/VIAL A 065506 001 Mar 24, 2009 Feb DISC TABLET;ORAL AZITHROMYCIN AB ALEMBIC PHARMS LTD EQ 600MG BASE A 211793 001 Jan 27, 2020 Jul CMFD AB YUNG SHIN PHARM EQ 500MG BASE A 211318 001 Mar 17, 2021 Mar NEWA AB EQ 600MG BASE A 211068 001 May 08, 2020 Feb CMFD

BACITRACIN INJECTABLE;INJECTION @ XELLIA PHARMS APS 50,000 UNITS/VIAL A 203177 001 Aug 25, 2014 Jun DISC

BACITRACIN ; HYDROCORTISONE; SULFATE; POLYMYXIN B SULFATE OINTMENT;TOPICAL CORTISPORIN + @ MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG N 050168 002 May 04, 1984 Jul DISC BASE/GM;5,000 UNITS/GM

BACLOFEN INJECTABLE;INTRATHECAL AP MAIA PHARMS INC 0.05MG/ML A 210777 001 Jan 15, 2021 Jan NEWA >D> @ 0.5MG/ML A 210048 001 Sep 11, 2019 Aug CMFD >A> AP 0.5MG/ML A 210048 001 Sep 11, 2019 Aug CMFD >D> @ 2MG/ML A 210048 002 Sep 11, 2019 Aug CMFD >A> AP 2MG/ML A 210048 002 Sep 11, 2019 Aug CMFD GABLOFEN AP +! PIRAMAL CRITICAL 0.05MG/ML N 022462 001 Nov 19, 2010 Mar CHRS AP + 0.05MG/ML N 022462 001 Nov 19, 2010 Mar CRLD AP +! 0.5MG/ML N 022462 002 Nov 19, 2010 Mar CHRS AP + 0.5MG/ML N 022462 002 Nov 19, 2010 Mar CRLD AP +! 2MG/ML N 022462 003 Nov 19, 2010 Mar CHRS AP + 2MG/ML N 022462 003 Nov 19, 2010 Mar CRLD TABLET;ORAL BACLOFEN AB AUROBINDO PHARMA LTD 10MG A 214099 001 Jul 13, 2021 Jul NEWA AB 20MG A 214099 002 Jul 13, 2021 Jul NEWA AB BEXIMCO PHARMS USA 10MG A 214114 001 Jul 16, 2021 Jul NEWA AB 20MG A 214114 002 Jul 16, 2021 Jul NEWA AB IMPAX 5MG A 077971 003 Jul 07, 2021 Jun NEWA AB 10MG A 077971 001 Oct 26, 2007 Jun CAHN AB 20MG A 077971 002 Oct 26, 2007 Jun CAHN AB INNOGENIX 5MG A 212378 003 Apr 30, 2021 Apr NEWA AB KARTHA 5MG A 214374 001 Mar 05, 2021 Feb NEWA AB 10MG A 214374 002 Mar 05, 2021 Feb NEWA AB 20MG A 214374 003 Mar 05, 2021 Feb NEWA TABLET, ORALLY DISINTEGRATING;ORAL KEMSTRO + @ UCB INC 10MG N 021589 001 Oct 30, 2003 May CRLD + @ 20MG N 021589 002 Oct 30, 2003 May CRLD

BALOXAVIR MARBOXIL TABLET;ORAL XOFLUZA + INC 80MG N 210854 003 Mar 18, 2021 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -15

BELUMOSUDIL MESYLATE TABLET;ORAL REZUROCK +! KADMON PHARMS LLC EQ 200MG BASE N 214783 001 Jul 16, 2021 Jul NEWA

>A> BELZUTIFAN >A> TABLET;ORAL >A> WELIREG >A> +! MERCK SHARP DOHME 40MG N 215383 001 Aug 13, 2021 Aug NEWA

BENAZEPRIL HYDROCHLORIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE >A> AB CADILA 5MG A 078848 001 May 23, 2008 Aug CAHN >A> AB 10MG A 078848 002 May 23, 2008 Aug CAHN >A> AB 20MG A 078848 003 May 23, 2008 Aug CAHN >A> AB 40MG A 078848 004 May 23, 2008 Aug CAHN >D> AB ZYDUS PHARMS USA 5MG A 078848 001 May 23, 2008 Aug CAHN >D> AB 10MG A 078848 002 May 23, 2008 Aug CAHN >D> AB 20MG A 078848 003 May 23, 2008 Aug CAHN >D> AB 40MG A 078848 004 May 23, 2008 Aug CAHN LOTENSIN AB + VALIDUS PHARMS 5MG N 019851 001 Jun 25, 1991 Feb CAHN AB + 10MG N 019851 002 Jun 25, 1991 Feb CAHN AB + 20MG N 019851 003 Jun 25, 1991 Feb CAHN AB +! 40MG N 019851 004 Jun 25, 1991 Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE MY LAN@ MYLAN@ 5MG;6.25MG A 076688 001 Feb 11, 2004 Jul DISC @ 10MG;12.5MG A 076688 002 Feb 11, 2004 Jul DISC @ 20MG;12.5MG A 076688 003 Feb 11, 2004 Jul DISC @ 20MG;25MG A 076688 004 Feb 11, 2004 Jul DISC SANDOZ 5MG;6.25MG A 076631 001 Feb 11, 2004 Jul CTEC LOTENSIN HCT + @ VALIDUS PHARMS 5MG;6.25MG N 020033 001 May 19, 1992 Feb CAHN AB + 10MG;12.5MG N 020033 002 May 19, 1992 Feb CAHN AB + 20MG;12.5MG N 020033 004 May 19, 1992 Feb CAHN AB +! 20MG;25MG N 020033 003 May 19, 1992 Feb CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM SOLUTION/DROPS;OPHTHALMIC FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE +! BAUSCH LOMB IRELAND 0.4%;0.3% N 211039 001 Mar 09, 2020 May CAHN

BENZOYL PEROXIDE; PHOSPHATE GEL;TOPICAL CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE AB ENCUBE 5%;1.2% A 212433 001 Apr 28, 2021 Apr NEWA DUAC AB + STIEFEL 5%;1.2% N 050741 001 Aug 26, 2002 Jan CHRS

BENZOYL PEROXIDE; CREAM;TOPICAL TWYNEO +! SOL-GEL TECHNOLOGIES 3%;0.1% N 214902 001 Jul 26, 2021 Jul NEWA

BEPOTASTINE BESILATE SOLUTION/DROPS;OPHTHALMIC BESILATE AT APOTEX 1.5% A 206066 001 Mar 05, 2019 May CMFD AT MYLAN 1.5% A 206220 001 Mar 18, 2019 May CMFD BEPREVE AT +! BAUSCH AND LOMB INC 1.5% N 022288 001 Sep 08, 2009 May CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -16

BETAMETHASONE ACETATE; SODIUM PHOSPHATE INJECTABLE;INJECTION CELESTONE SOLUSPAN >D> AB +! MERCK SHARP DOHME 3MG/ML;EQ 3MG BASE/ML N 014602 001 Aug CAHN >A> AB +! ORGANON 3MG/ML;EQ 3MG BASE/ML N 014602 001 Aug CAHN

BETAMETHASONE DIPROPIONATE LOTION;TOPICAL BETAMETHASONE DIPROPIONATE @ PHARMGEN EQ 0.05% BASE A 070274 001 Aug 12, 1985 May CAHN SPRAY;TOPICAL SERNIVO +! PRIMUS PHARMS EQ 0.05% BASE/SPRAY N 208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; LOTION;TOPICAL CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE AB ! TARO EQ 0.05% BASE;1% A 076493 001 Jul 28, 2004 Feb CHRS LOTRISONE + @ MERCK SHARP DOHME EQ 0.05% BASE;1% N 020010 001 Dec 08, 2000 Feb DISC

BETAXOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC HYDROCHLORIDE >A> AT ACELLA EQ 0.5% BASE A 078694 001 Nov 16, 2009 Aug CAHN >D> AT WOCKHARDT EQ 0.5% BASE A 078694 001 Nov 16, 2009 Aug CAHN

BETHANECHOL CHLORIDE TABLET;ORAL CHLORIDE @ WOCKHARDT 5MG A 040532 001 Sep 29, 2003 Jan DISC @ 50MG A 040518 001 Sep 29, 2003 Jan DISC URECHOLINE >D> @ ODYSSEY PHARMS 10MG A 088440 001 May 29, 1984 Aug CRLD >A> + @ 10MG A 088440 001 May 29, 1984 Aug CRLD >D> @ 25MG A 088441 001 May 29, 1984 Aug CRLD >A> + @ 25MG A 088441 001 May 29, 1984 Aug CRLD

BEXAROTENE CAPSULE;ORAL AB TEVA PHARMS USA 75MG A 209931 001 Jan 14, 2021 Jan NEWA

BIMATOPROST SOLUTION/DROPS;OPHTHALMIC @ AKORN 0.03% A 203299 001 Nov 08, 2018 Feb CAHN AT ! ALEMBIC PHARMS LTD 0.03% A 210263 001 Apr 12, 2019 Jan CHRS AT LUPIN LTD 0.03% A 203991 001 Feb 20, 2015 Jan CHRS

BISOPROLOL FUMARATE TABLET;ORAL FUMARATE AB UNICHEM 5MG A 078635 001 Aug 18, 2009 Apr CAHN AB ! 10MG A 078635 002 Aug 18, 2009 Apr CAHN

BIVALIRUDIN INJECTABLE;INTRAVENOUS BIVALIRUDIN AP HAINAN POLY PHARM 250MG/VIAL A 213078 001 May 28, 2021 May NEWA

BLEOMYCIN SULFATE INJECTABLE;INJECTION SULFATE >D> AP CIPLA EQ 15 UNITS BASE/VIAL A 209439 001 Mar 11, 2019 Aug DISC >A> @ EQ 15 UNITS BASE/VIAL A 209439 001 Mar 11, 2019 Aug DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -17

BORTEZOMIB INJECTABLE;INTRAVENOUS, SUBCUTANEOUS VELCADE +! TAKEDA PHARMS USA 3.5MG/VIAL N 021602 001 May 13, 2003 May CAHN

BOSENTAN TABLET;ORAL >D> AB ALEMBIC PHARMS LTD 62.5MG A 211461 001 Jan 23, 2020 Aug DISC >A> @ 62.5MG A 211461 001 Jan 23, 2020 Aug DISC AB 62.5MG A 211461 001 Jan 23, 2020 May CMFD >D> AB 125MG A 211461 002 Jan 23, 2020 Aug DISC >A> @ 125MG A 211461 002 Jan 23, 2020 Aug DISC AB 125MG A 211461 002 Jan 23, 2020 May CMFD TRACLEER AB + 62.5MG N 021290 001 Nov 20, 2001 Feb CAHN AB +! 125MG N 021290 002 Nov 20, 2001 Feb CAHN TABLET, FOR SUSPENSION;ORAL TRACLEER +! ACTELION 32MG N 209279 001 Sep 05, 2017 Feb CAHN

BRIGATINIB TABLET;ORAL ALUNBRIG + TAKEDA PHARMS USA 30MG N 208772 001 Apr 28, 2017 May CAHN + 90MG N 208772 002 Apr 28, 2017 May CAHN +! 180MG N 208772 003 Oct 02, 2017 May CAHN

BRINCIDOFOVIR SUSPENSION;ORAL TEMBEXA +! CHIMERIX 10MG/ML N 214460 001 Jun 04, 2021 Jun NEWA TABLET;ORAL TEMBEXA +! CHIMERIX 100MG N 214461 001 Jun 04, 2021 Jun NEWA

BRINZOLAMIDE SUSPENSION/DROPS;OPHTHALMIC >A> AB BAUSCH 1% A 204884 001 Aug 18, 2021 Aug NEWA

BROMOCRIPTINE MESYLATE CAPSULE;ORAL PARLODEL AB + VALIDUS PHARMS EQ 5MG BASE N 017962 002 Mar 01, 1982 Feb CAHN TABLET;ORAL PARLODEL AB + VALIDUS PHARMS EQ 2.5MG BASE N 017962 001 Feb CAHN

BUDESONIDE CAPSULE, DELAYED RELEASE;ORAL @ ALVOGEN 3MG A 206724 001 Nov 23, 2016 Apr CDFR AB AMNEAL PHARMS 3MG A 206200 001 Jul 31, 2017 Apr CDFR AB MAYNE PHARMA 3MG A 206623 001 Apr 08, 2016 Apr CDFR AB MYLAN 3MG A 090410 001 May 16, 2011 Apr CDFR AB RISING 3MG A 207367 001 Apr 07, 2017 Apr CDFR AB SCIECURE PHARMA INC 3MG A 209041 001 Sep 28, 2017 Apr CDFR AB ZYDUS PHARMS 3MG A 206134 001 May 04, 2017 Apr CDFR SUSPENSION;INHALATION BUDESONIDE AN SUN PHARM 0.25MG/2ML A 211922 001 Apr 14, 2021 Apr NEWA AN 0.5MG/2ML A 211922 002 Apr 14, 2021 Apr NEWA AN 1MG/2ML A 211922 003 Apr 14, 2021 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -18

BUPIVACAINE SOLUTION, EXTENDED RELEASE;INFILTRATION POSIMIR + @ DURECT 660MG/5ML (132MG/ML) N 204803 001 Feb 01, 2021 Mar DISC +! 660MG/5ML (132MG/ML) N 204803 001 Feb 01, 2021 Feb NEWA

BUPIVACAINE HYDROCHLORIDE INJECTABLE;INJECTION BUPIVACAINE HYDROCHLORIDE AP HIKMA PHARMS 0.25% A 205141 001 Feb 11, 2021 Feb NEWA AP 0.5% A 205141 002 Feb 11, 2021 Feb NEWA BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE AP HIKMA PHARMS 0.25% A 204842 001 Feb 11, 2021 Feb NEWA AP 0.5% A 204842 002 Feb 11, 2021 Feb NEWA AP 0.75% A 204842 003 Feb 11, 2021 Feb NEWA

BUPIVACAINE; SOLUTION, EXTENDED RELEASE;PERIARTICULAR ZYNRELEF KIT +! HERON THERAPS INC 60MG/2.3ML N 211988 001 May 12, 2021 Jun NEWA (29.25MG/ML);1.8MG/2.3ML +! 200MG/7ML (29.25MG/ML);6MG/7ML N 211988 002 May 12, 2021 Jun NEWA (0.88MG/ML) +! 300MG/10.5ML N 211988 003 May 12, 2021 Jun NEWA (29.25MG/ML);9MG/10.5ML +! 400MG/14ML (29.25MG/ML);12MG/14ML N 211988 004 May 12, 2021 Jun NEWA (0.88MG/ML)

BUPRENORPHINE FILM, EXTENDED RELEASE;TRANSDERMAL >A> @ MYLAN TECH VIATRIS 5MCG/HR A 210162 001 May 03, 2021 Aug DISC >A> @ 5MCG/HR A 210162 001 May 03, 2021 Aug DISC >A> @ 7.5MCG/HR A 210162 002 May 03, 2021 Aug DISC >A> @ 7.5MCG/HR A 210162 002 May 03, 2021 Aug DISC >A> @ 10MCG/HR A 210162 003 May 03, 2021 Aug DISC >A> @ 10MCG/HR A 210162 003 May 03, 2021 Aug DISC >A> @ 15MCG/HR A 210162 004 May 03, 2021 Aug DISC >A> @ 15MCG/HR A 210162 004 May 03, 2021 Aug DISC >A> @ 20MCG/HR A 210162 005 May 03, 2021 Aug DISC >A> @ 20MCG/HR A 210162 005 May 03, 2021 Aug DISC >D> AB MYLAN TECHNOLOGIES 5MCG/HR A 210162 001 May 03, 2021 Aug DISC AB 5MCG/HR A 210162 001 May 03, 2021 Apr NEWA >D> AB 7.5MCG/HR A 210162 002 May 03, 2021 Aug DISC AB 7.5MCG/HR A 210162 002 May 03, 2021 Apr NEWA >D> AB 10MCG/HR A 210162 003 May 03, 2021 Aug DISC AB 10MCG/HR A 210162 003 May 03, 2021 Apr NEWA >D> AB 15MCG/HR A 210162 004 May 03, 2021 Aug DISC AB 15MCG/HR A 210162 004 May 03, 2021 Apr NEWA >D> AB 20MCG/HR A 210162 005 May 03, 2021 Aug DISC AB 20MCG/HR A 210162 005 May 03, 2021 Apr NEWA AB WATSON LABS TEVA 7.5MCG/HR A 204937 005 Jun 29, 2021 Jun NEWA

BUPRENORPHINE HYDROCHLORIDE FILM;BUCCAL BUPRENORPHINE HYDROCHLORIDE >D> AB ALVOGEN EQ 0.075MG BASE A 211594 001 Aug 03, 2021 Aug CAHN >A> AB EQ 0.075MG BASE A 211594 001 Aug 03, 2021 Aug CAHN AB EQ 0.075MG BASE A 211594 001 Aug 03, 2021 Jul NFTG >D> AB EQ 0.15MG BASE A 211594 002 Aug 03, 2021 Aug CAHN >A> AB EQ 0.15MG BASE A 211594 002 Aug 03, 2021 Aug CAHN AB EQ 0.15MG BASE A 211594 002 Aug 03, 2021 Jul NFTG >D> AB EQ 0.3MG BASE A 211594 003 Aug 03, 2021 Aug CAHN >A> AB EQ 0.3MG BASE A 211594 003 Aug 03, 2021 Aug CAHN AB EQ 0.3MG BASE A 211594 003 Aug 03, 2021 Jul NFTG >D> AB EQ 0.45MG BASE A 211594 004 Aug 03, 2021 Aug CAHN >A> AB EQ 0.45MG BASE A 211594 004 Aug 03, 2021 Aug CAHN AB EQ 0.45MG BASE A 211594 004 Aug 03, 2021 Jul NFTG >D> AB EQ 0.6MG BASE A 211594 005 Aug 03, 2021 Aug CAHN >A> AB EQ 0.6MG BASE A 211594 005 Aug 03, 2021 Aug CAHN AB EQ 0.6MG BASE A 211594 005 Aug 03, 2021 Jul NFTG >D> AB EQ 0.75MG BASE A 211594 006 Aug 03, 2021 Aug CAHN >A> AB EQ 0.75MG BASE A 211594 006 Aug 03, 2021 Aug CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -19

FILM;BUCCAL BUPRENORPHINE HYDROCHLORIDE AB EQ 0.75MG BASE A 211594 006 Aug 03, 2021 Jul NFTG >D> AB EQ 0.9MG BASE A 211594 007 Aug 03, 2021 Aug CAHN >A> AB EQ 0.9MG BASE A 211594 007 Aug 03, 2021 Aug CAHN AB EQ 0.9MG BASE A 211594 007 Aug 03, 2021 Jul NFTG

BUPRENORPHINE HYDROCHLORIDE; HYDROCHLORIDE TABLET;SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE AB ALKEM LABS LTD EQ 2MG BASE;EQ 0.5MG BASE A 214930 001 Jun 15, 2021 Jun NEWA AB EQ 8MG BASE;EQ 2MG BASE A 214930 002 Jun 15, 2021 Jun NEWA @ MAYNE PHARMA INC EQ 2MG BASE;EQ 0.5MG BASE A 206953 001 Jul 17, 2020 Jan DISC @ EQ 8MG BASE;EQ 2MG BASE A 206953 002 Jul 17, 2020 Jul DISC AB EQ 8MG BASE;EQ 2MG BASE A 206953 002 Jul 17, 2020 May CMFD @ EQ 8MG BASE;EQ 2MG BASE A 206953 002 Jul 17, 2020 Jan DISC AB RHODES PHARMS EQ 2MG BASE;EQ 0.5MG BASE A 205601 001 Mar 30, 2020 Jul CMFD AB EQ 8MG BASE;EQ 2MG BASE A 205601 002 Mar 30, 2020 Jul CMFD

BUPROPION HYDROBROMIDE TABLET, EXTENDED RELEASE;ORAL APLENZIN + BAUSCH 174MG N 022108 001 Apr 23, 2008 Feb CAHN + 348MG N 022108 002 Apr 23, 2008 Feb CAHN +! 522MG N 022108 003 Apr 23, 2008 Feb CAHN

BUPROPION HYDROCHLORIDE TABLET;ORAL BUPROPION HYDROCHLORIDE >D> AB MYLAN 75MG A 075491 001 Apr 17, 2000 Aug DISC >A> @ 75MG A 075491 001 Apr 17, 2000 Aug DISC >D> AB 100MG A 075491 002 Apr 17, 2000 Aug DISC >A> @ 100MG A 075491 002 Apr 17, 2000 Aug DISC TABLET, EXTENDED RELEASE;ORAL BUPROPION HYDROCHLORIDE >D> AB3 IMPAX LABS 150MG A 077415 001 Nov 26, 2008 Aug DISC >A> @ 150MG A 077415 001 Nov 26, 2008 Aug DISC >D> AB1 200MG A 076711 001 Dec 03, 2004 Aug DISC >A> @ 200MG A 076711 001 Dec 03, 2004 Aug DISC @ TORRENT 100MG A 203969 001 Oct 31, 2014 Jan DISC @ 150MG A 203969 002 Oct 31, 2014 Jan DISC @ 200MG A 203969 003 Oct 31, 2014 Jan DISC WELLBUTRIN XL AB3 + BAUSCH 150MG N 021515 001 Aug 28, 2003 Feb CAHN AB3 +! 300MG N 021515 002 Aug 28, 2003 Feb CAHN

BUSPIRONE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB RUBICON 5MG A 075521 001 Apr 05, 2002 Feb CMFD AB 7.5MG A 075521 004 Mar 16, 2021 Mar NEWA AB 10MG A 075521 002 Apr 05, 2002 Feb CMFD AB 15MG A 075521 003 Apr 05, 2002 Feb CMFD AB 30MG A 075521 005 Mar 16, 2021 Mar NEWA

BUSULFAN INJECTABLE;INJECTION AP AM REGENT 6MG/ML A 202259 001 Dec 22, 2015 Feb CAHN

BUTABARBITAL SODIUM TABLET;ORAL SODIUM >D> @ SANDOZ 15MG A 085938 001 Aug CRLD >A> + @ 15MG A 085938 001 Aug CRLD

CABERGOLINE TABLET;ORAL DOSTINEX + @ PFIZER 0.5MG N 020664 001 Dec 23, 1996 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -20

CABOTEGRAVIR SODIUM TABLET;ORAL VOCABRIA +! VIIV HLTHCARE EQ 30MG BASE N 212887 001 Jan 21, 2021 Jan NEWA

CABOTEGRAVIR; RILPIVIRINE SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR CABENUVA KIT +! VIIV HLTHCARE 400MG/2ML (200MG/ML);600MG/2ML N 212888 001 Jan 21, 2021 Jan NEWA (300MG/ML) +! 600MG/3ML (200MG/ML);900MG/3ML N 212888 002 Jan 21, 2021 Jan NEWA (300MG/ML)

CAFFEINE CITRATE SOLUTION;INTRAVENOUS CAFCIT AP +! HIKMA PHARMS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N 020793 001 Sep 21, 1999 Jul CAHN SOLUTION;ORAL CAFCIT AA +! HIKMA PHARMS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N 020793 002 Apr 12, 2000 Jul CAHN

CAFFEINE; TARTRATE TABLET;ORAL CAFERGOT >D> @ SANDOZ 100MG;1MG A 084294 001 Aug CRLD >A> + @ 100MG;1MG A 084294 001 Aug CRLD @ 100MG;1MG A 084294 001 Jul DISC ERGOTAMINE TARTRATE AND CAFFEINE ! MIKART 100MG;1MG A 040590 001 Sep 16, 2005 Jul CHRS 100MG;1MG A 040590 001 Sep 16, 2005 Jul CTEC

CALCITONIN SALMON INJECTABLE;INJECTION -SALMON AP CUSTOPHARM INC 200 IU/ML A 212416 001 May 14, 2021 May NFTG

CALCIUM ACETATE TABLET;ORAL CALCIUM ACETATE AB ! CHARTWELL MOLECULAR 667MG A 202420 001 Feb 05, 2013 Apr CHRS

CALCIUM CARBONATE; RISEDRONATE SODIUM TABLET;ORAL ACTONEL WITH CALCIUM (COPACKAGED) + @ WARNER CHILCOTT EQ 500MG BASE;35MG N 021823 001 Aug 12, 2005 Jul CPOT + @ EQ 500MG BASE,N/A;N/A,35MG N 021823 001 Aug 12, 2005 Jul CDFR

CALCIUM GLUCEPTATE INJECTABLE;INJECTION CALCIUM GLUCEPTATE >D> @ ABBOTT EQ 90MG CALCIUM/5ML A 080001 001 Aug CRLD >A> + @ EQ 90MG CALCIUM/5ML A 080001 001 Aug CRLD

CALCIUM GLUCONATE SOLUTION;INTRAVENOUS >A> IN SODIUM CHLORIDE >A> +! FRESENIUS KABI USA 1GM/50ML (20MG/ML) N 208418 004 Jun 17, 2021 Aug NEWA >A> +! 2GM/100ML (20MG/ML) N 208418 005 Jun 17, 2021 Aug NEWA +! HQ SPCLT PHARMA 1GM/100ML (10MG/ML) N 210906 003 Jun 04, 2021 Jun NEWA

CAPREOMYCIN SULFATE INJECTABLE;INJECTION CAPASTAT SULFATE + @ AKORN EQ 1GM BASE/VIAL N 050095 001 Jun DISC

CAPTOPRIL TABLET;ORAL CAPTOPRIL AB ANNORA PHARMA 12.5MG A 074737 001 Oct 28, 1998 Jul CMFD AB 25MG A 074737 002 Oct 28, 1998 Jul CMFD AB 50MG A 074737 003 Oct 28, 1998 Jul CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -21

TABLET;ORAL CAPTOPRIL AB 100MG A 074737 004 Oct 28, 1998 Jul CMFD

CAPTOPRIL; HYDROCHLOROTHIAZIDE TABLET;ORAL CAPTOPRIL AND HYDROCHLOROTHIAZIDE >D> MYLAN 25MG;15MG A 074896 001 Dec 29, 1997 Aug CAHN >A> @ 25MG;15MG A 074896 001 Dec 29, 1997 Aug CAHN >D> ! 25MG;25MG A 074896 002 Dec 29, 1997 Aug CAHN >A> @ 25MG;25MG A 074896 002 Dec 29, 1997 Aug CAHN >D> ! 50MG;15MG A 074896 004 Dec 29, 1997 Aug CAHN >A> @ 50MG;15MG A 074896 004 Dec 29, 1997 Aug CAHN >D> 50MG;25MG A 074896 003 Dec 29, 1997 Aug CAHN >A> @ 50MG;25MG A 074896 003 Dec 29, 1997 Aug CAHN

CARBAMAZEPINE TABLET;ORAL >A> AB VGYAAN 200MG A 214328 001 Aug 16, 2021 Aug NEWA TABLET, EXTENDED RELEASE;ORAL CARBAMAZEPINE AB CSPC OUYI 100MG A 213311 001 Apr 13, 2021 Apr NEWA AB 200MG A 213311 002 Apr 13, 2021 Apr NEWA AB 400MG A 213311 003 Apr 13, 2021 Apr NEWA

CARBIDOPA; LEVODOPA TABLET;ORAL AND LEVODOPA AB SCIEGEN PHARMS INC 10MG;100MG A 214092 001 May 07, 2021 Apr NEWA AB 25MG;100MG A 214092 002 May 07, 2021 Apr NEWA AB 25MG;250MG A 214092 003 May 07, 2021 Apr NEWA SINEMET >D> AB + MERCK SHARP DOHME 10MG;100MG N 017555 001 Aug CAHN >D> AB + 25MG;100MG N 017555 003 Aug CAHN >D> AB + 25MG;250MG N 017555 002 Aug CAHN >A> AB + ORGANON 10MG;100MG N 017555 001 Aug CAHN >A> AB + 25MG;100MG N 017555 003 Aug CAHN >A> AB + 25MG;250MG N 017555 002 Aug CAHN TABLET, ORALLY DISINTEGRATING;ORAL CARBIDOPA AND LEVODOPA >D> AB MYLAN 10MG;100MG A 078893 001 Sep 18, 2008 Aug CAHN >A> @ 10MG;100MG A 078893 001 Sep 18, 2008 Aug CAHN >D> AB 25MG;100MG A 078893 002 Sep 18, 2008 Aug CAHN >A> @ 25MG;100MG A 078893 002 Sep 18, 2008 Aug CAHN >D> AB ! 25MG;250MG A 078893 003 Sep 18, 2008 Aug CAHN >A> @ 25MG;250MG A 078893 003 Sep 18, 2008 Aug CAHN >D> AB SUN PHARM 25MG;250MG A 078690 003 Jul 31, 2009 Aug CTEC >A> ! 25MG;250MG A 078690 003 Jul 31, 2009 Aug CTEC

CARBOPLATIN INJECTABLE;INTRAVENOUS AP ! HOSPIRA 50MG/5ML (10MG/ML) A 076517 001 Oct 14, 2004 Mar CHRS AP ! 150MG/15ML (10MG/ML) A 076517 002 Oct 14, 2004 Mar CHRS AP ! 450MG/45ML (10MG/ML) A 076517 003 Oct 14, 2004 Mar CHRS AP ! 600MG/60ML (10MG/ML) A 077059 001 Nov 23, 2004 Mar CHRS >D> AP MEITHEAL 50MG/5ML (10MG/ML) A 077096 001 Jun 14, 2005 Aug DISC >A> @ 50MG/5ML (10MG/ML) A 077096 001 Jun 14, 2005 Aug DISC >D> AP 150MG/15ML (10MG/ML) A 077096 002 Jun 14, 2005 Aug DISC >A> @ 150MG/15ML (10MG/ML) A 077096 002 Jun 14, 2005 Aug DISC >D> AP 450MG/45ML (10MG/ML) A 077096 003 Jun 14, 2005 Aug DISC >A> @ 450MG/45ML (10MG/ML) A 077096 003 Jun 14, 2005 Aug DISC >D> AP 600MG/60ML (10MG/ML) A 077096 004 Jun 03, 2013 Aug DISC >A> @ 600MG/60ML (10MG/ML) A 077096 004 Jun 03, 2013 Aug DISC AP PHARMACHEMIE BV 50MG/5ML (10MG/ML) A 077269 001 Oct 14, 2004 Mar CHRS AP 150MG/15ML (10MG/ML) A 077269 002 Oct 14, 2004 Mar CHRS AP 450MG/45ML (10MG/ML) A 077269 003 Oct 14, 2004 Mar CHRS AP 600MG/60ML (10MG/ML) A 077269 004 Dec 28, 2007 Mar CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -22

CARBOPROST TROMETHAMINE INJECTABLE;INJECTION TROMETHAMINE AP SUNNY PHARMTECH INC EQ 0.25MG BASE/ML A 213118 001 Mar 25, 2021 Mar NEWA

CARFILZOMIB POWDER;INTRAVENOUS >D> >D> AP BRECKENRIDGE 10MG/VIAL A 209330 001 Jun 11, 2021 Aug DISC >A> @ 10MG/VIAL A 209330 001 Jun 11, 2021 Aug DISC AP 10MG/VIAL A 209330 001 Jun 11, 2021 Jun NFTG >D> AP 60MG/VIAL A 209330 002 Jun 11, 2021 Aug DISC >A> @ 60MG/VIAL A 209330 002 Jun 11, 2021 Aug DISC AP 60MG/VIAL A 209330 002 Jun 11, 2021 Jun NEWA KYPROLIS >D> AP + ONYX THERAP 10MG/VIAL N 202714 003 Jun 07, 2018 Aug CTEC >A> + 10MG/VIAL N 202714 003 Jun 07, 2018 Aug CTEC

CARMUSTINE INJECTABLE;INJECTION BICNU >A> AP +! AVET LIFESCIENCES 100MG/VIAL N 017422 001 Aug CAHN >D> AP +! EMCURE PHARMS LTD 100MG/VIAL N 017422 001 Aug CAHN AP HONG KONG 100MG/VIAL A 213460 001 Aug 02, 2021 Jul NEWA AP JIANGSU HENGRUI MED 100MG/VIAL A 211202 001 Mar 12, 2021 Mar NEWA

CARVEDILOL TABLET;ORAL >A> @ AXXELENT PHARMA 3.125MG A 078786 001 Dec 22, 2009 Aug CAHN >A> @ 6.25MG A 078786 002 Dec 22, 2009 Aug CAHN >A> @ 12.5MG A 078786 003 Dec 22, 2009 Aug CAHN >A> @ 25MG A 078786 004 Dec 22, 2009 Aug CAHN >D> @ WOCKHARDT LTD 3.125MG A 078786 001 Dec 22, 2009 Aug CAHN >D> @ 6.25MG A 078786 002 Dec 22, 2009 Aug CAHN >D> @ 12.5MG A 078786 003 Dec 22, 2009 Aug CAHN >D> @ 25MG A 078786 004 Dec 22, 2009 Aug CAHN COREG AB + WOODWARD 3.125MG N 020297 004 May 29, 1997 Jul CAHN AB + 6.25MG N 020297 003 Sep 14, 1995 Jul CAHN AB +! 12.5MG N 020297 002 Sep 14, 1995 Jul CAHN AB + 25MG N 020297 001 Sep 14, 1995 Jul CAHN

CARVEDILOL PHOSPHATE CAPSULE, EXTENDED RELEASE;ORAL COREG CR AB + WOODWARD 10MG N 022012 001 Oct 20, 2006 Jul CAHN AB + 20MG N 022012 002 Oct 20, 2006 Jul CAHN AB +! 40MG N 022012 003 Oct 20, 2006 Jul CAHN AB + 80MG N 022012 004 Oct 20, 2006 Jul CAHN

CASIMERSEN SOLUTION;INTRAVENOUS AMONDYS 45 +! SAREPTA THERAPS INC 100MG/2ML (50MG/ML) N 213026 001 Feb 25, 2021 Feb NEWA

CEFAZOLIN SODIUM SOLUTION;INTRAVENOUS CEFAZOLIN IN PLASTIC CONTAINER +! BAXTER HLTHCARE CORP EQ 1GM BASE/50ML (EQ 20MG BASE/ML) N 207131 002 Feb 01, 2021 Mar NEWA +! EQ 2GM BASE/100ML (EQ 20MG N 207131 001 Aug 07, 2015 Mar CRLD BASE/ML) ! EQ 2GM BASE/100ML (EQ 20MG N 207131 001 Aug 07, 2015 Mar CHRS BASE/ML) RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -23

CEFDINIR CAPSULE;ORAL CEFDINIR AB ALKEM LABS LTD 300MG A 210220 001 Feb 19, 2021 Feb NEWA FOR SUSPENSION;ORAL CEFDINIR AB ALKEM LABS LTD 125MG/5ML A 210534 001 Feb 19, 2021 Feb NEWA AB 250MG/5ML A 210534 002 Feb 19, 2021 Feb NEWA

CEFEPIME HYDROCHLORIDE INJECTABLE;INJECTION CEFEPIME HYDROCHLORIDE @ ASTRAL EQ 1GM BASE/VIAL A 212721 001 Jul 21, 2020 Mar DISC @ EQ 2GM BASE/VIAL A 212721 002 Jul 21, 2020 Mar DISC

CEFIXIME FOR SUSPENSION;ORAL CEFIXIME AB ALKEM LABS LTD 100MG/5ML A 211775 001 Feb 19, 2021 Feb NEWA AB 200MG/5ML A 211775 002 Feb 19, 2021 Feb NEWA

CEFOTAXIME SODIUM INJECTABLE;INJECTION CLAFORAN + @ VALIDUS PHARMS EQ 500MG BASE/VIAL N 050547 001 Feb CAHN + @ EQ 1GM BASE/VIAL N 050547 002 Feb CAHN + @ EQ 2GM BASE/VIAL N 050547 003 Feb CAHN + @ EQ 10GM BASE/VIAL N 050547 004 Dec 29, 1983 Feb CAHN CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER @ VALIDUS PHARMS EQ 20MG BASE/ML N 050596 002 May 20, 1985 Feb CAHN @ EQ 40MG BASE/ML N 050596 004 May 20, 1985 Feb CAHN CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER @ VALIDUS PHARMS EQ 20MG BASE/ML N 050596 001 May 20, 1985 Feb CAHN @ EQ 40MG BASE/ML N 050596 003 May 20, 1985 Feb CAHN

CEFTAZIDIME SODIUM INJECTABLE;INJECTION FORTAZ IN PLASTIC CONTAINER @ TELIGENT EQ 10MG BASE/ML N 050634 001 Apr 28, 1989 Feb CAHN + @ EQ 20MG BASE/ML N 050634 002 Apr 28, 1989 Feb CAHN + @ EQ 40MG BASE/ML N 050634 003 Apr 28, 1989 Feb CAHN

CEFUROXIME SODIUM INJECTABLE;INJECTION ZINACEF AP +! TELIGENT EQ 1.5GM BASE/VIAL N 050558 003 Oct 19, 1983 Feb CAHN AP +! EQ 7.5GM BASE/VIAL N 050558 004 Oct 23, 1986 Feb CAHN INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ZINACEF AB +! TELIGENT EQ 750MG BASE/VIAL N 050558 002 Oct 19, 1983 Feb CAHN

CELECOXIB CAPSULE;ORAL CELEBREX AB + UPJOHN 50MG N 020998 004 Dec 15, 2006 Apr CAHN AB + 100MG N 020998 001 Dec 31, 1998 Apr CAHN AB + 200MG N 020998 002 Dec 31, 1998 Apr CAHN AB +! 400MG N 020998 003 Aug 29, 2002 Apr CAHN @ ACIC PHARMS 200MG A 212925 001 Dec 09, 2020 Jun DISC @ 400MG A 212925 002 Dec 09, 2020 Jun DISC @ JUBILANT GENERICS 50MG A 207061 001 Apr 04, 2017 Jun DISC @ 100MG A 207061 002 Apr 04, 2017 Jun DISC @ 200MG A 207061 003 Apr 04, 2017 Jun DISC @ 400MG A 207061 004 Apr 04, 2017 Jun DISC AB UNICHEM 50MG A 213301 001 Jan 12, 2021 Jan NEWA AB 100MG A 213301 002 Jan 12, 2021 Jan NEWA AB 200MG A 213301 003 Jan 12, 2021 Jan NEWA AB 400MG A 213301 004 Jan 12, 2021 Jan NEWA AB YILING 50MG A 211412 001 Mar 06, 2020 Jun CMFD AB 100MG A 211412 002 Mar 06, 2020 Jun CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -24

CAPSULE;ORAL CELECOXIB AB 200MG A 211412 003 Mar 06, 2020 Jun CMFD AB 400MG A 211412 004 Mar 06, 2020 Jun CMFD

CENOBAMATE TABLET;ORAL XCOPRI +! SK LIFE 12.5MG N 212839 001 Mar 10, 2020 Jul CHRS + 200MG N 212839 006 Mar 10, 2020 Jul CHRS

CEPHALEXIN CAPSULE;ORAL CEPHALEXIN >D> @ YUNG SHIN PHARM EQ 250MG BASE A 065152 001 Feb 24, 2005 Aug CMFD >A> AB EQ 250MG BASE A 065152 001 Feb 24, 2005 Aug CMFD @ EQ 250MG BASE A 065152 001 Feb 24, 2005 Mar DISC >D> @ EQ 500MG BASE A 065152 002 Feb 24, 2005 Aug CMFD >A> AB EQ 500MG BASE A 065152 002 Feb 24, 2005 Aug CMFD @ EQ 500MG BASE A 065152 002 Feb 24, 2005 Mar DISC KEFLEX + @ PRAGMA EQ 250MG BASE N 050405 002 May DISC + @ EQ 500MG BASE N 050405 003 May DISC

CETIRIZINE HYDROCHLORIDE SYRUP;ORAL HYDROCHLORIDE >A> AA MICRO LABS 5MG/5ML A 090191 001 Nov 12, 2009 Aug CAHN >D> AA MLV 5MG/5ML A 090191 001 Nov 12, 2009 Aug CAHN AA ! PADAGIS US 5MG/5ML A 078398 001 Jun 17, 2008 Jul CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE @ CHARTWELL RX 5MG A 084678 001 Apr CAHN @ 10MG A 084041 001 Apr CAHN @ 25MG A 084679 002 Apr CAHN >D> @ UPSHER SMITH LABS 10MG A 084920 001 Aug CRLD >A> + @ 10MG A 084920 001 Aug CRLD LIBRIUM >D> AB ! VALEANT PHARM INTL 25MG A 085475 001 Aug CRLD >A> AB +! 25MG A 085475 001 Aug CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CAPSULE;ORAL CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE AB ALKEM LABS LTD 5MG;2.5MG A 214065 001 Apr 26, 2021 Apr NEWA AB DR REDDYS 5MG;2.5MG A 214698 001 May 10, 2021 Apr NEWA

CHLORHEXIDINE GLUCONATE SOLUTION;DENTAL CHLORHEXIDINE GLUCONATE AT BAJAJ 0.12% A 075561 001 Nov 14, 2000 Feb CMFD

CHLOROQUINE PHOSPHATE TABLET;ORAL CHLOROQUINE PHOSPHATE >A> AA SUVEN PHARMS 500MG A 214756 001 Sep 03, 2021 Aug NEWA

CHLORPROMAZINE HYDROCHLORIDE CONCENTRATE;ORAL HYDROCHLORIDE GENUS 30MG/ML A 214542 001 Jun 02, 2021 May NEWA 100MG/ML A 214542 002 Jun 02, 2021 May NEWA TABLET;ORAL CHLORPROMAZINE HYDROCHLORIDE AB GLENMARK PHARMS LTD 10MG A 212144 001 Mar 23, 2021 Mar NEWA AB 25MG A 212144 002 Mar 23, 2021 Mar NEWA AB 50MG A 212144 003 Mar 23, 2021 Mar NEWA AB 100MG A 212144 004 Mar 23, 2021 Mar NEWA AB 200MG A 212144 005 Mar 23, 2021 Mar NEWA AB LANNETT CO INC 10MG A 212996 001 Jan 22, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -25

TABLET;ORAL CHLORPROMAZINE HYDROCHLORIDE AB 25MG A 212996 002 Jan 22, 2021 Jan NEWA AB 50MG A 212996 003 Jan 22, 2021 Jan NEWA AB 100MG A 212996 004 Jan 22, 2021 Jan NEWA AB 200MG A 212996 005 Jan 22, 2021 Jan NEWA @ MAYNE PHARMA 10MG A 213590 001 Aug 31, 2020 Mar DISC @ 25MG A 213590 002 Aug 31, 2020 Mar DISC @ 50MG A 213590 003 Aug 31, 2020 Mar DISC @ 100MG A 213590 004 Aug 31, 2020 Mar DISC @ 200MG A 213590 005 Aug 31, 2020 Mar DISC >D> AB UPSHER SMITH LABS 10MG A 083386 001 Aug CRLD >A> AB + 10MG A 083386 001 Aug CRLD >D> AB ! 25MG A 084112 001 Aug CRLD >A> AB +! 25MG A 084112 001 Aug CRLD >D> AB 50MG A 084113 001 Aug CRLD >A> AB + 50MG A 084113 001 Aug CRLD >D> AB ! 100MG A 084114 001 Aug CRLD >A> AB +! 100MG A 084114 001 Aug CRLD >D> AB 200MG A 084115 001 Aug CRLD >A> AB + 200MG A 084115 001 Aug CRLD

CHLORPROPAMIDE TABLET;ORAL @ RISING 100MG A 088725 001 Aug 31, 1984 Jan CAHN @ 250MG A 088726 001 Aug 31, 1984 Jan CAHN

CHLORTHALIDONE TABLET;ORAL CHLORTHALIDONE >D> AB MYLAN 25MG A 086831 002 Aug CRLD >A> AB + 25MG A 086831 002 Aug CRLD >D> AB ! 50MG A 086831 001 Aug CRLD >A> AB +! 50MG A 086831 001 Aug CRLD THALITONE + CASPER PHARMA LLC 15MG N 019574 001 Dec 20, 1988 May CMFD BX +! 25MG N 019574 002 Feb 12, 1992 May CMFD

CHLORZOXAZONE TABLET;ORAL >D> AA HAVIX 250MG A 215158 001 Jul 29, 2021 Aug CAHN AA 250MG A 215158 001 Jul 29, 2021 Jul NEWA AA ! MIKART 250MG A 207483 001 Jun 24, 2016 Jul CTEC AB PAR PHARM INC 375MG A 212743 002 Apr 29, 2021 Apr NEWA >A> AA SENORES PHARMS 250MG A 215158 001 Jul 29, 2021 Aug CAHN

CHOLESTYRAMINE POWDER;ORAL CHOLESTYRAMINE AB TAGI EQ 4GM RESIN/PACKET A 209597 001 Mar 09, 2021 Feb NEWA AB EQ 4GM RESIN/SCOOPFUL A 209597 002 Mar 09, 2021 Feb NEWA LOCHOLEST LIGHT @ CHARTWELL RX EQ 4GM RESIN/PACKET A 074562 001 Aug 15, 1996 Apr CAHN @ EQ 4GM RESIN/SCOOPFUL A 074562 002 Aug 15, 1996 Apr CAHN

CHOLINE FENOFIBRATE CAPSULE, DELAYED RELEASE;ORAL FENOFIBRIC ACID >A> AB ADAPTIS EQ 45MG FENOFIBRIC ACID A 211626 001 Jul 18, 2019 Aug CAHN >A> AB EQ 135MG FENOFIBRIC ACID A 211626 002 Jul 18, 2019 Aug CAHN >D> AB GRAVITI PHARMS EQ 45MG FENOFIBRIC ACID A 211626 001 Jul 18, 2019 Aug CAHN >D> AB EQ 135MG FENOFIBRIC ACID A 211626 002 Jul 18, 2019 Aug CAHN @ YICHANG HUMANWELL EQ 45MG FENOFIBRIC ACID A 212562 001 Dec 23, 2020 Jun DISC @ EQ 135MG FENOFIBRIC ACID A 212562 002 Dec 23, 2020 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -26

CICLESONIDE SPRAY, METERED;NASAL OMNARIS +! COVIS 0.05MG/SPRAY N 022004 001 Oct 20, 2006 May CPOT

CICLOPIROX GEL;TOPICAL AB +! ALVOGEN 0.77% N 020519 001 Jul 21, 1997 Jun CAHN SOLUTION;TOPICAL CICLOPIROX AK ORN@ AKORN@ 8% A 078975 001 Feb 17, 2010 Apr DISC AT RISING 8% A 078124 001 Sep 18, 2007 May CAHN

CILOSTAZOL TABLET;ORAL @ EPIC PHARMA LLC 50MG A 077022 002 Mar 11, 2005 Jan CMS1 @ NOSTRUM LABS INC 50MG A 077708 001 Sep 28, 2009 Mar DISC AB 50MG A 077708 001 Sep 28, 2009 Jan CAHN @ 100MG A 077708 002 Sep 28, 2009 Mar DISC AB 100MG A 077708 002 Sep 28, 2009 Jan CAHN

CIMETIDINE TABLET;ORAL @ NOVITIUM PHARMA 300MG A 074340 001 Jun 23, 1995 Feb CAHN @ 400MG A 074340 002 Jun 23, 1995 Feb CAHN @ 800MG A 074339 001 Jun 23, 1995 Feb CAHN

CINACALCET HYDROCHLORIDE TABLET;ORAL CINACALCET HYDROCHLORIDE >D> AB MYLAN EQ 30MG BASE A 203422 001 Oct 16, 2018 Aug CAHN >A> @ EQ 30MG BASE A 203422 001 Oct 16, 2018 Aug CAHN >D> AB EQ 60MG BASE A 203422 002 Oct 16, 2018 Aug CAHN >A> @ EQ 60MG BASE A 203422 002 Oct 16, 2018 Aug CAHN >D> AB EQ 90MG BASE A 203422 003 Oct 16, 2018 Aug CAHN >A> @ EQ 90MG BASE A 203422 003 Oct 16, 2018 Aug CAHN

CIPROFLOXACIN INJECTABLE, SUSPENSION;OTIC OTIPRIO +! ALK ABELLO 6% (60MG/ML) N 207986 001 Dec 10, 2015 Jun CAHN

CISATRACURIUM BESYLATE INJECTABLE;INJECTION CISATRACURIUM BESYLATE @ SAGENT PHARMS INC EQ 2MG BASE/ML A 201851 001 Nov 06, 2020 Jul DISC @ ZYDUS PHARMS EQ 2MG BASE/ML A 213527 001 Aug 31, 2020 Feb DISC

CITRIC ACID; C-13 FOR SOLUTION, TABLET, FOR SOLUTION;ORAL IDKIT:HP +! EXALENZ BIOSCIENCE 4GM;75MG N 021314 001 Dec 17, 2002 Jul CPOT

CLARITHROMYCIN TABLET;ORAL CLARITHROMYCIN @ WOCKHARDT 250MG A 065266 001 May 31, 2006 Jan DISC @ 500MG A 065266 002 May 31, 2006 Jan DISC

CLASCOTERONE CREAM;TOPICAL WINLEVI + @ CASSIOPEA SPA 1% N 213433 001 Aug 26, 2020 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -27

CLINDAMYCIN HYDROCHLORIDE CAPSULE;ORAL CLEOCIN HYDROCHLORIDE AB + PFIZER EQ 75MG BASE N 050162 001 Feb CAHN AB + EQ 150MG BASE N 050162 002 Feb CAHN AB +! EQ 300MG BASE N 050162 003 Apr 14, 1988 Feb CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR SOLUTION;ORAL CLEOCIN AA ! PFIZER EQ 75MG BASE/5ML A 062644 001 Apr 07, 1986 Feb CAHN

CLINDAMYCIN PHOSPHATE CREAM;VAGINAL CLEOCIN @ PFIZER EQ 2% BASE N 050680 001 Aug 11, 1992 Feb CAHN AB +! EQ 2% BASE N 050680 002 Mar 02, 1998 Feb CAHN GEL;TOPICAL CLEOCIN T >D> AB +! PFIZER EQ 1% BASE N 050615 001 Jan 07, 1987 Aug CTEC >A> AB1 +! EQ 1% BASE N 050615 001 Jan 07, 1987 Aug CTEC AB +! EQ 1% BASE N 050615 001 Jan 07, 1987 Feb CAHN CLINDAMYCIN PHOSPHATE >D> AB ENCUBE EQ 1% BASE A 212438 001 Mar 11, 2021 Aug CTEC >A> AB1 EQ 1% BASE A 212438 001 Mar 11, 2021 Aug CTEC AB EQ 1% BASE A 212438 001 Mar 11, 2021 Mar NEWA >D> AB FOUGERA PHARMS EQ 1% BASE A 064160 001 Jan 28, 2000 Aug CTEC >A> AB1 EQ 1% BASE A 064160 001 Jan 28, 2000 Aug CTEC >D> AB GLENMARK PHARMS LTD EQ 1% BASE A 214251 001 Feb 10, 2021 Aug CTEC >A> AB1 EQ 1% BASE A 214251 001 Feb 10, 2021 Aug CTEC AB EQ 1% BASE A 214251 001 Feb 10, 2021 Jan NEWA >D> AB PADAGIS ISRAEL EQ 1% BASE A 212104 001 Dec 31, 2020 Aug CTEC >A> AB1 EQ 1% BASE A 212104 001 Dec 31, 2020 Aug CTEC AB PERRIGO UK FINCO EQ 1% BASE A 212104 001 Dec 31, 2020 Jan CAHN >D> AB SOLARIS PHARMA CORP EQ 1% BASE A 211872 001 Jul 29, 2020 Aug CTEC >A> AB1 EQ 1% BASE A 211872 001 Jul 29, 2020 Aug CTEC >A> AB2 EQ 1% BASE A 212842 001 Aug 13, 2021 Aug NFTG >D> AB TARO PHARMS EQ 1% BASE A 214052 001 Nov 10, 2020 Aug CTEC >A> AB1 EQ 1% BASE A 214052 001 Nov 10, 2020 Aug CTEC INJECTABLE;INJECTION CLEOCIN PHOSPHATE AP PFIZER EQ 150MG BASE/ML A 062803 001 Oct 16, 1987 Feb CAHN AP +! EQ 150MG BASE/ML N 050441 001 Feb CAHN CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER + PFIZER@ EQ 6MG BASE/ML N 050639 001 Aug 30, 1989 Feb CAHN + @ EQ 12MG BASE/ML N 050639 002 Aug 30, 1989 Feb CAHN + @ EQ 18MG BASE/ML N 050639 003 Apr 10, 1991 Feb CAHN CLINDAMYCIN PHOSPHATE AP ALMAJECT EQ 150MG BASE/ML A 062800 001 Jul 24, 1987 Jul CAHN @ EQ 150MG BASE/ML A 062801 001 Jul 24, 1987 Jul CAHN AP EQ 150MG BASE/ML A 062943 001 Sep 29, 1988 Jul CAHN @ MYLAN LABS LTD EQ 150MG BASE/ML A 204748 001 Oct 10, 2017 Jan DISC LOTION;TOPICAL CLEOCIN T AB +! PFIZER EQ 1% BASE N 050600 001 May 31, 1989 Feb CAHN CLINDAMYCIN PHOSPHATE AB TARO PHARMS EQ 1% BASE A 214526 001 Jun 28, 2021 Jun NEWA SOLUTION;TOPICAL CLEOCIN T + @ PFIZER EQ 1% BASE N 050537 001 Feb CAHN + @ PHARMACIA AND UPJOHN EQ 1% BASE N 050537 001 Jan DISC SUPPOSITORY;VAGINAL CLEOCIN +! PFIZER 100MG N 050767 001 Aug 13, 1999 Feb CAHN SWAB;TOPICAL CLEOCIN + PFIZER@ EQ 1% BASE N 050537 002 Feb 22, 1994 Mar DISC AT +! EQ 1% BASE N 050537 002 Feb 22, 1994 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -28

CLINDAMYCIN PHOSPHATE; TRETINOIN GEL;TOPICAL ZIANA AB +! BAUSCH 1.2%;0.025% N 050802 001 Nov 07, 2006 May CAHN

CLOBAZAM SUSPENSION;ORAL CLOBAZAM AB ALKEM LABS LTD 2.5MG/ML A 213039 001 May 06, 2021 Apr NEWA AB TARO 2.5MG/ML A 210978 001 Apr 15, 2019 Jul CMFD TABLET;ORAL CLOBAZAM @ CELLTRION 10MG A 211959 001 Dec 09, 2020 Jun DISC @ 20MG A 211959 002 Dec 09, 2020 Jun DISC @ LANNETT CO INC 10MG A 212092 001 Oct 30, 2019 Mar DISC @ 20MG A 212092 002 Oct 30, 2019 Mar DISC AB MSN 10MG A 213404 001 May 11, 2021 Apr NEWA AB 20MG A 213404 002 May 11, 2021 Apr NEWA

CLOBETASOL PROPIONATE CREAM;TOPICAL CLOBETASOL PROPIONATE AB1 GLASSHOUSE PHARMS 0.05% A 211207 001 Mar 26, 2021 Mar NEWA IMPOYZ +! PRIMUS PHARMS 0.025% N 209483 001 Nov 28, 2017 Mar CAHN OINTMENT;TOPICAL CLOBETASOL PROPIONATE @ TORRENT 0.05% A 212926 001 Oct 25, 2019 Jan DISC SHAMPOO;TOPICAL CLOBETASOL PROPIONATE AB AMNEAL 0.05% A 214895 001 Jun 14, 2021 Jun NEWA AB TARO PHARMS 0.05% A 214867 001 Mar 25, 2021 Mar NEWA SOLUTION;TOPICAL CLOBETASOL PROPIONATE AT PRINSTON INC 0.05% A 213139 001 Feb 08, 2021 Jan NEWA SPRAY;TOPICAL CLOBETASOL PROPIONATE AK ORN@ AKORN@ 0.05% A 207218 001 Apr 28, 2017 Apr DISC

CLOFARABINE SOLUTION;INTRAVENOUS AP MEITHEAL 20MG/20ML (1MG/ML) A 213461 001 Oct 23, 2020 Jan CAHN @ NOVAST LABS 20MG/20ML (1MG/ML) A 210270 001 Sep 14, 2018 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB ALEMBIC PHARMS LTD 25MG A 211822 001 Aug 04, 2021 Jul NEWA AB 50MG A 211822 002 Aug 04, 2021 Jul NEWA AB 75MG A 211822 003 Aug 04, 2021 Jul NEWA AB VGYAAN 25MG A 213221 001 Jun 22, 2020 May CMFD AB 50MG A 213221 002 Jun 22, 2020 May CMFD AB 75MG A 213221 003 Jun 22, 2020 May CMFD

CLONIDINE SYSTEM;TRANSDERMAL CATAPRES-TTS-1 AB + LAVIPHARM 0.1MG/24HR N 018891 001 Oct 10, 1984 Jan CAHN AB + TECHNOMED 0.1MG/24HR N 018891 001 Oct 10, 1984 Jan CAHN CATAPRES-TTS-2 AB + LAVIPHARM 0.2MG/24HR N 018891 002 Oct 10, 1984 Jan CAHN AB + TECHNOMED 0.2MG/24HR N 018891 002 Oct 10, 1984 Jan CAHN CATAPRES-TTS-3 AB +! LAVIPHARM 0.3MG/24HR N 018891 003 Oct 10, 1984 Jan CAHN AB +! TECHNOMED 0.3MG/24HR N 018891 003 Oct 10, 1984 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -29

CLONIDINE HYDROCHLORIDE INJECTABLE;INJECTION CLONIDINE HYDROCHLORIDE AP ! HIKMA FARMACEUTICA 5MG/10ML (0.5MG/ML) A 200300 002 Jan 26, 2011 Mar CHRS DURACLON + @ MYLAN INSTITUTIONAL 5MG/10ML (0.5MG/ML) N 020615 002 Apr 27, 1999 Mar DISC

CLOPIDOGREL BISULFATE TABLET;ORAL BISULFATE AB POLYGEN PHARMS EQ 75MG BASE A 213351 001 Jul 17, 2020 Feb CMFD AB EQ 300MG BASE A 213351 002 Jul 17, 2020 Feb CMFD

CLORAZEPATE DIPOTASSIUM CAPSULE;ORAL TRANXENE + @ RECORDATI RARE 3.75MG N 017105 001 May CRLD + @ 7.5MG N 017105 002 May CRLD + @ 15MG N 017105 003 May CRLD TABLET;ORAL DIPOTASSIUM AB AUROLIFE PHARMA LLC 3.75MG A 071858 002 Jul 17, 1987 Jan CAHN AB 7.5MG A 071858 003 Jul 17, 1987 Jan CAHN AB ! 15MG A 071858 001 Jul 17, 1987 Jan CAHN TRANXENE + @ RECORDATI RARE 3.75MG N 017105 006 May CRLD TRANXENE SD + @ RECORDATI RARE 11.25MG N 017105 005 May CRLD + @ 22.5MG N 017105 004 May CRLD

CODEINE PHOSPHATE; HYDROCHLORIDE; HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE AA AKORN 10MG/5ML;5MG/5ML;6.25MG/5ML A 040674 001 Dec 23, 2014 Feb CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE >D> AA ! ACTAVIS MID ATLANTIC 10MG/5ML;6.25MG/5ML A 088763 001 Oct 31, 1984 Aug CRLD >A> AA +! 10MG/5ML;6.25MG/5ML A 088763 001 Oct 31, 1984 Aug CRLD

COLCHICINE TABLET;ORAL >A> AB HETERO LABS LTD V 0.6MG A 208993 001 Aug 13, 2021 Aug NEWA >A> AB PAR PHARM INC 0.6MG A 203976 001 Aug 12, 2021 Aug NEWA

COLCHICINE; PROBENECID TABLET;ORAL COL-PROBENECID >D> AB ! WATSON LABS 0.5MG;500MG A 084279 001 Aug CRLD >A> AB +! 0.5MG;500MG A 084279 001 Aug CRLD

COLESEVELAM HYDROCHLORIDE FOR SUSPENSION;ORAL COLESEVELAM HYDROCHLORIDE GLENMARK PHARMS LTD 1.875GM/PACKET A 202190 001 Jul 16, 2018 Feb CTEC @ WATSON LABS INC 1.875GM/PACKET A 202178 001 Sep 01, 2020 Feb DISC @ 3.75GM/PACKET A 202178 002 Sep 01, 2020 Feb DISC TABLET;ORAL COLESEVELAM HYDROCHLORIDE @ WATSON LABS INC 625MG A 200830 001 Sep 02, 2020 Feb DISC

COLESTIPOL HYDROCHLORIDE GRANULE;ORAL COLESTID AB + PFIZER 5GM/SCOOPFUL N 017563 003 Sep 22, 1995 Feb CAHN AB +! 5GM/PACKET N 017563 004 Sep 22, 1995 Feb CAHN FLAVORED COLESTID + PFIZER 5GM/PACKET N 017563 001 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -30

GRANULE;ORAL FLAVORED COLESTID + 5GM/SCOOPFUL N 017563 002 Feb CAHN TABLET;ORAL COLESTID AB +! PFIZER 1GM N 020222 001 Jul 19, 1994 Feb CAHN

CROTAMITON CREAM;TOPICAL EURAX + @ JOURNEY 10% N 006927 001 Jan CAHN LOTION;TOPICAL EURAX AT +! JOURNEY 10% N 009112 003 Jan CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE SOLUTION;INTRAVENOUS >A> MULTRYS >A> +! AM REGENT (1ML) EQ 0.3MG /ML;EQ 55MCG N 209376 001 Jul 02, 2020 Aug CTNA BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML >A> +! (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG N 209376 002 Dec 02, 2020 Aug CTNA BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML >A> +! (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG N 209376 003 Jun 30, 2021 Aug CTNA BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML >D> TRALEMENT >D> +! AM REGENT (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG N 209376 001 Jul 02, 2020 Aug CTNA BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML +! (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG N 209376 001 Jul 02, 2020 Jan CPOT BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML >D> +! (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG N 209376 002 Dec 02, 2020 Aug CTNA BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML +! (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG N 209376 002 Dec 02, 2020 Jan NEWA BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML >D> +! (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG N 209376 003 Jun 30, 2021 Aug CTNA BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML +! (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG N 209376 003 Jun 30, 2021 Jul NEWA BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML

CYANOCOBALAMIN INJECTABLE;INJECTION CYANOCOBALAMIN >A> AP XIROMED 1MG/ML A 215046 001 Aug 20, 2021 Aug NEWA VIBISONE >D> AP ! FRESENIUS KABI USA 1MG/ML A 080557 003 Aug CRLD >A> AP +! 1MG/ML A 080557 003 Aug CRLD

CYCLOBENZAPRINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE >D> AB MYLAN PHARMS INC 5MG A 073144 002 Feb 03, 2006 Aug DISC >A> @ 5MG A 073144 002 Feb 03, 2006 Aug DISC >D> AB 7.5MG A 073144 003 Mar 25, 2013 Aug DISC >A> @ 7.5MG A 073144 003 Mar 25, 2013 Aug DISC >D> AB 10MG A 073144 001 May 30, 1991 Aug DISC >A> @ 10MG A 073144 001 May 30, 1991 Aug DISC

CYCLOPENTOLATE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC AKPENTOLATE >D> @ AKORN 2% A 040165 001 Jan 13, 1997 Aug CMFD >A> AT 2% A 040165 001 Jan 13, 1997 Aug CMFD CYCLOGYL >D> AT ! ALCON LABS INC 0.5% A 084109 001 Aug CRLD >A> AT +! 0.5% A 084109 001 Aug CRLD >D> AT ! 1% A 084110 001 Aug CRLD >A> AT +! 1% A 084110 001 Aug CRLD

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -31

SOLUTION/DROPS;OPHTHALMIC CYCLOGYL >D> ! 2% A 084108 001 Aug CRLD >A> AT +! 2% A 084108 001 Aug CRLD

CYCLOPHOSPHAMIDE SOLUTION;INTRAVENOUS >A> +! AUROMEDICS PHARMA 500MG/2.5ML (200MG/ML) N 210735 001 Aug 25, 2021 Aug NEWA >A> +! 1GM/5ML (200MG/ML) N 210735 002 Aug 25, 2021 Aug NEWA

CYCLOSPORINE EMULSION;OPHTHALMIC VERKAZIA +! SANTEN 0.1% N 214965 001 Jun 23, 2021 Jun NEWA

CYPROHEPTADINE HYDROCHLORIDE SYRUP;ORAL HYDROCHLORIDE >D> @ ACTAVIS MID ATLANTIC 2MG/5ML A 086833 001 Aug CRLD >A> + @ 2MG/5ML A 086833 001 Aug CRLD TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE >D> AA ! HERITAGE PHARMA 4MG A 087056 001 Aug CRLD >A> AA +! 4MG A 087056 001 Aug CRLD AA QUAGEN 4MG A 212491 001 Feb 24, 2021 Feb NEWA

CYSTEAMINE BITARTRATE CAPSULE, DELAYED RELEASE;ORAL PROCYSBI + HORIZON EQ 25MG BASE N 203389 001 Apr 30, 2013 May CAHN +! EQ 75MG BASE N 203389 002 Apr 30, 2013 May CAHN

CYTARABINE INJECTABLE;INJECTION >D> AP MEITHEAL 20MG/ML A 206190 001 Nov 09, 2017 Aug DISC >A> @ 20MG/ML A 206190 001 Nov 09, 2017 Aug DISC @ MYLAN LABS LTD 20MG/ML A 200914 001 Dec 13, 2011 May DISC

DABIGATRAN ETEXILATE MESYLATE PELLET;ORAL PRADAXA + BOEHRINGER INGELHEIM EQ 20MG BASE/PACKET N 214358 001 Jun 21, 2021 Jun NEWA + EQ 30MG BASE/PACKET N 214358 002 Jun 21, 2021 Jun NEWA + EQ 40MG BASE/PACKET N 214358 003 Jun 21, 2021 Jun NEWA + EQ 50MG BASE/PACKET N 214358 004 Jun 21, 2021 Jun NEWA + EQ 110MG BASE/PACKET N 214358 005 Jun 21, 2021 Jun NEWA +! EQ 150MG BASE/PACKET N 214358 006 Jun 21, 2021 Jun NEWA PELLETS;ORAL PRADAXA + BOEHRINGER INGELHEIM EQ 20MG BASE/PACKET N 214358 001 Jun 21, 2021 Jul CDFR + EQ 30MG BASE/PACKET N 214358 002 Jun 21, 2021 Jul CDFR + EQ 40MG BASE/PACKET N 214358 003 Jun 21, 2021 Jul CDFR + EQ 50MG BASE/PACKET N 214358 004 Jun 21, 2021 Jul CDFR + EQ 110MG BASE/PACKET N 214358 005 Jun 21, 2021 Jul CDFR +! EQ 150MG BASE/PACKET N 214358 006 Jun 21, 2021 Jul CDFR

DACTINOMYCIN INJECTABLE;INJECTION >D> AP AUROMEDICS PHARMA 0.5MG/VIAL A 203385 001 Nov 09, 2017 Aug CAHN AP 0.5MG/VIAL A 203385 001 Nov 09, 2017 Jan CAHN >A> AP EUGIA PHARMA 0.5MG/VIAL A 203385 001 Nov 09, 2017 Aug CAHN @ HIKMA PHARMS 0.5MG/VIAL A 090304 001 Mar 16, 2010 Jul CAHN AP MEITHEAL 0.5MG/VIAL A 213463 001 Nov 13, 2020 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -32

DAPSONE TABLET;ORAL AB ALVOGEN 25MG A 205429 001 Jan 07, 2016 Jun CAHN AB 100MG A 205429 002 Jan 07, 2016 Jun CAHN >D> AB JACOBUS 25MG A 086841 001 Aug CRLD >A> AB + 25MG A 086841 001 Aug CRLD >D> AB ! 100MG A 086842 001 Aug CRLD >A> AB +! 100MG A 086842 001 Aug CRLD

DAPTOMYCIN POWDER;INTRAVENOUS DAPTOMYCIN >A> AP AUROBINDO PHARMA LTD 500MG/VIAL A 213171 001 Sep 02, 2021 Aug NEWA AP HISUN PHARM HANGZHOU 500MG/VIAL A 212250 001 Apr 21, 2021 Apr NEWA >D> AP HONG KONG 500MG/VIAL A 213623 001 Jun 29, 2021 Aug CAHN AP 500MG/VIAL A 213623 001 Jun 29, 2021 Jun NEWA +! HOSPIRA INC 350MG/VIAL N 210282 001 Jun 21, 2021 Jun NEWA +! 500MG/VIAL N 210282 002 Jun 21, 2021 Jun NEWA >A> AP MEITHEAL 500MG/VIAL A 213623 001 Jun 29, 2021 Aug CAHN >A> AP QILU 500MG/VIAL A 215316 001 Aug 24, 2021 Aug NEWA POWDER;IV (INFUSION) DAPTOMYCIN @ DR REDDYS 350MG/VIAL A 211403 001 Aug 31, 2020 May DISC >D> AP HONG KONG 350MG/VIAL A 213786 001 Jun 29, 2021 Aug CAHN AP 350MG/VIAL A 213786 001 Jun 29, 2021 Jun NEWA >A> AP MEITHEAL 350MG/VIAL A 213786 001 Jun 29, 2021 Aug CAHN

DARIFENACIN HYDROBROMIDE TABLET, EXTENDED RELEASE;ORAL HYDROBROMIDE @ JUBILANT GENERICS EQ 7.5MG BASE A 205550 001 Oct 12, 2016 Jun DISC @ EQ 15MG BASE A 205550 002 Oct 12, 2016 Jun DISC

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR TABLET;ORAL VIEKIRA PAK (COPACKAGED) >A> +! ABBVIE INC EQ 250MG BASE;12.5MG, 75MG, 50MG N 206619 001 Dec 19, 2014 Aug CPOT

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR TABLET, TABLET;ORAL VIEKIRA PAK (COPACKAGED) >D> +! ABBVIE INC 250.0MG;12.5MG;75.0MG;EQ 250MG N 206619 001 Dec 19, 2014 Aug CPOT BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG

DASIGLUCAGON HYDROCHLORIDE SOLUTION;SUBCUTANEOUS ZEGALOGUE +! ZEALAND PHARMA EQ 0.6MG BASE/0.6ML (EQ 0.6MG N 214231 001 Mar 22, 2021 May CAHN BASE/0.6ML) +! EQ 0.6MG BASE/0.6ML (EQ 0.6MG N 214231 001 Mar 22, 2021 Mar NEWA BASE/0.6ML) ZEGALOGUE (AUTOINJECTOR) +! ZEALAND PHARMA EQ 0.6MG BASE/0.6ML (EQ 0.6MG N 214231 002 Mar 22, 2021 May CAHN BASE/0.6ML) +! EQ 0.6MG BASE/0.6ML (EQ 0.6MG N 214231 002 Mar 22, 2021 Mar NEWA BASE/0.6ML)

DAUNORUBICIN HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE AP +! HIKMA PHARMS EQ 5MG BASE/ML N 050731 001 Jan 30, 1998 Jul CAHN

DECITABINE INJECTABLE;INTRAVENOUS @ APOTEX 50MG/VIAL A 205539 001 Nov 23, 2020 May DISC @ CIPLA 50MG/VIAL A 208601 001 Nov 16, 2017 May DISC AP GLAND 50MG/VIAL A 205539 001 Nov 23, 2020 Jul CMFD @ 50MG/VIAL A 205539 001 Nov 23, 2020 Jul CAHN AP HONG KONG 50MG/VIAL A 212959 001 Jul 02, 2021 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -33

INJECTABLE;INTRAVENOUS DECITABINE AP QILU 50MG/VIAL A 212826 001 Apr 12, 2021 Apr NEWA

DEFERASIROX GRANULE;ORAL DEFERASIROX AB AMNEAL 90MG A 214194 003 Aug 02, 2021 Jul NEWA AB 180MG A 214194 001 Feb 09, 2021 Jan NEWA AB 360MG A 214194 002 Feb 09, 2021 Jan NEWA AB AUCTA 90MG A 214559 001 Mar 09, 2021 Feb NEWA AB 180MG A 214559 002 Mar 09, 2021 Feb NEWA AB 360MG A 214559 003 Mar 09, 2021 Feb NEWA AB MSN 180MG A 214650 001 Mar 17, 2021 Mar NEWA AB 360MG A 214650 002 Mar 17, 2021 Mar NEWA TABLET;ORAL DEFERASIROX AB ANNORA PHARMA 90MG A 214341 001 May 14, 2021 May NEWA AB 180MG A 214341 002 May 14, 2021 May NEWA AB 360MG A 214341 003 May 14, 2021 May NEWA AB CELLTRION 90MG A 212669 001 May 27, 2021 May NEWA AB 180MG A 212669 002 May 27, 2021 May NEWA AB 360MG A 212669 003 May 27, 2021 May NEWA

DEFERIPRONE SOLUTION;ORAL FERRIPROX >D> + CHIESI 80MG/ML N 208030 002 Apr 20, 2018 Aug DISC >A> + @ 80MG/ML N 208030 002 Apr 20, 2018 Aug DISC TABLET;ORAL DEFERIPRONE AB HIKMA PHARMS 500MG A 213239 001 Mar 29, 2021 Mar NEWA FERRIPROX AB +! CHIESI 500MG N 021825 001 Oct 14, 2011 Mar CTEC

DEOXYCHOLIC ACID SOLUTION;SUBCUTANEOUS DEOXYCHOLIC ACID AP SLAYBACK PHARMA LLC 20MG/2ML (10MG/ML) A 212296 001 Apr 02, 2021 Mar NFTG

DESIPRAMINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ALEMBIC PHARMS LTD 10MG A 209785 001 Jul 07, 2021 Jun NEWA AB 25MG A 209785 002 Jul 07, 2021 Jun NEWA AB 50MG A 209785 003 Jul 07, 2021 Jun NEWA AB 75MG A 209785 004 Jul 07, 2021 Jun NEWA AB 100MG A 209785 005 Jul 07, 2021 Jun NEWA AB 150MG A 209785 006 Jul 07, 2021 Jun NEWA NORPRAMIN AB + VALIDUS PHARMS 10MG N 014399 007 Feb 11, 1982 Feb CAHN AB + 25MG N 014399 001 Feb CAHN AB + 50MG N 014399 003 Feb CAHN AB + 75MG N 014399 004 Feb CAHN AB +! 100MG N 014399 005 Feb CAHN AB + 150MG N 014399 006 Feb CAHN

DESLORATADINE TABLET;ORAL CLARINEX >D> AB +! MERCK SHARP DOHME 5MG N 021165 001 Dec 21, 2001 Aug CAHN >A> AB +! ORGANON 5MG N 021165 001 Dec 21, 2001 Aug CAHN >D> AB SUN PHARM INDS 5MG A 078359 001 Nov 16, 2010 Aug DISC >A> @ 5MG A 078359 001 Nov 16, 2010 Aug DISC

DESLORATADINE; SULFATE TABLET, EXTENDED RELEASE;ORAL CLARINEX-D 12 HOUR +! ORGANON 2.5MG;120MG N 021313 001 Feb 01, 2006 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -34

DESMOPRESSIN ACETATE SPRAY, METERED;NASAL NOCTIVA + @ ROIVANT 0.00083MG/SPRAY N 201656 001 Mar 03, 2017 Feb CAHN + @ 0.00166MG/SPRAY N 201656 002 Mar 03, 2017 Feb CAHN

DESONIDE GEL;TOPICAL DESONATE + @ LEO PHARMA AS 0.05% N 021844 001 Oct 20, 2006 Mar DISC DESONIDE ! CINTEX SVCS 0.05% A 202470 001 May 11, 2020 Mar CHRS 0.05% A 202470 001 May 11, 2020 Mar CTEC

DESOXIMETASONE CREAM;TOPICAL DESOXIMETASONE AK ORN@ AKORN@ 0.05% A 203787 001 Jan 06, 2017 Apr DISC @ 0.25% A 203234 001 Jun 12, 2015 Apr DISC OINTMENT;TOPICAL DESOXIMETASONE AB ! GLENMARK GENERICS 0.25% A 202838 001 Sep 20, 2013 Apr CHRS TOPICORT @ TARO PHARM INDS LTD 0.25% A 074286 001 Jun 07, 1996 Apr DISC

DEXAMETHASONE ELIXIR;ORAL >D> AA WOCKHARDT BIO AG 0.5MG/5ML A 088254 001 Jul 27, 1983 Aug CRLD >A> AA + 0.5MG/5ML A 088254 001 Jul 27, 1983 Aug CRLD TABLET;ORAL DEXAMETHASONE BP ALVOGEN 0.5MG A 088481 002 Apr 28, 1983 Jun CAHN BP 0.75MG A 088481 003 Apr 28, 1983 Jun CAHN BP 4MG A 088481 004 Apr 28, 1983 Jun CAHN BP 6MG A 088481 001 Nov 28, 1983 Jun CAHN BP ! HIKMA PHARMS 1MG A 088306 001 Sep 15, 1983 Apr CHRS BP ! 2MG A 087916 001 Aug 26, 1982 Apr CHRS

DEXAMETHASONE SODIUM PHOSPHATE INJECTABLE;INJECTION DEXAMETHASONE SODIUM PHOSPHATE AP GLAND PHARMA LTD EQ 4MG PHOSPHATE/ML A 215654 001 Aug 04, 2021 Jul NEWA >D> @ LUITPOLD EQ 4MG PHOSPHATE/ML A 087440 001 Jul 21, 1982 Aug CRLD >A> + @ EQ 4MG PHOSPHATE/ML A 087440 001 Jul 21, 1982 Aug CRLD

DEXAMETHASONE; TOBRAMYCIN SUSPENSION/DROPS;OPHTHALMIC TOBRAMYCIN AND DEXAMETHASONE AB AMNEAL 0.1%;0.3% A 212991 001 Jul 15, 2021 Jul NEWA

DEXCHLORPHENIRAMINE MALEATE SYRUP;ORAL MALEATE >D> AA ! WOCKHARDT BIO AG 2MG/5ML A 088251 001 Mar 23, 1984 Aug CRLD >A> AA +! 2MG/5ML A 088251 001 Mar 23, 1984 Aug CRLD TABLET;ORAL POLARAMINE >D> @ SCHERING 2MG A 086835 001 Aug CRLD >A> + @ 2MG A 086835 001 Aug CRLD

DEXMEDETOMIDINE HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE AP GLAND EQ 200MCG BASE/2ML (EQ 100MCG A 202126 001 Aug 20, 2015 May CAHN BASE/ML) AP HIKMA PHARMS EQ 200MCG BASE/2ML (EQ 100MCG A 205046 001 Apr 26, 2017 Jul CAHN BASE/ML) AP HONG KONG EQ 200MCG BASE/2ML (EQ 100MCG A 204843 001 Jan 18, 2019 Jun CMFD BASE/ML) >A> AP PIRAMAL CRITICAL EQ 200MCG BASE/2ML (EQ 100MCG A 214794 001 Sep 03, 2021 Aug NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -35

INJECTABLE;INJECTION DEXMEDETOMIDINE HYDROCHLORIDE BASE/ML)

DEXMETHYLPHENIDATE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL HYDROCHLORIDE @ MYLAN 5MG A 204266 001 Aug 25, 2015 Jul DISC @ 10MG A 204266 002 Aug 25, 2015 Jul DISC @ 15MG A 204266 003 Aug 25, 2015 Jul DISC @ 20MG A 204266 004 Dec 21, 2015 Jul DISC @ 25MG A 204266 005 May 04, 2021 Jul DISC AB 25MG A 204266 005 May 04, 2021 Apr NEWA @ 30MG A 202580 001 Aug 28, 2013 Jul CAHN @ 30MG A 202580 001 Aug 28, 2013 Jul DISC @ 35MG A 204266 006 May 04, 2021 Jul DISC AB 35MG A 204266 006 May 04, 2021 Apr NEWA @ 40MG A 204266 007 Aug 25, 2015 Jul DISC

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE CAPSULE;ORAL AZSTARYS + COMMAVE THERAP EQ 5.2MG BASE;EQ 26.1MG BASE N 212994 001 May 07, 2021 May NEWA + EQ 7.8MG BASE;EQ 39.2MG BASE N 212994 002 May 07, 2021 May NEWA +! EQ 10.4MG BASE;EQ 52.3MG BASE N 212994 003 May 07, 2021 May NEWA

DEXRAZOXANE HYDROCHLORIDE INJECTABLE;INJECTION DEXRAZOXANE HYDROCHLORIDE >D> AP AUROMEDICS PHARMA EQ 250MG BASE/VIAL A 200752 001 Oct 19, 2011 Aug CHRS AP EQ 250MG BASE/VIAL A 200752 001 Oct 19, 2011 Jan CAHN >D> AP EQ 500MG BASE/VIAL A 200752 002 Oct 19, 2011 Aug CHRS AP EQ 500MG BASE/VIAL A 200752 002 Oct 19, 2011 Jan CAHN >A> AP ! EUGIA PHARMA EQ 250MG BASE/VIAL A 200752 001 Oct 19, 2011 Aug CHRS >A> AP ! EQ 500MG BASE/VIAL A 200752 002 Oct 19, 2011 Aug CHRS TOTECT >D> +! CLINIGEN EQ 500MG BASE/VIAL N 022025 001 Sep 06, 2007 Aug DISC >A> + @ EQ 500MG BASE/VIAL N 022025 001 Sep 06, 2007 Aug DISC ZINECARD >D> AP +! PFIZER EQ 250MG BASE/VIAL N 020212 001 May 26, 1995 Aug DISC >A> + @ EQ 250MG BASE/VIAL N 020212 001 May 26, 1995 Aug DISC AP +! EQ 250MG BASE/VIAL N 020212 001 May 26, 1995 Mar CAHN >D> AP +! EQ 500MG BASE/VIAL N 020212 002 May 26, 1995 Aug DISC >A> + @ EQ 500MG BASE/VIAL N 020212 002 May 26, 1995 Aug DISC AP +! EQ 500MG BASE/VIAL N 020212 002 May 26, 1995 Mar CAHN

DEXTROAMPHETAMINE SULFATE TABLET;ORAL DEXEDRINE >D> @ GLAXOSMITHKLINE 5MG A 084935 001 Aug CRLD >A> + @ 5MG A 084935 001 Aug CRLD DEXTROAMPHETAMINE SULFATE AA ARBOR PHARMS LLC 2.5MG A 090533 001 Oct 25, 2011 May CTEC AA 7.5MG A 090533 003 Oct 25, 2011 May CTEC AA 15MG A 090533 005 Oct 25, 2011 May CTEC AA 20MG A 090533 006 Oct 25, 2011 May CTEC AA 30MG A 090533 007 Oct 25, 2011 May CTEC AA WINDER LABS LLC 2.5MG A 212160 001 Jun 07, 2021 May NEWA AA 5MG A 212160 002 Jun 07, 2021 May NEWA AA 7.5MG A 212160 003 Jun 07, 2021 May NEWA AA 10MG A 212160 004 Jun 07, 2021 May NEWA AA 15MG A 212160 005 Jun 07, 2021 May NEWA AA 20MG A 212160 006 Jun 07, 2021 May NEWA AA 30MG A 212160 007 Jun 07, 2021 May NEWA DEXTROSTAT >D> @ SHIRE 5MG A 084051 001 Aug CRLD >A> + @ 5MG A 084051 001 Aug CRLD >D> @ 10MG A 084051 002 Aug CRLD >A> + @ 10MG A 084051 002 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -36

DEXTROSE; POTASSIUM CHLORIDE INJECTABLE;INJECTION DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% @ FRESENIUS KABI USA 5GM/100ML;75MG/100ML A 212346 001 Sep 10, 2020 Mar DISC DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% @ FRESENIUS KABI USA 5GM/100ML;150MG/100ML A 212346 002 Sep 10, 2020 Mar DISC DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER + BAXTER HLTHCARE 5GM/100ML;224MG/100ML N 017634 003 Mar CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE INJECTABLE;INJECTION POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML A 212348 001 Jul 30, 2021 Jul NFTG POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% AP FRESENIUS KABI USA 5GM/100ML;74.5MG/100ML;450MG/100ML A 213523 001 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML A 212348 002 Jul 30, 2021 Jul NFTG POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% AP FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML A 213523 002 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% AP FRESENIUS KABI USA 5GM/100ML;149MG/100ML;900MG/100ML A 213445 001 Mar 09, 2021 Feb NFTG POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% AP FRESENIUS KABI USA 5GM/100ML;224MG/100ML;450MG/100ML A 213523 003 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% AP FRESENIUS KABI USA 5GM/100ML;298MG/100ML;450MG/100ML A 213523 004 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% AP FRESENIUS KABI USA 5GM/100ML;298MG/100ML;900MG/100ML A 213445 002 Mar 09, 2021 Feb NFTG

DEXTROSE; SODIUM CHLORIDE INJECTABLE;INJECTION DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 2.5GM/100ML;450MG/100ML A 211190 001 Dec 20, 2019 May CMFD DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 5GM/100ML;300MG/100ML A 211194 001 Aug 26, 2020 May CMFD @ 5GM/100ML;300MG/100ML A 211194 001 Aug 26, 2020 Feb DISC AP +! ICU MEDICAL INC 5GM/100ML;300MG/100ML N 017799 001 May CTEC +! 5GM/100ML;300MG/100ML N 017799 001 Feb CTEC DEXTROSE 5% AND SODIUM CHLORIDE 0.45% AP FRESENIUS KABI USA 5GM/100ML;450MG/100ML A 211276 001 Sep 15, 2020 May CMFD @ 5GM/100ML;450MG/100ML A 211276 001 Sep 15, 2020 Mar DISC DEXTROSE 5% AND SODIUM CHLORIDE 0.9% AP FRESENIUS KABI USA 5GM/100ML;900MG/100ML A 211211 001 Sep 14, 2020 May CMFD @ 5GM/100ML;900MG/100ML A 211211 001 Sep 14, 2020 Mar DISC

DIAZEPAM INJECTABLE;INJECTION >D> ! BELOTECA INC 10MG/2ML (5MG/ML) A 210363 001 Mar 18, 2019 Aug CTEC >A> AP ! 10MG/2ML (5MG/ML) A 210363 001 Mar 18, 2019 Aug CTEC >A> AP HIKMA 10MG/2ML (5MG/ML) A 070313 001 Dec 16, 1985 Aug CAHN >D> @ WEST-WARD PHARMS INT 5MG/ML A 070313 001 Dec 16, 1985 Aug CAHN

DICLOFENAC POTASSIUM TABLET;ORAL CATAFLAM AMICI 25MG A 076561 002 Jul 21, 2021 Jul NEWA AB 50MG A 076561 001 Mar 18, 2004 May CTNA

DICLOFENAC SODIUM GEL;TOPICAL DICLOFENAC SODIUM AB ! TARO 3% A 206298 001 Apr 28, 2016 Mar CHRS SOLARAZE + @ FOUGERA PHARMS 3% N 021005 001 Oct 16, 2000 Mar DISC SOLUTION;TOPICAL DICLOFENAC SODIUM AT AKORN 1.5% A 206655 001 Jan 28, 2021 Jan NEWA @ RISING 1.5% A 206715 001 Aug 07, 2017 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -37

SOLUTION/DROPS;OPHTHALMIC DICLOFENAC SODIUM >D> AT BAUSCH AND LOMB 0.1% A 078792 001 Dec 28, 2007 Aug CHRS >A> AT ! 0.1% A 078792 001 Dec 28, 2007 Aug CHRS VOLTAREN >D> AT +! 0.1% N 020037 001 Mar 28, 1991 Aug DISC >A> + @ 0.1% N 020037 001 Mar 28, 1991 Aug DISC TABLET, DELAYED RELEASE;ORAL DICLOFENAC SODIUM @ MICRO LABS 50MG A 074986 001 Feb 26, 1999 Feb CAHN @ 75MG A 074986 002 Feb 26, 1999 Feb CAHN

DICLOFENAC SODIUM; TABLET, DELAYED RELEASE;ORAL DICLOFENAC SODIUM AND MISOPROSTOL AB MICRO LABS 50MG;0.2MG A 204355 001 Jul 15, 2021 Jul NEWA AB 75MG;0.2MG A 204355 002 Jul 15, 2021 Jul NEWA

DICLOXACILLIN SODIUM CAPSULE;ORAL DICLOXACILLIN SODIUM @ SANDOZ EQ 125MG BASE A 061454 002 Jan DISC @ EQ 250MG BASE A 061454 001 Jan DISC @ EQ 500MG BASE A 061454 003 Jan DISC TEVA EQ 250MG BASE A 062286 001 Jun 03, 1982 Jan CTEC ! EQ 500MG BASE A 062286 002 Jun 03, 1982 Jan CTEC AB ! EQ 500MG BASE A 062286 002 Jun 03, 1982 Jan CHRS

DICYCLOMINE HYDROCHLORIDE INJECTABLE;INJECTION DICYCLOMINE HYDROCHLORIDE AP PRAXGEN 10MG/ML A 212058 001 Apr 26, 2019 Jun CAHN SYRUP;ORAL DICYCLOMINE HYDROCHLORIDE AA NOVITIUM PHARMA 10MG/5ML A 214721 001 Apr 23, 2021 Apr NEWA TABLET;ORAL DICYCLOMINE HYDROCHLORIDE >D> AB MYLAN 20MG A 040317 001 Sep 07, 1999 Aug DISC >A> @ 20MG A 040317 001 Sep 07, 1999 Aug DISC

DIDANOSINE CAPSULE, DELAYED REL PELLETS;ORAL DIDANOSINE @ AUROBINDO PHARMA 125MG A 090094 001 Sep 24, 2008 Jan DISC @ 200MG A 090094 002 Sep 24, 2008 Jan DISC @ 250MG A 090094 003 Sep 24, 2008 Jan DISC @ 400MG A 090094 004 Sep 24, 2008 Jan DISC

>A> DIFELIKEFALIN ACETATE >A> SOLUTION;INTRAVENOUS >A> KORSUVA >A> +! CARA THERAP EQ 0.065MG BASE/1.3ML (EQ 0.05MG N 214916 001 Aug 23, 2021 Aug NEWA BASE/ML)

DIFLORASONE DIACETATE CREAM;TOPICAL DIFLORASONE DIACETATE BX ! ANI PHARMS 0.05% A 076263 001 Dec 20, 2002 Apr CAHN OINTMENT;TOPICAL DIFLORASONE DIACETATE @ AKORN 0.05% A 206572 001 Jul 24, 2015 Apr DISC

DIFLUPREDNATE EMULSION;OPHTHALMIC DIFLUPREDNATE AB CIPLA 0.05% A 211776 001 Aug 09, 2021 Jul NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -38

DIHYDROERGOTAMINE MESYLATE INJECTABLE;INJECTION MESYLATE AP PROVEPHARM SAS 1MG/ML A 212046 001 Jan 07, 2020 Jan CAHN

DILTIAZEM HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL HYDROCHLORIDE AB1 GLENMARK PHARMS LTD 60MG A 212317 001 Mar 22, 2021 Mar NEWA AB1 90MG A 212317 002 Mar 22, 2021 Mar NEWA AB1 120MG A 212317 003 Mar 22, 2021 Mar NEWA AB1 MYLAN 60MG A 074910 001 May 02, 1997 Mar CTEC AB1 90MG A 074910 002 May 02, 1997 Mar CTEC AB1 ! 120MG A 074910 003 May 02, 1997 Mar CTEC INJECTABLE;INJECTION DILTIAZEM HYDROCHLORIDE @ INTL MEDICATION 5MG/ML A 075749 001 Nov 21, 2001 Jan DISC TABLET;ORAL DILTIAZEM HYDROCHLORIDE >D> AB MYLAN 30MG A 072838 004 Nov 05, 1992 Aug CAHN >A> @ 30MG A 072838 004 Nov 05, 1992 Aug CAHN >D> AB 60MG A 072838 003 Nov 05, 1992 Aug CAHN >A> @ 60MG A 072838 003 Nov 05, 1992 Aug CAHN >D> AB 90MG A 072838 002 Nov 05, 1992 Aug CAHN >A> @ 90MG A 072838 002 Nov 05, 1992 Aug CAHN >D> AB 120MG A 072838 001 Nov 05, 1992 Aug CAHN >A> @ 120MG A 072838 001 Nov 05, 1992 Aug CAHN

DIMENHYDRINATE INJECTABLE;INJECTION >D> @ WATSON LABS TEVA 50MG/ML A 080615 001 Aug CRLD >A> + @ 50MG/ML A 080615 001 Aug CRLD TABLET;ORAL DIMENHYDRINATE >D> @ WATSON LABS 50MG A 085166 001 Aug CRLD >A> + @ 50MG A 085166 001 Aug CRLD

DIMETHYL FUMARATE CAPSULE, DELAYED RELEASE;ORAL AB LUPIN 120MG A 210226 001 Oct 05, 2020 Jul CAHN AB 240MG A 210226 002 Oct 05, 2020 Jul CAHN AB PHARMATHEN 120MG A 210436 001 Mar 26, 2021 Mar NEWA AB 240MG A 210436 002 Mar 26, 2021 Mar NEWA @ ZYDUS PHARMS 120MG A 210538 001 Sep 24, 2020 Feb DISC @ 240MG A 210538 002 Sep 24, 2020 Feb DISC TECFIDERA AB + BIOGEN INC 120MG N 204063 001 Mar 27, 2013 Apr CAHN AB +! 240MG N 204063 002 Mar 27, 2013 Apr CAHN

DINOPROSTONE GEL;ENDOCERVICAL PREPIDIL +! PFIZER 0.5MG/3GM N 019617 001 Dec 09, 1992 Jan CAHN SUPPOSITORY;VAGINAL PROSTIN E2 +! PFIZER 20MG N 017810 001 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE >D> AP ! WEST-WARD PHARMS INT 50MG/ML A 080817 002 Aug CRLD >A> AP +! 50MG/ML A 080817 002 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -39

DIPYRIDAMOLE TABLET;ORAL DIPYRIDAMOLE AB OXFORD PHARMS 25MG A 040542 001 Apr 21, 2006 Jan CMFD AB 50MG A 040542 002 Apr 21, 2006 Jan CMFD AB 75MG A 040542 003 Apr 21, 2006 Jan CMFD

DIROXIMEL FUMARATE CAPSULE, DELAYED RELEASE;ORAL VUMERITY +! BIOGEN INC 231MG N 211855 001 Oct 29, 2019 Apr CAHN

DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL PHOSPHATE @ MAYNE PHARMA EQ 100MG BASE A 070173 001 May 31, 1985 Feb DISC @ EQ 150MG BASE A 070173 002 May 31, 1985 Feb DISC

DISULFIRAM TABLET;ORAL ANTABUSE >D> AB ODYSSEY PHARMS 250MG A 088482 001 Dec 08, 1983 Aug CRLD >A> AB + 250MG A 088482 001 Dec 08, 1983 Aug CRLD >D> AB ! 500MG A 088483 001 Dec 08, 1983 Aug CRLD >A> AB +! 500MG A 088483 001 Dec 08, 1983 Aug CRLD

DIVALPROEX SODIUM CAPSULE, DELAYED REL PELLETS;ORAL DIVALPROEX SODIUM @ TEVA PHARMS USA EQ 125MG VALPROIC ACID A 211505 001 Nov 17, 2020 May DISC TABLET, DELAYED RELEASE;ORAL DIVALPROEX SODIUM @ ANCHEN PHARMS EQ 500MG VALPROIC ACID A 078411 001 Nov 03, 2008 May DISC TABLET, EXTENDED RELEASE;ORAL DIVALPROEX SODIUM AB AMTA EQ 250MG VALPROIC ACID A 214462 001 Mar 15, 2021 Mar NEWA AB EQ 500MG VALPROIC ACID A 214462 002 Mar 15, 2021 Mar NEWA

DOCETAXEL INJECTABLE;INJECTION AP EUGIA PHARMA 20MG/2ML (10MG/ML) A 214575 001 Jun 25, 2021 Jun NEWA AP 80MG/8ML (10MG/ML) A 214575 002 Jun 25, 2021 Jun NEWA AP 160MG/16ML (10MG/ML) A 214575 003 Jun 25, 2021 Jun NEWA AP GLAND PHARMA LTD 20MG/2ML (10MG/ML) A 213510 001 Jul 01, 2021 Jun NEWA AP 80MG/8ML (10MG/ML) A 213510 002 Jul 01, 2021 Jun NEWA AP 160MG/16ML (10MG/ML) A 213510 003 Jul 01, 2021 Jun NEWA AP HIKMA 20MG/ML (20MG/ML) A 204490 001 Jan 14, 2021 Jan NEWA AP 80MG/4ML (20MG/ML) A 204490 002 Jan 14, 2021 Jan NEWA AP HONG KONG 20MG/2ML (10MG/ML) A 209634 001 Aug 24, 2018 Jun CMFD AP 80MG/8ML (10MG/ML) A 209634 002 Aug 24, 2018 Jun CMFD AP 160MG/16ML (10MG/ML) A 209634 003 Aug 24, 2018 Jun CMFD @ INGENUS PHARMS LLC 20MG/2ML (10MG/ML) A 207563 001 Aug 31, 2017 Apr DISC AP +! SHILPA 20MG/ML (20MG/ML) N 205934 001 Dec 22, 2015 Apr CHRS AP + 20MG/ML (20MG/ML) N 205934 001 Dec 22, 2015 Apr CRLD AP 20MG/ML (20MG/ML) N 205934 001 Dec 22, 2015 Jan CAHN AP +! 80MG/4ML (20MG/ML) N 205934 002 Dec 22, 2015 Apr CHRS AP + 80MG/4ML (20MG/ML) N 205934 002 Dec 22, 2015 Apr CRLD AP 80MG/4ML (20MG/ML) N 205934 002 Dec 22, 2015 Jan CAHN AP +! 160MG/8ML (20MG/ML) N 205934 003 Dec 22, 2015 Apr CHRS AP + 160MG/8ML (20MG/ML) N 205934 003 Dec 22, 2015 Apr CRLD AP 160MG/8ML (20MG/ML) N 205934 003 Dec 22, 2015 Jan CAHN

DOFETILIDE CAPSULE;ORAL @ RICONPHARMA LLC 0.125MG A 212410 001 Dec 27, 2019 Feb DISC @ 0.25MG A 212410 002 Dec 27, 2019 Feb DISC @ 0.5MG A 212410 003 Dec 27, 2019 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -40

DOLASETRON MESYLATE INJECTABLE;INJECTION ANZEMET + @ VALIDUS PHARMS 12.5MG/0.625ML (20MG/ML) N 020624 002 Sep 11, 1997 Feb CAHN + @ 100MG/5ML (20MG/ML) N 020624 001 Sep 11, 1997 Feb CAHN @ 500MG/25ML (20MG/ML) N 020624 003 Dec 11, 2001 Feb CAHN TABLET;ORAL ANZEMET + @ VALIDUS PHARMS 50MG N 020623 001 Sep 11, 1997 Feb CAHN + @ 100MG N 020623 002 Sep 11, 1997 Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; MALEATE SOLUTION/DROPS;OPHTHALMIC HYDROCHLORIDE AND TIMOLOL MALEATE AT ALEMBIC PHARMS LTD EQ 2% BASE;EQ 0.5% BASE A 213099 001 May 04, 2021 Apr NEWA AT FDC LTD EQ 2% BASE;EQ 0.5% BASE A 205295 001 Jun 13, 2019 Feb CMFD

DOXAPRAM HYDROCHLORIDE INJECTABLE;INJECTION DOPRAM AP +! HIKMA PHARMS 20MG/ML N 014879 001 Jul CAHN

DOXAZOSIN MESYLATE TABLET;ORAL MESYLATE @ MYLAN EQ 1MG BASE A 075509 001 Oct 19, 2000 Jul DISC @ EQ 2MG BASE A 075509 002 Oct 19, 2000 Jul DISC @ EQ 4MG BASE A 075509 003 Oct 19, 2000 Jul DISC @ EQ 8MG BASE A 075509 004 Oct 19, 2000 Jul DISC

DOXEPIN HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB ALEMBIC PHARMS LTD EQ 10MG BASE A 215076 001 Apr 21, 2021 Apr NEWA AB EQ 25MG BASE A 215076 002 Apr 21, 2021 Apr NEWA AB EQ 50MG BASE A 215076 003 Apr 21, 2021 Apr NEWA AB EQ 75MG BASE A 215076 004 Apr 21, 2021 Apr NEWA AB EQ 100MG BASE A 215076 005 Apr 21, 2021 Apr NEWA AB APPCO EQ 10MG BASE A 214908 001 Apr 01, 2021 Mar NEWA AB EQ 25MG BASE A 214908 002 Apr 01, 2021 Mar NEWA AB EQ 50MG BASE A 214908 003 Apr 01, 2021 Mar NEWA AB EQ 75MG BASE A 214908 004 Apr 01, 2021 Mar NEWA AB EQ 100MG BASE A 214908 005 Apr 01, 2021 Mar NEWA >A> @ CHARTWELL RX EQ 10MG BASE A 210268 001 Sep 04, 2020 Aug CAHN >A> @ EQ 25MG BASE A 210268 002 Sep 04, 2020 Aug CAHN >A> @ EQ 50MG BASE A 210268 003 Sep 04, 2020 Aug CAHN >A> @ EQ 75MG BASE A 210268 004 Sep 04, 2020 Aug CAHN >A> @ EQ 100MG BASE A 210268 005 Sep 04, 2020 Aug CAHN AB LEADING PHARMA LLC EQ 10MG BASE A 211619 001 Mar 09, 2021 Feb NEWA AB EQ 25MG BASE A 211619 002 Mar 09, 2021 Feb NEWA AB EQ 50MG BASE A 211619 003 Mar 09, 2021 Feb NEWA AB EQ 75MG BASE A 211619 004 Mar 09, 2021 Feb NEWA AB EQ 100MG BASE A 211619 005 Mar 09, 2021 Feb NEWA AB EQ 150MG BASE A 211618 001 Mar 01, 2021 Feb NEWA >D> @ UPSHER SMITH LABS EQ 10MG BASE A 210268 001 Sep 04, 2020 Aug CAHN @ EQ 10MG BASE A 210268 001 Sep 04, 2020 May CAHN @ EQ 10MG BASE A 210268 001 Sep 04, 2020 Feb DISC >D> @ EQ 25MG BASE A 210268 002 Sep 04, 2020 Aug CAHN @ EQ 25MG BASE A 210268 002 Sep 04, 2020 May CAHN @ EQ 25MG BASE A 210268 002 Sep 04, 2020 Feb DISC >D> @ EQ 50MG BASE A 210268 003 Sep 04, 2020 Aug CAHN @ EQ 50MG BASE A 210268 003 Sep 04, 2020 May CAHN @ EQ 50MG BASE A 210268 003 Sep 04, 2020 Feb DISC >D> @ EQ 75MG BASE A 210268 004 Sep 04, 2020 Aug CAHN @ EQ 75MG BASE A 210268 004 Sep 04, 2020 May CAHN @ EQ 75MG BASE A 210268 004 Sep 04, 2020 Feb DISC >D> @ EQ 100MG BASE A 210268 005 Sep 04, 2020 Aug CAHN @ EQ 100MG BASE A 210268 005 Sep 04, 2020 May CAHN @ EQ 100MG BASE A 210268 005 Sep 04, 2020 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -41

TABLET;ORAL DOXEPIN HYDROCHLORIDE @ PAR PHARM INC EQ 3MG BASE A 202510 001 Jul 24, 2020 Jan DISC @ EQ 6MG BASE A 202510 002 Jul 24, 2020 Jan DISC AB RK PHARMA EQ 3MG BASE A 202337 001 Jan 20, 2016 Jan CAHN AB EQ 6MG BASE A 202337 002 Jan 20, 2016 Jan CAHN

DOXERCALCIFEROL INJECTABLE;INJECTION DOXERCALCIFEROL >D> AP SUN PHARM 2MCG/ML (2MCG/ML) A 203875 001 Nov 14, 2019 Aug DISC >A> @ 2MCG/ML (2MCG/ML) A 203875 001 Nov 14, 2019 Aug DISC >D> AP 4MCG/2ML (2MCG/ML) A 203875 002 Nov 14, 2019 Aug DISC >A> @ 4MCG/2ML (2MCG/ML) A 203875 002 Nov 14, 2019 Aug DISC

DOXORUBICIN HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE @ ALMAJECT 2MG/ML A 065515 001 Nov 08, 2012 Jul CAHN

DOXYCYCLINE CAPSULE;ORAL @ MYLAN EQ 50MG BASE A 208942 001 Jan 21, 2021 Jan DISC AB EQ 50MG BASE A 208942 001 Jan 21, 2021 Jan NEWA @ EQ 75MG BASE A 208942 002 Jan 21, 2021 Jan DISC AB EQ 75MG BASE A 208942 002 Jan 21, 2021 Jan NEWA @ EQ 100MG BASE A 208942 003 Jan 21, 2021 Jan DISC AB EQ 100MG BASE A 208942 003 Jan 21, 2021 Jan NEWA MONODOX AB + CHARTWELL RX EQ 50MG BASE N 050641 002 Feb 10, 1992 Jun CMFD AB + EQ 75MG BASE N 050641 003 Oct 18, 2006 Jun CMFD AB + EQ 100MG BASE N 050641 001 Dec 29, 1989 Jun CMFD FOR SUSPENSION;ORAL DOXYCYCLINE AB CHARTWELL EQ 25MG BASE/5ML A 065454 001 Jul 16, 2008 Jun CAHN

DOXYCYCLINE HYCLATE CAPSULE;ORAL DOXYCYCLINE HYCLATE AB CHARTWELL EQ 50MG BASE A 062500 001 Sep 11, 1984 Jun CAHN AB EQ 100MG BASE A 062500 002 Sep 11, 1984 Jun CAHN @ NOSTRUM LABS INC EQ 50MG BASE A 209393 001 Dec 10, 2020 Jul DISC @ EQ 100MG BASE A 209393 002 Dec 10, 2020 Jul DISC CAPSULE, DELAYED RELEASE;ORAL DOXYCYCLINE HYCLATE @ BAUSCH EQ 75MG BASE A 065281 001 Dec 21, 2005 May CAHN @ EQ 100MG BASE A 065281 002 Dec 21, 2005 May CAHN INJECTABLE;INJECTION DOXYCYCLINE HYCLATE AP WEST-WARD PHARMS INT EQ 100MG BASE/VIAL A 062992 001 Feb 16, 1989 May CMFD AP EQ 200MG BASE/VIAL A 062992 002 Feb 16, 1989 May CMFD TABLET;ORAL DOXYCYCLINE HYCLATE AB CARIBE HOLDINGS EQ 50MG BASE A 062269 003 Oct 05, 1983 Jul CTEC AB CHARTWELL EQ 50MG BASE A 062505 002 Jul 27, 2021 Jul NEWA AB EQ 100MG BASE A 062505 001 Sep 11, 1984 Jun CAHN AB EQ 100MG BASE A 062505 001 Sep 11, 1984 Jun CAHN @ MYLAN EQ 100MG BASE A 062432 001 Feb 15, 1983 Jul DISC @ ORYZA EQ 100MG BASE A 213475 001 Mar 10, 2021 Apr DISC AB EQ 100MG BASE A 213475 001 Mar 10, 2021 Feb NEWA TABLET, DELAYED RELEASE;ORAL DOXYCYCLINE HYCLATE >D> @ MYLAN EQ 50MG BASE A 090431 003 May 23, 2016 Aug CAHN >A> @ EQ 50MG BASE A 090431 003 May 23, 2016 Aug CAHN @ EQ 50MG BASE A 090431 003 May 23, 2016 Jul DISC >D> @ EQ 75MG BASE A 090431 001 Dec 28, 2010 Aug CAHN >A> @ EQ 75MG BASE A 090431 001 Dec 28, 2010 Aug CAHN >D> @ EQ 80MG BASE A 090431 004 Apr 29, 2016 Aug CAHN >A> @ EQ 80MG BASE A 090431 004 Apr 29, 2016 Aug CAHN >D> @ EQ 100MG BASE A 090431 002 Dec 28, 2010 Aug CAHN >A> @ EQ 100MG BASE A 090431 002 Dec 28, 2010 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -42

TABLET, DELAYED RELEASE;ORAL DOXYCYCLINE HYCLATE >D> @ EQ 200MG BASE A 090431 005 May 19, 2016 Aug CAHN >A> @ EQ 200MG BASE A 090431 005 May 19, 2016 Aug CAHN

DROSPIRENONE; ESTETROL TABLET;ORAL NEXTSTELLIS +! MAYNE PHARMA 3MG;14.2MG N 214154 001 Apr 15, 2021 Apr NEWA

DROSPIRENONE; ETHINYL TABLET;ORAL DROSPIRENONE AND ETHINYL ESTRADIOL AB HLTHCARE 3MG;0.02MG A 203291 001 Jul 18, 2017 Jun CAHN @ JUBILANT CADISTA 3MG;0.02MG A 209423 001 Dec 22, 2017 Jun DISC >D> KYRA >D> AB SUN PHARM 3MG;0.02MG A 202318 001 Jul 23, 2019 Aug DISC >A> @ 3MG;0.02MG A 202318 001 Jul 23, 2019 Aug DISC TABLET;ORAL-28 DROSPIRENONE AND ETHINYL ESTRADIOL @ JUBILANT CADISTA 3MG;0.03MG A 210017 001 Sep 10, 2018 Jun DISC >D> KEMEYA >D> AB SUN PHARM 3MG;0.03MG A 202138 001 Mar 13, 2019 Aug DISC >A> @ 3MG;0.03MG A 202138 001 Mar 13, 2019 Aug DISC

DROXIDOPA CAPSULE;ORAL AB AJANTA PHARMA LTD 100MG A 214391 001 Feb 18, 2021 Feb NFTG AB 200MG A 214391 002 Feb 18, 2021 Feb NFTG AB 300MG A 214391 003 Feb 18, 2021 Feb NFTG AB ALKEM LABS LTD 100MG A 213911 001 Feb 18, 2021 Feb NFTG AB 200MG A 213911 002 Feb 18, 2021 Feb NFTG AB 300MG A 213911 003 Feb 18, 2021 Feb NFTG AB ANNORA 100MG A 211726 002 Aug 09, 2021 Jul NEWA AB 200MG A 211726 003 Aug 09, 2021 Jul NEWA AB 300MG A 211726 001 Feb 18, 2021 Feb NFTG AB AUROBINDO PHARMA LTD 100MG A 214387 001 Feb 18, 2021 Feb NFTG AB 200MG A 214387 002 Feb 18, 2021 Feb NFTG AB 300MG A 214387 003 Feb 18, 2021 Feb NFTG AB BIONPHARMA INC 100MG A 213033 001 Apr 28, 2021 May CAHN AB 200MG A 213033 002 Apr 28, 2021 May CAHN AB 300MG A 213033 003 Apr 28, 2021 May CAHN AB BLUEPHARMA 100MG A 214543 001 May 05, 2021 Apr NEWA AB 200MG A 214543 002 May 05, 2021 Apr NEWA AB 300MG A 214543 003 May 05, 2021 Apr NEWA AB HIKMA PHARMS 100MG A 212835 001 Feb 18, 2021 Feb NFTG AB 200MG A 212835 002 Feb 18, 2021 Feb NFTG AB 300MG A 212835 003 Feb 18, 2021 Feb NFTG AB LUPIN PHARMS 100MG A 211652 001 Feb 18, 2021 Feb NFTG AB 200MG A 211652 002 Feb 18, 2021 Feb NFTG AB 300MG A 211652 003 Feb 18, 2021 Feb NFTG AB MSN PHARMS INC 100MG A 211741 001 Feb 18, 2021 Feb NFTG AB 200MG A 211741 002 Feb 18, 2021 Feb NFTG AB 300MG A 211741 003 Feb 18, 2021 Feb NFTG AB MYLAN API 100MG A 213033 001 Apr 28, 2021 Apr NEWA AB 200MG A 213033 002 Apr 28, 2021 Apr NEWA AB 300MG A 213033 003 Apr 28, 2021 Apr NEWA AB SCIEGEN PHARMS INC 100MG A 214017 001 Feb 18, 2021 Feb NFTG AB 200MG A 214017 002 Feb 18, 2021 Feb NFTG AB 300MG A 214017 003 Feb 18, 2021 Feb NFTG AB SUN PHARM 100MG A 214384 001 Feb 18, 2021 Feb NFTG AB 200MG A 214384 002 Feb 18, 2021 Feb NFTG AB 300MG A 214384 003 Feb 18, 2021 Feb NFTG AB TASMAN PHARMA 100MG A 213661 001 Feb 18, 2021 Feb NFTG AB 200MG A 213661 002 Feb 18, 2021 Feb NFTG AB 300MG A 213661 003 Feb 18, 2021 Feb NFTG >D> AB TEVA PHARMS USA INC 100MG A 213162 001 Feb 18, 2021 Aug DISC >A> @ 100MG A 213162 001 Feb 18, 2021 Aug DISC AB 100MG A 213162 001 Feb 18, 2021 Feb NFTG >D> AB 200MG A 213162 002 Feb 18, 2021 Aug DISC >A> @ 200MG A 213162 002 Feb 18, 2021 Aug DISC AB 200MG A 213162 002 Feb 18, 2021 Feb NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -43

CAPSULE;ORAL DROXIDOPA >D> AB 300MG A 213162 003 Feb 18, 2021 Aug DISC >A> @ 300MG A 213162 003 Feb 18, 2021 Aug DISC AB 300MG A 213162 003 Feb 18, 2021 Feb NFTG AB PHARMA INC 100MG A 214543 001 May 05, 2021 Jun CAHN AB 200MG A 214543 002 May 05, 2021 Jun CAHN AB 300MG A 214543 003 May 05, 2021 Jun CAHN AB ZYDUS PHARMS 100MG A 211818 001 Feb 18, 2021 Feb NFTG AB 200MG A 211818 002 Feb 18, 2021 Feb NFTG AB 300MG A 211818 003 Feb 18, 2021 Feb NFTG

DULOXETINE HYDROCHLORIDE CAPSULE, DELAYED REL PELLETS;ORAL DRIZALMA SPRINKLE + SUN PHARMA GLOBAL EQ 20MG BASE N 212516 001 Jul 19, 2019 Apr CDFR + EQ 30MG BASE N 212516 002 Jul 19, 2019 Apr CDFR + EQ 40MG BASE N 212516 003 Jul 19, 2019 Apr CDFR +! EQ 60MG BASE N 212516 004 Jul 19, 2019 Apr CDFR HYDROCHLORIDE AB SUNSHINE EQ 20MG BASE A 212328 001 Feb 11, 2021 Feb NEWA AB EQ 30MG BASE A 212328 002 Feb 11, 2021 Feb NEWA AB EQ 60MG BASE A 212328 003 Feb 11, 2021 Feb NEWA

DUTASTERIDE CAPSULE;ORAL AVODART AB +! WOODWARD 0.5MG N 021319 001 Nov 20, 2001 Jul CAHN DUTASTERIDE @ NOSTRUM LABS INC 0.5MG A 204705 001 Nov 20, 2015 Apr CAHN

DUTASTERIDE; HYDROCHLORIDE CAPSULE;ORAL JALYN AB +! WOODWARD 0.5MG;0.4MG N 022460 001 Jun 14, 2010 Jul CAHN

DYDROGESTERONE TABLET;ORAL GYNOREST @ SOLVAY 5MG N 017388 001 Jul CRLD @ 10MG N 017388 002 Jul CRLD

ECHOTHIOPHATE IODIDE FOR SOLUTION;OPHTHALMIC PHOSPHOLINE IODIDE >A> @ FERA PHARMS LLC 0.03% N 011963 002 Aug CAHN >A> @ 0.06% N 011963 004 Aug CAHN >A> +! 0.125% N 011963 001 Aug CAHN >A> @ 0.25% N 011963 003 Aug CAHN >D> @ WYETH PHARMS 0.03% N 011963 002 Aug CAHN >D> @ 0.06% N 011963 004 Aug CAHN >D> +! 0.125% N 011963 001 Aug CAHN >D> @ 0.25% N 011963 003 Aug CAHN

ECONAZOLE AEROSOL, FOAM;TOPICAL ECOZA +! RESILIA PHARMS 1% N 205175 001 Oct 24, 2013 Feb CAHN

EDETATE CALCIUM DISODIUM INJECTABLE;INJECTION CALCIUM DISODIUM VERSENATE +! BAUSCH 200MG/ML N 008922 001 May CAHN TABLET;ORAL CALCIUM DISODIUM VERSENATE @ BAUSCH 500MG N 008922 002 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -44

EFAVIRENZ TABLET;ORAL AB STRIDES PHARMA 600MG A 078509 001 Jun 16, 2021 Jun NEWA

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE + @ AUROBINDO PHARMA LTD 600MG;300MG;300MG N 022343 001 Aug 15, 2018 Feb DISC

EFINACONAZOLE SOLUTION;TOPICAL AB ACRUX DDS 10% A 211969 001 Jun 21, 2021 Jun NEWA AB AUROBINDO PHARMA LTD 10% A 212066 001 Mar 29, 2021 Mar NEWA AB TEVA PHARMS USA 10% A 211827 001 Dec 16, 2020 Feb CTEC JUBLIA AB +! BAUSCH 10% N 203567 001 Jun 06, 2014 Feb CTEC

ELEXACAFTOR, , ; IVACAFTOR TABLET;ORAL TRIKAFTA (COPACKAGED) + VERTEX PHARMS INC 50MG,37.5MG,25MG; 75MG N 212273 002 Jun 08, 2021 Jun NEWA +! 100MG,75MG,50MG; 150MG N 212273 001 Oct 21, 2019 Jun CPOT

ELIGLUSTAT TARTRATE CAPSULE;ORAL >A> TARTRATE >A> AB AIZANT EQ 84MG BASE A 212463 001 Sep 08, 2021 Aug NFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE AB APOTEX 200MG;300MG A 208740 001 Jun 16, 2021 Jun NEWA AB CIPLA 200MG;300MG A 090958 001 Apr 02, 2021 Mar NEWA AB LAURUS LABS LTD 200MG;300MG A 212114 001 Jul 26, 2019 Jan CMFD AB LUPIN LTD 200MG;300MG A 204131 001 Jun 04, 2021 May NEWA AB MACLEODS PHARMS LTD 200MG;300MG A 203442 001 May 15, 2020 Feb CMFD AB MYLAN 200MG;300MG A 206436 001 Apr 09, 2018 Feb CMFD AB STRIDES PHARMA 200MG;300MG A 091055 001 Jan 13, 2021 Jan NEWA AB ZYDUS PHARMS 100MG;150MG A 212689 002 Jul 01, 2021 Jun NEWA AB 133MG;200MG A 212689 003 Jul 01, 2021 Jun NEWA AB 167MG;250MG A 212689 004 Jul 01, 2021 Jun NEWA

ENALAPRIL MALEATE SOLUTION;ORAL ENALAPRIL MALEATE AB BIONPHARMA INC 1MG/ML A 212408 001 Aug 10, 2021 Jul NFTG

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE TABLET;ORAL ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE @ MYLAN 5MG;12.5MG A 075624 001 Sep 18, 2001 Jul DISC @ 10MG;25MG A 075624 002 Sep 18, 2001 Jul DISC

ENZALUTAMIDE CAPSULE;ORAL AB ACTAVIS LABS FL INC 40MG A 209614 001 May 14, 2021 May NFTG

EPHEDRINE HYDROCHLORIDE SOLUTION;INTRAVENOUS REZIPRES +! ETON 23.5MG/5ML (4.7MG/ML) N 213536 001 Jun 14, 2021 Jun CAHN + @ 47MG/ML (47MG/ML) N 213536 002 Jun 14, 2021 Jun DISC +! 47MG/ML (47MG/ML) N 213536 002 Jun 14, 2021 Jun CAHN + @ 47MG/5ML (9.4MG/ML) N 213536 003 Jun 14, 2021 Jun DISC +! 47MG/5ML (9.4MG/ML) N 213536 003 Jun 14, 2021 Jun CAHN +! SINTETICA SA 23.5MG/5ML (4.7MG/ML) N 213536 001 Jun 14, 2021 Jun NEWA +! 47MG/ML (47MG/ML) N 213536 002 Jun 14, 2021 Jun NEWA +! 47MG/5ML (9.4MG/ML) N 213536 003 Jun 14, 2021 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -45

EPHEDRINE SULFATE SOLUTION;INTRAVENOUS AKOVAZ >A> +! EXELA PHARMA 25MG/5ML (5MG/ML) N 208289 002 Aug 02, 2021 Aug NEWA EPHEDRINE SULFATE AP AUROBINDO PHARMA LTD 50MG/ML (50MG/ML) A 214579 001 Jun 14, 2021 Jun NEWA

EPINEPHRINE; HYDROCHLORIDE INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE >A> AP B BRAUN MEDICAL INC 0.005MG/ML;1.5% A 208475 001 Sep 08, 2021 Aug NEWA

EPLERENONE TABLET;ORAL EPLERENONE AB CHARTWELL RX 25MG A 078482 001 Jul 30, 2008 Apr CAHN AB 50MG A 078482 002 Jul 30, 2008 Apr CAHN @ PIRAMAL HLTHCARE UK 25MG A 212765 001 Aug 10, 2020 Feb DISC @ 50MG A 212765 002 Aug 10, 2020 Feb DISC INSPRA AB + UPJOHN 25MG N 021437 001 Sep 27, 2002 Apr CAHN AB +! 50MG N 021437 002 Sep 27, 2002 Apr CAHN @ 100MG N 021437 003 Sep 27, 2002 Apr CAHN

EPOPROSTENOL SODIUM INJECTABLE;INJECTION EPOPROSTENOL SODIUM AP2 SUN PHARM EQ 0.5MG BASE/VIAL A 210473 001 Jan 15, 2021 Feb CTEC AP EQ 0.5MG BASE/VIAL A 210473 001 Jan 15, 2021 Jan NFTG AP2 EQ 1.5MG BASE/VIAL A 210473 002 Jan 15, 2021 Feb CTEC AP EQ 1.5MG BASE/VIAL A 210473 002 Jan 15, 2021 Jan NFTG AP1 TEVA PHARMS USA EQ 0.5MG BASE/VIAL A 078396 001 Apr 23, 2008 Feb CTEC AP1 EQ 1.5MG BASE/VIAL A 078396 002 Apr 23, 2008 Feb CTEC FLOLAN AP1 +! GLAXOSMITHKLINE LLC EQ 0.5MG BASE/VIAL N 020444 001 Sep 20, 1995 Feb CTEC AP1 +! EQ 1.5MG BASE/VIAL N 020444 002 Sep 20, 1995 Feb CTEC VELETRI AP2 +! ACTELION EQ 0.5MG BASE/VIAL N 022260 002 Jun 28, 2012 Feb CAHN AP2 +! EQ 1.5MG BASE/VIAL N 022260 001 Jun 27, 2008 Feb CAHN AP2 +! ACTELION PHARMS LTD EQ 0.5MG BASE/VIAL N 022260 002 Jun 28, 2012 Feb CHRS AP2 + EQ 0.5MG BASE/VIAL N 022260 002 Jun 28, 2012 Feb CTEC AP2 +! EQ 1.5MG BASE/VIAL N 022260 001 Jun 27, 2008 Feb CTEC

EPTIFIBATIDE INJECTABLE;INJECTION EPTIFIBATIDE AP ! MYLAN LABS LTD 2MG/ML A 203258 001 Jul 20, 2018 Apr CHRS AP ! 75MG/100ML A 203258 002 Jul 20, 2018 Apr CHRS >A> AP SHUANGCHENG 2MG/ML A 213081 001 Sep 07, 2021 Aug NEWA INTEGRILIN + @ SCHERING 2MG/ML N 020718 001 May 18, 1998 Apr DISC + @ 75MG/100ML N 020718 002 May 18, 1998 Apr DISC

ERGOCALCIFEROL CAPSULE;ORAL DRISDOL AA +! VALIDUS PHARMS 50,000 IU N 003444 001 Feb CAHN

ERLOTINIB HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ALEMBIC PHARMS LTD EQ 25MG BASE A 214719 001 Jul 08, 2021 Jul NEWA AB EQ 100MG BASE A 214719 002 Jul 08, 2021 Jul NEWA AB EQ 150MG BASE A 214719 003 Jul 08, 2021 Jul NEWA AB MSN EQ 25MG BASE A 214366 001 May 10, 2021 Apr NEWA AB EQ 100MG BASE A 214366 002 May 10, 2021 Apr NEWA AB EQ 150MG BASE A 214366 003 May 10, 2021 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -46

ERTAPENEM SODIUM INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ERTAPENEM SODIUM >D> AP AUROBINDO PHARMA LTD EQ 1GM BASE/VIAL A 209133 001 Jun 25, 2018 Aug CAHN >A> AP EUGIA PHARMA EQ 1GM BASE/VIAL A 209133 001 Jun 25, 2018 Aug CAHN AP GLAND PHARMA LTD EQ 1GM BASE/VIAL A 212040 001 Mar 26, 2021 Mar NEWA

ERYTHROMYCIN SOLUTION;TOPICAL ERYTHRA-DERM AT SAPTALIS PHARMS 2% A 062687 001 Feb 05, 1988 Apr CMFD TABLET;ORAL AB ORANGE 250MG A 213628 001 Jun 28, 2021 Jun NEWA AB 500MG A 213628 002 Jun 28, 2021 Jun NEWA AB TEVA PHARMS USA INC 250MG A 214549 001 Feb 11, 2021 Feb NEWA AB 500MG A 214549 002 Feb 11, 2021 Feb NEWA TABLET, DELAYED RELEASE;ORAL ERYTHROMYCIN AB TORRENT 250MG A 211975 001 Jul 26, 2021 Jul NEWA AB 500MG A 211975 002 Jul 26, 2021 Jul NEWA

ERYTHROMYCIN ETHYLSUCCINATE GRANULE;ORAL ERYTHROMYCIN ETHYLSUCCINATE @ PAR PHARM INC EQ 200MG BASE/5ML A 211991 001 Oct 23, 2019 May DISC @ EQ 400MG BASE/5ML A 211991 002 Oct 23, 2019 May DISC

ESCITALOPRAM OXALATE SOLUTION;ORAL OXALATE >D> AA ANTRIM PHARMS LLC EQ 5MG BASE/5ML A 203967 001 May 26, 2015 Aug DISC >A> @ EQ 5MG BASE/5ML A 203967 001 May 26, 2015 Aug DISC

ESLICARBAZEPINE ACETATE TABLET;ORAL AB DR REDDYS LABS LTD 200MG A 211238 001 Jun 29, 2021 Jun NFTG AB 400MG A 211238 002 Jun 29, 2021 Jun NFTG AB 600MG A 211238 003 Jun 29, 2021 Jun NFTG AB 800MG A 211238 004 Jun 29, 2021 Jun NFTG

ESOMEPRAZOLE CAPSULE, DELAYED REL PELLETS;ORAL ESOMEPRAZOLE MAGNESIUM @ AMTA EQ 20MG BASE A 213859 001 Nov 18, 2020 May DISC @ EQ 40MG BASE A 213859 002 Nov 18, 2020 May DISC AB ETHYPHARM EQ 20MG BASE A 090841 001 Mar 31, 2021 Mar NEWA AB EQ 40MG BASE A 090841 002 Mar 31, 2021 Mar NEWA AB GRAVITI PHARMS EQ 20MG BASE A 213486 001 Mar 19, 2021 Mar NEWA AB EQ 40MG BASE A 213486 002 Mar 19, 2021 Mar NEWA AB INDCHEMIE HEALTH EQ 40MG BASE A 210559 002 Feb 26, 2021 Feb NEWA

ESOMEPRAZOLE MAGNESIUM; TABLET, DELAYED RELEASE;ORAL NAPROXEN AND ESOMEPRAZOLE MAGNESIUM AB MYLAN EQ 20MG BASE;375MG A 204920 001 Jul 20, 2021 Jul NEWA AB EQ 20MG BASE;500MG A 204920 002 Jul 20, 2021 Jul NEWA

ESTRADIOL CREAM;VAGINAL ESTRACE >D> AB ! ALLERGAN 0.01% A 086069 001 Jan 31, 1984 Aug CRLD >A> AB +! 0.01% A 086069 001 Jan 31, 1984 Aug CRLD ESTRADIOL >A> AB ALVOGEN 0.01% A 209767 001 Mar 05, 2018 Aug CAHN >D> AB ALVOGEN PINE BROOK 0.01% A 209767 001 Mar 05, 2018 Aug CAHN AB PRASCO LABS LLC 0.01% A 212313 001 Jul 15, 2021 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -47

FILM, EXTENDED RELEASE;TRANSDERMAL ALORA @ ALLERGAN 0.025MG/24HR N 020655 004 Apr 05, 2002 Jul DISC @ 0.05MG/24HR N 020655 001 Dec 20, 1996 Jul DISC @ 0.075MG/24HR N 020655 002 Dec 20, 1996 Jul DISC @ 0.1MG/24HR N 020655 003 Dec 20, 1996 Jul DISC INSERT, EXTENDED RELEASE;VAGINAL ESTRING +! PFIZER 0.0075MG/24HR N 020472 001 Apr 26, 1996 Jan CAHN TABLET;ORAL ESTRACE >D> @ BRISTOL MYERS SQUIBB 1MG A 084499 001 Aug CRLD >A> + @ 1MG A 084499 001 Aug CRLD >D> @ 2MG A 084500 001 Aug CRLD >A> + @ 2MG A 084500 001 Aug CRLD

ESTRADIOL CYPIONATE INJECTABLE;INJECTION DEPO-ESTRADIOL @ PFIZER 1MG/ML A 085470 001 Mar CAHN @ 3MG/ML A 085470 002 Mar CAHN ! 5MG/ML A 085470 003 Mar CAHN

ESTRADIOL; NORETHINDRONE ACETATE; TABLET;ORAL MYFEMBREE +! MYOVANT SCIENCES 1MG;0.5MG;40MG N 214846 001 May 26, 2021 May NEWA

ESTROPIPATE TABLET;ORAL OGEN .625 >D> @ PFIZER 0.75MG A 083220 001 Aug CRLD >A> + @ 0.75MG A 083220 001 Aug CRLD @ 0.75MG A 083220 001 Jan CAHN OGEN 1.25 >D> @ PFIZER 1.5MG A 083220 002 Aug CRLD >A> + @ 1.5MG A 083220 002 Aug CRLD @ 1.5MG A 083220 002 Jan CAHN OGEN 2.5 >D> @ PFIZER 3MG A 083220 003 Aug CRLD >A> + @ 3MG A 083220 003 Aug CRLD @ 3MG A 083220 003 Jan CAHN OGEN 5 >D> PFIZER 6MG A 083220 004 Aug CRLD >A> + 6MG A 083220 004 Aug CRLD 6MG A 083220 004 Jan CAHN

ESZOPICLONE TABLET;ORAL @ NOSTRUM LABS INC 1MG A 203087 001 May 08, 2019 Jan CAHN @ 2MG A 203087 002 May 08, 2019 Jan CAHN @ 3MG A 203087 003 May 08, 2019 Jan CAHN

ETHACRYNIC ACID TABLET;ORAL ETHACRYNIC ACID AB ALVOGEN 25MG A 205709 001 Jul 24, 2018 Jun CAHN

ETHINYL ESTRADIOL; ETONOGESTREL RING;VAGINAL ETHINYL ESTRADIOL; ETONOGESTREL AB TEVA PHARMS USA INC 0.015MG/24HR;0.12MG/24HR A 204305 001 Jan 13, 2021 Jan NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL TABLET;ORAL >D> SYLEVIA >D> AB SUN PHARM 0.03MG;0.15MG A 202988 001 Feb 06, 2019 Aug DISC >A> @ 0.03MG;0.15MG A 202988 001 Feb 06, 2019 Aug DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -48

TABLET;ORAL-28 >D> CERINTA >D> AB1 SUN PHARM 0.02MG;0.1MG A 202817 001 Jan 07, 2019 Aug DISC >A> @ 0.02MG;0.1MG A 202817 001 Jan 07, 2019 Aug DISC

ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE;TRANSDERMAL ETHINYL ESTRADIOL AND NORELGESTROMIN AB AMNEAL 0.035MG/24HR;0.15MG/24HR A 213950 001 Feb 25, 2021 Feb NEWA ONSURA >A> AB TEVA PHARMS USA 0.035MG/24HR;0.15MG/24HR A 213977 001 Aug 25, 2021 Aug NEWA XULANE AB ! MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A 200910 001 Apr 16, 2014 Feb CTEC

ETHINYL ESTRADIOL; NORETHINDRONE TABLET;ORAL-21 NORINYL 1+35 21-DAY @ ALLERGAN 0.035MG;1MG N 017565 001 Jul DISC TABLET;ORAL-28 CYCLAFEM 1/35 >D> AB VINTAGE PHARMS LLC 0.035MG;1MG A 076337 001 Nov 12, 2010 Aug DISC >A> @ 0.035MG;1MG A 076337 001 Nov 12, 2010 Aug DISC CYCLAFEM 7/7/7 >D> AB VINTAGE PHARMS LLC 0.035MG,0.035MG,0.035MG;0.5MG,0.75 A 076338 001 Nov 16, 2010 Aug DISC MG,1MG >A> @ 0.035MG,0.035MG,0.035MG;0.5MG,0.75 A 076338 001 Nov 16, 2010 Aug DISC MG,1MG NORINYL 1+35 28-DAY @ ALLERGAN 0.035MG;1MG N 017565 002 Jul DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE CAPSULE;ORAL GEMMILY AB XIROMED 0.02MG;1MG A 213317 001 Nov 09, 2020 Mar CAHN NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE AB AMNEAL PHARMS 0.02MG;1MG A 214292 001 Jul 20, 2021 Jul NEWA TABLET;ORAL-21 GILDESS 1/20 @ VINTAGE PHARMS LLC 0.02MG;1MG A 077077 002 Jul 24, 2012 Jul DISC TABLET;ORAL-28 GILDESS FE 1/20 @ VINTAGE PHARMS LLC 0.02MG;1MG A 077077 001 May 20, 2005 Jul DISC

ETHOSUXIMIDE SYRUP;ORAL ZARONTIN >D> AA ! PARKE-DAVIS 250MG/5ML A 080258 001 Aug CRLD >A> AA +! 250MG/5ML A 080258 001 Aug CRLD

ETODOLAC TABLET;ORAL >D> @ BAYSHORE PHARMS LLC 400MG A 210704 001 Dec 16, 2020 Aug CMFD >A> AB 400MG A 210704 001 Dec 16, 2020 Aug CMFD @ 400MG A 210704 001 Dec 16, 2020 Jul DISC >D> @ 500MG A 210704 002 Dec 16, 2020 Aug CMFD >A> AB 500MG A 210704 002 Dec 16, 2020 Aug CMFD @ 500MG A 210704 002 Dec 16, 2020 Jul DISC

ETOMIDATE INJECTABLE;INJECTION AP CAPLIN 2MG/ML A 215028 001 Dec 18, 2020 Jul CMFD @ 2MG/ML A 215028 001 Dec 18, 2020 Jun DISC

ETRAVIRINE TABLET;ORAL ETRAVIRINE @ AMNEAL 25MG A 214196 001 Jun 14, 2021 Jul DISC AB 25MG A 214196 001 Jun 14, 2021 Jun NFTG AB 100MG A 214196 002 Jun 14, 2021 Jun NFTG AB 200MG A 214196 003 Jun 14, 2021 Jun NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -49

TABLET;ORAL INTELENCE + JANSSEN R AND D 25MG N 022187 003 Mar 26, 2012 Jul CTEC

EVEROLIMUS TABLET;ORAL AFINITOR AB + NOVARTIS 10MG N 022334 002 Mar 30, 2009 Feb CTEC >D> @ BIOCON PHARMA 2.5MG A 214182 001 Feb 11, 2021 Aug CMFD >A> AB 2.5MG A 214182 001 Feb 11, 2021 Aug CMFD @ 2.5MG A 214182 001 Feb 11, 2021 Feb DISC AB 2.5MG A 214182 001 Feb 11, 2021 Feb NEWA >D> @ 5MG A 214182 002 Feb 11, 2021 Aug CMFD >A> AB 5MG A 214182 002 Feb 11, 2021 Aug CMFD @ 5MG A 214182 002 Feb 11, 2021 Feb DISC AB 5MG A 214182 002 Feb 11, 2021 Feb NEWA >D> @ 7.5MG A 214182 003 Feb 11, 2021 Aug CMFD >A> AB 7.5MG A 214182 003 Feb 11, 2021 Aug CMFD @ 7.5MG A 214182 003 Feb 11, 2021 Feb DISC AB 7.5MG A 214182 003 Feb 11, 2021 Feb NEWA >D> @ 10MG A 214182 004 Feb 11, 2021 Aug CMFD >A> AB 10MG A 214182 004 Feb 11, 2021 Aug CMFD @ 10MG A 214182 004 Feb 11, 2021 Feb DISC AB 10MG A 214182 004 Feb 11, 2021 Feb NEWA AB BRECKENRIDGE 0.25MG A 205432 001 May 20, 2021 May NEWA AB 0.5MG A 205432 002 May 20, 2021 May NEWA AB 0.75MG A 205432 003 May 20, 2021 May NEWA AB 2.5MG A 205426 001 Mar 05, 2021 Feb NEWA AB 5MG A 205426 002 Mar 05, 2021 Feb NEWA AB 7.5MG A 205426 003 Mar 05, 2021 Feb NEWA AB 10MG A 205426 004 Mar 05, 2021 Feb NEWA >D> @ MYLAN 10MG A 212936 004 Jun 08, 2020 Aug CMFD >A> AB 10MG A 212936 004 Jun 08, 2020 Aug CMFD TABLET, FOR SUSPENSION;ORAL AFINITOR DISPERZ >D> + NOVARTIS PHARM 2MG N 203985 001 Aug 29, 2012 Aug CTEC >A> AB + 2MG N 203985 001 Aug 29, 2012 Aug CTEC >D> + 3MG N 203985 002 Aug 29, 2012 Aug CTEC >A> AB + 3MG N 203985 002 Aug 29, 2012 Aug CTEC >D> +! 5MG N 203985 003 Aug 29, 2012 Aug CTEC >A> AB +! 5MG N 203985 003 Aug 29, 2012 Aug CTEC EVEROLIMUS >D> @ MYLAN 2MG A 210130 001 Apr 19, 2019 Aug CMFD >A> AB 2MG A 210130 001 Apr 19, 2019 Aug CMFD >D> @ 3MG A 210130 002 Apr 19, 2019 Aug CMFD >A> AB 3MG A 210130 002 Apr 19, 2019 Aug CMFD >D> @ 5MG A 210130 003 Apr 19, 2019 Aug CMFD >A> AB 5MG A 210130 003 Apr 19, 2019 Aug CMFD

EXEMESTANE TABLET;ORAL AROMASIN AB +! PFIZER 25MG N 020753 001 Oct 21, 1999 Mar CAHN

>D> >D> SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS >D> BYDUREON BCISE >D> +! ASTRAZENECA AB 2MG/0.85ML (2MG/0.85ML) N 209210 001 Oct 20, 2017 Aug CAIN

EXENATIDE SYNTHETIC FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS BYDUREON + @ ASTRAZENECA AB 2MG/VIAL N 022200 001 Jan 27, 2012 Feb DISC BYDUREON PEN + @ ASTRAZENECA AB 2MG N 022200 002 Feb 28, 2014 Feb DISC >A> SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS >A> BYDUREON BCISE >A> +! ASTRAZENECA AB 2MG/0.85ML (2MG/0.85ML) N 209210 001 Oct 20, 2017 Aug CAIN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -50

EZETIMIBE TABLET;ORAL ZETIA AB +! ORGANON 10MG N 021445 001 Oct 25, 2002 Feb CAHN

EZETIMIBE; ROSUVASTATIN CALCIUM TABLET;ORAL ROSZET + ALTHERA PHARMS 10MG;EQ 5MG BASE N 213072 001 Mar 23, 2021 Mar NEWA + 10MG;EQ 5MG BASE N 213072 001 Mar 23, 2021 Mar NEWA + 10MG;EQ 10MG BASE N 213072 002 Mar 23, 2021 Mar NEWA + 10MG;EQ 10MG BASE N 213072 002 Mar 23, 2021 Mar NEWA + 10MG;EQ 20MG BASE N 213072 003 Mar 23, 2021 Mar NEWA + 10MG;EQ 20MG BASE N 213072 003 Mar 23, 2021 Mar NEWA +! 10MG;EQ 40MG BASE N 213072 004 Mar 23, 2021 Mar NEWA +! 10MG;EQ 40MG BASE N 213072 004 Mar 23, 2021 Mar NEWA

EZETIMIBE; TABLET;ORAL EZETIMIBE AND SIMVASTATIN @ ANI PHARMS 10MG;10MG A 201890 001 Apr 26, 2017 Jul DISC @ 10MG;20MG A 201890 002 Apr 26, 2017 Jul DISC @ 10MG;40MG A 201890 003 Apr 26, 2017 Jul DISC @ 10MG;80MG A 201890 004 Apr 26, 2017 Jul DISC MY LAN@ MYLAN@ 10MG;10MG A 200082 001 Dec 17, 2020 Jan DISC @ 10MG;20MG A 200082 002 Dec 17, 2020 Jan DISC @ 10MG;40MG A 200082 003 Dec 17, 2020 Jan DISC @ 10MG;80MG A 200082 004 Dec 17, 2020 Jan DISC VYTORIN AB + ORGANON 10MG;10MG N 021687 001 Jul 23, 2004 Feb CAHN AB + 10MG;20MG N 021687 002 Jul 23, 2004 Feb CAHN AB + 10MG;40MG N 021687 003 Jul 23, 2004 Feb CAHN AB +! 10MG;80MG N 021687 004 Jul 23, 2004 Feb CAHN

FAMOTIDINE FOR SUSPENSION;ORAL AB AKORN 40MG/5ML A 201995 001 May 30, 2014 Feb CAHN AB NOVITIUM PHARMA 40MG/5ML A 215043 001 Apr 20, 2021 Apr NEWA

FAMOTIDINE; TABLET;ORAL IBUPROFEN AND FAMOTIDINE AB ALKEM LABS LTD 26.6MG;800MG A 211890 001 Aug 03, 2021 Jul NFTG

FELODIPINE TABLET, EXTENDED RELEASE;ORAL @ JUBILANT GENERICS 2.5MG A 203983 001 Aug 19, 2016 Jun DISC @ 5MG A 203983 002 Aug 19, 2016 Jun DISC @ 10MG A 203983 003 Aug 19, 2016 Jun DISC

FENOFIBRATE TABLET;ORAL FENOFIBRATE >A> AB ADAPTIS 54MG A 210606 001 Aug 17, 2018 Aug CAHN >A> AB 160MG A 210606 002 Aug 17, 2018 Aug CAHN AB AUSTARPHARMA 48MG A 208476 001 Feb 10, 2021 Jan NEWA AB 145MG A 208476 002 Feb 10, 2021 Jan NEWA >D> AB GRAVITI PHARMS 54MG A 210606 001 Aug 17, 2018 Aug CAHN >D> AB 160MG A 210606 002 Aug 17, 2018 Aug CAHN

FENOPROFEN CALCIUM CAPSULE;ORAL CALCIUM @ RISING EQ 200MG BASE A 072394 001 Oct 17, 1988 Jan CAHN @ EQ 300MG BASE A 072395 001 Oct 17, 1988 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -51

FENTANYL CITRATE INJECTABLE;INJECTION CITRATE AP FRESENIUS KABI USA EQ 0.05MG BASE/ML A 212086 001 Sep 01, 2020 Jun CMFD @ EQ 0.05MG BASE/ML A 212086 001 Sep 01, 2020 Mar DISC

FERRIC CARBOXYMALTOSE SOLUTION;INTRAVENOUS INJECTAFER +! AM REGENT 1GM /20ML (50MG IRON/ML) N 203565 003 Apr 28, 2021 May NEWA

FERRIC MALTOL CAPSULE;ORAL ACCRUFER +! SHIELD TX 30MG IRON N 212320 001 Jul 25, 2019 Apr CMFD

FERRIC OXYHYDROXIDE INJECTABLE;INJECTION DEXFERRUM @ AM REGENT EQ 50MG IRON/ML N 040024 001 Feb 23, 1996 May CAIN FERRLECIT AB +! AVENTIS US EQ 62.5MG IRON/5ML (EQ 12.5MG N 020955 001 Feb 18, 1999 May CPOT IRON/ML) AB +! 62.5MG/5ML N 020955 001 Feb 18, 1999 May CAIN INFED BP +! ALLERGAN EQ 100MG IRON/2ML (EQ 50MG N 017441 001 May CAIN IRON/ML) IRON DEXTRAN @ SANOFI AVENTIS US EQ 50MG IRON/ML N 010787 002 May CAIN PROFERDEX @ NEW RIVER EQ 50MG IRON/ML N 017807 001 May CAIN SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE AB WEST-WARD PHARMS INT EQ 62.5MG IRON/5ML (EQ 12.5MG A 078215 001 Mar 31, 2011 May CPOT IRON/ML) AB 62.5MG/5ML A 078215 001 Mar 31, 2011 May CAIN INJECTABLE;INTRAVENOUS VENOFER + AM REGENT EQ 50MG IRON/2.5ML (EQ 20MG N 021135 002 Mar 20, 2005 May CPOT IRON/ML) + EQ 50MG BASE/2.5ML (EQ 20MG N 021135 002 Mar 20, 2005 May CAIN BASE/ML) @ EQ 65MG IRON/3.25ML (EQ 20MG N 021135 005 Mar 29, 2013 May CPOT IRON/ML) @ EQ 65MG BASE/3.25ML (EQ 20MG N 021135 005 Mar 29, 2013 May CAIN BASE/ML) @ EQ 75MG IRON/3.75ML (EQ 20MG N 021135 003 Mar 29, 2005 May CPOT IRON/ML) @ EQ 75MG BASE/3.75ML (EQ 20MG N 021135 003 Mar 29, 2005 May CAIN BASE/ML) +! EQ 100MG IRON/5ML (EQ 20MG N 021135 001 Nov 06, 2000 May CPOT IRON/ML) +! EQ 100MG BASE/5ML (EQ 20MG N 021135 001 Nov 06, 2000 May CAIN BASE/ML) + EQ 200MG IRON/10ML (EQ 20MG N 021135 004 Feb 09, 2007 May CPOT IRON/ML) + EQ 200MG BASE/10ML (EQ 20MG N 021135 004 Feb 09, 2007 May CAIN BASE/ML) TABLET, CHEWABLE;ORAL VELPHORO +! VIFOR FRESENIUS EQ 500MG IRON N 205109 001 Nov 27, 2013 May CPOT +! 500MG N 205109 001 Nov 27, 2013 May CAIN

FERUMOXYTOL SOLUTION;INTRAVENOUS FERAHEME AB +! COVIS EQ 510MG IRON/17ML (EQ 30MG N 022180 001 Jun 30, 2009 Mar CAHN IRON/ML) FERUMOXYTOL AB SANDOZ INC EQ 510MG IRON/17ML (EQ 30MG A 206604 001 Jan 15, 2021 Jan NFTG IRON/ML) RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -52

FEXINIDAZOLE TABLET;ORAL FEXINIDAZOLE +! DNDI 600MG N 214429 001 Jul 16, 2021 Jul NEWA +! SANOFI 600MG N 214429 001 Jul 16, 2021 Jul CAHN

FINASTERIDE TABLET;ORAL FINASTERIDE @ ACTAVIS TOTOWA TEVA 5MG A 077914 001 Mar 28, 2007 May DISC

FINERENONE TABLET;ORAL KERENDIA + BAYER HLTHCARE 10MG N 215341 001 Jul 09, 2021 Jul NEWA +! 20MG N 215341 002 Jul 09, 2021 Jul NEWA

FINGOLIMOD HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE >D> AB ALKEM LABS LTD EQ 0.5MG BASE A 208004 001 Dec 30, 2020 Aug DISC >A> @ EQ 0.5MG BASE A 208004 001 Dec 30, 2020 Aug DISC @ APOTEX EQ 0.5MG BASE A 207993 001 Dec 18, 2020 Jun DISC AB DR REDDYS EQ 0.5MG BASE A 208000 001 Mar 05, 2021 Feb NEWA >D> AB GLENMARK PHARMS LTD EQ 0.5MG BASE A 207985 001 Jun 18, 2020 Aug DISC >A> @ EQ 0.5MG BASE A 207985 001 Jun 18, 2020 Aug DISC @ MYLAN EQ 0.5MG BASE A 208005 001 Jan 19, 2021 Jan DISC AB EQ 0.5MG BASE A 208005 001 Jan 19, 2021 Jan NEWA >D> AB STRIDES PHARMA EQ 0.5MG BASE A 207971 001 Jun 29, 2020 Aug DISC >A> @ EQ 0.5MG BASE A 207971 001 Jun 29, 2020 Aug DISC >D> AB SUN PHARM EQ 0.5MG BASE A 208014 001 Dec 04, 2019 Aug DISC >A> @ EQ 0.5MG BASE A 208014 001 Dec 04, 2019 Aug DISC @ ZYDUS PHARMS EQ 0.5MG BASE A 207994 001 Oct 14, 2020 Mar DISC

FLECAINIDE ACETATE TABLET;ORAL TAMBOCOR + @ ALVOGEN 50MG N 018830 004 Aug 23, 1988 Jun CAHN + @ 100MG N 018830 001 Oct 31, 1985 Jun CAHN + @ 150MG N 018830 003 Jun 03, 1988 Jun CAHN @ 200MG N 018830 002 Oct 31, 1985 Jun CAHN + @ CNTY LINE PHARMS 50MG N 018830 004 Aug 23, 1988 Jan DISC + @ 100MG N 018830 001 Oct 31, 1985 Jan DISC + @ 150MG N 018830 003 Jun 03, 1988 Jan DISC

FLUDEOXYGLUCOSE F-18 INJECTABLE;INTRAVENOUS FLUDEOXYGLUCOSE F18 AP CARDINAL HEALTH 414 20-500mCi/ML A 203603 002 Sep 27, 2018 Mar NEWA NUKEMED 4-500mCi/ML A 203911 001 Apr 22, 2015 Jan CAHN AP PHARMALOGIC HLDGS 20-200mCi/ML A 203664 001 Feb 04, 2014 Jan CAHN AP PRECISION NUCLEAR 20-500mCi/ML A 204546 001 Apr 07, 2015 Mar CTEC

FLUMAZENIL INJECTABLE;INJECTION AP BAXTER HLTHCARE CORP 0.5MG/5ML (0.1MG/ML) A 076755 002 Oct 12, 2004 Mar CMFD AP 1MG/10ML (0.1MG/ML) A 076755 001 Oct 12, 2004 Mar CMFD

FLUOCINOLONE ACETONIDE OIL;TOPICAL FLUOCINOLONE ACETONIDE AK ORN@ AKORN@ 0.01% A 091514 001 Jun 25, 2015 Jul DISC AT SOLARIS PHARMA CORP 0.01% A 212760 001 Apr 02, 2021 Mar NEWA AT 0.01% A 212761 001 Apr 02, 2021 Mar NEWA OIL/DROPS;OTIC FLUOCINOLONE ACETONIDE AK ORN@ AKORN@ 0.01% A 202705 001 Sep 09, 2016 Jul DISC AT SOLARIS PHARMA CORP 0.01% A 212762 001 Apr 02, 2021 Mar NEWA AT TASMAN PHARMA 0.01% A 213264 001 Feb 05, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -53

FLUOCINONIDE CREAM;TOPICAL LIDEX + @ ALVOGEN 0.05% N 016908 002 Jun CAHN LIDEX-E AB2 + ALVOGEN 0.05% N 016908 003 Jun CAHN VANOS AB +! BAUSCH 0.1% N 021758 001 Feb 11, 2005 May CAHN GEL;TOPICAL FLUOCINONIDE AB + ALVOGEN 0.05% N 017373 001 Jun CAHN OINTMENT;TOPICAL LIDEX AB + ALVOGEN 0.05% N 016909 002 Jun CAHN SOLUTION;TOPICAL LIDEX AT + ALVOGEN 0.05% N 018849 001 Apr 06, 1984 Jun CAHN

FLUOROURACIL CREAM;TOPICAL >D> FLUOROPLEX >D> +! ALMIRALL 1% N 016988 001 Aug DISC >A> + @ 1% N 016988 001 Aug DISC INJECTABLE;INJECTION AP FRESENIUS KABI USA 500MG/10ML (50MG/ML) A 040279 002 Sep 30, 1998 May CHRS AP 1GM/20ML (50MG/ML) A 040279 001 Sep 30, 1998 May CHRS AP 2.5GM/50ML (50MG/ML) A 040278 001 Sep 30, 1998 May CHRS AP 5GM/100ML (50MG/ML) A 040278 002 Sep 30, 1998 May CHRS @ NOVAST LABS 5GM/100ML (50MG/ML) A 209271 001 Dec 11, 2019 Mar CPOT AP TEVA PHARMS USA 500MG/10ML (50MG/ML) A 040333 001 Jan 27, 2000 May CHRS

FLUOXETINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE @ ACCORD HLTHCARE EQ 10MG BASE A 202729 001 Aug 27, 2020 Feb DISC @ EQ 20MG BASE A 202729 002 Aug 27, 2020 Feb DISC @ EQ 40MG BASE A 202729 003 Aug 27, 2020 Feb DISC @ GRANULES EQ 10MG BASE A 078143 001 Jan 16, 2008 Jun CAHN @ EQ 20MG BASE A 078143 002 Jan 16, 2008 Jun CAHN @ EQ 40MG BASE A 078143 003 Jan 16, 2008 Jun CAHN >D> @ HERITAGE PHARMS INC EQ 10MG BASE A 201336 001 Oct 01, 2012 Aug CMFD >A> AB1 EQ 10MG BASE A 201336 001 Oct 01, 2012 Aug CMFD >D> @ EQ 20MG BASE A 201336 002 Oct 01, 2012 Aug CMFD >A> AB1 EQ 20MG BASE A 201336 002 Oct 01, 2012 Aug CMFD >D> @ EQ 40MG BASE A 201336 003 Oct 01, 2012 Aug CMFD >A> AB EQ 40MG BASE A 201336 003 Oct 01, 2012 Aug CMFD TABLET;ORAL FLUOXETINE HYDROCHLORIDE AB ! DR REDDYS LABS LTD EQ 20MG BASE A 076006 002 Apr 23, 2018 Jul CHRS MY LAN@ MYLAN@ EQ 10MG BASE A 075755 001 Aug 02, 2001 Jul DISC @ EQ 20MG BASE A 075755 002 Aug 02, 2001 Jul DISC TORRENT EQ 10MG BASE A 206937 001 Oct 21, 2016 Mar CHRS ! EQ 20MG BASE A 206937 002 Oct 21, 2016 Mar CHRS AB UPSHER SMITH LABS EQ 10MG BASE A 211696 001 Jan 30, 2019 May CAHN AB EQ 20MG BASE A 211696 002 Jan 30, 2019 May CAHN SARAFEM + @ APIL EQ 10MG BASE N 021860 001 May 19, 2006 Mar DISC + @ EQ 20MG BASE N 021860 003 May 19, 2006 Mar DISC

FLUOXYMESTERONE TABLET;ORAL FLUOXYMESTERONE @ UPSHER SMITH LABS 10MG A 088342 001 Oct 21, 1983 Jan DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -54

FLUPHENAZINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB CEROVENE INC 1MG A 214534 001 Jan 07, 2021 Jan NEWA AB 2.5MG A 214534 002 Jan 07, 2021 Jan NEWA AB 5MG A 214534 003 Jan 07, 2021 Jan NEWA AB 10MG A 214534 004 Jan 07, 2021 Jan NEWA AB NOVITIUM PHARMA 1MG A 214674 001 Mar 01, 2021 Feb NEWA AB 2.5MG A 214674 002 Mar 01, 2021 Feb NEWA AB 5MG A 214674 003 Mar 01, 2021 Feb NEWA AB 10MG A 214674 004 Mar 01, 2021 Feb NEWA AB ZYDUS 1MG A 214552 001 May 27, 2021 May NEWA AB 2.5MG A 214552 002 May 27, 2021 May NEWA AB 5MG A 214552 003 May 27, 2021 May NEWA AB 10MG A 214552 004 May 27, 2021 May NEWA

FLURBIPROFEN SODIUM SOLUTION/DROPS;OPHTHALMIC SODIUM ! BAUSCH AND LOMB 0.03% A 074447 001 Jan 04, 1995 Jan CHRS 0.03% A 074447 001 Jan 04, 1995 Jan CTEC OCUFEN + @ ALLERGAN 0.03% N 019404 001 Dec 31, 1986 Jan DISC

FLUTAMIDE CAPSULE;ORAL @ CIPLA 125MG A 075780 001 Sep 19, 2001 Mar DISC ! PAR PHARM 125MG A 075298 001 Sep 18, 2001 Mar CHRS 125MG A 075298 001 Sep 18, 2001 Mar CTEC ! WAYLIS THERAP 125MG A 075298 001 Sep 18, 2001 Jun CAHN

FLUTICASONE PROPIONATE POWDER;INHALATION ARMONAIR RESPICLICK + TEVA PHARM 0.03MG/INH N 208798 007 Jul 09, 2021 Jul NEWA

FLUVASTATIN SODIUM TABLET, EXTENDED RELEASE;ORAL FLUVASTATIN SODIUM AB BEIJING EQ 80MG BASE A 209397 001 Apr 26, 2021 Apr NEWA

FLUVOXAMINE MALEATE CAPSULE, EXTENDED RELEASE;ORAL MALEATE @ BIONPHARMA INC 100MG A 212182 002 Sep 16, 2020 Feb DISC

FOLIC ACID TABLET;ORAL FOLIC ACID >D> AA ! WATSON LABS 1MG A 080680 001 Aug CRLD >A> AA +! 1MG A 080680 001 Aug CRLD

FORMOTEROL FUMARATE SOLUTION;INHALATION FORMOTEROL FUMARATE AN TEVA PHARMS USA INC 0.02MG/2ML A 091141 001 Jun 22, 2021 Jun NFTG

FORMOTEROL FUMARATE; FUROATE AEROSOL, METERED;INHALATION DULERA + ORGANON 0.005MG/INH;0.05MG/INH N 022518 003 Aug 12, 2019 Jun CAHN +! 0.005MG/INH;0.1MG/INH N 022518 001 Jun 22, 2010 Jun CAHN +! 0.005MG/INH;0.2MG/INH N 022518 002 Jun 22, 2010 Jun CAHN

FOSAPREPITANT DIMEGLUMINE POWDER;INTRAVENOUS FOSAPREPITANT DIMEGLUMINE AP ASPIRO EQ 150MG BASE/VIAL A 214616 001 Jul 29, 2021 Jul NEWA AP AUROBINDO PHARMA LTD EQ 150MG BASE/VIAL A 210625 001 Jan 12, 2021 Jan NEWA @ MYLAN LABS LTD EQ 115MG BASE/VIAL A 204015 001 Sep 05, 2019 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -55

POWDER;INTRAVENOUS FOSAPREPITANT DIMEGLUMINE AP PRAXGEN EQ 150MG BASE/VIAL A 211624 001 Sep 05, 2019 Jun CAHN

FOSCARNET SODIUM INJECTABLE;INJECTION FOSCARNET SODIUM AP FRESENIUS KABI USA 2.4GM/100ML A 212483 001 Jan 29, 2021 Jan NEWA AP GLAND PHARMA LTD 2.4GM/100ML A 213001 001 Apr 21, 2021 Apr NEWA FOSCAVIR AP +! CLINIGEN HLTHCARE 2.4GM/100ML N 020068 001 Sep 27, 1991 Jan CTEC

FOSDENOPTERIN HYDROBROMIDE POWDER;INTRAVENOUS NULIBRY +! ORIGIN EQ 9.5MG BASE/VIAL N 214018 001 Feb 26, 2021 Feb NEWA

FOSINOPRIL SODIUM TABLET;ORAL FOSINOPRIL SODIUM >A> AB CHARTWELL RX 10MG A 076483 001 Apr 23, 2004 Aug CAHN >A> AB 20MG A 076483 002 Apr 23, 2004 Aug CAHN >A> AB 40MG A 076483 003 Apr 23, 2004 Aug CAHN >D> AB UPSHER SMITH LABS 10MG A 076483 001 Apr 23, 2004 Aug CAHN >D> AB 20MG A 076483 002 Apr 23, 2004 Aug CAHN >D> AB 40MG A 076483 003 Apr 23, 2004 Aug CAHN

FOSPHENYTOIN SODIUM SOLUTION;INTRAVENOUS SESQUIENT + @ SEDOR PHARMS LLC EQ 100MG NA/2ML (EQ 50MG N 210864 001 Nov 05, 2020 Jul DISC PHENYTOIN NA/ML) + @ EQ 500MG PHENYTOIN NA/10ML (EQ N 210864 002 Nov 05, 2020 Jul DISC 50MG PHENYTOIN NA/ML)

FULVESTRANT INJECTABLE;INTRAMUSCULAR FULVESTRANT AO APOTEX 50MG/ML A 211730 001 Jun 11, 2021 Jun NEWA >D> AO AUROMEDICS PHARMA 50MG/ML A 208811 001 Jul 23, 2019 Aug CAHN AO 50MG/ML A 208811 001 Jul 23, 2019 Jan CAHN >A> AO EUGIA PHARMA 50MG/ML A 208811 001 Jul 23, 2019 Aug CAHN >A> AO XIROMED 50MG/ML A 213553 001 Aug 13, 2021 Aug CAHN AO ZYDUS PHARMS 50MG/ML A 215234 001 Jul 29, 2021 Jul NEWA

FUROSEMIDE INJECTABLE;INJECTION AP ACCORD HLTHCARE 10MG/ML A 070017 001 Dec 15, 1986 Apr CMFD AP ATHENEX INC 10MG/ML A 214766 001 Jan 27, 2021 Jan NEWA HI KMA@ HIKMA@ 10MG/ML N 018267 001 Jun CAHN @ HIKMA PHARMS 10MG/ML N 018267 001 Jul CAHN TABLET;ORAL LASIX AB + VALIDUS PHARMS 20MG N 016273 002 Feb CAHN AB + 40MG N 016273 001 Feb CAHN AB +! 80MG N 016273 003 Feb CAHN

GABAPENTIN CAPSULE;ORAL AB ASCENT PHARMS INC 100MG A 214956 001 May 10, 2021 Apr NEWA AB 300MG A 214956 002 May 10, 2021 Apr NEWA AB 400MG A 214956 003 May 10, 2021 Apr NEWA AB GRAVITI PHARMS 100MG A 207099 001 Mar 24, 2017 Jun CAHN AB 300MG A 207099 002 Mar 24, 2017 Jun CAHN AB 400MG A 207099 003 Mar 24, 2017 Jun CAHN AB ZHEJIANG YONGTAI 100MG A 213603 001 Aug 17, 2020 Apr CMFD @ 100MG A 213603 001 Aug 17, 2020 Feb DISC AB 300MG A 213603 002 Aug 17, 2020 Apr CMFD @ 300MG A 213603 002 Aug 17, 2020 Feb DISC AB 400MG A 213603 003 Aug 17, 2020 Apr CMFD @ 400MG A 213603 003 Aug 17, 2020 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -56

GALANTAMINE HYDROBROMIDE TABLET;ORAL HYDROBROMIDE AB ! YABAO PHARM EQ 4MG BASE A 077604 001 Feb 06, 2009 May CHRS RAZADYNE + @ JANSSEN PHARMS EQ 4MG BASE N 021169 001 Feb 28, 2001 May DISC + @ EQ 8MG BASE N 021169 002 Feb 28, 2001 May DISC + @ EQ 12MG BASE N 021169 003 Feb 28, 2001 May DISC

GANCICLOVIR SODIUM INJECTABLE;INJECTION CYTOVENE + @ CHEPLAPHARM EQ 500MG BASE/VIAL N 019661 001 Jun 23, 1989 Jul DISC GANCICLOVIR SODIUM AP ! PHARMASCIENCE INC EQ 500MG BASE/VIAL A 207645 001 Dec 08, 2017 Jul CHRS

GATIFLOXACIN SOLUTION/DROPS;OPHTHALMIC AT AKORN 0.5% A 203189 001 Sep 03, 2014 Feb CAHN @ MYLAN 0.5% A 206446 001 Jun 08, 2018 Jun DISC

GEMCITABINE HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE AP HIKMA INTL PHARMS EQ 200MG BASE/VIAL A 206617 001 Jun 25, 2021 Jun NEWA AP EQ 1GM BASE/VIAL A 206617 002 Jun 25, 2021 Jun NEWA AP ! JIANGSU HANSOH PHARM EQ 200MG BASE/VIAL A 202485 001 May 07, 2013 Feb CHRS AP ! EQ 1GM BASE/VIAL A 202485 002 May 07, 2013 Feb CHRS AP MEITHEAL 200MG/5.26ML (38MG/ML) A 212129 001 Dec 11, 2020 Jan CAHN AP 1GM/26.3ML (38MG/ML) A 212129 002 Dec 11, 2020 Jan CAHN AP 2GM/52.6ML (38MG/ML) A 212129 003 Dec 11, 2020 Jan CAHN GEMZAR + @ LILLY EQ 200MG BASE/VIAL N 020509 001 May 15, 1996 Feb DISC + @ EQ 1GM BASE/VIAL N 020509 002 May 15, 1996 Feb DISC

GEMFIBROZIL TABLET;ORAL GEMFIBROZIL AB ASCENT PHARMS INC 600MG A 214603 001 Jan 13, 2021 Jan NEWA

GENTAMICIN SULFATE INJECTABLE;INJECTION SULFATE @ HIKMA PHARMS EQ 10MG BASE/ML A 062251 002 Jun CAHN @ EQ 40MG BASE/ML A 062251 001 Jun CAHN

GLECAPREVIR; PIBRENTASVIR PELLETS;ORAL MAVYRET +! ABBVIE INC 50MG;20MG/PACKET N 215110 001 Jun 10, 2021 Jun NEWA

GLIPIZIDE TABLET;ORAL GLUCOTROL >D> @ PFIZER 2.5MG N 017783 003 May 11, 1993 Aug CRLD >A> + @ 2.5MG N 017783 003 May 11, 1993 Aug CRLD

GLYBURIDE TABLET;ORAL GLYNASE AB + PFIZER 1.5MG N 020051 001 Mar 04, 1992 Feb CAHN AB + 3MG N 020051 002 Mar 04, 1992 Feb CAHN + @ 4.5MG N 020051 003 Sep 24, 1993 Feb CAHN AB +! 6MG N 020051 004 Sep 24, 1993 Feb CAHN MICRONASE + PFIZER@ 1.25MG N 017498 001 May 01, 1984 Feb CAHN @ 2.5MG N 017498 002 May 01, 1984 Feb CAHN + @ 5MG N 017498 003 May 01, 1984 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -57

GLYCOPYRROLATE INJECTABLE;INJECTION GLYCOPYRROLATE AP ATHENEX INC 0.2MG/ML A 210083 001 Feb 21, 2020 Jan CAHN AP HONG KONG 0.2MG/ML A 212802 001 Jul 06, 2021 Jun NEWA AP XIROMED 0.2MG/ML A 212227 001 Mar 04, 2021 Feb NEWA ROBINUL + @ HIKMA PHARMS 0.2MG/ML N 017558 001 Jul CAHN SOLUTION;ORAL GLYCOPYRROLATE AA PAR PHARM INC 1MG/5ML A 204438 001 Aug 09, 2021 Jul NFTG TABLET;ORAL ROBINUL AA + CASPER PHARMA LLC 1MG N 012827 001 Jun CMFD ROBINUL FORTE AA + CASPER PHARMA LLC 2MG N 012827 002 Jun CMFD

GLYCOPYRRONIUM TOSYLATE CLOTH;TOPICAL QBREXZA +! JOURNEY EQ 2.4% BASE N 210361 001 Jun 28, 2018 May CAHN

GONADORELIN HYDROCHLORIDE INJECTABLE;INJECTION FACTREL @ HIKMA PHARMS EQ 0.1MG BASE/VIAL N 018123 001 Sep 30, 1982 Jul CAHN @ EQ 0.2MG BASE/VIAL N 018123 002 Sep 30, 1982 Jul CAHN @ EQ 0.5MG BASE/VIAL N 018123 003 Sep 30, 1982 Jul CAHN

GRANISETRON HYDROCHLORIDE SOLUTION;ORAL GRANISOL @ INTRA SANA LABS EQ 2MG BASE/10ML A 078334 001 Feb 28, 2008 Jan CAHN

GUANABENZ ACETATE TABLET;ORAL ACETATE >A> @ CHARTWELL RX EQ 4MG BASE A 074517 001 Sep 30, 1998 Aug CAHN >A> @ EQ 8MG BASE A 074517 002 Sep 30, 1998 Aug CAHN >D> @ YAOPHARMA CO LTD EQ 4MG BASE A 074517 001 Sep 30, 1998 Aug CAHN >D> @ EQ 8MG BASE A 074517 002 Sep 30, 1998 Aug CAHN

GUANFACINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ! AMNEAL PHARM EQ 2MG BASE A 075109 002 Nov 25, 1998 Jan CHRS @ MYLAN EQ 1MG BASE A 074796 001 Jan 27, 1997 Jan DISC @ EQ 2MG BASE A 074796 002 Jan 27, 1997 Jan DISC AB UNICHEM EQ 1MG BASE A 214689 001 Mar 03, 2021 Feb NEWA AB EQ 2MG BASE A 214689 002 Mar 03, 2021 Feb NEWA TABLET, EXTENDED RELEASE;ORAL GUANFACINE HYDROCHLORIDE @ YICHANG HUMANWELL EQ 1MG BASE A 213428 001 Nov 25, 2020 May DISC @ EQ 2MG BASE A 213428 002 Nov 25, 2020 May DISC @ EQ 3MG BASE A 213428 003 Nov 25, 2020 May DISC @ EQ 4MG BASE A 213428 004 Nov 25, 2020 May DISC

HALCINONIDE CREAM;TOPICAL HALCINONIDE >A> AB GLASSHOUSE PHARMS 0.1% A 214723 001 Sep 08, 2021 Aug NEWA SOLUTION;TOPICAL HALOG +! SUN PHARM INDS INC 0.1% N 017823 001 Apr CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -58

HALOBETASOL PROPIONATE OINTMENT;TOPICAL HALOBETASOL PROPIONATE @ COSETTE 0.05% A 077721 001 Sep 07, 2006 Mar DISC ULTRAVATE + @ SUN PHARM INDS INC 0.05% N 019968 001 Dec 17, 1990 Mar DISC

HALOPERIDOL TABLET;ORAL AB CYCLE PHARMS LTD 2MG A 071130 001 Feb 17, 1987 Apr CMFD AB 5MG A 071131 001 Feb 17, 1987 Apr CMFD AB 10MG A 071132 001 May 12, 1987 Apr CMFD

HALOPERIDOL DECANOATE INJECTABLE;INJECTION AO HONG KONG EQ 50MG BASE/ML A 214507 001 Jul 26, 2021 Jul NEWA AO EQ 100MG BASE/ML A 214507 002 Jul 26, 2021 Jul NEWA

HALOPERIDOL LACTATE CONCENTRATE;ORAL HALDOL + @ ORTHO MCNEIL EQ 2MG BASE/ML N 015922 001 Mar CRLD

HEPARIN SODIUM INJECTABLE;INJECTION HEPARIN SODIUM @ BE PHARMS 1,000 UNITS/ML A 214804 001 Dec 29, 2020 Jun DISC @ 10,000 UNITS/ML A 214839 001 Dec 29, 2020 Jun DISC AP +! HIKMA PHARMS 1,000 UNITS/ML N 017037 001 Jul CAHN AP +! 5,000 UNITS/ML N 017037 002 Jul CAHN @ 5,000 UNITS/0.5ML N 017037 013 Apr 07, 1986 Jul CAHN AP +! 10,000 UNITS/ML N 017037 003 Jul CAHN >D> AP NANJING KING-FRIEND 5,000 UNITS/ML A 212061 001 Jul 15, 2020 Aug DISC >A> @ 5,000 UNITS/ML A 212061 001 Jul 15, 2020 Aug DISC HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 200 UNITS/100ML A 212441 001 Jul 24, 2020 Apr CMFD @ 200 UNITS/100ML A 212441 001 Jul 24, 2020 Jan DISC HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 200 UNITS/100ML A 212441 002 Jul 24, 2020 Apr CMFD @ 200 UNITS/100ML A 212441 002 Jul 24, 2020 Jan DISC HEPARIN SODIUM PRESERVATIVE FREE >D> AP NANJING KING-FRIEND 10,000 UNITS/ML A 212060 001 Apr 02, 2020 Aug DISC >A> @ 10,000 UNITS/ML A 212060 001 Apr 02, 2020 Aug DISC @ SHENZHEN TECHDOW 1,000 UNITS/ML A 202732 001 Jun 12, 2014 Apr DISC

HYDRALAZINE HYDROCHLORIDE TABLET;ORAL HYDRALAZINE HYDROCHLORIDE >D> AA ! PLIVA 25MG A 088467 001 May 01, 1984 Aug CRLD >A> AA +! 25MG A 088467 001 May 01, 1984 Aug CRLD >D> AA ! 50MG A 088468 001 May 01, 1984 Aug CRLD >A> AA +! 50MG A 088468 001 May 01, 1984 Aug CRLD >D> AA UPSHER SMITH LABS 10MG A 209251 001 Jul 09, 2018 Aug DISC >A> @ 10MG A 209251 001 Jul 09, 2018 Aug DISC AA 10MG A 209251 001 Jul 09, 2018 May CAHN >D> AA 25MG A 209251 002 Jul 09, 2018 Aug DISC >A> @ 25MG A 209251 002 Jul 09, 2018 Aug DISC AA 25MG A 209251 002 Jul 09, 2018 May CAHN >D> AA 50MG A 209251 003 Jul 09, 2018 Aug DISC >A> @ 50MG A 209251 003 Jul 09, 2018 Aug DISC AA 50MG A 209251 003 Jul 09, 2018 May CAHN >D> AA 100MG A 209251 004 Jul 09, 2018 Aug DISC >A> @ 100MG A 209251 004 Jul 09, 2018 Aug DISC AA 100MG A 209251 004 Jul 09, 2018 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -59

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE CAPSULE;ORAL APRESAZIDE >D> @ NOVARTIS 25MG;25MG A 084735 001 Aug CRLD >A> + @ 25MG;25MG A 084735 001 Aug CRLD >D> @ 50MG;50MG A 084810 001 Aug CRLD >A> + @ 50MG;50MG A 084810 001 Aug CRLD

HYDROCHLOROTHIAZIDE CAPSULE;ORAL MICROZIDE AB +! TEVA BRANDED PHARM 12.5MG N 020504 001 Dec 27, 1996 Mar CAHN SOLUTION;ORAL HYDROCHLOROTHIAZIDE >D> ROXANE@ 50MG/5ML A 088587 001 Jul 02, 1984 Aug CRLD >A> + @ 50MG/5ML A 088587 001 Jul 02, 1984 Aug CRLD TABLET;ORAL HYDROCHLOROTHIAZIDE >D> AB IVAX SUB TEVA PHARMS 25MG A 083177 001 Aug CRLD >A> AB + 25MG A 083177 001 Aug CRLD >D> AB ! 50MG A 083177 002 Aug CRLD >A> AB +! 50MG A 083177 002 Aug CRLD >D> @ 100MG A 085022 001 Aug CRLD >A> + @ 100MG A 085022 001 Aug CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL TABLET;ORAL ZESTORETIC AB + ALMATICA 12.5MG;10MG N 019888 003 Nov 18, 1993 Jan CAHN AB +! 12.5MG;20MG N 019888 001 Sep 20, 1990 Jan CAHN AB +! 25MG;20MG N 019888 002 Jul 20, 1989 Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM TABLET;ORAL HYZAAR >D> + @ ORGANON 12.5MG;50MG N 020387 001 Apr 28, 1995 Aug CMFD >A> AB + 12.5MG;50MG N 020387 001 Apr 28, 1995 Aug CMFD >D> + @ 25MG;100MG N 020387 002 Nov 10, 1998 Aug CMFD >A> AB + 25MG;100MG N 020387 002 Nov 10, 1998 Aug CMFD LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE AB JUBILANT CADISTA 12.5MG;50MG A 201845 001 Sep 18, 2012 Jun CAHN AB 12.5MG;100MG A 201845 002 Sep 18, 2012 Jun CAHN AB 25MG;100MG A 201845 003 Sep 18, 2012 Jun CAHN

HYDROCHLOROTHIAZIDE; SUCCINATE TABLET, EXTENDED RELEASE;ORAL DUTOPROL + @ CONCORDIA 12.5MG;EQ 25MG TARTRATE N 021956 001 Aug 28, 2006 Jun DISC + @ 12.5MG;EQ 50MG TARTRATE N 021956 002 Aug 28, 2006 Jun DISC + @ 12.5MG;EQ 100MG TARTRATE N 021956 003 Aug 28, 2006 Jun DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE TABLET;ORAL LOPRESSOR HCT AB + VALIDUS PHARMS 25MG;50MG N 018303 001 Dec 31, 1984 Feb CAHN + @ 25MG;100MG N 018303 002 Dec 31, 1984 Feb CAHN + @ 50MG;100MG N 018303 003 Dec 31, 1984 Feb CAHN

HYDROCHLOROTHIAZIDE; HYDROCHLORIDE TABLET;ORAL PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ ANI PHARMS 25MG;40MG A 070705 002 Oct 01, 1986 Jul CMS1 >D> ! MYLAN 25MG;40MG A 070947 002 Mar 04, 1987 Aug CAHN >A> @ 25MG;40MG A 070947 002 Mar 04, 1987 Aug CAHN >D> AB ! 25MG;80MG A 070947 001 Apr 01, 1987 Aug CAHN >A> @ 25MG;80MG A 070947 001 Apr 01, 1987 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -60

HYDROCHLOROTHIAZIDE; VALSARTAN TABLET;ORAL VALSARTAN AND HYDROCHLOROTHIAZIDE >A> @ CADILA 12.5MG;80MG A 203000 001 Mar 15, 2019 Aug CAHN >A> @ 12.5MG;160MG A 203000 002 Mar 15, 2019 Aug CAHN >A> @ 12.5MG;320MG A 203000 003 Mar 15, 2019 Aug CAHN >A> @ 25MG;160MG A 203000 004 Mar 15, 2019 Aug CAHN >A> @ 25MG;320MG A 203000 005 Mar 15, 2019 Aug CAHN >D> @ ZYDUS PHARMS 12.5MG;80MG A 203000 001 Mar 15, 2019 Aug CAHN >D> @ 12.5MG;160MG A 203000 002 Mar 15, 2019 Aug CAHN >D> @ 12.5MG;320MG A 203000 003 Mar 15, 2019 Aug CAHN >D> @ 25MG;160MG A 203000 004 Mar 15, 2019 Aug CAHN >D> @ 25MG;320MG A 203000 005 Mar 15, 2019 Aug CAHN

HYDROCODONE BITARTRATE CAPSULE, EXTENDED RELEASE;ORAL ZOHYDRO ER AB +! RECRO GAINESVILLE 10MG N 202880 001 Oct 25, 2013 May CAHN AB + 15MG N 202880 002 Oct 25, 2013 May CAHN AB + 20MG N 202880 003 Oct 25, 2013 May CAHN AB + 30MG N 202880 004 Oct 25, 2013 May CAHN AB + 40MG N 202880 005 Oct 25, 2013 May CAHN AB + 50MG N 202880 006 Oct 25, 2013 May CAHN TABLET, EXTENDED RELEASE;ORAL HYDROCODONE BITARTRATE AB ALVOGEN PINE BROOK 20MG A 208269 001 Mar 01, 2021 Feb NFTG AB 30MG A 208269 002 Mar 01, 2021 Feb NFTG AB 40MG A 208269 003 Mar 01, 2021 Feb NFTG AB 60MG A 208269 004 Mar 01, 2021 Feb NFTG AB 80MG A 208269 005 Mar 01, 2021 Feb NFTG AB 100MG A 208269 006 Mar 01, 2021 Feb NFTG AB 120MG A 208269 007 Mar 01, 2021 Feb NFTG

HYDROCODONE BITARTRATE; IBUPROFEN TABLET;ORAL HYDROCODONE BITARTRATE AND IBUPROFEN AB NOSTRUM LABS INC 5MG;200MG A 077727 001 Nov 06, 2006 Jan CAHN AB 7.5MG;200MG A 077723 001 Nov 06, 2006 Jan CAHN 10MG;200MG A 077723 002 Nov 06, 2006 Mar CTEC AB 10MG;200MG A 077723 002 Nov 06, 2006 Jan CAHN REPREXAIN @ AMNEAL PHARMS NY 2.5MG;200MG A 076642 003 Oct 19, 2007 Mar DISC @ 10MG;200MG A 076642 004 Oct 19, 2007 Mar DISC

HYDROCORTISONE CREAM;TOPICAL HYTONE >D> @ VALEANT INTL 1% A 080472 003 Aug CRLD >A> + @ 1% A 080472 003 Aug CRLD >D> @ 2.5% A 080472 004 Aug CRLD >A> + @ 2.5% A 080472 004 Aug CRLD SYNACORT BA USC H@ BAUSCH@ 0.5% A 087459 001 May CAHN >D> @ 1% A 087458 001 Aug CRLD >A> + @ 1% A 087458 001 Aug CRLD @ 1% A 087458 001 May CAHN >D> @ 2.5% A 087457 001 Aug CRLD >A> + @ 2.5% A 087457 001 Aug CRLD @ 2.5% A 087457 001 May CAHN ENEMA;RECTAL COLOCORT AB CHARTWELL 100MG/60ML A 075172 001 Dec 03, 1999 Apr CAHN LOTION;TOPICAL HYTONE >D> @ VALEANT INTL 1% A 080473 003 Aug CRLD >A> + @ 1% A 080473 003 Aug CRLD >D> @ 2.5% A 080473 004 Nov 30, 1982 Aug CRLD >A> + @ 2.5% A 080473 004 Nov 30, 1982 Aug CRLD OINTMENT;TOPICAL HYDROCORTISONE >D> AT ! FOUGERA PHARMS 1% A 080692 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -61

OINTMENT;TOPICAL HYDROCORTISONE >A> AT +! 1% A 080692 001 Aug CRLD HYTONE >D> @ DERMIK LABS 1% A 080474 003 Aug CRLD >A> + @ 1% A 080474 003 Aug CRLD >D> @ 2.5% A 080474 004 Aug CRLD >A> + @ 2.5% A 080474 004 Aug CRLD SOLUTION;TOPICAL PENECORT >D> @ ALLERGAN HERBERT 1% A 088214 001 Jun 06, 1984 Aug CRLD >A> + @ 1% A 088214 001 Jun 06, 1984 Aug CRLD

HYDROCORTISONE ACETATE CREAM;TOPICAL CARMOL HC >D> @ FOUGERA PHARMS 1% A 080505 001 Aug CRLD >A> + @ 1% A 080505 001 Aug CRLD HYDROCORTISONE ACETATE >D> @ PUREPAC PHARM 1% A 086052 001 Aug CRLD >A> + @ 1% A 086052 001 Aug CRLD

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE CREAM;TOPICAL CORTISPORIN + @ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 N 050218 001 Aug 09, 1985 Jul DISC UNITS/GM

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE AEROSOL, METERED;TOPICAL PROCTOFOAM HC >D> BX MYLAN SPECIALITY LP 1%;1% A 086195 001 Aug CHRS >A> BX +! 1%;1% A 086195 001 Aug CHRS

HYDROCORTISONE PROBUTATE CREAM;TOPICAL PANDEL +! ANI PHARMS 0.1% N 020453 001 Feb 28, 1997 Apr CAHN

HYDROCORTISONE SODIUM PHOSPHATE INJECTABLE;INJECTION HYDROCORTONE + @ MERCK EQ 50MG BASE/ML N 012052 001 Feb CRLD

HYDROCORTISONE VALERATE CREAM;TOPICAL HYDROCORTISONE VALERATE AB COSETTE 0.2% A 213724 001 Feb 11, 2021 Feb NEWA

HYDROMORPHONE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE @ LANNETT CO INC 2MG A 077471 002 Dec 09, 2009 Mar DISC @ 4MG A 077471 003 Dec 09, 2009 Mar DISC @ 8MG A 077471 001 Dec 09, 2009 Mar DISC

HYDROXYCHLOROQUINE SULFATE TABLET;ORAL HYDROXYCHLOROQUINE SULFATE >A> ACCORD HLTHCARE 100MG A 213342 002 Aug 18, 2021 Aug NEWA >A> 300MG A 213342 003 Aug 18, 2021 Aug NEWA >A> 400MG A 213342 004 Aug 18, 2021 Aug NEWA AB SENORES PHARMS 200MG A 212902 001 May 14, 2020 Jul CAHN

HYDROXYPROGESTERONE CAPROATE SOLUTION;INTRAMUSCULAR MAKENA AP1 +! COVIS 1250MG/5ML (250MG/ML) N 021945 001 Feb 03, 2011 Mar CAHN MAKENA PRESERVATIVE FREE AP +! COVIS 250MG/ML (250MG/ML) N 021945 002 Feb 19, 2016 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -62

SOLUTION;SUBCUTANEOUS MAKENA (AUTOINJECTOR) +! COVIS 275MG/1.1ML (250MG/ML) N 021945 004 Feb 14, 2018 Mar CAHN

HYDROXYUREA TABLET;ORAL SIKLOS +! ADDMEDICA SAS 1GM N 208843 002 Dec 21, 2017 Mar CHRS

HYDROXYZINE HYDROCHLORIDE SYRUP;ORAL HYDROCHLORIDE >D> AA ! WOCKHARDT BIO AG 10MG/5ML A 087294 001 Apr 12, 1982 Aug CRLD >A> AA +! 10MG/5ML A 087294 001 Apr 12, 1982 Aug CRLD TABLET;ORAL HYDROXYZINE HYDROCHLORIDE >D> AB ! PLIVA 10MG A 088617 001 Jan 10, 1986 Aug CRLD >A> AB +! 10MG A 088617 001 Jan 10, 1986 Aug CRLD >D> AB ! 25MG A 088618 001 Jan 10, 1986 Aug CRLD >A> AB +! 25MG A 088618 001 Jan 10, 1986 Aug CRLD >D> AB ! 50MG A 088619 001 Jan 10, 1986 Aug CRLD >A> AB +! 50MG A 088619 001 Jan 10, 1986 Aug CRLD AB PRINSTON INC 10MG A 040580 003 May 27, 2005 Feb CMS1 AB 25MG A 040580 002 May 27, 2005 Feb CMS1

IBANDRONATE SODIUM INJECTABLE;INTRAVENOUS IBANDRONATE SODIUM AP NANG KUANG PHARM CO EQ 3MG BASE/3ML A 204329 001 Jun 16, 2021 Jun NEWA

IBREXAFUNGERP CITRATE TABLET;ORAL BREXAFEMME +! SCYNEXIS EQ 150MG BASE N 214900 001 Jun 01, 2021 Jun NEWA

IBRUTINIB CAPSULE;ORAL ZY DUS@ ZYDUS@ 70MG A 211344 001 Mar 31, 2021 Jul DISC AB 70MG A 211344 001 Mar 31, 2021 Mar NFTG @ 140MG A 211344 002 Mar 31, 2021 Jul DISC AB 140MG A 211344 002 Mar 31, 2021 Mar NFTG IMBRUVICA + PHARMACYCLICS INC 70MG N 205552 002 Dec 20, 2017 Jul CTEC +! 140MG N 205552 001 Nov 13, 2013 Jul CTEC

IBUPROFEN SUSPENSION;ORAL IBUPROFEN AB PADAGIS US 100MG/5ML A 076925 001 Sep 23, 2004 Jul CAHN TABLET;ORAL IBUPROFEN AB L PERRIGO CO 400MG A 077114 001 Jul 18, 2005 Jul CAHN AB 600MG A 077114 002 Jul 18, 2005 Jul CAHN AB 800MG A 077114 003 Jul 18, 2005 Jul CAHN @ VINTAGE PHARMS 400MG A 071644 001 Feb 01, 1988 Feb DISC

IBUTILIDE FUMARATE INJECTABLE;INJECTION CORVERT AP +! PFIZER 0.1MG/ML N 020491 001 Dec 28, 1995 Feb CAHN

ICATIBANT ACETATE INJECTABLE;SUBCUTANEOUS ACETATE @ DR REDDYS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A 213054 001 Oct 05, 2020 May DISC AP GLENMARK PHARMS LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A 213222 001 May 21, 2021 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -63

ICOSAPENT ETHYL CAPSULE;ORAL ICOSAPENT ETHYL AB APOTEX 1GM A 209437 001 Jun 30, 2021 Jun NEWA @ TEVA PHARMS USA 500MG A 209525 001 Sep 11, 2020 Mar DISC @ 1GM A 209525 002 Sep 11, 2020 Mar DISC VASCEPA + AMARIN PHARMS 500MG N 202057 002 Feb 16, 2017 Mar CTEC

ILOPROST SOLUTION;INHALATION VENTAVIS +! ACTELION 10MCG/ML (10MCG/ML) N 021779 002 Dec 08, 2005 Feb CAHN @ 20MCG/2ML (10MCG/ML) N 021779 001 Dec 29, 2004 Feb CAHN +! 20MCG/ML (20MCG/ML) N 021779 003 Aug 07, 2009 Feb CAHN

IMIPRAMINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE >D> AB SPECGX LLC 10MG A 087846 002 May 22, 1984 Aug CRLD >A> AB + 10MG A 087846 002 May 22, 1984 Aug CRLD >D> AB 25MG A 087846 003 May 22, 1984 Aug CRLD >A> AB + 25MG A 087846 003 May 22, 1984 Aug CRLD TOFRANIL >D> AB ! SPECGX LLC 50MG A 087846 001 May 22, 1984 Aug CRLD >A> AB +! 50MG A 087846 001 May 22, 1984 Aug CRLD

IMIQUIMOD CREAM;TOPICAL AB TARO 3.75% A 205971 001 Jan 26, 2021 Jan NFTG

INDAPAMIDE TABLET;ORAL INDAPAMIDE AB ! ANI PHARMS 2.5MG A 074299 001 Jul 27, 1995 Jul CHRS @ MYLAN 1.25MG A 074461 002 Mar 26, 1997 Jul DISC @ 2.5MG A 074461 001 Mar 27, 1996 Jul DISC

INDOCYANINE GREEN INJECTABLE;INJECTION INDOCYANINE GREEN AP RENEW PHARMS 25MG/VIAL A 040811 001 Nov 21, 2007 Jun CAHN

INDOMETHACIN CAPSULE;ORAL INDOMETHACIN @ JUBILANT GENERICS 25MG A 205215 001 Aug 25, 2017 Jan DISC @ 50MG A 205215 002 Aug 25, 2017 Jan DISC TIVORBEX + @ GENUS 20MG N 204768 001 Feb 24, 2014 Apr DISC + @ 40MG N 204768 002 Feb 24, 2014 Apr DISC CAPSULE, EXTENDED RELEASE;ORAL INDOMETHACIN @ AUROBINDO PHARMA LTD 75MG A 204243 001 Dec 27, 2016 Jan DISC @ JUBILANT GENERICS 75MG A 202706 001 Oct 05, 2015 Jun DISC

INFIGRATINIB PHOSPHATE CAPSULE;ORAL TRUSELTIQ + QED THERAP 25MG N 214622 001 May 28, 2021 May NEWA +! 100MG N 214622 002 May 28, 2021 May NEWA

IOPAMIDOL INJECTABLE;INJECTION ISOVUE-300 +! BRACCO 61% N 018735 002 Dec 31, 1985 Jan CTEC ISOVUE-370 +! BRACCO 76% N 018735 003 Dec 31, 1985 Jan CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -64

INJECTABLE;INJECTION SCANLUX-300 @ SANOCHEMIA CORP USA 61% A 090394 001 Jun 18, 2010 Jan DISC SCANLUX-370 @ SANOCHEMIA CORP USA 76% A 090394 002 Jun 18, 2010 Jan DISC

IPRATROPIUM BROMIDE SOLUTION;INHALATION IPRATROPIUM BROMIDE >D> AN AUROBINDO PHARMA LTD 0.02% A 206543 001 Oct 27, 2016 Aug CAHN >A> AN LUOXIN AUROVITAS 0.02% A 206543 001 Oct 27, 2016 Aug CAHN

IRBESARTAN TABLET;ORAL IRBESARTAN @ US ANTIBIOTICS 75MG A 203161 001 Sep 27, 2012 May CAHN @ 150MG A 203161 002 Sep 27, 2012 May CAHN @ 300MG A 203161 003 Sep 27, 2012 May CAHN

IRINOTECAN HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE @ US ANTIBIOTICS 40MG/2ML (20MG/ML) A 078953 001 Apr 15, 2010 May CAHN @ 100MG/5ML (20MG/ML) A 078953 002 Apr 15, 2010 May CAHN

ISOETHARINE HYDROCHLORIDE SOLUTION;INHALATION ISOETHARINE HYDROCHLORIDE >D> @ ASTRAZENECA 0.062% A 087937 001 Nov 15, 1982 Aug CRLD >A> + @ 0.062% A 087937 001 Nov 15, 1982 Aug CRLD >D> @ 0.125% A 087938 001 Nov 15, 1982 Aug CRLD >A> + @ 0.125% A 087938 001 Nov 15, 1982 Aug CRLD >D> @ 0.167% A 088470 001 Mar 14, 1984 Aug CRLD >A> + @ 0.167% A 088470 001 Mar 14, 1984 Aug CRLD >D> @ 0.2% A 088471 001 Mar 14, 1984 Aug CRLD >A> + @ 0.2% A 088471 001 Mar 14, 1984 Aug CRLD >D> @ 0.25% A 088472 001 Mar 14, 1984 Aug CRLD >A> + @ 0.25% A 088472 001 Mar 14, 1984 Aug CRLD >D> @ DEY 1% A 086763 001 Aug CRLD >A> + @ 1% A 086763 001 Aug CRLD

ISOFLURANE LIQUID;INHALATION >D> AN PIRAMAL ENT 99.9% A 074502 001 Jun 27, 1995 Aug CAHN >A> AN PIRAMAL PHARMA 99.9% A 074502 001 Jun 27, 1995 Aug CAHN

ISONIAZID SYRUP;ORAL >D> ! CMP PHARMA INC 50MG/5ML A 088235 001 Nov 10, 1983 Aug CRLD >A> +! 50MG/5ML A 088235 001 Nov 10, 1983 Aug CRLD

ISOPROTERENOL HYDROCHLORIDE INJECTABLE;INJECTION ISOPROTERENOL HYDROCHLORIDE AP AMRING PHARMS 0.2MG/ML A 211237 001 May 19, 2021 May NEWA >D> AP AUROBINDO PHARMA LTD 0.2MG/ML A 211864 001 Feb 09, 2021 Aug DISC >A> @ 0.2MG/ML A 211864 001 Feb 09, 2021 Aug DISC AP 0.2MG/ML A 211864 001 Feb 09, 2021 Jan NEWA >D> AP CIPLA 0.2MG/ML A 211738 001 Jun 28, 2019 Aug DISC >A> @ 0.2MG/ML A 211738 001 Jun 28, 2019 Aug DISC AP MICRO LABS 0.2MG/ML A 210845 001 Feb 16, 2021 Feb NEWA

ISOTRETINOIN CAPSULE;ORAL AMNESTEEM AB1 MYLAN PHARMS INC 10MG A 075945 001 Nov 08, 2002 Mar CTEC AB1 20MG A 075945 002 Nov 08, 2002 Mar CTEC AB1 40MG A 075945 003 Nov 08, 2002 Mar CTEC CLARAVIS AB1 TEVA PHARMS USA 10MG A 076356 001 Apr 11, 2003 Mar CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -65

CAPSULE;ORAL CLARAVIS AB1 20MG A 076135 002 Apr 11, 2003 Mar CTEC AB1 30MG A 076135 003 May 11, 2006 Mar CTEC AB1 ! 40MG A 076135 001 Apr 11, 2003 Mar CTEC AB2 ACTAVIS LABS FL 10MG A 205063 001 Mar 31, 2021 Mar NFTG AB2 20MG A 205063 002 Mar 31, 2021 Mar NFTG AB2 25MG A 205063 003 Mar 31, 2021 Mar NFTG AB2 30MG A 205063 004 Mar 31, 2021 Mar NFTG AB2 35MG A 205063 005 Mar 31, 2021 Mar NFTG AB2 40MG A 205063 006 Mar 31, 2021 Mar NFTG AB1 AMNEAL PHARMS NY 10MG A 207792 001 Sep 29, 2017 Mar CTEC AB1 20MG A 207792 002 Sep 29, 2017 Mar CTEC AB1 30MG A 207792 003 Sep 29, 2017 Mar CTEC AB1 40MG A 207792 004 Sep 29, 2017 Mar CTEC AB2 UPSHER SMITH LABS 40MG A 213571 001 Apr 12, 2021 Apr NEWA MYORISAN AB1 DOUGLAS PHARMS 10MG A 076485 001 Jan 19, 2012 Mar CTEC AB1 20MG A 076485 002 Jan 19, 2012 Mar CTEC AB1 30MG A 076485 004 Aug 25, 2015 Mar CTEC AB1 40MG A 076485 003 Jan 19, 2012 Mar CTEC ZENATANE AB1 DR REDDYS LABS LTD 10MG A 202099 001 Mar 25, 2013 Mar CTEC AB1 20MG A 202099 002 Mar 25, 2013 Mar CTEC AB1 30MG A 202099 004 Feb 23, 2015 Mar CTEC AB1 40MG A 202099 003 Mar 25, 2013 Mar CTEC

ITRACONAZOLE TABLET;ORAL ONMEL + @ SEBELA IRELAND LTD 200MG N 022484 001 Apr 29, 2010 Apr DISC

IVACAFTOR; IVACAFTOR, TEZACAFTOR TABLET;ORAL SYMDEKO (COPACKAGED) + VERTEX PHARMS INC 75MG;75MG, 50MG N 210491 002 Jun 21, 2019 Jul CPOT + 75MG,N/A;75MG, 50MG N 210491 002 Jun 21, 2019 Jul CDFR +! 150MG;150MG, 100MG N 210491 001 Feb 12, 2018 Jul CPOT +! 150MG,N/A;150MG, 100MG N 210491 001 Feb 12, 2018 Jul CDFR

IVOSIDENIB TABLET;ORAL TIBSOVO +! SERVIER 250MG N 211192 001 Jul 20, 2018 Apr CAHN

IXAZOMIB CITRATE CAPSULE;ORAL NINLARO + TAKEDA PHARMS USA EQ 2.3MG BASE N 208462 001 Nov 20, 2015 May CAHN + EQ 3MG BASE N 208462 002 Nov 20, 2015 May CAHN +! EQ 4MG BASE N 208462 003 Nov 20, 2015 May CAHN

KETAMINE HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE >D> AP AUROMEDICS PHARMA EQ 10MG BASE/ML A 076092 001 Sep 30, 2008 Aug CAHN AP EQ 10MG BASE/ML A 076092 001 Sep 30, 2008 Jan CAHN >D> AP EQ 50MG BASE/ML A 076092 002 Dec 28, 2001 Aug CAHN AP EQ 50MG BASE/ML A 076092 002 Dec 28, 2001 Jan CAHN >D> AP EQ 100MG BASE/ML A 076092 003 Oct 25, 2002 Aug CAHN AP EQ 100MG BASE/ML A 076092 003 Oct 25, 2002 Jan CAHN >A> AP EUGIA PHARMA EQ 10MG BASE/ML A 076092 001 Sep 30, 2008 Aug CAHN >A> AP EQ 50MG BASE/ML A 076092 002 Dec 28, 2001 Aug CAHN >A> AP EQ 100MG BASE/ML A 076092 003 Oct 25, 2002 Aug CAHN

KETOCONAZOLE AEROSOL, FOAM;TOPICAL AT XIROMED 2% A 213601 001 May 21, 2021 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -66

CREAM;TOPICAL KETOCONAZOLE AB ENCUBE 2% A 212443 001 May 20, 2021 May NEWA TABLET;ORAL KETOCONAZOLE >D> AB HAVIX 200MG A 075912 001 Jan 10, 2002 Aug CAHN @ MYLAN 200MG A 075597 001 Dec 23, 1999 Mar DISC >A> AB SENORES PHARMS 200MG A 075912 001 Jan 10, 2002 Aug CAHN

KETOPROFEN CAPSULE;ORAL ! HERITAGE PHARMS INC 75MG A 074014 003 Jan 29, 1993 Jul CTEC AB ! 75MG A 074014 003 Jan 29, 1993 Jul CHRS @ RISING 50MG A 074024 001 Dec 29, 1995 Jan CAHN @ 75MG A 074024 002 Dec 29, 1995 Jan CAHN @ TEVA 75MG A 073517 001 Dec 22, 1992 Jul DISC

KETOROLAC TROMETHAMINE INJECTABLE;INJECTION TROMETHAMINE @ AUROBINDO PHARMA LTD 15MG/ML A 212939 001 Oct 20, 2020 Apr DISC @ 30MG/ML A 212939 002 Oct 20, 2020 Apr DISC @ HOSPIRA 15MG/ML A 074993 001 Jan 27, 1999 Mar DISC

LABETALOL HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE AP BAXTER HLTHCARE CORP 5MG/ML A 076051 001 Jul 05, 2002 Mar CMFD >A> AP CAPLIN 5MG/ML A 214533 001 Sep 07, 2021 Aug NEWA TABLET;ORAL LABETALOL HYDROCHLORIDE AB ! PAR FORM 200MG A 200908 002 Jul 10, 2012 Jul CHRS >A> AB RUBICON 100MG A 211953 001 Aug 18, 2021 Aug NEWA >A> AB 200MG A 211953 002 Aug 18, 2021 Aug NEWA >A> AB 300MG A 211953 003 Aug 18, 2021 Aug NEWA TRANDATE + @ ALVOGEN 100MG N 018716 001 May 24, 1985 Jul DISC AB + 100MG N 018716 001 May 24, 1985 Jul CAHN + @ 200MG N 018716 002 Aug 01, 1984 Jul DISC AB +! 200MG N 018716 002 Aug 01, 1984 Jul CAHN + @ 300MG N 018716 003 Aug 01, 1984 Jul DISC AB + 300MG N 018716 003 Aug 01, 1984 Jul CAHN + @ 400MG N 018716 004 Aug 01, 1984 Jul CAHN AB +! CNTY LINE PHARMS 200MG N 018716 002 Aug 01, 1984 Apr CHRS

LACTULOSE SOLUTION;ORAL LACTULOSE AA TORRENT 10GM/15ML A 207786 001 Jun 11, 2018 Jun CMFD SOLUTION;ORAL, RECTAL LACTULOSE AA TORRENT 10GM/15ML A 203762 001 Mar 27, 2015 Jun CMFD

LAMIVUDINE TABLET;ORAL LAMIVUDINE AB CENTAUR PHARMS PVT 150MG A 203586 001 Nov 21, 2016 Jun CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE + @ AUROBINDO PHARMA LTD 300MG;300MG N 022344 001 May 15, 2018 Feb DISC TEMIXYS >D> +! CELLTRION 300MG;300MG N 211284 001 Nov 16, 2018 Aug DISC >A> + @ 300MG;300MG N 211284 001 Nov 16, 2018 Aug DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -67

LAMOTRIGINE TABLET;ORAL @ GRANULES 25MG A 078982 001 Jan 27, 2009 Jun CAHN @ 100MG A 078982 002 Jan 27, 2009 Jun CAHN @ 150MG A 078982 003 Jan 27, 2009 Jun CAHN @ 200MG A 078982 004 Jan 27, 2009 Jun CAHN TABLET, CHEWABLE;ORAL LAMOTRIGINE @ JUBILANT GENERICS 5MG A 200220 001 Feb 28, 2011 Jun DISC @ 25MG A 200220 002 Feb 28, 2011 Jun DISC TABLET, EXTENDED RELEASE;ORAL LAMOTRIGINE AB ACTAVIS ELIZABETH 250MG A 200672 006 Nov 13, 2013 Jul CMS1 TABLET, ORALLY DISINTEGRATING;ORAL LAMOTRIGINE AB AJANTA PHARMA LTD 25MG A 213271 001 Jan 19, 2021 Jan NEWA AB 50MG A 213271 002 Jan 19, 2021 Jan NEWA AB 100MG A 213271 003 Jan 19, 2021 Jan NEWA AB 200MG A 213271 004 Jan 19, 2021 Jan NEWA

LANSOPRAZOLE CAPSULE, DELAYED REL PELLETS;ORAL PREVACID + @ TAKEDA PHARMS USA 15MG N 020406 001 May 10, 1995 Jun DISC TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL LANSOPRAZOLE AB DR REDDYS LABS LTD 15MG A 210465 001 Feb 01, 2021 Jan NEWA AB 30MG A 210465 002 Feb 01, 2021 Jan NEWA

LASMIDITAN SUCCINATE TABLET;ORAL REYVOW + ELI LILLY AND CO EQ 50MG BASE N 211280 001 Jan 31, 2020 May CPOT >D> + EQ 100MG BASE N 211280 002 Jan 31, 2020 Aug CHRS >A> +! EQ 100MG BASE N 211280 002 Jan 31, 2020 Aug CHRS + EQ 100MG BASE N 211280 002 Jan 31, 2020 May CHRS +! EQ 100MG BASE N 211280 002 Jan 31, 2020 May CPOT >D> +! EQ 200MG BASE N 211280 003 Dec 18, 2020 Aug DISC >A> + @ EQ 200MG BASE N 211280 003 Dec 18, 2020 Aug DISC +! EQ 200MG BASE N 211280 003 Dec 18, 2020 May CHRS + EQ 200MG BASE N 211280 003 Dec 18, 2020 May CPOT

LEFLUNOMIDE TABLET;ORAL AB AET PHARMA 10MG A 213497 001 May 10, 2021 Jun CAHN AB 20MG A 213497 002 May 10, 2021 Jun CAHN AB AUROBINDO PHARMA LTD 10MG A 213652 001 Mar 29, 2021 Mar NEWA AB 20MG A 213652 002 Mar 29, 2021 Mar NEWA AB AXUNIO 10MG A 213497 001 May 10, 2021 Apr NEWA AB 20MG A 213497 002 May 10, 2021 Apr NEWA

LENALIDOMIDE CAPSULE;ORAL AB ARROW INTL 5MG A 201452 001 May 21, 2021 Jul CAHN AB 10MG A 201452 002 May 21, 2021 Jul CAHN AB 15MG A 201452 003 May 21, 2021 Jul CAHN AB 25MG A 201452 004 May 21, 2021 Jul CAHN AB NATCO PHARMA LTD 5MG A 201452 001 May 21, 2021 May NFTG AB 10MG A 201452 002 May 21, 2021 May NFTG AB 15MG A 201452 003 May 21, 2021 May NFTG AB 25MG A 201452 004 May 21, 2021 May NFTG

LETROZOLE TABLET;ORAL LETROZOLE @ APOTEX INC 2.5MG A 091303 001 Apr 19, 2012 Jan DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -68

LETROZOLE; SUCCINATE TABLET;ORAL KISQALI FEMARA CO-PACK (COPACKAGED) +! NOVARTIS 2.5MG;EQ 200MG BASE N 209935 001 May 04, 2017 Jul CPOT +! 2.5MG,N/A;N/A,EQ 200MG BASE N 209935 001 May 04, 2017 Jul CDFR

LEUCOVORIN CALCIUM INJECTABLE;INJECTION LEUCOVORIN CALCIUM AP ! HIKMA PHARMS EQ 50MG BASE/VIAL A 089384 001 Sep 14, 1987 Jul CAHN AP ! EQ 100MG BASE/VIAL A 089717 001 Mar 28, 1988 Jul CAHN TABLET;ORAL LEUCOVORIN CALCIUM AB EPIC PHARMA LLC EQ 10MG BASE A 074544 003 May 19, 2021 May NEWA AB EQ 15MG BASE A 074544 004 May 19, 2021 May NEWA

LEUPROLIDE ACETATE INJECTABLE;INJECTION LEUPROLIDE ACETATE >A> AP VGYAAN 1MG/0.2ML A 213829 001 Aug 13, 2021 Aug NEWA

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE INJECTABLE, TABLET;INTRAMUSCULAR, ORAL LUPANETA PACK >D> + ABBVIE ENDOCRINE 3.75MG/VIAL,N/A;N/A,5MG N 203696 001 Dec 14, 2012 Aug DISC >A> + @ 3.75MG/VIAL,N/A;N/A,5MG N 203696 001 Dec 14, 2012 Aug DISC >D> +! 11.25MG/VIAL,N/A;N/A,5MG N 203696 002 Dec 14, 2012 Aug DISC >A> + @ 11.25MG/VIAL,N/A;N/A,5MG N 203696 002 Dec 14, 2012 Aug DISC

LEUPROLIDE MESYLATE EMULSION;SUBCUTANEOUS CAMCEVI KIT +! FORESEE PHARMS EQ 42MG BASE N 211488 001 May 25, 2021 May NEWA

LEVALBUTEROL HYDROCHLORIDE SOLUTION;INHALATION LEVALBUTEROL HYDROCHLORIDE >D> AN AUROBINDO PHARMA LTD EQ 0.25% BASE A 207628 001 Jan 31, 2017 Aug CAHN >D> AN EQ 0.0103% BASE A 207625 001 Dec 30, 2016 Aug CAHN >D> AN EQ 0.021% BASE A 207625 002 Dec 30, 2016 Aug CAHN >D> AN EQ 0.042% BASE A 207625 003 Dec 30, 2016 Aug CAHN >A> AN LUOXIN AUROVITAS EQ 0.25% BASE A 207628 001 Jan 31, 2017 Aug CAHN >A> AN EQ 0.0103% BASE A 207625 001 Dec 30, 2016 Aug CAHN >A> AN EQ 0.021% BASE A 207625 002 Dec 30, 2016 Aug CAHN >A> AN EQ 0.042% BASE A 207625 003 Dec 30, 2016 Aug CAHN

LEVETIRACETAM INJECTABLE;INTRAVENOUS @ JUBILANT GENERICS 500MG/5ML (100MG/ML) A 206838 001 Jun 02, 2016 Jun DISC LEVETIRACETAM IN SODIUM CHLORIDE AP AUROBINDO PHARMA LTD 1GM/100ML (10MG/ML) A 207160 002 Jan 04, 2017 Feb CPOT AP 1.5GM/100ML (15MG/ML) A 207160 003 Jan 04, 2017 Feb CPOT AP GLAND PHARMA LTD 1GM/100ML (10MG/ML) A 206880 002 Oct 25, 2017 Feb CPOT AP 1.5GM/100ML (15MG/ML) A 206880 003 Oct 25, 2017 Feb CDFR AP +! HQ SPECIALITY PHARMA 1GM/100ML (10MG/ML) N 202543 002 Nov 09, 2011 Feb CPOT AP +! 1.5GM/100ML (15MG/ML) N 202543 003 Nov 09, 2011 Feb CPOT AP NEXUS PHARMS 1GM/100ML (10MG/ML) A 213532 002 Jul 06, 2020 Feb CPOT AP 1.5GM/100ML (15MG/ML) A 213532 003 Jul 06, 2020 Feb CPOT SOLUTION;ORAL LEVETIRACETAM AA AKORN 100MG/ML A 090601 001 Feb 28, 2012 Feb CAHN TABLET;ORAL LEVETIRACETAM >D> AB LOTUS PHARM CO LTD 250MG A 090906 002 Oct 31, 2016 Aug DISC >A> @ 250MG A 090906 002 Oct 31, 2016 Aug DISC >D> AB 750MG A 090906 003 Oct 31, 2016 Aug DISC >A> @ 750MG A 090906 003 Oct 31, 2016 Aug DISC >D> AB 1GM A 090906 004 Oct 31, 2016 Aug DISC >A> @ 1GM A 090906 004 Oct 31, 2016 Aug DISC @ NOSTRUM LABS INC 250MG A 090511 001 Aug 18, 2011 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -69

TABLET;ORAL LEVETIRACETAM AB 250MG A 090511 001 Aug 18, 2011 Jan CAHN @ 500MG A 090511 002 Aug 18, 2011 Mar DISC AB 500MG A 090511 002 Aug 18, 2011 Jan CAHN @ 750MG A 090511 003 Aug 18, 2011 Mar DISC AB 750MG A 090511 003 Aug 18, 2011 Jan CAHN @ 1GM A 090511 004 Aug 18, 2011 Mar DISC AB 1GM A 090511 004 Aug 18, 2011 Jan CAHN AB SCIEGEN PHARMS INC 750MG A 215069 001 Jun 11, 2021 Jun NEWA AB 1GM A 215069 002 Jun 11, 2021 Jun NEWA TABLET, EXTENDED RELEASE;ORAL ELEPSIA XR + TRIPOINT 1GM N 204417 001 Dec 20, 2018 Jan CAHN +! 1.5GM N 204417 002 Dec 20, 2018 Jan CAHN LEVETIRACETAM >D> AB LOTUS PHARM CO LTD 500MG A 202095 002 Jun 06, 2016 Aug DISC >A> @ 500MG A 202095 002 Jun 06, 2016 Aug DISC >D> AB 750MG A 202095 001 Jun 06, 2016 Aug DISC >A> @ 750MG A 202095 001 Jun 06, 2016 Aug DISC AB OVERSEAS 750MG A 212688 001 Jun 11, 2020 May CMFD

LEVOBUNOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC AKBETA AK ORN@ AKORN@ 0.25% A 074779 001 Oct 29, 1996 Jul DISC @ 0.5% A 074780 001 Oct 29, 1996 Jul DISC BETAGAN + @ ALLERGAN 0.25% N 019814 001 Jun 28, 1989 Jun DISC

LEVOCETIRIZINE DIHYDROCHLORIDE SOLUTION;ORAL DIHYDROCHLORIDE AA ! PADAGIS US 2.5MG/5ML A 091263 001 Nov 07, 2011 Jul CAHN XYZAL + @ SANOFI 2.5MG/5ML N 022157 001 Jan 28, 2008 Apr DISC TABLET;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE AB ! GLENMARK GENERICS 5MG A 090385 001 Feb 24, 2011 Apr CHRS @ GRANULES 5MG A 090486 001 Mar 26, 2013 Apr CAHN @ NEOPHARMA 5MG A 204323 001 Dec 20, 2016 Mar DISC @ US ANTIBIOTICS 5MG A 204323 001 Dec 20, 2016 May CAHN XYZAL + @ SANOFI 5MG N 022064 001 May 25, 2007 Apr DISC

LEVOFLOXACIN TABLET;ORAL LEVOFLOXACIN AB CADILA 250MG A 077652 001 Sep 07, 2012 Jun CAHN AB 500MG A 077652 002 Sep 07, 2012 Jun CAHN AB 750MG A 077652 003 Sep 07, 2012 Jun CAHN @ JUBILANT GENERICS 250MG A 203613 001 Jun 19, 2015 Jun DISC @ 500MG A 203613 002 Jun 19, 2015 Jun DISC

LEVOLEUCOVORIN CALCIUM POWDER;INTRAVENOUS LEVOLEUCOVORIN CALCIUM AP HIKMA PHARMS EQ 50MG BASE/VIAL A 206263 001 Jun 16, 2016 Jul CAHN

LEVORPHANOL TARTRATE TABLET;ORAL TARTRATE NOVITIUM PHARMA 1MG A 213479 003 Jul 20, 2021 Jul NEWA AB 3MG A 213479 002 Jan 12, 2021 Jan NEWA AB ! SENTYNL THERAPS INC 3MG A 074278 003 Jun 18, 2018 Jan CTEC AB SUN PHARM INDS INC 2MG A 213906 001 Jun 17, 2021 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -70

LEVOTHYROXINE SODIUM CAPSULE;ORAL LEVOTHYROXINE SODIUM @ TEVA PHARMS USA INC 0.075MG A 211369 001 Oct 28, 2020 Apr DISC @ 0.088MG A 213256 001 Jan 06, 2021 Jul DISC @ 0.1MG A 213256 002 Jan 06, 2021 Jul DISC AB 0.112MG A 211369 003 Apr 16, 2021 Apr NFTG @ 0.125MG A 213256 003 Jan 06, 2021 Jul DISC @ 0.15MG A 211369 002 Oct 28, 2020 Apr DISC TIROSINT + INSTITUT BIOCHIMIQUE 0.075MG N 021924 004 Oct 13, 2006 Apr CTEC + 0.15MG N 021924 007 Oct 13, 2006 Apr CTEC POWDER;INTRAVENOUS LEVOTHYROXINE SODIUM @ DR REDDYS 100MCG/VIAL A 208837 001 Mar 27, 2020 Feb DISC SOLUTION;INTRAVENOUS LEVOTHYROXINE SODIUM +! CUSTOPHARM INC 100MCG/ML N 214253 001 May 17, 2021 May NEWA SOLUTION;ORAL THYQUIDITY +! VISTAPHARM 100MCG/5ML N 214047 001 Nov 30, 2020 Apr CAHN TIROSINT-SOL + INSTITUT BIOCHIMIQUE 37.5MCG/ML N 206977 013 Jan 13, 2021 Jan NEWA + 44MCG/ML N 206977 014 Jan 13, 2021 Jan NEWA + 62.5MCG/ML N 206977 015 Jan 13, 2021 Jan NEWA

LIDOCAINE OINTMENT;TOPICAL LIDOCAINE >D> AT ! FOUGERA PHARMS INC 5% A 080198 001 Aug CRLD >A> AT +! 5% A 080198 001 Aug CRLD AT QUAGEN 5% A 212695 001 Apr 20, 2021 Apr NEWA RI SIN G@ RISING@ 5% A 208604 001 Sep 20, 2017 May CAHN PATCH;TOPICAL LIDOCAINE AB NAL PHARM 5% A 205882 001 Apr 29, 2021 Apr NEWA @ NOVEN PHARMS INC 5% A 203265 001 Dec 01, 2020 Jun DISC

LIDOCAINE HYDROCHLORIDE JELLY;TOPICAL XYLOCAINE + @ AKORN 2% N 008816 001 Jan DISC SOLUTION;ORAL LIDOCAINE HYDROCHLORIDE VISCOUS AT LANNETT CO INC 2% A 040708 001 Feb 27, 2007 Jan CMFD

LIDOCAINE; CREAM;TOPICAL LIDOCAINE AND PRILOCAINE AB ACRUX DDS PTY 2.5%;2.5% A 212482 001 Jul 27, 2021 Jul NEWA

LINACLOTIDE CAPSULE;ORAL LINACLOTIDE MY LAN@ MYLAN@ 145MCG A 209564 001 Feb 09, 2021 Feb DISC AB 145MCG A 209564 001 Feb 09, 2021 Jan NFTG @ 290MCG A 209564 002 Feb 09, 2021 Feb DISC AB 290MCG A 209564 002 Feb 09, 2021 Jan NFTG LINZESS +! ALLERGAN 145MCG N 202811 001 Aug 30, 2012 Feb CTEC + 290MCG N 202811 002 Aug 30, 2012 Feb CTEC

LINAGLIPTIN TABLET;ORAL >A> >A> AB SUNSHINE 5MG A 208335 001 Aug 31, 2021 Aug NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -71

LINAGLIPTIN; HYDROCHLORIDE TABLET;ORAL >A> LINAGLIPTIN AND METFORMIN HYDROCHLORIDE >A> AB SUNSHINE 2.5MG;500MG A 208336 001 Aug 30, 2021 Aug NFTG >A> AB 2.5MG;850MG A 208336 002 Aug 30, 2021 Aug NFTG >A> AB 2.5MG;1GM A 208336 003 Aug 30, 2021 Aug NFTG

LINCOMYCIN HYDROCHLORIDE INJECTABLE;INJECTION LINCOCIN AP +! PFIZER EQ 300MG BASE/ML N 050317 001 Feb CAHN LINCOMYCIN HYDROCHLORIDE AP PRAXGEN EQ 300MG BASE/ML A 212770 001 Mar 12, 2021 Mar NEWA

LIOTHYRONINE SODIUM TABLET;ORAL LIOTHYRONINE SODIUM AB ZYDUS EQ 0.005MG BASE A 214803 001 Jan 22, 2021 Jan NEWA AB EQ 0.025MG BASE A 214803 002 Jan 22, 2021 Jan NEWA AB EQ 0.05MG BASE A 214803 003 Jan 22, 2021 Jan NEWA

LISINOPRIL TABLET;ORAL LISINOPRIL AB YILING 20MG A 208920 001 Mar 04, 2021 Feb NEWA AB 30MG A 208920 002 Mar 04, 2021 Feb NEWA AB 40MG A 208920 003 Mar 04, 2021 Feb NEWA

LOPINAVIR; RITONAVIR TABLET;ORAL LOPINAVIR AND RITONAVIR AB HETERO LABS LTD III 100MG;25MG A 091677 001 Jun 04, 2021 May NFTG AB 200MG;50MG A 091677 002 Jun 04, 2021 May NFTG

LORAZEPAM >A> CAPSULE, EXTENDED RELEASE;ORAL >A> LOREEV XR >A> + ALMATICA 1MG N 214826 001 Aug 27, 2021 Aug NEWA >A> + 2MG N 214826 002 Aug 27, 2021 Aug NEWA >A> +! 3MG N 214826 003 Aug 27, 2021 Aug NEWA CONCENTRATE;ORAL AA AKORN 2MG/ML A 200169 001 Jan 30, 2012 Feb CAHN INJECTABLE;INJECTION ATIVAN AP +! HIKMA PHARMS 2MG/ML N 018140 001 Jul CAHN AP +! 4MG/ML N 018140 002 Jul CAHN

LOSARTAN POTASSIUM TABLET;ORAL COZAAR >D> + @ ORGANON 25MG N 020386 001 Apr 14, 1995 Aug CMFD >A> AB + 25MG N 020386 001 Apr 14, 1995 Aug CMFD >D> + @ 50MG N 020386 002 Apr 14, 1995 Aug CMFD >A> AB + 50MG N 020386 002 Apr 14, 1995 Aug CMFD LOSARTAN POTASSIUM AB HIKMA PHARMS 25MG A 077459 001 Oct 06, 2010 Jul CMFD AB 50MG A 077459 002 Oct 06, 2010 Jul CMFD AB 100MG A 077459 003 Oct 06, 2010 Jul CMFD AB JUBILANT CADISTA 25MG A 201170 001 Sep 18, 2012 Jun CAHN AB 50MG A 201170 002 Sep 18, 2012 Jun CAHN AB 100MG A 201170 003 Sep 18, 2012 Jun CAHN

LOTEPREDNOL ETABONATE GEL;OPHTHALMIC LOTEPREDNOL ETABONATE AB AKORN 0.5% A 212080 001 Feb 10, 2021 Jan NFTG SUSPENSION/DROPS;OPHTHALMIC LOTEPREDNOL ETABONATE AB SUN PHARM 0.5% A 212450 001 Feb 26, 2021 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -72

LOXAPINE SUCCINATE CAPSULE;ORAL SUCCINATE >D> @ MYLAN EQ 5MG BASE A 076762 001 Nov 01, 2004 Aug CAHN >A> @ EQ 5MG BASE A 076762 001 Nov 01, 2004 Aug CAHN @ EQ 5MG BASE A 076762 001 Nov 01, 2004 Jul DISC >D> @ EQ 10MG BASE A 076762 002 Nov 01, 2004 Aug CAHN >A> @ EQ 10MG BASE A 076762 002 Nov 01, 2004 Aug CAHN @ EQ 10MG BASE A 076762 002 Nov 01, 2004 Jul DISC >D> @ EQ 25MG BASE A 076762 003 Nov 01, 2004 Aug CAHN >A> @ EQ 25MG BASE A 076762 003 Nov 01, 2004 Aug CAHN @ EQ 25MG BASE A 076762 003 Nov 01, 2004 Jul DISC >D> @ EQ 50MG BASE A 076762 004 Nov 01, 2004 Aug CAHN >A> @ EQ 50MG BASE A 076762 004 Nov 01, 2004 Aug CAHN @ EQ 50MG BASE A 076762 004 Nov 01, 2004 Jul DISC

LULICONAZOLE CREAM;TOPICAL LUZU +! BAUSCH 1% N 204153 001 Nov 14, 2013 May CAHN

LURASIDONE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ALEMBIC PHARMS LTD 20MG A 213248 001 May 13, 2021 May NEWA AB 40MG A 213248 002 May 13, 2021 May NEWA AB 60MG A 213248 003 May 13, 2021 May NEWA AB 80MG A 213248 004 May 13, 2021 May NEWA AB 120MG A 213248 005 May 13, 2021 May NEWA >A> AB DR REDDYS LABS LTD 20MG A 208047 001 Aug 24, 2021 Aug NEWA >A> AB 40MG A 208047 002 Aug 24, 2021 Aug NEWA >A> AB 60MG A 208047 003 Aug 24, 2021 Aug NEWA >A> AB 80MG A 208047 004 Aug 24, 2021 Aug NEWA >D> AB PIRAMAL HLTHCARE UK 20MG A 212091 001 Dec 28, 2020 Aug DISC >A> @ 20MG A 212091 001 Dec 28, 2020 Aug DISC >D> AB 40MG A 212091 002 Dec 28, 2020 Aug DISC >A> @ 40MG A 212091 002 Dec 28, 2020 Aug DISC >D> AB 60MG A 212091 003 Dec 28, 2020 Aug DISC >A> @ 60MG A 212091 003 Dec 28, 2020 Aug DISC >D> AB 80MG A 212091 004 Dec 28, 2020 Aug DISC >A> @ 80MG A 212091 004 Dec 28, 2020 Aug DISC >D> AB 120MG A 212091 005 Dec 28, 2020 Aug DISC >A> @ 120MG A 212091 005 Dec 28, 2020 Aug DISC AB WATSON LABS TEVA 20MG A 208016 001 Feb 02, 2021 Jan NEWA AB 40MG A 208016 002 Feb 02, 2021 Jan NEWA AB 60MG A 208016 003 Feb 02, 2021 Jan NEWA AB 80MG A 208016 004 Feb 02, 2021 Jan NEWA AB 120MG A 208016 005 Feb 02, 2021 Jan NEWA

MACITENTAN TABLET;ORAL >D> >D> AB ZYDUS 10MG A 211224 001 Apr 06, 2021 Aug DISC >A> @ 10MG A 211224 001 Apr 06, 2021 Aug DISC AB 10MG A 211224 001 Apr 06, 2021 Mar NFTG OPSUMIT >D> AB +! ACTELION 10MG N 204410 001 Oct 18, 2013 Aug CTEC >A> +! 10MG N 204410 001 Oct 18, 2013 Aug CTEC +! 10MG N 204410 001 Oct 18, 2013 Feb CAHN

MAGNESIUM SULFATE INJECTABLE;INJECTION MAGNESIUM SULFATE AP B BRAUN MEDICAL INC 2GM/50ML (40MG/ML) A 207967 001 Apr 26, 2021 Apr NEWA AP 4GM/100ML (40MG/ML) A 207967 002 Apr 26, 2021 Apr NEWA AP 4GM/50ML (80MG/ML) A 207967 003 Apr 26, 2021 Apr NEWA MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER AP BAXTER HLTHCARE CORP 1GM/100ML A 211965 001 Aug 11, 2020 Feb CMFD MAGNESIUM SULFATE IN PLASTIC CONTAINER AP BAXTER HLTHCARE CORP 2GM/50ML (40MG/ML) A 211966 001 Jun 01, 2020 Feb CMFD AP 4GM/50ML (80MG/ML) A 211966 002 Jun 01, 2020 Feb CMFD AP 4GM/100ML (40MG/ML) A 211966 003 Jun 01, 2020 Feb CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -73

MAPROTILINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE @ HERITAGE PHARMA 50MG A 072163 001 Jun 01, 1988 Jun CAHN @ MYLAN 25MG A 072285 002 Oct 03, 1988 Jul DISC @ 50MG A 072285 001 Oct 03, 1988 Jul DISC @ 75MG A 072285 003 Oct 03, 1988 Jul DISC

MEDROXYPROGESTERONE ACETATE INJECTABLE;INJECTION DEPO-PROVERA + PFIZER@ 100MG/ML N 012541 002 Mar CAHN AB +! 150MG/ML N 020246 001 Oct 29, 1992 Mar CAHN + @ 400MG/ML N 012541 003 May DISC +! 400MG/ML N 012541 003 Mar CAHN INJECTABLE;SUBCUTANEOUS DEPO-SUBQ PROVERA 104 +! PFIZER 104MG/0.65ML N 021583 001 Dec 17, 2004 Mar CAHN TABLET;ORAL PROVERA AB + PFIZER 2.5MG N 011839 001 Mar CAHN AB + 5MG N 011839 003 Mar CAHN AB +! 10MG N 011839 004 Mar CAHN

MEFENAMIC ACID CAPSULE;ORAL @ STRIDES PHARMA 250MG A 209209 001 Sep 18, 2020 Mar DISC

MEFLOQUINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE >D> ! BARR 250MG A 076392 001 Dec 29, 2003 Aug CTEC >A> AB ! 250MG A 076392 001 Dec 29, 2003 Aug CTEC >D> @ HIKMA 250MG A 076523 001 Oct 01, 2004 Aug CMFD >A> AB HIKMA PHARMS 250MG A 076523 001 Oct 01, 2004 Aug CMFD

MELOXICAM CAPSULE;ORAL MELOXICAM AB LUPIN LTD 5MG A 209487 001 Jun 01, 2020 Feb CTEC AB ! 10MG A 209487 002 Jun 01, 2020 Feb CTEC AB NOVITIUM PHARMA 5MG A 211398 001 Mar 09, 2021 Feb NEWA AB 10MG A 211398 002 Mar 09, 2021 Feb NEWA

MELPHALAN TABLET;ORAL ! ALVOGEN 2MG A 207809 001 Mar 22, 2017 Jan CAHN

MELPHALAN FLUFENAMIDE POWDER;INTRAVENOUS PEPAXTO +! ONCOPEPTIDES AB 20MG/VIAL N 214383 001 Feb 26, 2021 Feb NEWA

MELPHALAN FLUFENAMIDE HYDROCHLORIDE POWDER;INTRAVENOUS PEPAXTO +! ONCOPEPTIDES AB EQ 20MG BASE/VIAL N 214383 001 Feb 26, 2021 Mar CPOT +! 20MG/VIAL N 214383 001 Feb 26, 2021 Mar CAIN

MELPHALAN HYDROCHLORIDE INJECTABLE;INJECTION ALKERAN + APOTEX@ EQ 50MG BASE/VIAL N 020207 001 Nov 18, 1992 Jan DISC MELPHALAN HYDROCHLORIDE AP ALMAJECT EQ 50MG BASE/VIAL A 204817 001 May 17, 2019 Jul CAHN AP HIKMA PHARMS EQ 50MG BASE/VIAL A 090303 001 Oct 28, 2010 Jul CAHN >D> AP HONG KONG EQ 50MG BASE/VIAL A 212960 001 May 28, 2021 Aug CAHN AP EQ 50MG BASE/VIAL A 212960 001 May 28, 2021 May NEWA >A> AP MEITHEAL EQ 50MG BASE/VIAL A 212960 001 May 28, 2021 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -74

MEMANTINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL HYDROCHLORIDE AB AUROBINDO PHARMA LTD 7MG A 214651 001 Aug 09, 2021 Jul NEWA AB 14MG A 214651 002 Aug 09, 2021 Jul NEWA AB 21MG A 214651 003 Aug 09, 2021 Jul NEWA AB 28MG A 214651 004 Aug 09, 2021 Jul NEWA MY LAN@ MYLAN@ 7MG A 206032 001 Sep 28, 2016 Jul DISC @ 14MG A 206032 002 Sep 28, 2016 Jul DISC @ 21MG A 206032 003 Sep 28, 2016 Jul DISC @ 28MG A 206032 004 Sep 28, 2016 Jul DISC AB YICHANG HUMANWELL 7MG A 211100 001 Apr 02, 2021 Mar NEWA AB 14MG A 211100 002 Apr 02, 2021 Mar NEWA AB 21MG A 211100 003 Apr 02, 2021 Mar NEWA AB 28MG A 211100 004 Apr 02, 2021 Mar NEWA SOLUTION;ORAL MEMANTINE HYDROCHLORIDE AA SETON PHARMS 2MG/ML A 210319 001 Aug 31, 2020 May CAHN TABLET;ORAL MEMANTINE HYDROCHLORIDE @ JUBILANT GENERICS 5MG A 091585 001 Oct 13, 2015 Jun DISC @ 10MG A 091585 002 Oct 13, 2015 Jun DISC

MEPERIDINE HYDROCHLORIDE INJECTABLE;INJECTION DEMEROL @ VALIDUS PHARMS 25MG/ML N 005010 007 Feb CAHN @ 50MG/ML N 005010 002 Feb CAHN @ 75MG/ML N 005010 009 Feb CAHN @ 100MG/ML N 005010 003 Feb CAHN MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE >D> @ ICU MEDICAL INC 10MG/ML A 088432 001 Aug 16, 1984 Aug CRLD >A> + @ 10MG/ML A 088432 001 Aug 16, 1984 Aug CRLD SYRUP;ORAL DEMEROL @ VALIDUS PHARMS 50MG/5ML N 005010 005 Feb CAHN TABLET;ORAL DEMEROL + @ VALIDUS PHARMS 50MG N 005010 001 Feb CAHN + @ 100MG N 005010 004 Feb CAHN

MEPROBAMATE TABLET;ORAL AA ! ALEMBIC PHARMS LTD 200MG A 090122 001 Feb 18, 2009 Mar CHRS AA ! 400MG A 090122 002 Feb 18, 2009 Mar CHRS >D> @ WATSON LABS 200MG A 083304 001 Aug CRLD >A> + @ 200MG A 083304 001 Aug CRLD @ 200MG A 083304 001 Mar DISC >D> @ 400MG A 083308 001 Aug CRLD >A> + @ 400MG A 083308 001 Aug CRLD @ 400MG A 083308 001 Mar DISC

MEROPENEM INJECTABLE;INJECTION MEROPENEM >D> AP AUROBINDO PHARMA LTD 500MG/VIAL A 205835 001 Mar 27, 2017 Aug CAHN >D> AP 1GM/VIAL A 205835 002 Mar 27, 2017 Aug CAHN >A> AP EUGIA PHARMA 500MG/VIAL A 205835 001 Mar 27, 2017 Aug CAHN >A> AP 1GM/VIAL A 205835 002 Mar 27, 2017 Aug CAHN

MEROPENEM; VABORBACTAM POWDER;INTRAVENOUS VABOMERE +! REMPEX 1GM/VIAL;1GM/VIAL N 209776 001 Aug 29, 2017 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -75

MESALAMINE CAPSULE, EXTENDED RELEASE;ORAL MESALAMINE AB ALKEM LABS LTD 375MG A 214242 001 Jul 15, 2021 Jul NEWA >A> AB ZYDUS PHARMS 375MG A 208954 001 Aug 12, 2021 Aug NEWA

METARAMINOL BITARTRATE INJECTABLE;INJECTION BITARTRATE >A> SLAYBACK PHARMA LLC EQ 10MG BASE/ML A 211304 001 Aug 24, 2021 Aug NEWA

METFORMIN HYDROCHLORIDE TABLET;ORAL METFORMIN HYDROCHLORIDE AB CHARTWELL 500MG A 075972 001 Jan 24, 2002 Jun CAHN 625MG A 075972 005 Jan 24, 2002 Jun CAHN 750MG A 075972 004 Jan 24, 2002 Jun CAHN AB 850MG A 075972 002 Jan 24, 2002 Jun CAHN AB 1GM A 075972 003 Jan 24, 2002 Jun CAHN @ INDICUS PHARMA 500MG A 079148 001 Nov 25, 2008 May DISC @ 850MG A 079148 002 Nov 25, 2008 May DISC @ 1GM A 079148 003 Nov 25, 2008 May DISC TABLET, EXTENDED RELEASE;ORAL METFORMIN HYDROCHLORIDE AB3 AJANTA PHARMA LTD 500MG A 213962 001 Mar 09, 2021 Feb NEWA AB3 1GM A 213962 002 Mar 09, 2021 Feb NEWA AB2 AMTA 500MG A 213394 001 Aug 03, 2021 Jul NEWA AB2 1GM A 213394 002 Aug 03, 2021 Jul NEWA @ APOTEX 500MG A 076706 001 Dec 14, 2004 Apr DISC AB3 GRANULES 500MG A 213344 001 Jan 12, 2021 Jan NEWA AB3 1GM A 213344 002 Jan 12, 2021 Jan NEWA AB3 SCIEGEN PHARMS INC 500MG A 213334 001 Apr 16, 2021 Apr NEWA AB3 1GM A 213334 002 Apr 16, 2021 Apr NEWA AB1 UNICHEM 500MG A 213359 001 Aug 11, 2021 Jul NEWA AB 750MG A 213359 002 Aug 11, 2021 Jul NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE TABLET;ORAL PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE @ TORRENT PHARMS LTD 500MG;EQ 15MG BASE A 202001 001 Feb 13, 2013 Jan DISC @ 850MG;EQ 15MG BASE A 202001 002 Feb 13, 2013 Jan DISC

METHADONE HYDROCHLORIDE CONCENTRATE;ORAL HYDROCHLORIDE >D> AA LANNETT CO INC 10MG/ML A 212094 001 Mar 03, 2021 Aug DISC >A> @ 10MG/ML A 212094 001 Mar 03, 2021 Aug DISC AA 10MG/ML A 212094 001 Mar 03, 2021 Feb NEWA SOLUTION;ORAL METHADONE HYDROCHLORIDE >D> AA ! HIKMA PHARMS 5MG/5ML A 087393 001 Aug CRLD >A> AA +! 5MG/5ML A 087393 001 Aug CRLD >D> AA ! 10MG/5ML A 087997 001 Aug 30, 1982 Aug CRLD >A> AA +! 10MG/5ML A 087997 001 Aug 30, 1982 Aug CRLD

METHENAMINE HIPPURATE TABLET;ORAL HIPREX + @ VALIDUS PHARMS 1GM N 017681 001 Mar DISC AB +! 1GM N 017681 001 Feb CAHN METHENAMINE HIPPURATE AB ! AUROBINDO PHARMA LTD 1GM A 205661 001 Jul 05, 2016 Mar CHRS UREX AB ALVOGEN 1GM N 016151 001 Jul CAHN

METHOCARBAMOL SOLUTION;IM-IV ROBAXIN AP +! HIKMA PHARMS 1GM/10ML (100MG/ML) N 011790 001 Jul CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -76

TABLET;ORAL @ AUROBINDO PHARMA LTD 750MG A 213967 001 Aug 12, 2020 Feb DISC AA GRANULATION TECH 500MG A 212623 001 Apr 30, 2021 Apr NEWA AA 750MG A 212623 002 Apr 30, 2021 Apr NEWA AA MLV 500MG A 212623 001 Apr 30, 2021 Jun CAHN AA 750MG A 212623 002 Apr 30, 2021 Jun CAHN

METHOTREXATE SODIUM INJECTABLE;INJECTION FOLEX >D> @ PHARMACIA AND UPJOHN EQ 25MG BASE/VIAL A 087695 001 Apr 08, 1983 Aug CRLD >A> + @ EQ 25MG BASE/VIAL A 087695 001 Apr 08, 1983 Aug CRLD >D> @ EQ 100MG BASE/VIAL A 087695 003 Apr 08, 1983 Aug CRLD >A> + @ EQ 100MG BASE/VIAL A 087695 003 Apr 08, 1983 Aug CRLD SODIUM AP ! HIKMA PHARMS EQ 100MG BASE/4ML (EQ 25MG A 089341 001 Sep 16, 1986 Jul CAHN BASE/ML) ! EQ 200MG BASE/8ML (EQ 25MG A 089342 001 Sep 16, 1986 Jul CAHN BASE/ML) METHOTREXATE SODIUM PRESERVATIVE FREE AP ! HIKMA PHARMS EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A 089340 001 Sep 16, 1986 Jul CAHN AP ! EQ 250MG BASE/10ML (EQ 25MG A 089343 001 Sep 16, 1986 Jul CAHN BASE/ML) >A> @ MYLAN EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A 201530 001 Mar 29, 2012 Aug CAHN @ MYLAN LABS LTD EQ 250MG BASE/10ML (EQ 25MG A 201529 004 Mar 29, 2012 May DISC BASE/ML) >D> AP EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A 201530 001 Mar 29, 2012 Aug CAHN MEXATE >D> @ BRISTOL EQ 20MG BASE/VIAL A 086358 001 Aug CRLD >A> + @ EQ 20MG BASE/VIAL A 086358 001 Aug CRLD >D> @ EQ 50MG BASE/VIAL A 086358 002 Aug CRLD >A> + @ EQ 50MG BASE/VIAL A 086358 002 Aug CRLD >D> @ EQ 100MG BASE/VIAL A 086358 003 Aug CRLD >A> + @ EQ 100MG BASE/VIAL A 086358 003 Aug CRLD >D> @ EQ 250MG BASE/VIAL A 086358 004 Aug CRLD >A> + @ EQ 250MG BASE/VIAL A 086358 004 Aug CRLD TABLET;ORAL METHOTREXATE SODIUM AB LOTUS PHARM CO LTD EQ 2.5MG BASE A 209787 001 Apr 23, 2021 Apr NEWA

METHYLERGONOVINE MALEATE TABLET;ORAL METHYLERGONOVINE MALEATE AB RISING 0.2MG A 211919 001 Jan 15, 2021 Jan NEWA

METHYLPHENIDATE HYDROCHLORIDE SOLUTION;ORAL HYDROCHLORIDE AA ASCENT PHARMS INC 5MG/5ML A 207417 001 Jan 29, 2021 Jan NEWA AA 10MG/5ML A 207417 002 Jan 29, 2021 Jan NEWA @ LANNETT CO INC 5MG/5ML A 207414 001 Dec 16, 2020 Jan DISC @ 10MG/5ML A 207414 002 Dec 16, 2020 Jan DISC TABLET;ORAL METHYLPHENIDATE HYDROCHLORIDE @ ALVOGEN 5MG A 206840 001 Sep 15, 2016 Jun CAHN @ 10MG A 206840 002 Sep 15, 2016 Jun CAHN @ 20MG A 206840 003 Sep 15, 2016 Jun CAHN TABLET, EXTENDED RELEASE;ORAL METHYLPHENIDATE HYDROCHLORIDE AB ALVOGEN 10MG A 204772 001 Feb 29, 2016 Jun CAHN >A> AB 18MG A 210818 001 Nov 30, 2018 Aug CAHN AB 20MG A 204772 002 Feb 29, 2016 Jun CAHN >A> AB 27MG A 210818 002 Nov 30, 2018 Aug CAHN >A> AB 36MG A 210818 003 Nov 30, 2018 Aug CAHN >A> AB 54MG A 210818 004 Nov 30, 2018 Aug CAHN >D> AB ALVOGEN PINE BROOK 18MG A 210818 001 Nov 30, 2018 Aug CAHN >D> AB 27MG A 210818 002 Nov 30, 2018 Aug CAHN >D> AB 36MG A 210818 003 Nov 30, 2018 Aug CAHN >D> AB 54MG A 210818 004 Nov 30, 2018 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -77

METHYLPREDNISOLONE TABLET;ORAL METHYLPREDNISOLONE AB PRAXGEN 4MG A 212262 001 Jun 27, 2019 Feb CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE INJECTABLE;INJECTION METHYLPREDNISOLONE SODIUM SUCCINATE AP GENEYORK PHARMS EQ 40MG BASE/VIAL A 212396 001 Apr 20, 2021 Apr NEWA AP EQ 125MG BASE/VIAL A 212396 002 Apr 20, 2021 Apr NEWA AP EQ 500MG BASE/VIAL A 212396 003 Apr 20, 2021 Apr NEWA AP EQ 1GM BASE/VIAL A 212396 004 Apr 20, 2021 Apr NEWA AP EQ 2GM BASE/VIAL A 212396 005 Apr 20, 2021 Apr NEWA AP TIANJIN KINGYORK EQ 40MG BASE/VIAL A 212396 001 Apr 20, 2021 May CAHN AP EQ 125MG BASE/VIAL A 212396 002 Apr 20, 2021 May CAHN AP EQ 500MG BASE/VIAL A 212396 003 Apr 20, 2021 May CAHN AP EQ 1GM BASE/VIAL A 212396 004 Apr 20, 2021 May CAHN AP EQ 2GM BASE/VIAL A 212396 005 Apr 20, 2021 May CAHN

METHYLTESTOSTERONE CAPSULE;ORAL TESTRED >D> @ BAUSCH 10MG A 083976 001 Aug CRLD >A> + @ 10MG A 083976 001 Aug CRLD

METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE;INJECTION REGLAN @ HIKMA PHARMS EQ 5MG BASE/ML N 017862 001 Jul CAHN @ EQ 10MG BASE/ML N 017862 004 May 28, 1987 Jul CAHN

METOLAZONE TABLET;ORAL METOLAZONE AB BAYSHORE PHARMS LLC 2.5MG A 214799 001 Mar 30, 2021 Mar NEWA AB 5MG A 214799 002 Mar 30, 2021 Mar NEWA AB 10MG A 214799 003 Mar 30, 2021 Mar NEWA AB INNOGENIX 2.5MG A 213827 001 Mar 30, 2021 Mar NEWA AB 5MG A 213827 002 Mar 30, 2021 Mar NEWA AB 10MG A 213827 003 Mar 30, 2021 Mar NEWA >A> AB RUBICON 2.5MG A 215184 001 Aug 20, 2021 Aug NEWA >A> AB 5MG A 215184 002 Aug 20, 2021 Aug NEWA >A> AB 10MG A 215184 003 Aug 20, 2021 Aug NEWA AB ! SANDOZ 5MG A 076466 001 Dec 19, 2003 May CHRS AB ! 10MG A 076466 002 Dec 19, 2003 May CHRS ZAROXOLYN + @ LANNETT CO INC 2.5MG N 017386 001 May DISC + @ 5MG N 017386 002 May DISC + @ 10MG N 017386 003 May DISC

METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE;ORAL METOPROLOL SUCCINATE AB ACTAVIS ELIZABETH EQ 25MG TARTRATE A 204161 001 Nov 25, 2016 May CMFD AB EQ 50MG TARTRATE A 204161 002 Nov 25, 2016 May CMFD AB EQ 100MG TARTRATE A 204161 003 Nov 25, 2016 May CMFD AB EQ 200MG TARTRATE A 204161 004 Nov 25, 2016 May CMFD AB YICHANG HUMANWELL EQ 100MG TARTRATE A 213854 001 Feb 12, 2021 Feb NEWA AB EQ 200MG TARTRATE A 213854 002 Feb 12, 2021 Feb NEWA

METOPROLOL TARTRATE TABLET;ORAL LOPRESSOR AB + VALIDUS PHARMS 50MG N 017963 001 Feb CAHN AB + 100MG N 017963 002 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -78

METRONIDAZOLE GEL;TOPICAL >A> AB ALEOR DERMACEUTICALS 1% A 212646 001 Sep 03, 2021 Aug NEWA

MEXILETINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB RICONPHARMA LLC 150MG A 214352 001 Jan 25, 2021 Jan NEWA AB 200MG A 214352 002 Jan 25, 2021 Jan NEWA AB 250MG A 214352 003 Jan 25, 2021 Jan NEWA

MICAFUNGIN SODIUM INJECTABLE;INTRAVENOUS SODIUM AP HIKMA EQ 50MG BASE/VIAL A 213261 001 Jul 09, 2021 Jul NEWA AP EQ 100MG BASE/VIAL A 213261 002 Jul 09, 2021 Jul NEWA AP JIANGSU HANSOH PHARM EQ 50MG BASE/VIAL A 213363 001 Jul 09, 2021 Jul NEWA AP EQ 100MG BASE/VIAL A 213363 002 Jul 09, 2021 Jul NEWA AP XELLIA PHARMS APS EQ 50MG BASE/VIAL A 211713 001 Jun 02, 2021 May NEWA AP EQ 100MG BASE/VIAL A 211713 002 Jun 02, 2021 May NEWA POWDER;INTRAVENOUS MICAFUNGIN +! PAR STERILE PRODUCTS EQ 50MG BASE/VIAL N 212156 001 Jun 16, 2021 Jun NEWA +! EQ 100MG BASE/VIAL N 212156 002 Jun 16, 2021 Jun NEWA +! TEVA PHARMS USA INC EQ 50MG BASE/VIAL N 212125 001 Jul 30, 2021 Jul NEWA +! EQ 100MG BASE/VIAL N 212125 002 Jul 30, 2021 Jul NEWA

MIDAZOLAM SOLUTION;INTRAVENOUS IN 0.9% SODIUM CHLORIDE +! INFORLIFE 50MG/50ML (1MG/ML) N 211844 001 Mar 22, 2021 Mar NEWA +! 100MG/100ML (1MG/ML) N 211844 002 Mar 22, 2021 Mar NEWA

MIDAZOLAM HYDROCHLORIDE INJECTABLE;INJECTION MIDAZOLAM HYDROCHLORIDE >D> AP HOSPIRA EQ 1MG BASE/ML A 075856 001 Jun 13, 2002 Aug DISC >A> @ EQ 1MG BASE/ML A 075856 001 Jun 13, 2002 Aug DISC >D> AP EQ 5MG BASE/ML A 075856 002 Jun 13, 2002 Aug DISC >A> @ EQ 5MG BASE/ML A 075856 002 Jun 13, 2002 Aug DISC

MIDODRINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ALEMBIC PHARMS LTD 2.5MG A 214734 001 Jan 21, 2021 Jan NEWA AB 5MG A 214734 002 Jan 21, 2021 Jan NEWA AB 10MG A 214734 003 Jan 21, 2021 Jan NEWA

MIGLITOL TABLET;ORAL GLYSET AB +! PFIZER 25MG N 020682 001 Dec 18, 1996 Feb CAHN AB + 50MG N 020682 002 Dec 18, 1996 Feb CAHN AB + 100MG N 020682 003 Dec 18, 1996 Feb CAHN

MILNACIPRAN HYDROCHLORIDE TABLET;ORAL MILNACIPRAN HYDROCHLORIDE >A> @ LIBERTY PHARMA INC 12.5MG A 205071 001 Jan 27, 2016 Aug CAHN >A> @ 25MG A 205071 002 Jan 27, 2016 Aug CAHN >A> @ 50MG A 205071 003 Jan 27, 2016 Aug CAHN >A> @ 100MG A 205071 004 Jan 27, 2016 Aug CAHN >D> @ USPHARMA 12.5MG A 205071 001 Jan 27, 2016 Aug CAHN >D> @ 25MG A 205071 002 Jan 27, 2016 Aug CAHN >D> @ 50MG A 205071 003 Jan 27, 2016 Aug CAHN >D> @ 100MG A 205071 004 Jan 27, 2016 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -79

MILRINONE LACTATE INJECTABLE;INJECTION LACTATE AP CAPLIN EQ 1MG BASE/ML A 214380 001 Apr 16, 2021 Apr NEWA

MINOCYCLINE HYDROCHLORIDE AEROSOL, FOAM;TOPICAL AMZEEQ +! VYNE EQ 4% BASE N 212379 001 Oct 18, 2019 Mar CAHN ZILXI +! VYNE EQ 1.5% BASE N 213690 001 May 28, 2020 Mar CAHN CAPSULE;ORAL DYNACIN AB ALVOGEN EQ 50MG BASE A 063067 003 Aug 14, 1990 Jun CAHN AB EQ 75MG BASE A 063067 002 Sep 15, 1999 Jun CAHN AB EQ 100MG BASE A 063067 001 Jul 31, 1990 Jun CAHN INJECTABLE;INJECTION MINOCIN +! REMPEX EQ 100MG BASE/VIAL N 050444 001 May CAHN TABLET, EXTENDED RELEASE;ORAL HYDROCHLORIDE @ BARR LABS INC EQ 65MG BASE A 065485 004 May 18, 2012 May DISC @ EQ 80MG BASE A 065485 007 Apr 26, 2017 May DISC @ EQ 105MG BASE A 065485 008 Apr 26, 2017 May DISC @ EQ 115MG BASE A 065485 005 May 18, 2012 May DISC SOLODYN + BAUSCH@ EQ 45MG BASE N 050808 001 May 08, 2006 May CAHN AB + EQ 55MG BASE N 050808 008 Aug 27, 2010 May CAHN AB + EQ 65MG BASE N 050808 004 Jul 23, 2009 May CAHN AB + EQ 80MG BASE N 050808 007 Aug 27, 2010 May CAHN + @ EQ 90MG BASE N 050808 002 May 08, 2006 May CAHN AB + EQ 105MG BASE N 050808 006 Aug 27, 2010 May CAHN AB +! EQ 115MG BASE N 050808 005 Jul 23, 2009 May CAHN + @ EQ 135MG BASE N 050808 003 May 08, 2006 May CAHN

MINOXIDIL TABLET;ORAL LONITEN + @ PFIZER 2.5MG N 018154 001 Feb CAHN + @ 10MG N 018154 003 Feb CAHN

MIRABEGRON FOR SUSPENSION, EXTENDED RELEASE;ORAL MYRBETRIQ GRANULES +! APGDI 8MG/ML N 213801 001 Mar 25, 2021 Mar NEWA

MODAFINIL TABLET;ORAL @ MYLAN PHARMS INC 100MG A 076594 001 Jul 16, 2012 Jul DISC @ 200MG A 076594 002 Jul 16, 2012 Jul DISC

MOMETASONE FUROATE AEROSOL, METERED;INHALATION ASMANEX HFA + ORGANON 0.05MG/INH N 205641 003 Aug 12, 2019 Jun CAHN + 0.10MG/INH N 205641 001 Apr 25, 2014 Jun CAHN +! 0.20MG/INH N 205641 002 Apr 25, 2014 Jun CAHN OINTMENT;TOPICAL MOMETASONE FUROATE @ TORRENT 0.1% A 207899 001 Jul 13, 2018 Jan DISC POWDER;INHALATION ASMANEX TWISTHALER + ORGANON 0.11MG/INH N 021067 002 Feb 01, 2008 Jun CAHN +! 0.22MG/INH N 021067 001 Mar 30, 2005 Jun CAHN SPRAY, METERED;NASAL MOMETASONE FUROATE AB ! APOTEX INC 0.05MG/SPRAY A 091161 001 Mar 22, 2016 May CHRS NASONEX + @ ORGANON 0.05MG/SPRAY N 020762 001 Oct 01, 1997 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -80

SPRAY, METERED;NASAL NASONEX AB +! 0.05MG/SPRAY N 020762 001 Oct 01, 1997 Feb CAHN

MONTELUKAST SODIUM TABLET;ORAL SODIUM @ AJANTA PHARMA LTD EQ 10MG BASE A 203432 001 Jul 31, 2015 Jul DISC TABLET, CHEWABLE;ORAL MONTELUKAST SODIUM @ AJANTA PHARMA LTD EQ 4MG BASE A 203328 001 Jul 31, 2015 Jul DISC @ EQ 5MG BASE A 203328 002 Jul 31, 2015 Jul DISC @ HIKMA PHARMS EQ 4MG BASE A 091128 001 Aug 03, 2012 Jul DISC @ EQ 5MG BASE A 091128 002 Aug 03, 2012 Jul DISC >D> @ UNICHEM EQ 4MG BASE A 208621 001 Jul 02, 2018 Aug CMFD >A> AB EQ 4MG BASE A 208621 001 Jul 02, 2018 Aug CMFD >D> @ EQ 5MG BASE A 208621 002 Jul 02, 2018 Aug CMFD >A> AB EQ 5MG BASE A 208621 002 Jul 02, 2018 Aug CMFD

MORPHINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL KADIAN + @ ALLERGAN 40MG N 020616 009 Jul 09, 2012 May DISC + @ 70MG N 020616 010 Jul 09, 2012 May DISC + @ 130MG N 020616 011 Jul 09, 2012 May DISC + @ 150MG N 020616 012 Jul 09, 2012 May DISC + @ 200MG N 020616 007 Feb 27, 2007 May DISC SULFATE IMPAX LABS INC 40MG A 200411 007 Jul 25, 2018 May CTEC AB NORTEC DEV ASSOC 20MG A 203158 001 Aug 04, 2021 Jul NEWA AB 30MG A 203158 002 Aug 04, 2021 Jul NEWA AB 50MG A 203158 003 Aug 04, 2021 Jul NEWA AB 60MG A 203158 004 Aug 04, 2021 Jul NEWA AB 80MG A 203158 005 Aug 04, 2021 Jul NEWA AB 100MG A 203158 006 Aug 04, 2021 Jul NEWA INJECTABLE;INJECTION MORPHINE SULFATE +! HOSPIRA INC 50MG/ML N 202515 006 Apr 29, 2021 Apr NEWA INTL MEDICATION SYS 1MG/ML A 202861 001 Apr 29, 2021 Apr NFTG SOLUTION;ORAL MORPHINE SULFATE @ ANI PHARMS 10MG/5ML A 205509 001 Apr 17, 2018 Jan DISC @ 20MG/5ML A 205509 002 Apr 17, 2018 Jan DISC @ 100MG/5ML A 205509 003 Apr 17, 2018 Jan DISC >D> AA WINDER LABS LLC 10MG/5ML A 211454 001 Feb 12, 2021 Aug DISC >A> @ 10MG/5ML A 211454 001 Feb 12, 2021 Aug DISC AA 10MG/5ML A 211454 001 Feb 12, 2021 Feb NEWA >D> AA 20MG/5ML A 211454 002 Feb 12, 2021 Aug DISC >A> @ 20MG/5ML A 211454 002 Feb 12, 2021 Aug DISC AA 20MG/5ML A 211454 002 Feb 12, 2021 Feb NEWA >D> AA 100MG/5ML A 211454 003 Feb 12, 2021 Aug DISC >A> @ 100MG/5ML A 211454 003 Feb 12, 2021 Aug DISC AA 100MG/5ML A 211454 003 Feb 12, 2021 Feb NEWA TABLET;ORAL MORPHINE SULFATE AB UPSHER SMITH LABS 15MG A 210610 001 Jul 22, 2019 May CAHN AB 30MG A 210610 002 Jul 22, 2019 May CAHN

MOXIFLOXACIN HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC HYDROCHLORIDE AT1 UPSHER SMITH LABS EQ 0.5% BASE A 212616 001 Feb 10, 2021 Jan NEWA

MUPIROCIN CALCIUM CREAM;TOPICAL >A> AB ENCUBE EQ 2% BASE A 213076 001 Aug 31, 2021 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -81

MYCOPHENOLATE MOFETIL SUSPENSION;ORAL MYCOPHENOLATE MOFETIL AB LANNETT CO INC 200MG/ML A 214525 001 Jul 29, 2021 Jul NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE INJECTABLE;INJECTION MYCOPHENOLATE MOFETIL HYDROCHLORIDE AP AMNEAL 500MG/VIAL A 211374 001 Mar 05, 2021 Feb NEWA AP MEITHEAL 500MG/VIAL A 212130 001 Jan 15, 2021 Jan CAHN AP NANJING KING-FRIEND 500MG/VIAL A 212130 001 Jan 15, 2021 Jan NEWA

MYCOPHENOLIC ACID TABLET, DELAYED RELEASE;ORAL AB AMTA 180MG A 214376 001 Feb 10, 2021 Jan NEWA AB 360MG A 214376 002 Feb 10, 2021 Jan NEWA

NABUMETONE TABLET;ORAL AB ANNORA PHARMA 500MG A 090445 001 Jan 12, 2011 Mar CAHN AB 750MG A 090445 002 Jan 12, 2011 Mar CAHN

NADOLOL TABLET;ORAL @ NOVAST LABS 20MG A 210786 001 Jun 01, 2018 May DISC @ 40MG A 210786 002 Jun 01, 2018 May DISC @ 80MG A 210786 003 Jun 01, 2018 May DISC AB VGYAAN 20MG A 212856 001 Sep 13, 2019 May CMFD AB 40MG A 212856 002 Sep 13, 2019 May CMFD AB 80MG A 212856 003 Sep 13, 2019 May CMFD

NALOXONE HYDROCHLORIDE INJECTABLE;INJECTION NALOXONE HYDROCHLORIDE AP AUROBINDO PHARMA LTD 1MG/ML A 213279 001 Jan 14, 2021 Jan NEWA @ BAXTER HLTHCARE CORP 0.4MG/ML A 214785 001 Jan 29, 2021 Jul DISC AP 0.4MG/ML A 214785 001 Jan 29, 2021 Jan NEWA SPRAY;NASAL KLOXXADO +! HIKMA PHARMS 8MG/SPRAY N 212045 001 Apr 29, 2021 Apr NEWA

NALTREXONE HYDROCHLORIDE TABLET;ORAL REVIA + @ TEVA WOMENS 50MG N 018932 001 Nov 20, 1984 Jul CRLD

NANDROLONE DECANOATE INJECTABLE;INJECTION NANDROLONE DECANOATE >D> @ WATSON LABS 200MG/ML A 088128 001 Dec 05, 1983 Aug CRLD >A> + @ 200MG/ML A 088128 001 Dec 05, 1983 Aug CRLD

NAPHAZOLINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC NAPHCON FORTE >D> @ ALCON 0.1% A 080229 001 Aug CRLD >A> + @ 0.1% A 080229 001 Aug CRLD

NAPROXEN SUSPENSION;ORAL NAPROXEN AB NOVITIUM PHARMA 25MG/ML A 211910 001 Mar 10, 2021 Feb NEWA TABLET;ORAL NAPROXEN AB GRANULES 250MG A 074140 001 Dec 21, 1993 Feb CMFD AB 375MG A 074140 002 Dec 21, 1993 Feb CMFD AB 500MG A 074140 003 Dec 21, 1993 Feb CMFD AB L PERRIGO CO 250MG A 077339 001 Apr 27, 2005 Jul CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -82

TABLET;ORAL NAPROXEN AB 375MG A 077339 002 Apr 27, 2005 Jul CAHN AB 500MG A 077339 003 Apr 27, 2005 Jul CAHN

NEBIVOLOL HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ANI PHARMS EQ 2.5MG BASE A 203659 001 Apr 16, 2015 Jul CMFD AB EQ 5MG BASE A 203659 002 Apr 16, 2015 Jul CMFD AB EQ 10MG BASE A 203659 003 Apr 16, 2015 Jul CMFD AB EQ 20MG BASE A 203659 004 Apr 16, 2015 Jul CMFD AB INDCHEMIE HEALTH EQ 2.5MG BASE A 203828 001 Jul 29, 2015 Jul CMFD AB EQ 5MG BASE A 203828 002 Jul 29, 2015 Jul CMFD AB EQ 10MG BASE A 203828 003 Jul 29, 2015 Jul CMFD AB EQ 20MG BASE A 203828 004 Jul 29, 2015 Jul CMFD >D> @ TORRENT EQ 2.5MG BASE A 203966 001 Mar 02, 2018 Aug CMFD >A> AB EQ 2.5MG BASE A 203966 001 Mar 02, 2018 Aug CMFD >D> @ EQ 5MG BASE A 203966 002 Mar 02, 2018 Aug CMFD >A> AB EQ 5MG BASE A 203966 002 Mar 02, 2018 Aug CMFD >D> @ EQ 10MG BASE A 203966 003 Mar 02, 2018 Aug CMFD >A> AB EQ 10MG BASE A 203966 003 Mar 02, 2018 Aug CMFD >D> @ EQ 20MG BASE A 203966 004 Mar 02, 2018 Aug CMFD >A> AB EQ 20MG BASE A 203966 004 Mar 02, 2018 Aug CMFD

NEOSTIGMINE METHYLSULFATE SOLUTION;INTRAVENOUS METHYLSULFATE AP CAPLIN 5MG/10ML (0.5MG/ML) A 213074 001 Apr 20, 2021 Apr NEWA AP 10MG/10ML (1MG/ML) A 213074 002 Apr 20, 2021 Apr NEWA AP HONG KONG 5MG/10ML (0.5MG/ML) A 212804 001 Apr 05, 2021 Mar NEWA AP 10MG/10ML (1MG/ML) A 212804 002 Apr 05, 2021 Mar NEWA AP MEITHEAL 5MG/10ML (0.5MG/ML) A 212804 001 Apr 05, 2021 Apr CAHN AP 10MG/10ML (1MG/ML) A 212804 002 Apr 05, 2021 Apr CAHN

NIACIN TABLET;ORAL NICOLAR >D> @ SANOFI AVENTIS US 500MG A 083823 001 Aug CRLD >A> + @ 500MG A 083823 001 Aug CRLD TABLET, EXTENDED RELEASE;ORAL @ JUBILANT GENERICS 500MG A 209156 001 May 14, 2018 Jun DISC @ 750MG A 209156 002 May 14, 2018 Jun DISC @ 1GM A 209156 003 May 14, 2018 Jun DISC >D> AB SUN PHARM 750MG A 201273 001 Apr 23, 2014 Aug CHRS >A> AB ! 750MG A 201273 001 Apr 23, 2014 Aug CHRS >D> AB 1GM A 200484 002 Apr 23, 2014 Aug CHRS >A> AB ! 1GM A 200484 002 Apr 23, 2014 Aug CHRS >D> NIASPAN >D> AB + ABBVIE 500MG N 020381 002 Jul 28, 1997 Aug DISC >A> + @ 500MG N 020381 002 Jul 28, 1997 Aug DISC >D> AB +! 750MG N 020381 003 Jul 28, 1997 Aug DISC >A> + @ 750MG N 020381 003 Jul 28, 1997 Aug DISC >D> AB +! 1GM N 020381 004 Jul 28, 1997 Aug DISC >A> + @ 1GM N 020381 004 Jul 28, 1997 Aug DISC

NICARDIPINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB ANI PHARMS 20MG A 074670 001 Oct 28, 1996 May CMFD AB 30MG A 074670 002 Oct 28, 1996 May CMFD AB EPIC PHARMA 20MG A 074928 001 Mar 19, 1998 May CTEC AB ! 30MG A 074928 002 Mar 19, 1998 May CTEC INJECTABLE;INJECTION NICARDIPINE HYDROCHLORIDE AP ! AM REGENT 25MG/10ML (2.5MG/ML) A 090534 001 Nov 17, 2009 Apr CTEC ! 25MG/10ML (2.5MG/ML) A 090534 001 Nov 17, 2009 Feb CHRS AP AUROBINDO PHARMA LTD 25MG/10ML (2.5MG/ML) A 211121 001 Apr 08, 2021 Apr NEWA AP SUN PHARM 25MG/10ML (2.5MG/ML) N 078405 001 Nov 17, 2009 Jun CMFD @ 25MG/10ML (2.5MG/ML) N 078405 001 Nov 17, 2009 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -83

NIFEDIPINE TABLET, EXTENDED RELEASE;ORAL AB1 AUROBINDO PHARMA LTD 30MG A 213361 001 Jul 19, 2021 Jul NEWA AB1 60MG A 213361 002 Jul 19, 2021 Jul NEWA AB1 90MG A 213361 003 Jul 19, 2021 Jul NEWA @ ELITE 90MG A 212016 001 Nov 18, 2020 Jun DISC @ MYLAN 30MG A 201071 001 Dec 03, 2010 Jul DISC @ 60MG A 201071 002 Dec 03, 2010 Jul DISC @ 90MG A 201071 003 Dec 03, 2010 Jul DISC @ PAR PHARM 30MG A 077899 001 Dec 13, 2006 Apr DISC @ 60MG A 077899 002 Dec 13, 2006 Apr DISC @ 90MG A 077899 003 May 25, 2012 Apr DISC

NISOLDIPINE TABLET, EXTENDED RELEASE;ORAL ! MYLAN 20MG A 079051 001 Jul 25, 2008 Jan CHRS 30MG A 079051 002 Jul 25, 2008 Jan CHRS

NITROFURANTOIN, MACROCRYSTALLINE CAPSULE;ORAL AB ALEMBIC PHARMS LTD 25MG A 211935 001 Jun 25, 2021 Jun NEWA AB 50MG A 211935 002 Jun 25, 2021 Jun NEWA AB 100MG A 211935 003 Jun 25, 2021 Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE CAPSULE;ORAL NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) @ MYLAN 75MG;25MG A 076648 001 Mar 22, 2004 Jul DISC

NITROGLYCERIN FILM, EXTENDED RELEASE;TRANSDERMAL MINITRAN @ BAUSCH 0.4MG/HR A 089773 001 Aug 30, 1996 May CAHN NITRO-DUR >D> BX +! USPHARMA 0.1MG/HR N 020145 001 Apr 04, 1995 Aug CTEC >A> +! 0.1MG/HR N 020145 001 Apr 04, 1995 Aug CTEC >D> BX +! 0.2MG/HR N 020145 002 Apr 04, 1995 Aug CTEC >A> +! 0.2MG/HR N 020145 002 Apr 04, 1995 Aug CTEC >D> BX +! 0.4MG/HR N 020145 004 Apr 04, 1995 Aug CTEC >A> +! 0.4MG/HR N 020145 004 Apr 04, 1995 Aug CTEC >D> BX +! 0.6MG/HR N 020145 005 Apr 04, 1995 Aug CTEC >A> +! 0.6MG/HR N 020145 005 Apr 04, 1995 Aug CTEC TABLET;SUBLINGUAL NITROGLYCERIN AB RUBICON 0.3MG A 209779 001 May 03, 2021 Apr NEWA AB 0.4MG A 209779 002 May 03, 2021 Apr NEWA AB 0.6MG A 209779 003 May 03, 2021 Apr NEWA

NOREPINEPHRINE BITARTRATE INJECTABLE;INJECTION BITARTRATE AP ANDERSEN GLOBAL EQ 1MG BASE/ML A 214455 001 Jan 22, 2021 Jan NEWA AP BRECKENRIDGE EQ 1MG BASE/ML A 214455 001 Jan 22, 2021 Mar CAHN AP GLAND PHARMA LTD EQ 1MG BASE/ML A 214323 001 May 06, 2021 Apr NEWA AP SUN PHARM EQ 1MG BASE/ML A 211980 001 Jan 29, 2021 Jan NEWA

NORTRIPTYLINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE >D> AB ZYDUS EQ 10MG BASE A 213441 001 Feb 24, 2021 Aug DISC >A> @ EQ 10MG BASE A 213441 001 Feb 24, 2021 Aug DISC AB EQ 10MG BASE A 213441 001 Feb 24, 2021 Feb NEWA >D> AB EQ 25MG BASE A 213441 002 Feb 24, 2021 Aug DISC >A> @ EQ 25MG BASE A 213441 002 Feb 24, 2021 Aug DISC AB EQ 25MG BASE A 213441 002 Feb 24, 2021 Feb NEWA >D> AB EQ 50MG BASE A 213441 003 Feb 24, 2021 Aug DISC >A> @ EQ 50MG BASE A 213441 003 Feb 24, 2021 Aug DISC AB EQ 50MG BASE A 213441 003 Feb 24, 2021 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -84

CAPSULE;ORAL NORTRIPTYLINE HYDROCHLORIDE >D> AB EQ 75MG BASE A 213441 004 Feb 24, 2021 Aug DISC >A> @ EQ 75MG BASE A 213441 004 Feb 24, 2021 Aug DISC AB EQ 75MG BASE A 213441 004 Feb 24, 2021 Feb NEWA

NYSTATIN CREAM;TOPICAL AT MACLEODS PHARMS LTD 100,000 UNITS/GM A 213566 001 Aug 10, 2021 Jul NEWA OINTMENT;TOPICAL NYSTATIN AT MACLEODS PHARMS LTD 100,000 UNITS/GM A 213826 001 Jan 14, 2021 Jan NEWA POWDER;TOPICAL NYSTATIN AT ZYDUS PHARMS 100,000 UNITS/GM A 208581 001 Jun 08, 2017 Jul CAHN SUSPENSION;ORAL NYSTATIN AA NIVAGEN PHARMS INC 100,000 UNITS/ML A 062832 001 Dec 27, 1991 Jun CAHN

NYSTATIN; ACETONIDE CREAM;TOPICAL NYSTATIN AND TRIAMCINOLONE ACETONIDE AT ALEOR DERMACEUTICALS 100,000 UNITS/GM;0.1% A 214090 001 Mar 31, 2021 Mar NEWA OINTMENT;TOPICAL NYSTATIN AND TRIAMCINOLONE ACETONIDE >A> AT MACLEODS PHARMS LTD 100,000 UNITS/GM;0.1% A 214751 001 Aug 17, 2021 Aug NEWA

ODEVIXIBAT CAPSULE;ORAL BYLVAY + ALBIREO 0.4MG N 215498 002 Jul 20, 2021 Jul NEWA +! 1.2MG N 215498 004 Jul 20, 2021 Jul NEWA CAPSULE, PELLETS;ORAL BYLVAY + ALBIREO 0.2MG N 215498 001 Jul 20, 2021 Jul NEWA +! 0.6MG N 215498 003 Jul 20, 2021 Jul NEWA

OFLOXACIN SOLUTION/DROPS;OPHTHALMIC @ ALVOGEN 0.3% A 076830 001 Aug 31, 2004 Jun CAHN @ 0.3% A 076830 001 Aug 31, 2004 Jan DISC SOLUTION/DROPS;OTIC OFLOXACIN @ ALVOGEN 0.3% A 090395 001 Aug 11, 2009 Jun CAHN TABLET;ORAL FLOXIN + @ JANSSEN PHARMS 200MG N 019735 001 Dec 28, 1990 Jan CRLD + @ 300MG N 019735 002 Dec 28, 1990 Jan CRLD + @ 400MG N 019735 003 Dec 28, 1990 Jan CRLD OFLOXACIN AB LARKEN LABS 400MG A 076093 003 Sep 02, 2003 May CMFD

OLANZAPINE TABLET;ORAL @ HISUN PHARM HANGZHOU 2.5MG A 206924 001 Dec 31, 2020 Jul DISC AB 2.5MG A 206924 001 Dec 31, 2020 Feb CAHN @ 5MG A 206924 002 Dec 31, 2020 Jul DISC AB 5MG A 206924 002 Dec 31, 2020 Feb CAHN @ 7.5MG A 206924 003 Dec 31, 2020 Jul DISC AB 7.5MG A 206924 003 Dec 31, 2020 Feb CAHN @ 10MG A 206924 004 Dec 31, 2020 Jul DISC AB 10MG A 206924 004 Dec 31, 2020 Feb CAHN @ 15MG A 206924 005 Dec 31, 2020 Jul DISC AB 15MG A 206924 005 Dec 31, 2020 Feb CAHN @ 20MG A 206924 006 Dec 31, 2020 Jul DISC AB 20MG A 206924 006 Dec 31, 2020 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -85

TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE @ HISUN PHARM HANGZHOU 5MG A 206892 001 Dec 31, 2020 Jul DISC AB 5MG A 206892 001 Dec 31, 2020 Feb CAHN @ 10MG A 206892 002 Dec 31, 2020 Jul DISC AB 10MG A 206892 002 Dec 31, 2020 Feb CAHN @ 15MG A 206892 003 Dec 31, 2020 Jul DISC AB 15MG A 206892 003 Dec 31, 2020 Feb CAHN @ 20MG A 206892 004 Dec 31, 2020 Jul DISC AB 20MG A 206892 004 Dec 31, 2020 Feb CAHN >A> AB TORRENT 5MG A 091415 001 Oct 25, 2011 Aug CAHN >A> AB 10MG A 091415 002 Oct 25, 2011 Aug CAHN >A> AB 15MG A 091415 003 Oct 25, 2011 Aug CAHN >A> AB 20MG A 091415 004 Oct 25, 2011 Aug CAHN >D> AB TORRENT PHARMS LLC 5MG A 091415 001 Oct 25, 2011 Aug CAHN >D> AB 10MG A 091415 002 Oct 25, 2011 Aug CAHN >D> AB 15MG A 091415 003 Oct 25, 2011 Aug CAHN >D> AB 20MG A 091415 004 Oct 25, 2011 Aug CAHN

OLANZAPINE; SAMIDORPHAN L-MALATE TABLET;ORAL LYBALVI +! ALKERMES INC 5MG;EQ 10MG BASE N 213378 001 May 28, 2021 May NEWA + 10MG;EQ 10MG BASE N 213378 002 May 28, 2021 May NEWA + 15MG;EQ 10MG BASE N 213378 003 May 28, 2021 May NEWA + 20MG;EQ 10MG BASE N 213378 004 May 28, 2021 May NEWA

OLMESARTAN MEDOXOMIL TABLET;ORAL OLMESARTAN MEDOXOMIL >D> AB LUPIN LTD 5MG A 206631 001 Apr 27, 2017 Aug DISC >A> @ 5MG A 206631 001 Apr 27, 2017 Aug DISC >D> AB 20MG A 206631 002 Apr 27, 2017 Aug DISC >A> @ 20MG A 206631 002 Apr 27, 2017 Aug DISC >D> AB 40MG A 206631 003 Apr 27, 2017 Aug DISC >A> @ 40MG A 206631 003 Apr 27, 2017 Aug DISC @ MYLAN 5MG A 078276 001 Oct 26, 2016 Jul DISC @ 20MG A 078276 002 Oct 26, 2016 Jul DISC @ 40MG A 078276 003 Oct 26, 2016 Jul DISC

OLOPATADINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC HYDROCHLORIDE AKORN EQ 0.2% BASE A 204723 001 Dec 05, 2017 Mar CTEC SOMERSET THERAPS LLC EQ 0.1% BASE A 206306 001 Dec 07, 2015 Jul CTEC >D> @ WOCKHARDT LTD EQ 0.1% BASE A 200810 001 Jun 28, 2017 Aug CMKT @ EQ 0.1% BASE A 200810 001 Jun 28, 2017 Jul DISC SPRAY, METERED;NASAL OLOPATADINE HYDROCHLORIDE AB AMNEAL 0.665MG/SPRAY A 210901 001 Jan 28, 2020 Mar CMFD @ 0.665MG/SPRAY A 210901 001 Jan 28, 2020 Jan DISC

OMEGA-3-ACID ETHYL ESTERS CAPSULE;ORAL LOVAZA AB +! WOODWARD 1GM CONTAINS AT LEAST 900MG OF THE N 021654 001 Nov 10, 2004 Feb CAHN ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

ONDANSETRON FILM;ORAL ZUPLENZ + @ AQUESTIVE 4MG N 022524 001 Jul 02, 2010 Feb CAHN + @ 8MG N 022524 002 Jul 02, 2010 Feb CAHN

ONDANSETRON HYDROCHLORIDE INJECTABLE;INJECTION ONDANSETRON HYDROCHLORIDE @ HOSPIRA EQ 2MG BASE/ML A 077840 001 Jan 19, 2007 Jun DISC ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE @ EMCURE PHARMS LTD EQ 2MG BASE/ML A 078945 001 Jan 03, 2013 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -86

ORITAVANCIN DIPHOSPHATE POWDER;INTRAVENOUS KIMYRSA +! MELINTA THERAP EQ 1.2GM BASE/VIAL N 214155 001 Mar 12, 2021 Mar NEWA ORBACTIV +! MELINTA THERAP EQ 400MG BASE/VIAL N 206334 001 Aug 06, 2014 May CAHN

ORPHENADRINE CITRATE TABLET, EXTENDED RELEASE;ORAL NORFLEX + BAUSCH@ 100MG N 012157 001 May CAHN ORPHENADRINE CITRATE @ IMPAX PHARMS 100MG A 040368 001 Jun 23, 2000 Jan DISC

OSELTAMIVIR PHOSPHATE CAPSULE;ORAL OSELTAMIVIR PHOSPHATE MY LAN@ MYLAN@ EQ 30MG BASE A 210157 001 Jan 21, 2021 Jan DISC AB EQ 30MG BASE A 210157 001 Jan 21, 2021 Jan NEWA @ EQ 45MG BASE A 210157 002 Jan 21, 2021 Jan DISC AB EQ 45MG BASE A 210157 002 Jan 21, 2021 Jan NEWA @ EQ 75MG BASE A 210157 003 Jan 21, 2021 Jan DISC AB EQ 75MG BASE A 210157 003 Jan 21, 2021 Jan NEWA FOR SUSPENSION;ORAL OSELTAMIVIR PHOSPHATE >A> AB APTAPHARMA INC EQ 6MG BASE/ML A 212858 001 Aug 30, 2021 Aug NEWA

OXALIPLATIN INJECTABLE;INTRAVENOUS @ CIPLA 50MG/10ML (5MG/ML) A 208523 001 Feb 10, 2017 May DISC @ 100MG/20ML (5MG/ML) A 208523 002 Feb 10, 2017 May DISC >D> AP QILU 50MG/10ML (5MG/ML) A 204368 001 Jun 07, 2016 Aug CAHN >D> AP 100MG/20ML (5MG/ML) A 204368 002 Jun 07, 2016 Aug CAHN >D> ! 200MG/40ML (5MG/ML) A 204368 003 Jun 07, 2016 Aug CAHN >A> AP QILU PHARM HAINAN 50MG/10ML (5MG/ML) A 204368 001 Jun 07, 2016 Aug CAHN >A> AP 100MG/20ML (5MG/ML) A 204368 002 Jun 07, 2016 Aug CAHN >A> ! 200MG/40ML (5MG/ML) A 204368 003 Jun 07, 2016 Aug CAHN

OXCARBAZEPINE SUSPENSION;ORAL AB AKORN 300MG/5ML A 211420 001 Jul 09, 2021 Jul NEWA AB GLASSHOUSE PHARMS 300MG/5ML A 212428 001 Jun 21, 2021 Jun NEWA

OXICONAZOLE NITRATE LOTION;TOPICAL OXISTAT +! ANI PHARMS EQ 1% BASE N 020209 001 Sep 30, 1992 Apr CAHN

OXYBUTYNIN CHLORIDE TABLET;ORAL CHLORIDE AB APPCO 5MG A 209025 001 Dec 21, 2017 Jan CAHN @ STRIDES PHARMA 5MG A 208165 001 Dec 17, 2020 Jun DISC

OXYCODONE HYDROCHLORIDE CAPSULE;ORAL OXYCODONE HYDROCHLORIDE @ LANNETT CO INC 5MG A 203823 001 Aug 01, 2014 Apr DISC SOLUTION;ORAL OXYCODONE HYDROCHLORIDE AA QUAGEN 5MG/5ML A 213761 001 Jun 02, 2021 May NEWA AA 100MG/5ML A 213761 002 Jun 02, 2021 May NEWA TABLET;ORAL OXAYDO + ZYLA 5MG N 202080 001 Jun 17, 2011 Mar CRLD + 7.5MG N 202080 002 Jun 17, 2011 Mar CRLD OXYCODONE HYDROCHLORIDE AB ALVOGEN 5MG A 202116 001 Dec 30, 2011 Apr CAHN AB 15MG A 202116 002 Dec 30, 2011 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -87

TABLET;ORAL OXYCODONE HYDROCHLORIDE AB 30MG A 202116 003 Dec 30, 2011 Apr CAHN

OXYMETHOLONE TABLET;ORAL ANADROL-50 + @ MYLAN SPECIALITY LP 50MG N 016848 001 Apr DISC

OXYTOCIN INJECTABLE;INJECTION AP +! HIKMA PHARMS 10USP UNITS/ML (10USP UNITS/ML) N 018243 001 Jul CAHN AP +! 100USP UNITS/10ML (10USP UNITS/ML) N 018243 002 Jan 10, 2007 Jul CAHN

OZANIMOD HYDROCHLORIDE CAPSULE;ORAL ZEPOSIA + CELGENE INTL EQ 0.23MG BASE N 209899 001 Mar 25, 2020 May CPOT + EQ 0.46MG BASE N 209899 002 Mar 25, 2020 May CPOT +! EQ 0.92MG BASE N 209899 003 Mar 25, 2020 May CPOT

PACLITAXEL INJECTABLE;INJECTION AP ACCORD HLTHCARE 6MG/ML A 205720 001 Aug 17, 2018 May CMFD @ MYLAN LABS LTD 6MG/ML A 091540 001 Sep 29, 2011 Mar DISC

PALIPERIDONE PALMITATE SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR INVEGA SUSTENNA AB + JANSSEN PHARMS 39MG/0.25ML (39MG/0.25ML) N 022264 001 Jul 31, 2009 Jul CTEC AB + 78MG/0.5ML (78MG/0.5ML) N 022264 002 Jul 31, 2009 Jul CTEC AB + 117MG/0.75ML (117MG/0.75ML) N 022264 003 Jul 31, 2009 Jul CTEC AB +! 156MG/ML (156MG/ML) N 022264 004 Jul 31, 2009 Jul CTEC AB + 234MG/1.5ML (156MG/ML) N 022264 005 Jul 31, 2009 Jul CTEC PALMITATE AB TEVA PHARMS USA 39MG/0.25ML (39MG/0.25ML) A 211149 001 Jul 06, 2021 Jul CTEC AP 39MG/0.25ML (39MG/0.25ML) A 211149 001 Jul 06, 2021 Jun NFTG AB 78MG/0.5ML (78MG/0.5ML) A 211149 002 Jul 06, 2021 Jul CTEC AP 78MG/0.5ML (78MG/0.5ML) A 211149 002 Jul 06, 2021 Jun NFTG AB 117MG/0.75ML (117MG/0.75ML) A 211149 003 Jul 06, 2021 Jul CTEC AP 117MG/0.75ML (117MG/0.75ML) A 211149 003 Jul 06, 2021 Jun NFTG AB 156MG/ML (156MG/ML) A 211149 004 Jul 06, 2021 Jul CTEC AP 156MG/ML (156MG/ML) A 211149 004 Jul 06, 2021 Jun NFTG AB 234MG/1.5ML (156MG/ML) A 211149 005 Jul 06, 2021 Jul CTEC AP 234MG/1.5ML (156MG/ML) A 211149 005 Jul 06, 2021 Jun NFTG

PALONOSETRON HYDROCHLORIDE INJECTABLE;INTRAVENOUS ALOXI + @ HELSINN HLTHCARE EQ 0.075MG BASE/1.5ML (EQ 0.05MG N 021372 002 Feb 29, 2008 Apr DISC BASE/ML) + @ EQ 0.25MG BASE/5ML (EQ 0.05MG N 021372 001 Jul 25, 2003 Apr DISC BASE/ML) HYDROCHLORIDE AP ACCORD HLTHCARE EQ 0.25MG BASE/5ML (EQ 0.05MG A 204615 001 Mar 15, 2021 Mar NEWA BASE/ML) AP ! DR REDDYS LABS LTD EQ 0.25MG BASE/5ML (EQ 0.05MG A 201533 002 Apr 21, 2016 Apr CHRS BASE/ML) EMCURE PHARMS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG A 202951 001 Jun 29, 2021 Jun NEWA BASE/ML) AP EQ 0.25MG BASE/5ML (EQ 0.05MG A 202951 002 Jun 29, 2021 Jun NEWA BASE/ML) @ HOSPIRA INC EQ 0.075MG BASE/1.5ML (EQ 0.05MG A 207005 002 Sep 19, 2018 Apr DISC BASE/ML) @ QILU EQ 0.075MG BASE/1.5ML (EQ 0.05MG A 205648 002 Sep 19, 2018 Apr DISC BASE/ML) @ TEVA PHARMS USA EQ 0.075MG BASE/1.5ML (EQ 0.05MG A 090713 002 Mar 23, 2018 Apr DISC BASE/ML) SOLUTION;INTRAVENOUS PALONOSETRON HYDROCHLORIDE + @ FRESENIUS KABI USA EQ 0.25MG BASE/5ML (EQ 0.05MG N 208109 001 Nov 21, 2017 May DISC BASE/ML) RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -88

PAMIDRONATE DISODIUM INJECTABLE;INJECTION PAMIDRONATE DISODIUM AP +! HIKMA PHARMS 30MG/10ML (3MG/ML) N 021113 001 Mar 04, 2002 Jul CAHN AP +! 90MG/10ML (9MG/ML) N 021113 002 Mar 04, 2002 Jul CAHN

PANTOPRAZOLE SODIUM INJECTABLE;IV (INFUSION) PANTOPRAZOLE SODIUM >A> AP ACIC PHARMS EQ 40MG BASE/VIAL A 209524 001 Aug 30, 2021 Aug NEWA TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM @ JUBILANT GENERICS EQ 20MG BASE A 090901 001 Aug 30, 2011 Jun DISC @ EQ 40MG BASE A 090901 002 Aug 30, 2011 Jun DISC

PAROXETINE HYDROCHLORIDE SUSPENSION;ORAL HYDROCHLORIDE >A> AB NOVITIUM PHARMA EQ 10MG BASE/5ML A 215003 001 Sep 03, 2021 Aug NEWA PAXIL >D> +! APOTEX TECHNOLOGIES EQ 10MG BASE/5ML N 020710 001 Jun 25, 1997 Aug CTEC >A> AB +! EQ 10MG BASE/5ML N 020710 001 Jun 25, 1997 Aug CTEC TABLET, EXTENDED RELEASE;ORAL PAROXETINE HYDROCHLORIDE >A> AB CADILA PHARMS LTD EQ 12.5MG BASE A 212645 001 Aug 27, 2021 Aug NEWA >A> AB EQ 25MG BASE A 212645 002 Aug 27, 2021 Aug NEWA >A> AB EQ 37.5MG BASE A 212645 003 Aug 27, 2021 Aug NEWA AB CSPC OUYI EQ 12.5MG BASE A 213485 001 Feb 16, 2021 Feb NEWA AB EQ 25MG BASE A 213485 002 Feb 16, 2021 Feb NEWA AB EQ 37.5MG BASE A 213485 003 Feb 16, 2021 Feb NEWA AB SINOTHERAPEUTICS INC EQ 12.5MG BASE A 213612 001 Aug 11, 2021 Jul NEWA AB EQ 25MG BASE A 213612 002 Aug 11, 2021 Jul NEWA

PATIROMER SORBITEX CALCIUM POWDER;ORAL VELTASSA + VIFOR PHARMA EQ 8.4GM BASE/PACKET N 205739 001 Oct 21, 2015 Jun CAHN + EQ 16.8GM BASE/PACKET N 205739 002 Oct 21, 2015 Jun CAHN +! EQ 25.2GM BASE/PACKET N 205739 003 Oct 21, 2015 Jun CAHN

PEGCETACOPLAN SOLUTION;SUBCUTANEOUS EMPAVELI +! APELLIS PHARMS 1080MG/20ML (54MG/ML) N 215014 001 May 14, 2021 May NEWA

PEMETREXED SOLUTION;INTRAVENOUS + @ ACTAVIS LLC 100MG/4ML (25MG/ML) N 208419 001 Aug 21, 2020 Jan DISC + @ 500MG/20ML (25MG/ML) N 208419 002 Aug 21, 2020 Jan DISC + @ 1GM/40ML (25MG/ML) N 208419 003 Aug 21, 2020 Jan DISC

PENICILLAMINE CAPSULE;ORAL >A> AB AGGREGA 250MG A 215409 001 Aug 23, 2021 Aug NEWA >A> AB INVAGEN PHARMS 250MG A 213293 001 Aug 19, 2021 Aug NEWA

PENICILLIN G POTASSIUM INJECTABLE;INJECTION G POTASSIUM HQ SPECLT PHARMA 1,000,000 UNITS/VIAL A 065149 001 Jul 23, 2009 Mar CAHN AP 5,000,000 UNITS/VIAL A 065149 002 Jul 23, 2009 Mar CAHN AP 20,000,000 UNITS/VIAL A 065149 003 Jul 23, 2009 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -89

PENICILLIN V POTASSIUM FOR SOLUTION;ORAL PENICILLIN V POTASSIUM @ DAVA PHARMS INC EQ 125MG BASE/5ML A 062981 001 Feb 10, 1989 Mar DISC @ EQ 250MG BASE/5ML A 062981 002 Feb 10, 1989 Mar DISC PENICILLIN-VK TEVA EQ 125MG BASE/5ML A 060456 001 Mar CTEC ! EQ 250MG BASE/5ML A 060456 002 Mar CTEC

PENTAMIDINE ISETHIONATE INJECTABLE;INJECTION ISETHIONATE AP EMCURE PHARMS LTD 300MG/VIAL A 213806 001 Jan 07, 2021 Jan NEWA

PENTOBARBITAL SODIUM INJECTABLE;INJECTION NEMBUTAL SODIUM >D> AP ! AKORN 50MG/ML A 083246 001 Aug CRLD >A> AP +! 50MG/ML A 083246 001 Aug CRLD

PENTOXIFYLLINE TABLET, EXTENDED RELEASE;ORAL PENTOXIL @ UPSHER SMITH LABS 400MG A 074962 001 Mar 31, 1999 May DISC TRENTAL + @ VALIDUS PHARMS 400MG N 018631 001 Aug 30, 1984 Feb CAHN

PERAMPANEL TABLET;ORAL FYCOMPA + EISAI INC 2MG N 202834 001 Oct 22, 2012 Jun CTEC + 4MG N 202834 002 Oct 22, 2012 Jun CTEC + 6MG N 202834 003 Oct 22, 2012 Jun CTEC + 8MG N 202834 004 Oct 22, 2012 Jun CTEC + 10MG N 202834 005 Oct 22, 2012 Jun CTEC +! 12MG N 202834 006 Oct 22, 2012 Jun CTEC

PHENDIMETRAZINE TARTRATE TABLET;ORAL BONTRIL PDM >D> AA ! VALEANT 35MG A 085272 001 Aug CRLD >A> AA +! 35MG A 085272 001 Aug CRLD

PHENTERMINE HYDROCHLORIDE CAPSULE;ORAL ADIPEX-P >D> AA ! TEVA 37.5MG A 088023 001 Aug 02, 1983 Aug CRLD >A> AA +! 37.5MG A 088023 001 Aug 02, 1983 Aug CRLD HYDROCHLORIDE >D> AA ! SANDOZ 15MG A 087190 002 Aug CRLD >A> AA +! 15MG A 087190 002 Aug CRLD >D> AA ! 30MG A 086945 001 Jul 20, 1983 Aug CRLD >A> AA +! 30MG A 086945 001 Jul 20, 1983 Aug CRLD TABLET;ORAL ADIPEX-P >D> AA ! TEVA 37.5MG A 085128 001 Aug CRLD >A> AA +! 37.5MG A 085128 001 Aug CRLD PHENTERMINE HYDROCHLORIDE >D> @ USL PHARMA 8MG A 083804 001 Aug CRLD >A> + @ 8MG A 083804 001 Aug CRLD

PHENYLEPHRINE HYDROCHLORIDE SOLUTION;INTRAVENOUS BIORPHEN +! ETON PHARMS 0.5MG/5ML (0.1MG/ML) N 212909 001 Oct 21, 2019 Feb CPOT + @ 10MG/ML (10MG/ML) N 212909 002 Mar 11, 2021 Apr DISC +! 10MG/ML (10MG/ML) N 212909 002 Mar 11, 2021 Mar NEWA PHENYLEPHRINE HYDROCHLORIDE AP2 AUROBINDO PHARMA LTD 10MG/ML (10MG/ML) A 210696 001 Jan 07, 2021 Jan NEWA AP1 CAPLIN 10MG/ML (10MG/ML) A 213318 001 Jun 11, 2020 Jul CMFD AP1 50MG/5ML (10MG/ML) A 213318 002 Jun 11, 2020 Jul CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -90

SOLUTION;INTRAVENOUS PHENYLEPHRINE HYDROCHLORIDE AP1 100MG/10ML (10MG/ML) A 213318 003 Jun 11, 2020 Jul CMFD AP1 GLAND PHARMA LTD 10MG/ML (10MG/ML) A 211920 003 Apr 08, 2021 Apr NEWA AP2 +! HIKMA 10MG/ML (10MG/ML) N 203826 001 Dec 20, 2012 Jan CAHN AP2 +! 50MG/5ML (10MG/ML) N 203826 002 Jun 19, 2019 Jan CAHN AP2 +! 100MG/10ML (10MG/ML) N 203826 003 Jun 19, 2019 Jan CAHN AP1 PROVEPHARM SAS 10MG/ML (10MG/ML) A 211081 001 Jul 17, 2020 Jan CAHN AP1 50MG/5ML (10MG/ML) A 211081 002 Jul 17, 2020 Jan CAHN AP1 100MG/10ML (10MG/ML) A 211081 003 Jul 17, 2020 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE AA AKORN 5MG/5ML;6.25MG/5ML A 040675 001 Dec 23, 2014 Feb CAHN PROMETH VC PLAIN >D> @ G AND W LABS INC 5MG/5ML;6.25MG/5ML A 088761 001 Nov 08, 1984 Aug CRLD >A> + @ 5MG/5ML;6.25MG/5ML A 088761 001 Nov 08, 1984 Aug CRLD

PHENYTOIN TABLET, CHEWABLE;ORAL DILANTIN >D> AB ! PHARMACIA 50MG A 084427 001 Aug CRLD >A> AB +! 50MG A 084427 001 Aug CRLD

PHENYTOIN SODIUM CAPSULE;ORAL DILANTIN >D> ! UPJOHN 30MG EXTENDED A 084349 001 Aug CRLD >A> +! 30MG EXTENDED A 084349 001 Aug CRLD >D> AB ! 100MG EXTENDED A 084349 002 Aug CRLD >A> AB +! 100MG EXTENDED A 084349 002 Aug CRLD INJECTABLE;INJECTION PHENYTOIN SODIUM >D> AP ! WEST-WARD PHARMS INT 50MG/ML A 084307 001 Aug CRLD >A> AP +! 50MG/ML A 084307 001 Aug CRLD

PHYTONADIONE INJECTABLE;INJECTION PHYTONADIONE BP +! INTL MEDICATION 1MG/0.5ML A 083722 001 May CRLD VITAMIN K1 >D> AB ! HOSPIRA 10MG/ML A 087955 001 Jul 25, 1983 Aug CRLD >A> AB +! 10MG/ML A 087955 001 Jul 25, 1983 Aug CRLD

PIFLUFOLASTAT F-18 SOLUTION;INTRAVENOUS PYLARIFY +! PROGENICS PHARMS INC 50ML (1-80mCi/ML) N 214793 001 May 26, 2021 May NEWA

PILOCARPINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE >A> AB INNOGENIX 5MG A 076963 001 Dec 22, 2004 Aug CAHN >A> AB 7.5MG A 076963 002 Feb 27, 2007 Aug CAHN >D> AB MLV 5MG A 076963 001 Dec 22, 2004 Aug CAHN >D> AB 7.5MG A 076963 002 Feb 27, 2007 Aug CAHN

PIOGLITAZONE HYDROCHLORIDE TABLET;ORAL PIOGLITAZONE HYDROCHLORIDE AB ANNORA PHARMA EQ 15MG BASE A 204133 001 Apr 07, 2014 Jan CAHN AB EQ 30MG BASE A 204133 002 Apr 07, 2014 Jan CAHN AB EQ 45MG BASE A 204133 003 Apr 07, 2014 Jan CAHN AB SHUANGCHENG EQ 15MG BASE A 210165 001 Jan 22, 2021 Jan NEWA AB EQ 30MG BASE A 210165 002 Jan 22, 2021 Jan NEWA AB EQ 45MG BASE A 210165 003 Jan 22, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -91

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM INJECTABLE;INJECTION PIPERACILLIN AND TAZOBACTAM @ MYLAN LABS LTD EQ 2GM BASE/VIAL;EQ 250MG A 065458 001 Aug 15, 2014 Apr DISC BASE/VIAL @ EQ 3GM BASE/VIAL;EQ 375MG A 065458 002 Aug 15, 2014 Mar DISC BASE/VIAL @ EQ 4GM BASE/VIAL;EQ 500MG A 065458 003 Aug 15, 2014 Jul DISC BASE/VIAL AP PROVEPHARM SAS EQ 2GM BASE/VIAL;EQ 250MG A 207847 001 Jan 13, 2017 Jan CAHN BASE/VIAL AP EQ 3GM BASE/VIAL;EQ 375MG A 207847 002 Jan 13, 2017 Jan CAHN BASE/VIAL AP EQ 36GM BASE/VIAL;EQ 4.5GM A 207848 002 Jan 13, 2017 Jan CAHN BASE/VIAL AP EQ 4GM BASE/VIAL;EQ 500MG A 207847 003 Jan 13, 2017 Jan CAHN BASE/VIAL AP EQ 12GM BASE/VIAL;EQ 1.5GM A 207848 001 May 11, 2018 Jan CAHN BASE/VIAL AP SAGENT PHARMS INC EQ 2GM BASE/VIAL;EQ 250MG A 208674 001 Feb 16, 2021 Feb NEWA BASE/VIAL AP EQ 3GM BASE/VIAL;EQ 375MG A 208674 002 Feb 16, 2021 Feb NEWA BASE/VIAL AP EQ 4GM BASE/VIAL;EQ 500MG A 208674 003 Feb 16, 2021 Feb NEWA BASE/VIAL AP EQ 36GM BASE/VIAL;EQ 4.5GM A 208675 001 Feb 16, 2021 Feb NEWA BASE/VIAL AP SANDOZ INC EQ 36GM BASE/VIAL;EQ 4.5GM A 203557 002 Jul 08, 2021 Jul NEWA BASE/VIAL AP ! WOCKHARDT BIO AG EQ 2GM BASE/VIAL;EQ 250MG A 206996 001 Mar 22, 2017 Jan CHRS BASE/VIAL AP ! EQ 3GM BASE/VIAL;EQ 375MG A 206996 002 Mar 22, 2017 Jan CHRS BASE/VIAL AP ! EQ 4GM BASE/VIAL;EQ 500MG A 206996 003 Mar 22, 2017 Jan CHRS BASE/VIAL AP ! EQ 36GM BASE/VIAL;EQ 4.5GM A 207146 001 Mar 17, 2017 Jan CHRS BASE/VIAL ZOSYN + @ WYETH PHARMS EQ 2GM BASE/VIAL;EQ 250MG N 050684 001 Oct 22, 1993 Jan DISC BASE/VIAL + @ EQ 3GM BASE/VIAL;EQ 375MG N 050684 002 Oct 22, 1993 Jan DISC BASE/VIAL + @ EQ 4GM BASE/VIAL;EQ 500MG N 050684 003 Oct 22, 1993 Jan DISC BASE/VIAL + @ EQ 36GM BASE/VIAL;EQ 4.5GM N 050684 004 Oct 22, 1993 Jan DISC BASE/VIAL

PIRBUTEROL ACETATE AEROSOL, METERED;INHALATION MAXAIR @ BAUSCH EQ 0.2MG BASE/INH N 020014 001 Nov 30, 1992 May CAHN

PIROXICAM CAPSULE;ORAL AB NOSTRUM LABS INC 10MG A 074118 002 Jun 15, 1993 Jan CMS1

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE FOR SOLUTION;ORAL LAX-LYTE WITH FLAVOR PACKS >A> AA L PERRIGO CO 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 079232 001 Feb 25, 2010 Aug CAHN .2GM/BOT >D> AA PADDOCK LLC 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 079232 001 Feb 25, 2010 Aug CAHN .2GM/BOT

POLYMYXIN B SULFATE INJECTABLE;INJECTION POLYMYXIN B SULFATE @ GLAND EQ 500,000 UNITS BASE/VIAL A 207322 001 Apr 14, 2016 May DISC AP ! XELLIA PHARMS APS EQ 500,000 UNITS BASE/VIAL A 202766 001 Jan 15, 2014 May CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -92

POMALIDOMIDE CAPSULE;ORAL @ BRECKENRIDGE 1MG A 210111 001 Oct 30, 2020 Feb DISC @ 2MG A 210111 002 Oct 30, 2020 Feb DISC @ 3MG A 210111 003 Oct 30, 2020 Feb DISC @ 4MG A 210111 004 Oct 30, 2020 Feb DISC @ EUGIA PHARMA 1MG A 210249 001 Oct 30, 2020 Apr DISC @ 2MG A 210249 002 Oct 30, 2020 Apr DISC @ 3MG A 210249 003 Oct 30, 2020 Apr DISC @ 4MG A 210249 004 Oct 30, 2020 Apr DISC POMALYST + CELGENE 1MG N 204026 001 Feb 08, 2013 Apr CTEC + 2MG N 204026 002 Feb 08, 2013 Apr CTEC + 3MG N 204026 003 Feb 08, 2013 Apr CTEC +! 4MG N 204026 004 Feb 08, 2013 Apr CTEC

PONATINIB HYDROCHLORIDE TABLET;ORAL ICLUSIG + TAKEDA PHARMS USA EQ 10MG BASE N 203469 004 Dec 18, 2020 May CAHN + EQ 15MG BASE N 203469 001 Dec 14, 2012 May CAHN + EQ 30MG BASE N 203469 003 Apr 23, 2015 May CAHN +! EQ 45MG BASE N 203469 002 Dec 14, 2012 May CAHN

PONESIMOD TABLET;ORAL PONVORY + JANSSEN PHARMS 2MG N 213498 001 Mar 18, 2021 Mar NEWA + 3MG N 213498 002 Mar 18, 2021 Mar NEWA + 4MG N 213498 003 Mar 18, 2021 Mar NEWA + 5MG N 213498 004 Mar 18, 2021 Mar NEWA + 6MG N 213498 005 Mar 18, 2021 Mar NEWA + 7MG N 213498 006 Mar 18, 2021 Mar NEWA + 8MG N 213498 007 Mar 18, 2021 Mar NEWA + 9MG N 213498 008 Mar 18, 2021 Mar NEWA + 10MG N 213498 009 Mar 18, 2021 Mar NEWA +! 20MG N 213498 010 Mar 18, 2021 Mar NEWA

POSACONAZOLE FOR SUSPENSION, DELAYED RELEASE;ORAL NOXAFIL POWDERMIX KIT +! MSD MERCK CO 300MG N 214770 001 May 31, 2021 May NEWA TABLET, DELAYED RELEASE;ORAL AB AET PHARMA 100MG A 213454 001 Feb 01, 2021 Jan NEWA

POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL POTASSIUM CHLORIDE AB GRANULES 8MEQ A 214686 001 Feb 16, 2021 Feb NEWA AB 10MEQ A 214686 002 Feb 16, 2021 Feb NEWA FOR SOLUTION;ORAL POTASSIUM CHLORIDE >D> AA STRIDES PHARMA 20MEQ A 211667 001 Mar 11, 2021 Aug DISC >A> @ 20MEQ A 211667 001 Mar 11, 2021 Aug DISC AA 20MEQ A 211667 001 Mar 11, 2021 Mar NEWA INJECTABLE;INJECTION POTASSIUM CHLORIDE >D> @ ABRAXIS PHARM 2MEQ/ML A 080204 001 Aug CRLD >A> + @ 2MEQ/ML A 080204 001 Aug CRLD >D> AP FRESENIUS KABI USA 2MEQ/ML A 080225 001 Aug CRLD >A> AP + 2MEQ/ML A 080225 001 Aug CRLD POTASSIUM CHLORIDE 10MEQ @ FRESENIUS KABI USA 14.9MG/ML A 211087 001 Sep 09, 2020 Mar DISC @ 746MG/100ML A 211087 002 Sep 09, 2020 Mar DISC AP NEXUS PHARMS 14.9MG/ML A 214727 001 Mar 18, 2021 Mar NFTG AP 745MG/100ML A 214727 002 Mar 18, 2021 Mar NFTG POTASSIUM CHLORIDE 20MEQ @ FRESENIUS KABI USA 29.8MG/ML A 211087 003 Sep 09, 2020 Mar DISC AP 1.49GM/100ML A 211087 005 May 07, 2021 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -93

INJECTABLE;INJECTION POTASSIUM CHLORIDE 20MEQ AP NEXUS PHARMS 29.8MG/ML A 214727 003 Mar 18, 2021 Mar NFTG AP 1.49GM/100ML A 214727 004 Mar 18, 2021 Mar NFTG POTASSIUM CHLORIDE 40MEQ @ FRESENIUS KABI USA 2.98GM/100ML A 211087 004 Sep 09, 2020 Mar DISC AP NEXUS PHARMS 2.98GM/100ML A 214727 005 Mar 18, 2021 Mar NFTG SOLUTION;ORAL POTASSIUM CHLORIDE AA GRANULES 20MEQ/15ML A 213392 001 Jan 29, 2021 Jan NEWA AA 40MEQ/15ML A 213392 002 Jan 29, 2021 Jan NEWA AA SAPTALIS PHARMS 20MEQ/15ML A 211648 001 May 21, 2021 May NEWA AA 40MEQ/15ML A 211648 002 May 21, 2021 May NEWA TABLET, EXTENDED RELEASE;ORAL POTASSIUM CHLORIDE @ AMTA 10MEQ A 214395 001 Jan 28, 2021 Jul DISC AB1 10MEQ A 214395 001 Jan 28, 2021 Jan NEWA @ 20MEQ A 214395 002 Jan 28, 2021 Jul DISC AB1 20MEQ A 214395 002 Jan 28, 2021 Jan NEWA AB1 AUROBINDO PHARMA LTD 10MEQ A 214728 001 Mar 31, 2021 Mar NEWA AB1 15MEQ A 214728 002 Mar 31, 2021 Mar NEWA AB1 20MEQ A 214728 003 Mar 31, 2021 Mar NEWA @ CENTAUR PHARMS PVT 10MEQ A 213588 001 Aug 21, 2020 Mar DISC @ 20MEQ A 213588 002 Aug 21, 2020 Mar DISC

POTASSIUM CHLORIDE; SODIUM CHLORIDE INJECTABLE;INJECTION POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% +! BAXTER HLTHCARE 150MG/100ML;450MG/100ML N 017648 005 Nov 26, 2002 Mar CTNA +! 150MG/100ML;450MG/100ML N 017648 005 Nov 26, 2002 Mar CTEC @ FRESENIUS KABI USA 150MG/100ML;450MG/100ML A 212347 001 Sep 17, 2020 Mar DISC POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% AP +! BAXTER HLTHCARE 150MG/100ML;900MG/100ML N 017648 001 Mar CTNA AP +! 150MG/100ML;900MG/100ML N 017648 001 Mar CHRS AP FRESENIUS KABI USA 150MG/100ML;900MG/100ML A 212347 003 Jun 02, 2021 May NEWA POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% +! BAXTER HLTHCARE 300MG/100ML;900MG/100ML N 017648 002 Mar CTNA +! 300MG/100ML;900MG/100ML N 017648 002 Mar CHRS + 300MG/100ML;900MG/100ML N 017648 002 Mar CTEC @ FRESENIUS KABI USA 300MG/100ML;900MG/100ML A 212347 002 Sep 17, 2020 Mar DISC SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% @ BAXTER HLTHCARE 75MG/100ML;900MG/100ML N 017648 004 Mar CTNA

POTASSIUM CITRATE TABLET, EXTENDED RELEASE;ORAL POTASSIUM CITRATE AB ASCENT PHARMS INC 5MEQ A 214420 001 Feb 05, 2021 Jan NEWA AB 10MEQ A 214420 002 Feb 05, 2021 Jan NEWA AB 15MEQ A 214420 003 Feb 05, 2021 Jan NEWA AB BIONPHARMA INC 10MEQ A 212799 001 Jun 29, 2020 Apr CMFD @ 10MEQ A 212799 001 Jun 29, 2020 Feb DISC AB 15MEQ A 212799 002 Jun 29, 2020 Apr CMFD @ 15MEQ A 212799 002 Jun 29, 2020 Feb DISC AB EYWA 5MEQ A 214426 001 Feb 19, 2021 Feb NEWA AB 10MEQ A 214426 002 Feb 19, 2021 Feb NEWA AB 15MEQ A 214426 003 Feb 19, 2021 Feb NEWA

PRALSETINIB CAPSULE;ORAL GAVRETO +! GENENTECH INC 100MG N 213721 001 Sep 04, 2020 Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE TABLET;ORAL DIHYDROCHLORIDE @ NOSTRUM LABS INC 0.125MG A 091450 001 Oct 08, 2010 Jul DISC AB 0.125MG A 091450 001 Oct 08, 2010 Apr CAHN @ 0.25MG A 091450 002 Oct 08, 2010 Jul DISC AB 0.25MG A 091450 002 Oct 08, 2010 Apr CAHN @ 0.5MG A 091450 003 Oct 08, 2010 Jul DISC AB 0.5MG A 091450 003 Oct 08, 2010 Apr CAHN @ 1MG A 091450 004 Oct 08, 2010 Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -94

TABLET;ORAL PRAMIPEXOLE DIHYDROCHLORIDE AB 1MG A 091450 004 Oct 08, 2010 Apr CAHN @ 1.5MG A 091450 005 Oct 08, 2010 Jul DISC AB 1.5MG A 091450 005 Oct 08, 2010 Apr CAHN TABLET, EXTENDED RELEASE;ORAL PRAMIPEXOLE DIHYDROCHLORIDE AB XIAMEN LP PHARM CO 0.375MG A 212797 001 Jun 11, 2021 Jun NEWA AB 0.75MG A 212797 002 Jun 11, 2021 Jun NEWA

PRASUGREL HYDROCHLORIDE TABLET;ORAL @ DR REDDYS LABS LTD EQ 5MG BASE A 205926 001 Jul 07, 2020 Jan DISC @ EQ 10MG BASE A 205926 002 Jul 07, 2020 Jan DISC AB PANACEA EQ 5MG BASE A 205897 001 Oct 16, 2017 Jul CAHN AB EQ 10MG BASE A 205897 002 Oct 16, 2017 Jul CAHN

PRAVASTATIN SODIUM TABLET;ORAL PRAVACHOL + @ BRISTOL MYERS SQUIBB 20MG N 019898 003 Oct 31, 1991 Jun DISC + @ 40MG N 019898 004 Mar 22, 1993 Jun DISC + @ 80MG N 019898 008 Dec 18, 2001 Jun DISC PRAVASTATIN SODIUM AB BIOCON PHARMA 10MG A 209869 001 Apr 13, 2018 Jan CAHN AB 20MG A 209869 002 Apr 13, 2018 Jan CAHN AB 40MG A 209869 003 Apr 13, 2018 Jan CAHN AB 80MG A 209869 004 Apr 13, 2018 Jan CAHN @ HISUN PHARM HANGZHOU 20MG A 206061 001 Nov 23, 2018 Jan DISC @ 40MG A 206061 002 Nov 23, 2018 Jan DISC @ 80MG A 206061 003 Nov 23, 2018 Jan DISC AB ! TEVA PHARMS 80MG A 077793 001 Jan 15, 2008 Jun CHRS

PRAZOSIN HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB ANI PHARMS EQ 1MG BASE A 072577 002 May 16, 1989 Feb CMFD AB EQ 2MG BASE A 072577 001 May 16, 1989 Feb CMFD AB EQ 5MG BASE A 072577 003 May 16, 1989 Feb CMFD

PREDNISOLONE SYRUP;ORAL PREDNISOLONE AA CHARTWELL RX 15MG/5ML A 040323 001 May 13, 1999 Mar CMFD TABLET;ORAL PREDNISOLONE RI SIN G@ RISING@ 5MG A 084773 001 Jan CAHN

PREDNISOLONE SODIUM PHOSPHATE SOLUTION;ORAL PREDNISOLONE SODIUM PHOSPHATE @ BAUSCH EQ 15MG BASE/5ML A 075250 001 Jul 12, 2002 May CAHN SOLUTION/DROPS;OPHTHALMIC INFLAMASE FORTE >D> @ NOVARTIS EQ 0.9% PHOSPHATE A 080751 002 Aug CRLD >A> + @ EQ 0.9% PHOSPHATE A 080751 002 Aug CRLD INFLAMASE MILD >D> @ NOVARTIS EQ 0.11% PHOSPHATE A 080751 001 Aug CRLD >A> + @ EQ 0.11% PHOSPHATE A 080751 001 Aug CRLD TABLET, ORALLY DISINTEGRATING;ORAL ORAPRED ODT + CONCORDIA PHARMS INC EQ 10MG BASE N 021959 001 Jun 01, 2006 Jul CTEC + EQ 15MG BASE N 021959 002 Jun 01, 2006 Jul CTEC +! EQ 30MG BASE N 021959 003 Jun 01, 2006 Jul CTEC PREDNISOLONE SODIUM PHOSPHATE @ MYLAN PHARMS INC EQ 10MG BASE A 202179 001 Apr 10, 2013 Jul DISC @ EQ 15MG BASE A 202179 002 Apr 10, 2013 Jul DISC @ EQ 30MG BASE A 202179 003 Apr 10, 2013 Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -95

PREDNISONE TABLET;ORAL PREDNISONE >D> AB ! HIKMA PHARMS 1MG A 087800 001 Apr 22, 1982 Aug CRLD >A> AB +! 1MG A 087800 001 Apr 22, 1982 Aug CRLD >D> AB ! 10MG A 084122 001 Aug CRLD >A> AB +! 10MG A 084122 001 Aug CRLD >D> AB ! 20MG A 087342 001 Aug CRLD >A> AB +! 20MG A 087342 001 Aug CRLD AB NOVITIUM PHARMA 1MG A 215246 001 Jul 06, 2021 Jun NEWA @ RISING 10MG A 089983 001 Jan 12, 1989 Jan CAHN @ 20MG A 085813 001 Jan CAHN @ 50MG A 089984 001 Jan 12, 1989 Jan CAHN AB STRIDES PHARMA 10MG A 208412 001 Feb 11, 2021 Feb NEWA AB 20MG A 208412 002 Feb 11, 2021 Feb NEWA TABLET, DELAYED RELEASE;ORAL RAYOS + HORIZON 1MG N 202020 001 Jul 26, 2012 Apr CAHN + 2MG N 202020 002 Jul 26, 2012 Apr CAHN +! 5MG N 202020 003 Jul 26, 2012 Apr CAHN

PREGABALIN CAPSULE;ORAL LYRICA AB + UPJOHN 25MG N 021446 001 Dec 30, 2004 Apr CAHN AB + 50MG N 021446 002 Dec 30, 2004 Apr CAHN AB + 75MG N 021446 003 Dec 30, 2004 Apr CAHN AB + 100MG N 021446 004 Dec 30, 2004 Apr CAHN AB + 150MG N 021446 005 Dec 30, 2004 Apr CAHN AB + 200MG N 021446 006 Dec 30, 2004 Apr CAHN AB + 225MG N 021446 007 Dec 30, 2004 Apr CAHN AB +! 300MG N 021446 008 Dec 30, 2004 Apr CAHN AB ALKEM LABS LTD 25MG A 207799 007 Sep 30, 2019 Feb CMS1 AB 50MG A 207799 008 Sep 30, 2019 Feb CMS1 AB APOTEX 25MG A 211685 001 Jul 07, 2021 Jun NEWA AB 50MG A 211685 002 Jul 07, 2021 Jun NEWA AB 75MG A 211685 003 Jul 07, 2021 Jun NEWA AB 100MG A 211685 004 Jul 07, 2021 Jun NEWA AB 150MG A 211685 005 Jul 07, 2021 Jun NEWA AB 200MG A 211685 006 Jul 07, 2021 Jun NEWA AB 225MG A 211685 007 Jul 07, 2021 Jun NEWA AB 300MG A 211685 008 Jul 07, 2021 Jun NEWA AB CHANGZHOU PHARM 50MG A 214322 001 Jul 15, 2021 Jul NEWA AB 75MG A 214322 002 Jul 15, 2021 Jul NEWA AB 100MG A 214322 003 Jul 15, 2021 Jul NEWA AB 150MG A 214322 004 Jul 15, 2021 Jul NEWA AB 200MG A 214322 005 Jul 15, 2021 Jul NEWA AB 225MG A 214322 006 Jul 15, 2021 Jul NEWA AB 300MG A 214322 007 Jul 15, 2021 Jul NEWA SOLUTION;ORAL LYRICA AA +! UPJOHN 20MG/ML N 022488 001 Jan 04, 2010 Apr CAHN TABLET, EXTENDED RELEASE;ORAL LYRICA CR AB + UPJOHN 82.5MG N 209501 001 Oct 11, 2017 Apr CAHN AB + 165MG N 209501 002 Oct 11, 2017 Apr CAHN AB +! 330MG N 209501 003 Oct 11, 2017 Apr CAHN PREGABALIN AB ALVOGEN 82.5MG A 211687 001 Jul 06, 2021 Jun NEWA AB 165MG A 211687 002 Jul 06, 2021 Jun NEWA AB 330MG A 211687 003 Jul 06, 2021 Jun NEWA AB ALVOGEN PINE BROOK 82.5MG A 211593 001 Apr 13, 2021 Apr NFTG AB 165MG A 211593 002 Apr 13, 2021 Apr NFTG AB 330MG A 211593 003 Apr 13, 2021 Apr NFTG AB APOTEX 165MG A 213313 001 Apr 13, 2021 Apr NFTG AB 330MG A 213313 002 Apr 13, 2021 Apr NFTG AB MSN 82.5MG A 213226 001 Apr 13, 2021 Apr NFTG AB 165MG A 213226 002 Apr 13, 2021 Apr NFTG AB 330MG A 213226 003 Apr 13, 2021 Apr NFTG AB MYLAN 82.5MG A 211948 001 Apr 13, 2021 Apr NFTG AB 330MG A 211431 001 Jul 02, 2021 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -96

TABLET, EXTENDED RELEASE;ORAL PREGABALIN AB SUN PHARM 82.5MG A 211889 001 Apr 13, 2021 Apr NFTG AB 165MG A 211889 002 Apr 13, 2021 Apr NFTG AB 330MG A 211889 003 Apr 13, 2021 Apr NFTG

PROBENECID TABLET;ORAL PROBENECID >D> AB MYLAN 500MG A 084211 002 Aug CAHN >A> @ 500MG A 084211 002 Aug CAHN >D> ! WATSON LABS TEVA 500MG A 084442 004 Mar 29, 1983 Aug CTEC >A> AB ! 500MG A 084442 004 Mar 29, 1983 Aug CTEC

PROCAINAMIDE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL PROCAN SR >D> @ PARKE DAVIS 250MG A 086468 001 Aug CRLD >A> + @ 250MG A 086468 001 Aug CRLD >D> @ PARKEDALE 500MG A 086065 001 Aug CRLD >A> + @ 500MG A 086065 001 Aug CRLD >D> @ 750MG A 087510 001 Apr 01, 1982 Aug CRLD >A> + @ 750MG A 087510 001 Apr 01, 1982 Aug CRLD

PROCHLORPERAZINE EDISYLATE INJECTABLE;INJECTION EDISYLATE AP CAPLIN EQ 5MG BASE/ML A 214379 001 Apr 22, 2021 Apr NEWA @ HIKMA PHARMS EQ 5MG BASE/ML A 089523 001 May 03, 1988 Jul CAHN AP EQ 5MG BASE/ML A 089903 001 Aug 29, 1989 Jul CAHN

PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE >D> @ AMNEAL PHARMS 6.25MG/5ML A 040882 001 Dec 30, 2009 Aug CMFD >A> AA 6.25MG/5ML A 040882 001 Dec 30, 2009 Aug CMFD @ 6.25MG/5ML A 040882 001 Dec 30, 2009 Feb DISC AA QUAGEN 6.25MG/5ML A 213890 001 Jul 12, 2021 Jul NEWA PROMETHAZINE PLAIN >D> AA ! WOCKHARDT BIO AG 6.25MG/5ML A 087953 001 Nov 15, 1982 Aug CRLD >A> AA +! 6.25MG/5ML A 087953 001 Nov 15, 1982 Aug CRLD TABLET;ORAL PROMETHAZINE HYDROCHLORIDE >D> AB SANDOZ 25MG A 084176 003 Aug CRLD >A> AB + 25MG A 084176 003 Aug CRLD >D> AB ! 50MG A 084176 001 Aug CRLD >A> AB +! 50MG A 084176 001 Aug CRLD

PROPAFENONE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL HYDROCHLORIDE @ MYLAN 225MG A 203803 001 Apr 29, 2016 Jul DISC @ 325MG A 203803 002 Apr 29, 2016 Jul DISC @ 425MG A 203803 003 Apr 29, 2016 Jul DISC AB ZYDUS 225MG A 214184 001 Apr 21, 2021 Apr NEWA AB 325MG A 214184 002 Apr 21, 2021 Apr NEWA AB 425MG A 214184 003 Apr 21, 2021 Apr NEWA

PROPANTHELINE BROMIDE TABLET;ORAL @ HIKMA PHARMS 15MG A 080927 002 Apr DISC

PROPRANOLOL HYDROCHLORIDE TABLET;ORAL PROPRANOLOL HYDROCHLORIDE >D> @ IMPAX LABS INC 40MG A 071972 003 Apr 06, 1988 Aug CMFD >A> AB 40MG A 071972 003 Apr 06, 1988 Aug CMFD @ WATSON LABS 60MG A 070178 002 Apr 23, 2018 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -97

PROPYLTHIOURACIL TABLET;ORAL PROPYLTHIOURACIL BD QUAGEN 50MG A 080154 001 Mar CMFD

PROTAMINE SULFATE INJECTABLE;INJECTION @ HIKMA PHARMS 10MG/ML A 089474 001 Nov 05, 1986 Jul CAHN @ 10MG/ML A 089475 001 Nov 05, 1986 Jul CAHN

PYRAZINAMIDE TABLET;ORAL PYRAZINAMIDE >D> AB NOVITIUM PHARMA 500MG A 080157 001 Aug CRLD >A> AB + 500MG A 080157 001 Aug CRLD AB 500MG A 080157 001 Apr CMFD

PYRIDOXINE HYDROCHLORIDE INJECTABLE;INJECTION PYRIDOXINE HYDROCHLORIDE >D> ! FRESENIUS KABI USA 100MG/ML A 080618 001 Aug CRLD >A> +! 100MG/ML A 080618 001 Aug CRLD

PYRIMETHAMINE TABLET;ORAL PYRIMETHAMINE >A> AB ALVOGEN 25MG A 211271 001 Jul 27, 2021 Aug CAHN >D> AB FERA PHARMS LLC 25MG A 211271 001 Jul 27, 2021 Aug CAHN AB 25MG A 211271 001 Jul 27, 2021 Jul NEWA >A> AB TEVA PHARMS 25MG A 215506 001 Aug 13, 2021 Aug NEWA

QUETIAPINE FUMARATE TABLET;ORAL FUMARATE @ JUBILANT GENERICS EQ 25MG BASE A 203150 001 Nov 26, 2013 Jun DISC TABLET, EXTENDED RELEASE;ORAL QUETIAPINE FUMARATE @ ANCHEN PHARMS EQ 150MG BASE A 090757 001 Dec 01, 2017 Jun DISC @ EQ 200MG BASE A 090757 002 Dec 01, 2017 Jun DISC @ EQ 300MG BASE A 090757 003 Dec 01, 2017 Jun DISC @ EQ 400MG BASE A 090757 004 Dec 01, 2017 Jun DISC @ MYLAN EQ 50MG BASE A 202228 001 Feb 02, 2021 Feb DISC AB EQ 50MG BASE A 202228 001 Feb 02, 2021 Jan NEWA @ EQ 150MG BASE A 202228 002 Feb 02, 2021 Feb DISC AB EQ 150MG BASE A 202228 002 Feb 02, 2021 Jan NEWA @ EQ 200MG BASE A 202228 003 Feb 02, 2021 Feb DISC AB EQ 200MG BASE A 202228 003 Feb 02, 2021 Jan NEWA @ EQ 300MG BASE A 202228 004 Feb 02, 2021 Feb DISC AB EQ 300MG BASE A 202228 004 Feb 02, 2021 Jan NEWA @ EQ 400MG BASE A 202228 005 Feb 02, 2021 Feb DISC AB EQ 400MG BASE A 202228 005 Feb 02, 2021 Jan NEWA

QUINIDINE GLUCONATE TABLET, EXTENDED RELEASE;ORAL GLUCONATE @ RISING 324MG A 089894 001 Dec 15, 1988 Jan CAHN

QUINIDINE SULFATE TABLET;ORAL CIN-QUIN >D> SOLVAY@ 100MG A 085299 001 Aug CRLD >A> + @ 100MG A 085299 001 Aug CRLD >D> @ 200MG A 084932 001 Aug CRLD >A> + @ 200MG A 084932 001 Aug CRLD QUINORA >D> @ SCHERING 300MG A 085222 001 Aug CRLD >A> + @ 300MG A 085222 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -98

RABEPRAZOLE SODIUM TABLET, DELAYED RELEASE;ORAL ACIPHEX + @ WOODWARD 10MG N 020973 001 May 29, 2002 Jul CAHN AB +! 20MG N 020973 002 Aug 19, 1999 Jul CAHN

RANITIDINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE @ AUROBINDO PHARMA LTD EQ 150MG BASE A 211058 001 Jul 16, 2018 Jun DISC @ EQ 300MG BASE A 211058 002 Jul 16, 2018 Jun DISC SYRUP;ORAL RANITIDINE HYDROCHLORIDE @ AUROBINDO PHARMA LTD EQ 15MG BASE/ML A 090623 001 Jul 28, 2010 Jun DISC TABLET;ORAL RANITIDINE HYDROCHLORIDE @ WOCKHARDT LTD EQ 150MG BASE A 075208 001 Dec 17, 1998 Jan DISC @ EQ 300MG BASE A 075208 002 Dec 17, 1998 Jan DISC

RANOLAZINE TABLET, EXTENDED RELEASE;ORAL AB ACCORD HLTHCARE 500MG A 212930 001 May 18, 2021 May NEWA AB 1GM A 212930 002 May 18, 2021 May NEWA @ AMNEAL 500MG A 207690 001 Mar 11, 2021 Apr DISC AB 500MG A 207690 001 Mar 11, 2021 Mar NEWA @ 1GM A 207690 002 Mar 11, 2021 Apr DISC AB 1GM A 207690 002 Mar 11, 2021 Mar NEWA AB GRAVITI PHARMS 500MG A 212889 001 Jan 28, 2021 Jan NEWA AB 1GM A 212889 002 Jan 28, 2021 Jan NEWA AB PRAXGEN 500MG A 212781 001 Mar 23, 2020 Feb CAHN AB 1GM A 212781 002 Mar 23, 2020 Feb CAHN

REPAGLINIDE TABLET;ORAL AB PADAGIS US 0.5MG A 201189 001 Jul 17, 2013 Jul CAHN AB 0.5MG A 201189 001 Jul 17, 2013 Jul CAHN AB 1MG A 201189 002 Jan 22, 2014 Jul CAHN AB 1MG A 201189 002 Jan 22, 2014 Jul CAHN AB 2MG A 201189 003 Jan 22, 2014 Jul CAHN AB 2MG A 201189 003 Jan 22, 2014 Jul CAHN

RIFAXIMIN TABLET;ORAL XIFAXAN >A> +! SALIX PHARMS 550MG N 021361 002 Mar 24, 2010 Aug CMS1

RILUZOLE FILM;ORAL EXSERVAN +! MITSUBISHI HOLDINGS 50MG N 212640 001 Nov 22, 2019 Feb CAHN

RIMEGEPANT SULFATE TABLET, ORALLY DISINTEGRATING;ORAL NURTEC ODT +! BIOHAVEN IRELAND EQ 75MG BASE N 212728 001 Feb 27, 2020 Jul CAHN

RISPERIDONE TABLET, ORALLY DISINTEGRATING;ORAL RISPERDAL + @ JANSSEN PHARMS 0.5MG N 021444 001 Apr 02, 2003 Feb DISC + @ 1MG N 021444 002 Apr 02, 2003 Feb DISC + @ 2MG N 021444 003 Apr 02, 2003 Feb DISC + @ 3MG N 021444 004 Dec 23, 2004 Feb DISC + @ 4MG N 021444 005 Dec 23, 2004 Feb DISC AB ! JUBILANT GENERICS 1MG A 090839 002 Nov 04, 2011 Feb CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -99

RITONAVIR CAPSULE;ORAL RITONAVIR @ HIKMA PHARMS 100MG A 205801 001 Dec 03, 2020 Mar DISC

RIZATRIPTAN BENZOATE TABLET, ORALLY DISINTEGRATING;ORAL BENZOATE @ JUBILANT GENERICS EQ 5MG BASE A 203334 001 Oct 16, 2015 Jun DISC @ EQ 10MG BASE A 203334 002 Oct 16, 2015 Jun DISC AB PANACEA EQ 5MG BASE A 204722 001 Jan 11, 2017 Jul CAHN AB EQ 10MG BASE A 204722 002 Jan 11, 2017 Jul CAHN

ROPINIROLE HYDROCHLORIDE TABLET;ORAL REQUIP + @ GLAXOSMITHKLINE LLC EQ 0.25MG BASE N 020658 001 Sep 19, 1997 Jul DISC + @ EQ 0.5MG BASE N 020658 002 Sep 19, 1997 Jul DISC + @ EQ 1MG BASE N 020658 003 Sep 19, 1997 Jul DISC + @ EQ 2MG BASE N 020658 004 Sep 19, 1997 Jul DISC + @ EQ 3MG BASE N 020658 006 Jan 27, 1999 Jul DISC + @ EQ 4MG BASE N 020658 007 Jan 27, 1999 Jul DISC + @ EQ 5MG BASE N 020658 005 Sep 19, 1997 Jul DISC HYDROCHLORIDE AB ! PRINSTON INC EQ 0.25MG BASE A 078110 001 May 05, 2008 Jul CHRS TABLET, EXTENDED RELEASE;ORAL REQUIP XL + @ GLAXOSMITHKLINE LLC EQ 2MG BASE N 022008 001 Jun 13, 2008 Jun DISC AB + EQ 2MG BASE N 022008 001 Jun 13, 2008 Jun CHRS + @ EQ 6MG BASE N 022008 006 Apr 10, 2009 Jun DISC + @ EQ 12MG BASE N 022008 005 Oct 31, 2008 Jun DISC ROPINIROLE HYDROCHLORIDE AB ! DR REDDYS LABS LTD EQ 2MG BASE A 201576 001 Jun 06, 2012 Jun CHRS

ROPIVACAINE HYDROCHLORIDE SOLUTION;INJECTION NAROPIN + @ FRESENIUS KABI USA 50MG/10ML (5MG/ML) N 020533 013 May 01, 1998 Mar CRLD + @ 75MG/10ML (7.5MG/ML) N 020533 012 Sep 24, 1996 Mar CRLD HYDROCHLORIDE @ MYLAN ASI 150MG/30ML (5MG/ML) A 090318 002 Sep 23, 2014 Jan DISC @ 200MG/20ML (10MG/ML) A 090318 004 Sep 23, 2014 Jan DISC

ROSIGLITAZONE MALEATE TABLET;ORAL AVANDIA + WOODWARD EQ 2MG BASE N 021071 002 May 25, 1999 Jul CAHN + EQ 4MG BASE N 021071 003 May 25, 1999 Jul CAHN + @ EQ 8MG BASE N 021071 004 May 25, 1999 Jul CAHN

ROSUVASTATIN CALCIUM TABLET;ORAL CRESTOR AB + IPR EQ 5MG BASE N 021366 002 Aug 12, 2003 Apr CPOT AB + EQ 10MG BASE N 021366 003 Aug 12, 2003 Apr CPOT AB +! EQ 40MG BASE N 021366 005 Aug 12, 2003 Apr CPOT ROSUVASTATIN CALCIUM AB ACCORD HLTHCARE EQ 5MG BASE A 206434 001 Oct 31, 2016 Apr CPOT AB EQ 10MG BASE A 206434 002 Oct 31, 2016 Apr CPOT AB EQ 20MG BASE A 206434 003 Oct 31, 2016 Apr CPOT AB EQ 40MG BASE A 206434 004 Oct 31, 2016 Apr CPOT AB ALKEM LABS LTD EQ 5MG BASE A 206465 001 Mar 21, 2017 Apr CPOT AB EQ 10MG BASE A 206465 002 Mar 21, 2017 Apr CPOT AB EQ 20MG BASE A 206465 003 Mar 21, 2017 Apr CPOT AB EQ 40MG BASE A 206465 004 Mar 21, 2017 Apr CPOT AB ALLIED EQ 5MG BASE A 079168 001 Jul 19, 2016 Apr CPOT AB EQ 10MG BASE A 079168 002 Jul 19, 2016 Apr CPOT AB EQ 20MG BASE A 079168 003 Jul 19, 2016 Apr CPOT AB EQ 40MG BASE A 079168 004 Jul 19, 2016 Apr CPOT @ AMNEAL PHARMS CO EQ 5MG BASE A 208850 001 Oct 16, 2018 Apr CPOT @ EQ 10MG BASE A 208850 002 Oct 16, 2018 Apr CPOT RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -100

TABLET;ORAL ROSUVASTATIN CALCIUM @ EQ 20MG BASE A 208850 003 Oct 16, 2018 Apr CPOT @ EQ 40MG BASE A 208850 004 Oct 16, 2018 Apr CPOT @ APOTEX INC EQ 5MG BASE A 079145 001 Jul 19, 2016 Apr CPOT @ EQ 10MG BASE A 079145 002 Jul 19, 2016 Apr CPOT @ EQ 20MG BASE A 079145 003 Jul 19, 2016 Apr CPOT @ EQ 40MG BASE A 079145 004 Jul 19, 2016 Apr CPOT AB AUROBINDO PHARMA LTD EQ 5MG BASE A 079170 001 Jul 19, 2016 Apr CPOT AB EQ 10MG BASE A 079170 002 Jul 19, 2016 Apr CPOT AB EQ 20MG BASE A 079170 003 Jul 19, 2016 Apr CPOT AB EQ 40MG BASE A 079170 004 Jul 19, 2016 Apr CPOT AB BIOCON LTD EQ 5MG BASE A 207752 001 Oct 31, 2016 Apr CPOT AB EQ 10MG BASE A 207752 002 Oct 31, 2016 Apr CPOT AB EQ 20MG BASE A 207752 003 Oct 31, 2016 Apr CPOT AB EQ 40MG BASE A 207752 004 Oct 31, 2016 Apr CPOT AB BIOCON PHARMA EQ 5MG BASE A 207752 001 Oct 31, 2016 Jul CAHN AB EQ 10MG BASE A 207752 002 Oct 31, 2016 Jul CAHN AB EQ 20MG BASE A 207752 003 Oct 31, 2016 Jul CAHN AB EQ 40MG BASE A 207752 004 Oct 31, 2016 Jul CAHN AB CADILA PHARMS LTD EQ 5MG BASE A 207453 001 Nov 23, 2016 Apr CPOT AB EQ 10MG BASE A 207453 002 Nov 23, 2016 Apr CPOT AB EQ 20MG BASE A 207453 003 Nov 23, 2016 Apr CPOT AB EQ 40MG BASE A 207453 004 Nov 23, 2016 Apr CPOT AB CHANGZHOU PHARM EQ 5MG BASE A 207408 001 Oct 31, 2016 Apr CPOT AB EQ 10MG BASE A 207408 002 Oct 31, 2016 Apr CPOT AB EQ 20MG BASE A 207408 003 Oct 31, 2016 Apr CPOT AB EQ 40MG BASE A 207408 004 Oct 31, 2016 Apr CPOT AB GLENMARK PHARMS EQ 5MG BASE A 079172 001 Jul 19, 2016 Apr CPOT AB EQ 10MG BASE A 079172 002 Jul 19, 2016 Apr CPOT AB EQ 20MG BASE A 079172 003 Jul 19, 2016 Apr CPOT AB EQ 40MG BASE A 079172 004 Jul 19, 2016 Apr CPOT AB HETERO LABS LTD V EQ 5MG BASE A 207616 001 Oct 31, 2016 Apr CPOT AB EQ 10MG BASE A 207616 002 Oct 31, 2016 Apr CPOT AB EQ 20MG BASE A 207616 003 Oct 31, 2016 Apr CPOT AB EQ 40MG BASE A 207616 004 Oct 31, 2016 Apr CPOT @ INVENTIA EQ 5MG BASE A 207653 001 Feb 05, 2021 May DISC AB EQ 5MG BASE A 207653 001 Feb 05, 2021 Apr CPOT AB 5MG A 207653 001 Feb 05, 2021 Jan NEWA @ EQ 10MG BASE A 207653 002 Feb 05, 2021 May DISC AB EQ 10MG BASE A 207653 002 Feb 05, 2021 Apr CPOT AB 10MG A 207653 002 Feb 05, 2021 Jan NEWA @ EQ 20MG BASE A 207653 003 Feb 05, 2021 May DISC AB EQ 20MG BASE A 207653 003 Feb 05, 2021 Apr CPOT AB 20MG A 207653 003 Feb 05, 2021 Jan NEWA @ EQ 40MG BASE A 207653 004 Feb 05, 2021 May DISC AB EQ 40MG BASE A 207653 004 Feb 05, 2021 Apr CPOT AB 40MG A 207653 004 Feb 05, 2021 Jan NEWA AB LUPIN EQ 5MG BASE A 205587 001 Jul 31, 2017 Apr CPOT AB EQ 10MG BASE A 205587 002 Jul 31, 2017 Apr CPOT AB EQ 20MG BASE A 205587 003 Jul 31, 2017 Apr CPOT AB EQ 40MG BASE A 205587 004 Jul 31, 2017 Apr CPOT AB MSN EQ 5MG BASE A 208898 001 Nov 22, 2017 Apr CPOT AB EQ 10MG BASE A 208898 002 Nov 22, 2017 Apr CPOT AB EQ 20MG BASE A 208898 003 Nov 22, 2017 Apr CPOT AB EQ 40MG BASE A 208898 004 Nov 22, 2017 Apr CPOT @ MYLAN EQ 5MG BASE A 079161 001 Jul 19, 2016 Apr CPOT @ EQ 10MG BASE A 079161 002 Jul 19, 2016 Apr CPOT @ EQ 20MG BASE A 079161 003 Jul 19, 2016 Apr CPOT @ EQ 40MG BASE A 079161 004 Jul 19, 2016 Apr CPOT AB RENATA EQ 5MG BASE A 207062 001 Oct 31, 2016 Apr CPOT AB EQ 10MG BASE A 207062 002 Oct 31, 2016 Apr CPOT AB EQ 20MG BASE A 207062 003 Oct 31, 2016 Apr CPOT AB EQ 40MG BASE A 207062 004 Oct 31, 2016 Apr CPOT AB SANDOZ INC EQ 5MG BASE A 079171 001 Jul 19, 2016 Apr CPOT AB EQ 10MG BASE A 079171 002 Jul 19, 2016 Apr CPOT AB EQ 20MG BASE A 079171 003 Jul 19, 2016 Apr CPOT AB EQ 40MG BASE A 079171 004 Jul 19, 2016 Apr CPOT @ SCIEGEN PHARMS INC EQ 5MG BASE A 206381 001 Apr 24, 2019 Apr CPOT @ EQ 10MG BASE A 206381 002 Apr 24, 2019 Apr CPOT @ EQ 20MG BASE A 206381 003 Apr 24, 2019 Apr CPOT @ EQ 40MG BASE A 206381 004 Apr 24, 2019 Apr CPOT AB SHANDONG EQ 5MG BASE A 207375 001 May 07, 2019 Apr CPOT AB EQ 10MG BASE A 207375 002 May 07, 2019 Apr CPOT RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -101

TABLET;ORAL ROSUVASTATIN CALCIUM AB EQ 20MG BASE A 207375 003 May 07, 2019 Apr CPOT AB EQ 40MG BASE A 207375 004 May 07, 2019 Apr CPOT AB SUN PHARM EQ 5MG BASE A 079169 001 Jul 19, 2016 Apr CPOT AB EQ 10MG BASE A 079169 002 Jul 19, 2016 Apr CPOT AB EQ 20MG BASE A 079169 003 Jul 19, 2016 Apr CPOT AB EQ 40MG BASE A 079169 004 Jul 19, 2016 Apr CPOT @ SUNSHINE EQ 5MG BASE A 210667 001 Apr 01, 2020 Apr CPOT @ EQ 10MG BASE A 210667 002 Apr 01, 2020 Apr CPOT @ EQ 20MG BASE A 210667 003 Apr 01, 2020 Apr CPOT @ EQ 40MG BASE A 210667 004 Apr 01, 2020 Apr CPOT @ TEVA PHARMS USA EQ 5MG BASE A 079166 001 Jul 19, 2016 Apr CPOT @ EQ 10MG BASE A 079166 002 Jul 19, 2016 Apr CPOT @ EQ 20MG BASE A 079166 003 Jul 19, 2016 Apr CPOT @ EQ 40MG BASE A 079166 004 Jul 19, 2016 Apr CPOT AB TORRENT EQ 5MG BASE A 201619 001 Oct 31, 2016 Apr CPOT AB EQ 10MG BASE A 201619 002 Oct 31, 2016 Apr CPOT AB EQ 20MG BASE A 201619 003 Oct 31, 2016 Apr CPOT AB EQ 40MG BASE A 201619 004 Oct 31, 2016 Apr CPOT @ UMEDICA LABS PVT LTD EQ 5MG BASE A 207626 001 Apr 09, 2019 Apr CPOT @ EQ 10MG BASE A 207626 002 Apr 09, 2019 Apr CPOT @ EQ 20MG BASE A 207626 003 Apr 09, 2019 Apr CPOT @ EQ 40MG BASE A 207626 004 Apr 09, 2019 Apr CPOT AB WATSON LABS INC EQ 5MG BASE A 079167 001 Apr 29, 2016 Apr CPOT AB EQ 10MG BASE A 079167 002 Apr 29, 2016 Apr CPOT AB EQ 20MG BASE A 079167 003 Apr 29, 2016 Apr CPOT AB EQ 40MG BASE A 079167 004 Apr 29, 2016 Apr CPOT AB ZHEJIANG YONGTAI EQ 5MG BASE A 212059 001 Nov 04, 2019 Apr CPOT AB 5MG A 212059 001 Nov 04, 2019 Feb CMFD AB EQ 10MG BASE A 212059 002 Nov 04, 2019 Apr CPOT AB 10MG A 212059 002 Nov 04, 2019 Feb CMFD AB EQ 20MG BASE A 212059 003 Nov 04, 2019 Apr CPOT AB 20MG A 212059 003 Nov 04, 2019 Feb CMFD AB EQ 40MG BASE A 212059 004 Nov 04, 2019 Apr CPOT AB 40MG A 212059 004 Nov 04, 2019 Feb CMFD @ ZYDUS PHARMS EQ 5MG BASE A 206513 001 Mar 01, 2019 Apr CPOT @ EQ 10MG BASE A 206513 002 Mar 01, 2019 Apr CPOT @ EQ 20MG BASE A 206513 003 Mar 01, 2019 Apr CPOT @ EQ 40MG BASE A 206513 004 Mar 01, 2019 Apr CPOT

RUFINAMIDE SUSPENSION;ORAL AB ALKEM LABS LTD 40MG/ML A 213410 001 Feb 23, 2021 Feb NEWA TABLET;ORAL RUFINAMIDE AB HETERO LABS LTD III 200MG A 204993 001 May 11, 2021 Apr NEWA AB 400MG A 204993 002 May 11, 2021 Apr NEWA AB MYLAN 200MG A 205095 001 May 16, 2016 May CMFD AB 400MG A 205095 002 May 16, 2016 May CMFD

SAFINAMIDE MESYLATE TABLET;ORAL XADAGO + MDD US EQ 50MG BASE N 207145 001 Mar 21, 2017 Jul CPOT +! EQ 100MG BASE N 207145 002 Mar 21, 2017 Jul CPOT

SAPROPTERIN DIHYDROCHLORIDE POWDER;ORAL SAPROPTERIN DIHYDROCHLORIDE AB DR REDDYS 100MG/PACKET A 209452 001 Mar 30, 2021 Mar NEWA TABLET;ORAL SAPROPTERIN DIHYDROCHLORIDE AB DR REDDYS 100MG A 207685 001 Jun 15, 2021 Jun NEWA

SCOPOLAMINE SYSTEM;TRANSDERMAL AB PADAGIS US 1MG/72HR A 078830 001 Jan 30, 2015 Jul CAHN TRANSDERM SCOP AB +! BAXTER HLTHCARE CORP 1MG/72HR N 017874 001 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -102

SELEGILINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB NOVITIUM PHARMA 5MG A 075352 001 Nov 30, 1998 Apr CMFD

SELENIOUS ACID SOLUTION;INTRAVENOUS SELENIOUS ACID >A> +! AM REGENT EQ 12MCG BASE/2ML (EQ 6MCG N 209379 003 Aug 30, 2021 Aug NEWA BASE/ML) +! EQ 60MCG BASE/ML (EQ 60MCG N 209379 002 Jan 25, 2021 Jan NEWA BASE/ML)

SELEXIPAG POWDER;INTRAVENOUS UPTRAVI +! ACTELION 1.8MG/VIAL N 214275 001 Jul 29, 2021 Jul NEWA TABLET;ORAL UPTRAVI + ACTELION 0.2MG N 207947 001 Dec 21, 2015 Feb CAHN +! 0.4MG N 207947 002 Dec 21, 2015 Feb CAHN + 0.6MG N 207947 003 Dec 21, 2015 Feb CAHN + 0.8MG N 207947 004 Dec 21, 2015 Feb CAHN + 1MG N 207947 005 Dec 21, 2015 Feb CAHN + 1.2MG N 207947 006 Dec 21, 2015 Feb CAHN + 1.4MG N 207947 007 Dec 21, 2015 Feb CAHN + 1.6MG N 207947 008 Dec 21, 2015 Feb CAHN

SELINEXOR TABLET;ORAL XPOVIO + KARYOPHARM THERAPS 40MG N 212306 002 Apr 15, 2021 Apr NEWA + 50MG N 212306 003 Apr 15, 2021 Apr NEWA + 60MG N 212306 004 Apr 15, 2021 Apr NEWA

SEMAGLUTIDE SOLUTION;SUBCUTANEOUS WEGOVY +! NOVO 0.25MG/0.5ML (0.25MG/0.5ML) N 215256 001 Jun 04, 2021 Jun NEWA +! 0.5MG/0.5ML (0.5MG/0.5ML) N 215256 002 Jun 04, 2021 Jun NEWA +! 1MG/0.5ML (1MG/0.5ML) N 215256 003 Jun 04, 2021 Jun NEWA +! 1.7MG/0.75ML (1.7MG/0.75ML) N 215256 004 Jun 04, 2021 Jun NEWA +! 2.4MG/0.75ML (2.4MG/0.75ML) N 215256 005 Jun 04, 2021 Jun NEWA

SERTRALINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ACI HEALTHCARE LTD EQ 25MG BASE A 076881 001 Feb 06, 2007 Jan CMFD AB EQ 50MG BASE A 076881 002 Feb 06, 2007 Jan CMFD AB EQ 100MG BASE A 076881 003 Feb 06, 2007 Jan CMFD AB ASCENT PHARMS INC EQ 25MG BASE A 214790 001 May 03, 2021 Apr NEWA AB EQ 50MG BASE A 214790 002 May 03, 2021 Apr NEWA AB EQ 100MG BASE A 214790 003 May 03, 2021 Apr NEWA AB GRANULES EQ 25MG BASE A 078403 001 Jan 08, 2008 May CAHN AB EQ 50MG BASE A 078403 002 Jan 08, 2008 May CAHN AB EQ 100MG BASE A 078403 003 Jan 08, 2008 May CAHN AB SCIEGEN PHARMS INC EQ 25MG BASE A 076442 001 Apr 30, 2007 Apr CMFD AB EQ 50MG BASE A 076442 002 Apr 30, 2007 Apr CMFD AB EQ 100MG BASE A 076442 003 Apr 30, 2007 Apr CMFD

SEVELAMER CARBONATE FOR SUSPENSION;ORAL SEVELAMER CARBONATE AB BIONPHARMA INC 800MG/PACKET A 209374 001 May 17, 2021 May NEWA >D> @ IMPAX 800MG/PACKET A 211316 001 Nov 20, 2020 Aug CMFD >A> AB 800MG/PACKET A 211316 001 Nov 20, 2020 Aug CMFD @ 800MG/PACKET A 211316 001 Nov 20, 2020 Mar DISC >D> @ 2.4GM/PACKET A 211316 002 Nov 20, 2020 Aug CMFD >A> AB 2.4GM/PACKET A 211316 002 Nov 20, 2020 Aug CMFD @ 2.4GM/PACKET A 211316 002 Nov 20, 2020 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -103

TABLET;ORAL SEVELAMER CARBONATE AB ANXIN 800MG A 212970 001 Apr 09, 2020 Mar CMFD AB LUPIN LTD 800MG A 204600 001 Jan 14, 2021 Jan NEWA

SEVELAMER HYDROCHLORIDE TABLET;ORAL SEVELAMER HYDROCHLORIDE AB LUPIN LTD 400MG A 213145 001 Jun 16, 2021 Jun NEWA AB 800MG A 213145 002 Jun 16, 2021 Jun NEWA

SILDENAFIL CITRATE FOR SUSPENSION;ORAL CITRATE AB APPCO EQ 10MG BASE/ML A 213814 001 Apr 29, 2021 Apr NEWA AB HETERO LABS LTD V EQ 10MG BASE/ML A 213014 001 May 11, 2021 Apr NEWA TABLET;ORAL SILDENAFIL CITRATE AB REYOUNG EQ 25MG BASE A 208494 001 Jun 12, 2020 Mar CAHN AB EQ 50MG BASE A 208494 002 Jun 12, 2020 Mar CAHN AB EQ 100MG BASE A 208494 003 Jun 12, 2020 Mar CAHN AB UMEDICA LABS PVT LTD EQ 25MG BASE A 209302 003 Jun 15, 2021 Jun NEWA @ WATSON LABS INC EQ 25MG BASE A 202506 001 Nov 25, 2020 May DISC @ EQ 50MG BASE A 202506 002 Nov 25, 2020 May DISC @ EQ 100MG BASE A 202506 003 Nov 25, 2020 May DISC

SIMVASTATIN TABLET;ORAL SIMVASTATIN AB BIOCON PHARMA 5MG A 078034 001 Dec 20, 2006 Mar CAHN AB 10MG A 078034 002 Dec 20, 2006 Mar CAHN AB 20MG A 078034 003 Dec 20, 2006 Mar CAHN AB 40MG A 078034 004 Dec 20, 2006 Mar CAHN AB 80MG A 078034 005 Dec 20, 2006 Mar CAHN AB HISUN PHARM HANGZHOU 10MG A 206557 001 Nov 13, 2017 Apr CMFD AB 20MG A 206557 002 Nov 13, 2017 Apr CMFD AB 40MG A 206557 003 Nov 13, 2017 Apr CMFD AB 80MG A 206557 004 Nov 13, 2017 Apr CMFD AB ! LUPIN 80MG A 078103 004 May 11, 2007 Jun CHRS ZOCOR AB + ORGANON 5MG N 019766 001 Dec 23, 1991 Feb CAHN AB + 10MG N 019766 002 Dec 23, 1991 Feb CAHN AB + 20MG N 019766 003 Dec 23, 1991 Feb CAHN AB + 40MG N 019766 004 Dec 23, 1991 Feb CAHN + @ 80MG N 019766 005 Jul 10, 1998 Jun DISC AB +! 80MG N 019766 005 Jul 10, 1998 Feb CAHN

SINECATECHINS OINTMENT;TOPICAL VEREGEN +! ANI PHARMS 15% N 021902 001 Oct 31, 2006 Apr CAHN

SIPONIMOD TABLET;ORAL MAYZENT >A> + NOVARTIS EQ 1MG BASE N 209884 003 Aug 24, 2021 Aug NEWA

SIROLIMUS TABLET;ORAL AB ALKEM LABS LTD 0.5MG A 214753 001 Mar 12, 2021 Mar NEWA AB 1MG A 214753 002 Mar 12, 2021 Mar NEWA AB 2MG A 214753 003 Mar 12, 2021 Mar NEWA

SODIUM ACETATE INJECTABLE;INJECTION SODIUM ACETATE AP MILLA PHARMS 2MEQ/ML A 214805 001 May 04, 2021 Apr NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -104

SODIUM BENZOATE; SODIUM PHENYLACETATE SOLUTION;INTRAVENOUS SODIUM PHENYLACETATE AND +! MAIA PHARMS INC 10%;10% (2GM/20ML;2GM/20ML) N 215025 001 Jun 10, 2021 Jun NEWA

SODIUM CHLORIDE INJECTABLE;INJECTION SODIUM CHLORIDE 0.9% HIKMA PHARMS 9MG/ML A 201833 001 Sep 24, 2013 Jul CAHN AP 9MG/ML A 201850 001 Jan 20, 2012 Jul CAHN >D> +! MEDEFIL INC 9MG/ML (9MG/ML) N 202832 001 Jan 06, 2012 Aug DISC >A> + @ 9MG/ML (9MG/ML) N 202832 001 Jan 06, 2012 Aug DISC >D> +! 18MG/2ML (9MG/ML) N 202832 002 Jan 06, 2012 Aug DISC >A> + @ 18MG/2ML (9MG/ML) N 202832 002 Jan 06, 2012 Aug DISC >D> +! 22.5MG/2.5ML (9MG/ML) N 202832 003 Jan 06, 2012 Aug DISC >A> + @ 22.5MG/2.5ML (9MG/ML) N 202832 003 Jan 06, 2012 Aug DISC >D> +! 27MG/3ML (9MG/ML) N 202832 004 Jan 06, 2012 Aug DISC >A> + @ 27MG/3ML (9MG/ML) N 202832 004 Jan 06, 2012 Aug DISC >D> +! 45MG/5ML (9MG/ML) N 202832 005 Jan 06, 2012 Aug DISC >A> + @ 45MG/5ML (9MG/ML) N 202832 005 Jan 06, 2012 Aug DISC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER @ JUBILANT CADISTA 9MG/ML A 203352 001 May 18, 2016 Jun DISC SODIUM CHLORIDE 23.4% FRESENIUS KABI USA 234MG/ML A 212248 001 Apr 28, 2021 Apr NFTG SOLUTION;INTRAVENOUS SODIUM CHLORIDE 14.6% FRESENIUS KABI USA 50MEQ/20ML (2.5MEQ/ML) A 212070 001 Apr 28, 2021 Apr NFTG AP 100MEQ/40ML (2.5MEQ/ML) A 212070 002 Apr 28, 2021 Apr NFTG SOLUTION FOR SLUSH;IRRIGATION SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER +! BAXTER HLTHCARE 900MG/100ML N 019319 002 May 17, 1985 Jul CHRS + 900MG/100ML N 019319 002 May 17, 1985 Jul CRLD

SODIUM FLUORIDE F-18 INJECTABLE;INTRAVENOUS SODIUM FLUORIDE F-18 >D> AP DECATUR 10-200mCi/ML A 204464 001 Oct 21, 2014 Aug DISC >A> @ 10-200mCi/ML A 204464 001 Oct 21, 2014 Aug DISC AP NUKEMED 10-200mCi/ML A 203912 001 Apr 22, 2015 Jan CAHN

SODIUM NITROPRUSSIDE INJECTABLE;INJECTION SODIUM NITROPRUSSIDE @ AUROBINDO PHARMA LTD 25MG/ML A 211934 001 Dec 10, 2020 Jun DISC AP BE PHARMS 25MG/ML A 214971 001 Jul 12, 2021 Jul NEWA >D> AP CIPLA 25MG/ML A 210855 001 Jul 16, 2018 Aug DISC >A> @ 25MG/ML A 210855 001 Jul 16, 2018 Aug DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE TABLET;ORAL MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE AB NOVEL LABS INC 0.398GM;1.102GM A 079247 001 Dec 30, 2011 Jan CMFD OSMOPREP AB +! SALIX PHARMS 0.398GM;1.102GM N 021892 001 Mar 16, 2006 Jan CTEC

SODIUM POLYSTYRENE SULFONATE POWDER;ORAL, RECTAL KIONEX AA ANI PHARMS 454GM/BOT A 040029 001 Feb 06, 1998 Mar CAHN AA L PERRIGO CO 454GM/BOT A 040029 001 Feb 06, 1998 Mar CAHN SODIUM POLYSTYRENE SULFONATE >D> @ WOCKHARDT 453.6GM/BOT A 088786 001 Sep 11, 1984 Aug CRLD >A> + @ 453.6GM/BOT A 088786 001 Sep 11, 1984 Aug CRLD SUSPENSION;ORAL, RECTAL KIONEX @ ANI PHARMS 15GM/60ML A 040028 001 Sep 17, 2007 Mar CAHN @ L PERRIGO CO 15GM/60ML A 040028 001 Sep 17, 2007 Mar CAHN SODIUM POLYSTYRENE SULFONATE @ ANI PHARMS 15GM/60ML A 090590 001 May 13, 2011 Mar CAHN @ L PERRIGO CO 15GM/60ML A 090590 001 May 13, 2011 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -105

SUSPENSION;ORAL, RECTAL SPS >D> ! CMP PHARMA INC 15GM/60ML A 087859 001 Dec 08, 1982 Aug CRLD >A> +! 15GM/60ML A 087859 001 Dec 08, 1982 Aug CRLD

SOFOSBUVIR; VELPATASVIR PELLETS;ORAL EPCLUSA + GILEAD SCIENCES INC 150MG;37.5MG/PACKET N 214187 001 Jun 10, 2021 Jun NEWA +! 200MG;50MG/PACKET N 214187 002 Jun 10, 2021 Jun NEWA

SOLIFENACIN SUCCINATE TABLET;ORAL SUCCINATE @ AJANTA PHARMA LTD 5MG A 205483 001 May 20, 2019 Jun DISC @ 10MG A 205483 002 May 20, 2019 Jun DISC >D> AB BRECKENRIDGE 5MG A 209818 001 May 20, 2019 Aug DISC >A> @ 5MG A 209818 001 May 20, 2019 Aug DISC >D> AB 10MG A 209818 002 May 20, 2019 Aug DISC >A> @ 10MG A 209818 002 May 20, 2019 Aug DISC @ ZYDUS PHARMS 5MG A 207721 001 Oct 19, 2020 Mar DISC @ 10MG A 207721 002 Oct 19, 2020 Mar DISC

SORAFENIB TOSYLATE TABLET;ORAL NEXAVAR +! BAYER HLTHCARE EQ 200MG BASE N 021923 001 Dec 20, 2005 May CTEC TOSYLATE @ TEVA PHARMS USA INC EQ 200MG BASE A 209567 001 Nov 12, 2020 May DISC

SOTALOL HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE @ MYLAN 80MG A 077616 001 Feb 07, 2007 Feb DISC @ 120MG A 077616 002 Feb 07, 2007 Feb DISC @ 160MG A 077616 003 Feb 07, 2007 Feb DISC

SOTORASIB TABLET;ORAL LUMAKRAS +! INC 120MG N 214665 001 May 28, 2021 May NEWA

SPIRONOLACTONE TABLET;ORAL >D> AB OXFORD PHARMS 25MG A 040750 001 Aug 29, 2006 Aug DISC >A> @ 25MG A 040750 001 Aug 29, 2006 Aug DISC >D> AB 50MG A 040750 002 Aug 29, 2006 Aug DISC >A> @ 50MG A 040750 002 Aug 29, 2006 Aug DISC >D> AB 100MG A 040750 003 Aug 29, 2006 Aug DISC >A> @ 100MG A 040750 003 Aug 29, 2006 Aug DISC

STERILE WATER FOR INJECTION LIQUID;N/A STERILE WATER FOR INJECTION AP HIKMA PHARMS 100% (10ML) A 206369 001 Sep 02, 2015 Jul CAHN @ 100% (20ML) A 206369 002 Sep 02, 2015 Jul CAHN ! NEPHRON 100% (5ML) A 211222 001 Feb 10, 2021 Jan NEWA

SUCCINYLCHOLINE CHLORIDE INJECTABLE;INJECTION SUCCINYLCHOLINE CHLORIDE AP ACCORD HLTHCARE 20MG/ML A 213705 001 May 20, 2020 Mar CMFD AP HIKMA 20MG/ML A 213229 001 Jun 12, 2020 Apr CMFD @ 20MG/ML A 213229 001 Jun 12, 2020 Feb DISC AP SAGENT PHARMS INC 20MG/ML A 215022 001 Mar 29, 2021 Mar NEWA SOLUTION;INTRAMUSCULAR, INTRAVENOUS SUCCINYLCHOLINE CHLORIDE >A> +! HIKMA PHARMS 100MG/5ML (20MG/ML) N 215143 001 Aug 20, 2021 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -106

SULFACETAMIDE SODIUM SOLUTION/DROPS;OPHTHALMIC BLEPH-10 >D> AT ! ALLERGAN 10% A 080028 001 Aug CRLD >A> AT +! 10% A 080028 001 Aug CRLD

SULFAMETHOXAZOLE TABLET;ORAL @ RISING 500MG A 085844 001 Jan CAHN

SULFASALAZINE TABLET;ORAL AZULFIDINE AB +! PFIZER 500MG N 007073 001 Mar CAHN SULFASALAZINE AB CHARTWELL 500MG A 080197 001 Jun CMFD TABLET, DELAYED RELEASE;ORAL AZULFIDINE EN-TABS AB +! PFIZER 500MG N 007073 002 Apr 06, 1983 Mar CAHN

SULFISOXAZOLE TABLET;ORAL SULFISOXAZOLE @ RISING 500MG A 085628 001 Jan CAHN

SULINDAC TABLET;ORAL >D> AB MYLAN 150MG A 073039 002 Jun 22, 1993 Aug CAHN >A> @ 150MG A 073039 002 Jun 22, 1993 Aug CAHN >D> AB 200MG A 073039 001 Jun 22, 1993 Aug CAHN >A> @ 200MG A 073039 001 Jun 22, 1993 Aug CAHN

SUMATRIPTAN SPRAY;NASAL AB CIPLA 20MG/SPRAY A 214209 001 Feb 22, 2021 Feb NEWA AB 20MG/SPRAY A 208967 001 Feb 17, 2021 Mar CAHN AB PHARMASERVE NW 20MG/SPRAY A 208967 001 Feb 17, 2021 Feb NEWA

SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS SUMATRIPTAN SUCCINATE AP CAPLIN EQ 6MG BASE/0.5ML (EQ 12MG A 213998 001 Jul 13, 2021 Jul NEWA BASE/ML) @ MYLAN ASI EQ 6MG BASE/0.5ML (EQ 12MG A 090314 001 Jun 10, 2010 May DISC BASE/ML) @ EQ 6MG BASE/0.5ML (EQ 12MG A 090641 001 Jul 28, 2010 Jan DISC BASE/ML)

SUNITINIB MALATE CAPSULE;ORAL MALATE >A> AB SUN PHARM EQ 12.5MG BASE A 213914 001 Aug 16, 2021 Aug NFTG >A> AB EQ 25MG BASE A 213914 002 Aug 16, 2021 Aug NFTG >A> AB EQ 37.5MG BASE A 213914 003 Aug 16, 2021 Aug NFTG >A> AB EQ 50MG BASE A 213914 004 Aug 16, 2021 Aug NFTG SUTENT >D> + CPPI CV EQ 12.5MG BASE N 021938 001 Jan 26, 2006 Aug CTEC >A> AB + EQ 12.5MG BASE N 021938 001 Jan 26, 2006 Aug CTEC >D> + EQ 25MG BASE N 021938 002 Jan 26, 2006 Aug CTEC >A> AB + EQ 25MG BASE N 021938 002 Jan 26, 2006 Aug CTEC >D> + EQ 37.5MG BASE N 021938 004 Mar 31, 2009 Aug CTEC >A> AB + EQ 37.5MG BASE N 021938 004 Mar 31, 2009 Aug CTEC >D> +! EQ 50MG BASE N 021938 003 Jan 26, 2006 Aug CTEC >A> AB +! EQ 50MG BASE N 021938 003 Jan 26, 2006 Aug CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -107

TACROLIMUS CAPSULE;ORAL @ CONCORD BIOTECH LTD EQ 0.5MG BASE A 213112 001 Nov 10, 2020 Apr DISC AB PANACEA EQ 0.5MG BASE A 090802 001 Sep 28, 2012 Jul CAHN AB EQ 1MG BASE A 090802 002 Sep 28, 2012 Jul CAHN AB EQ 5MG BASE A 090802 003 Sep 28, 2012 Jul CAHN

TADALAFIL TABLET;ORAL CIALIS AB1 + LILLY 2.5MG N 021368 004 Jan 07, 2008 Feb CTEC AB1 + 5MG N 021368 001 Nov 21, 2003 Feb CTEC AB1 + 10MG N 021368 002 Nov 21, 2003 Feb CTEC AB1 ACCORD HLTHCARE 2.5MG A 209167 001 Mar 26, 2019 Feb CTEC AB1 5MG A 209167 002 Mar 26, 2019 Feb CTEC AB1 10MG A 209167 003 Oct 23, 2019 Feb CTEC AB1 AJANTA PHARMA LTD 2.5MG A 209654 001 Mar 26, 2019 Feb CTEC AB1 5MG A 209654 002 Mar 26, 2019 Feb CTEC AB1 10MG A 209654 003 Mar 26, 2019 Feb CTEC AB1 ALEMBIC PHARMS LTD 2.5MG A 204809 001 Mar 26, 2019 Feb CTEC AB1 5MG A 204809 002 Mar 26, 2019 Feb CTEC AB1 10MG A 204809 003 Mar 26, 2019 Feb CTEC AB1 AMNEAL PHARMS CO 2.5MG A 209744 001 Mar 26, 2019 Feb CTEC AB1 5MG A 209744 002 Mar 26, 2019 Feb CTEC AB1 10MG A 209744 003 Mar 26, 2019 Feb CTEC AB1 AUROBINDO PHARMA LTD 2.5MG A 206285 001 Mar 26, 2019 Feb CTEC AB1 5MG A 206285 002 Mar 26, 2019 Feb CTEC AB1 10MG A 206285 003 Mar 26, 2019 Feb CTEC AB1 CIPLA 2.5MG A 209539 001 Mar 26, 2019 Feb CTEC AB1 5MG A 209539 002 Mar 26, 2019 Feb CTEC AB1 10MG A 209539 003 Mar 26, 2019 Feb CTEC AB1 DR REDDYS LABS LTD 2.5MG A 210069 001 Mar 26, 2019 Feb CTEC AB1 5MG A 210069 002 Mar 26, 2019 Feb CTEC AB1 10MG A 210069 003 Mar 26, 2019 Feb CTEC @ GLENMARK PHARMS LTD 2.5MG A 210716 001 Dec 29, 2020 Feb DISC @ 5MG A 210716 002 Dec 29, 2020 Feb DISC @ 10MG A 210716 003 Dec 29, 2020 Feb DISC @ 20MG A 210716 004 Dec 29, 2020 Feb DISC AB1 HETERO LABS LTD III 2.5MG A 209908 001 Mar 26, 2019 Feb CTEC AB1 5MG A 209908 002 Mar 26, 2019 Feb CTEC AB1 10MG A 209908 003 Mar 26, 2019 Feb CTEC AB1 LUPIN LTD 2.5MG A 210567 001 Mar 26, 2019 Feb CTEC AB1 5MG A 210567 002 Mar 26, 2019 Feb CTEC AB1 10MG A 210567 003 Mar 26, 2019 Feb CTEC AB1 MACLEODS PHARMS LTD 2.5MG A 207244 001 Oct 07, 2019 Feb CTEC AB1 5MG A 207244 002 Oct 07, 2019 Feb CTEC AB1 10MG A 207244 003 Oct 07, 2019 Feb CTEC >D> AB1 MYLAN 2.5MG A 206956 001 Apr 29, 2019 Aug CAHN >A> @ 2.5MG A 206956 001 Apr 29, 2019 Aug CAHN AB1 2.5MG A 206956 001 Apr 29, 2019 Feb CTEC >D> AB1 5MG A 206957 001 Apr 29, 2019 Aug CAHN >A> @ 5MG A 206957 001 Apr 29, 2019 Aug CAHN AB1 5MG A 206957 001 Apr 29, 2019 Feb CTEC >D> AB1 10MG A 206956 002 Apr 29, 2019 Aug CAHN >A> @ 10MG A 206956 002 Apr 29, 2019 Aug CAHN AB1 10MG A 206956 002 Apr 29, 2019 Feb CTEC >D> AB1 20MG A 206956 003 Apr 29, 2019 Aug CAHN >A> @ 20MG A 206956 003 Apr 29, 2019 Aug CAHN AB1 QILU 2.5MG A 210420 001 Mar 26, 2019 Feb CTEC AB1 5MG A 210420 002 Mar 26, 2019 Feb CTEC AB1 10MG A 210420 003 Mar 26, 2019 Feb CTEC AB1 SUN PHARM 2.5MG A 208934 001 Mar 26, 2019 Feb CTEC AB1 5MG A 208934 002 Mar 26, 2019 Feb CTEC AB1 10MG A 208934 003 Mar 26, 2019 Feb CTEC AB1 SUNSHINE 2.5MG A 211335 001 Mar 26, 2019 Feb CTEC AB1 5MG A 211335 002 Mar 26, 2019 Feb CTEC AB1 10MG A 211335 003 Mar 26, 2019 Feb CTEC AB1 TEVA PHARMS USA 2.5MG A 090141 001 May 22, 2018 Feb CTEC AB1 5MG A 090141 002 May 22, 2018 Feb CTEC AB1 10MG A 090141 003 May 22, 2018 Feb CTEC AB1 TORRENT 2.5MG A 211839 001 Mar 26, 2019 Feb CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -108

TABLET;ORAL TADALAFIL AB1 5MG A 211839 002 Mar 26, 2019 Feb CTEC AB1 10MG A 211839 003 Mar 26, 2019 Feb CTEC AB1 UMEDICA LABS PVT LTD 2.5MG A 211298 001 Oct 23, 2020 Feb CTEC AB1 5MG A 211298 002 Oct 23, 2020 Feb CTEC AB1 10MG A 211298 003 Oct 23, 2020 Feb CTEC AB1 UNICHEM 2.5MG A 209250 001 Mar 26, 2019 Feb CTEC AB1 5MG A 209250 002 Mar 26, 2019 Feb CTEC AB1 10MG A 209250 003 Mar 26, 2019 Feb CTEC AB1 YANGLING BUCHANG 2.5MG A 208824 001 Oct 27, 2020 Feb CTEC AB1 5MG A 208824 002 Oct 27, 2020 Feb CTEC AB1 10MG A 208824 003 Oct 27, 2020 Feb CTEC AB1 ZYDUS PHARMS 2.5MG A 206693 001 Mar 26, 2019 Feb CTEC AB1 5MG A 206693 002 Mar 26, 2019 Feb CTEC AB1 10MG A 206693 003 Mar 26, 2019 Feb CTEC

TAMSULOSIN HYDROCHLORIDE CAPSULE;ORAL TAMSULOSIN HYDROCHLORIDE >D> @ ANBISON LAB 0.4MG A 211885 001 Oct 17, 2019 Aug CMFD >A> AB 0.4MG A 211885 001 Oct 17, 2019 Aug CMFD @ ANCHEN PHARMS 0.4MG A 202010 001 Jan 04, 2013 Jun DISC

TAVABOROLE SOLUTION;TOPICAL AB CIPLA 5% A 212224 001 Feb 09, 2021 Jan NEWA AB FLATWING 5% A 211963 001 Feb 03, 2021 Feb CPOT AB 5.0% A 211963 001 Feb 03, 2021 Jan NEWA AB IDENTIRX 5% A 211963 001 Feb 03, 2021 Feb CAHN AB LUPIN LTD 5% A 212168 001 Feb 08, 2021 Jan NEWA AB TARO PHARMS 5% A 212215 001 May 07, 2021 Apr NEWA

TECHNETIUM TC-99M MEDRONATE KIT INJECTABLE;INJECTION CIS-MDP AP SUN PHARM INDS INC N/A N 018124 001 Jul CTEC TECHNETIUM TC-99M MEDRONATE KIT AP CARDINAL HEALTH 414 N/A N 018107 001 Jul CTNA AP N/A N 018107 001 Jul CMFD

TELMISARTAN TABLET;ORAL TELMISARTAN AB CELLTRION 20MG A 078710 001 Jan 08, 2014 Feb CMFD AB 40MG A 078710 002 Jan 08, 2014 Feb CMFD AB 80MG A 078710 003 Jan 08, 2014 Feb CMFD >D> AB MYLAN 20MG A 202397 001 Jul 07, 2014 Aug CAHN >A> AB 20MG A 202397 001 Jul 07, 2014 Aug CAHN >D> AB 40MG A 202397 002 Jul 07, 2014 Aug CAHN >A> AB 40MG A 202397 002 Jul 07, 2014 Aug CAHN >D> AB 80MG A 202397 003 Jul 07, 2014 Aug CAHN >A> AB 80MG A 202397 003 Jul 07, 2014 Aug CAHN

TEMOZOLOMIDE CAPSULE;ORAL @ HERITAGE 5MG A 078879 001 Mar 01, 2010 Feb CAHN @ 20MG A 078879 002 Mar 01, 2010 Feb CAHN @ 100MG A 078879 003 Mar 01, 2010 Feb CAHN @ 140MG A 078879 005 Mar 01, 2010 Feb CAHN @ 180MG A 078879 006 Mar 01, 2010 Feb CAHN @ 250MG A 078879 004 Mar 01, 2010 Feb CAHN @ WATSON LABS TEVA 5MG A 203959 001 Apr 18, 2017 Jan DISC @ 20MG A 203959 002 Apr 18, 2017 Jan DISC @ 100MG A 203959 003 Apr 18, 2017 Jan DISC @ 140MG A 203959 004 Apr 18, 2017 Jan DISC @ 250MG A 203959 005 Apr 18, 2017 Jan DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -109

TEPOTINIB HYDROCHLORIDE TABLET;ORAL TEPMETKO +! EMD SERONO INC EQ 225MG BASE N 214096 001 Feb 03, 2021 Feb NEWA

TERAZOSIN HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB HERITAGE PHARMA EQ 1MG BASE A 075614 002 Jan 30, 2001 May CMFD AB EQ 2MG BASE A 075614 001 Jan 30, 2001 May CMFD AB EQ 5MG BASE A 075614 003 Jan 30, 2001 May CMFD AB EQ 10MG BASE A 075614 004 Jan 30, 2001 May CMFD >D> AB MYLAN EQ 1MG BASE A 075140 002 Feb 11, 2000 Aug CAHN >A> @ EQ 1MG BASE A 075140 002 Feb 11, 2000 Aug CAHN >D> AB EQ 2MG BASE A 075140 003 Feb 11, 2000 Aug CAHN >A> @ EQ 2MG BASE A 075140 003 Feb 11, 2000 Aug CAHN >D> AB EQ 5MG BASE A 075140 001 Feb 11, 2000 Aug CAHN >A> @ EQ 5MG BASE A 075140 001 Feb 11, 2000 Aug CAHN >D> AB EQ 10MG BASE A 075140 004 Feb 11, 2000 Aug CAHN >A> @ EQ 10MG BASE A 075140 004 Feb 11, 2000 Aug CAHN

TERIFLUNOMIDE TABLET;ORAL @ IMPAX 14MG A 209677 001 Jun 17, 2020 Feb DISC

TESTOSTERONE GEL;TRANSDERMAL AB2 ACTAVIS LABS UT INC 1.62% (20.25MG/1.25GM PACKET) A 204570 002 Jul 17, 2020 Feb NEWA AB2 1.62% (40.5MG/2.5GM PACKET) A 204570 003 Jul 17, 2020 Feb NEWA GEL, METERED;TRANSDERMAL TESTOSTERONE AB ALEOR DERMACEUTICALS 1.62% (20.25MG/1.25GM ACTUATION) A 213922 001 Mar 03, 2021 Feb NEWA SOLUTION, METERED;TRANSDERMAL TESTOSTERONE AT ALEOR DERMACEUTICALS 30MG/1.5ML ACTUATION A 212882 001 Jun 14, 2021 Jun NEWA @ APOTEX 30MG/1.5ML ACTUATION A 209181 001 Nov 25, 2020 May DISC AT DASH PHARMS 30MG/1.5ML ACTUATION A 212301 001 Jan 11, 2021 May CAHN AT FEMPHARM 30MG/1.5ML ACTUATION A 212301 001 Jan 11, 2021 Jan NEWA >A> AT TWI PHARMS 30MG/1.5ML ACTUATION A 209836 001 Sep 03, 2021 Aug NEWA

TESTOSTERONE CYPIONATE INJECTABLE;INJECTION DEPO-TESTOSTERONE @ PFIZER 50MG/ML A 085635 001 Mar CAHN >D> AO ! 100MG/ML A 085635 002 Aug CRLD >A> AO +! 100MG/ML A 085635 002 Aug CRLD AO ! 100MG/ML A 085635 002 Mar CAHN >D> AO ! 200MG/ML A 085635 003 Aug CRLD >A> AO +! 200MG/ML A 085635 003 Aug CRLD AO ! 200MG/ML A 085635 003 Mar CAHN TESTOSTERONE CYPIONATE AO HIKMA PHARMS 100MG/ML A 090387 001 Jul 15, 2010 Jul CAHN AO 200MG/ML A 090387 002 Jul 15, 2010 Jul CAHN

TETRABENAZINE TABLET;ORAL @ AJANTA PHARMA LTD 12.5MG A 213621 001 Dec 04, 2020 May DISC @ 25MG A 213621 002 Dec 04, 2020 May DISC

TETRACAINE HYDROCHLORIDE SOLUTION;OPHTHALMIC HYDROCHLORIDE +! BAUSCH LOMB IRELAND 0.5% N 210821 001 Mar 12, 2019 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -110

THALLOUS CHLORIDE TL-201 INJECTABLE;INJECTION THALLOUS CHLORIDE TL 201 + @ GE HEALTHCARE 1mCi/ML N 018110 002 Feb 27, 1996 Jun DISC

THEOPHYLLINE CAPSULE, EXTENDED RELEASE;ORAL SLO-PHYLLIN >D> @ SANOFI AVENTIS US 125MG A 085203 001 May 24, 1982 Aug CRLD >A> + @ 125MG A 085203 001 May 24, 1982 Aug CRLD SOMOPHYLLIN-CRT >D> @ GRAHAM DM 250MG A 087193 001 Aug CRLD >A> + @ 250MG A 087193 001 Aug CRLD THEO-24 >D> AUXILIUM PHARMS LLC 200MG A 087943 001 Aug 22, 1983 Aug CRLD >A> + 200MG A 087943 001 Aug 22, 1983 Aug CRLD ELIXIR;ORAL >D> @ PRECISION DOSE 80MG/15ML A 085863 001 Aug CRLD >A> + @ 80MG/15ML A 085863 001 Aug CRLD SOLUTION;ORAL THEOPHYLLINE >D> ROXANE@ 80MG/15ML A 087449 001 Sep 15, 1983 Aug CRLD >A> + @ 80MG/15ML A 087449 001 Sep 15, 1983 Aug CRLD SOLUTION, ELIXIR;ORAL ELIXOPHYLLIN >D> AA ! NOSTRUM LABS INC 80MG/15ML A 085186 001 Aug CRLD >A> AA +! 80MG/15ML A 085186 001 Aug CRLD SYRUP;ORAL THEOPHYLLINE >D> @ ALPHARMA US PHARMS 150MG/15ML A 086545 001 Aug CRLD >A> + @ 150MG/15ML A 086545 001 Aug CRLD TABLET, EXTENDED RELEASE;ORAL THEO-DUR >D> @ SCHERING 200MG A 086998 001 Aug CRLD >A> + @ 200MG A 086998 001 Aug CRLD THEOPHYLLINE AB ALEMBIC PHARMS LTD 300MG A 090430 001 Oct 27, 2010 May CTEC AB ! 450MG A 090430 002 Oct 27, 2010 May CTEC AB GLENMARK PHARMS LTD 300MG A 212184 001 Jun 03, 2021 May NEWA AB 450MG A 212184 002 Jun 03, 2021 May NEWA @ HERITAGE PHARMA 100MG A 089807 001 Apr 30, 1990 Jul DISC @ 200MG A 089808 001 Apr 30, 1990 Jul DISC >D> AB RHODES PHARMS 400MG A 040086 002 Sep 01, 1982 Aug CRLD >A> AB + 400MG A 040086 002 Sep 01, 1982 Aug CRLD

THIAMINE HYDROCHLORIDE INJECTABLE;INJECTION BETALIN S >D> LILLY@ 100MG/ML A 080853 001 Aug CRLD >A> + @ 100MG/ML A 080853 001 Aug CRLD THIAMINE HYDROCHLORIDE >D> AP ! FRESENIUS KABI USA 100MG/ML A 080556 001 Aug CRLD >A> AP +! 100MG/ML A 080556 001 Aug CRLD AP WEST-WARD PHARMS INT 100MG/ML A 080575 001 Apr CMFD

THIORIDAZINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE MYLAN 10MG A 088004 002 Mar 15, 1983 Jan CTEC 25MG A 088004 003 Mar 15, 1983 Jan CTEC 50MG A 088004 004 Mar 15, 1983 Jan CTEC ! 100MG A 088004 001 Nov 18, 1983 Jan CTEC @ SUN PHARM INDUSTRIES 10MG A 089953 004 Aug 01, 1986 Jan DISC @ 25MG A 089953 003 Aug 01, 1986 Jan DISC @ 50MG A 089953 002 Aug 01, 1986 Jan DISC @ 100MG A 089953 001 Oct 07, 1988 Jan DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -111

THIOTEPA POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL AP GLAND PHARMA LTD 15MG/VIAL A 214222 001 Mar 08, 2021 Feb NEWA

TIAGABINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE @ WILSHIRE PHARMS INC 2MG A 206857 001 Oct 13, 2017 Jan DISC @ 4MG A 206857 002 Oct 13, 2017 Jan DISC @ 12MG A 206857 003 Oct 13, 2017 Jan DISC @ 16MG A 206857 004 Oct 13, 2017 Jan DISC

TICAGRELOR TABLET;ORAL AB MYLAN 60MG A 208597 001 Jul 09, 2021 Jul NFTG AB 90MG A 208597 002 Jul 09, 2021 Jul NEWA

TICLOPIDINE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE >A> @ CHARTWELL RX 250MG A 075318 001 Aug 20, 1999 Aug CAHN >A> @ 250MG A 075326 001 Aug 20, 1999 Aug CAHN >D> @ YAOPHARMA CO LTD 250MG A 075318 001 Aug 20, 1999 Aug CAHN >D> @ 250MG A 075326 001 Aug 20, 1999 Aug CAHN

TIGECYCLINE POWDER;INTRAVENOUS TIGECYCLINE >D> AP HONG KONG 50MG/VIAL A 214020 001 May 13, 2021 Aug CAHN AP 50MG/VIAL A 214020 001 May 13, 2021 May NEWA >A> AP MEITHEAL 50MG/VIAL A 214020 001 May 13, 2021 Aug CAHN

TIMOLOL MALEATE SOLUTION, GEL FORMING/DROPS;OPHTHALMIC TIMOLOL MALEATE AB ! ALEMBIC PHARMS LTD EQ 0.25% BASE A 212942 001 Oct 22, 2020 Apr CHRS AB ! EQ 0.5% BASE A 212942 002 Oct 22, 2020 Apr CHRS TIMOPTIC-XE AB + VALEANT PHARMS LLC EQ 0.25% BASE N 020330 001 Nov 04, 1993 Apr CHRS AB + EQ 0.5% BASE N 020330 002 Nov 04, 1993 Apr CHRS SOLUTION/DROPS;OPHTHALMIC TIMOLOL MALEATE AT MANKIND PHARMA EQ 0.25% BASE A 078771 001 Sep 28, 2009 Apr CAHN AT1 EQ 0.5% BASE A 078771 002 Sep 28, 2009 Apr CAHN

TIOPRONIN TABLET;ORAL AB TEVA PHARMS USA INC 100MG A 214326 001 Apr 26, 2021 Apr NFTG

TIOTROPIUM BROMIDE SPRAY, METERED;INHALATION SPIRIVA RESPIMAT +! BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH N 021936 002 Sep 15, 2015 Mar CHRS

TIROFIBAN HYDROCHLORIDE SOLUTION;INTRAVENOUS AGGRASTAT + MEDICURE EQ 5MG BASE/100ML (EQ 0.05MG N 020913 002 May 17, 2002 Apr CDFR BASE/ML) @ EQ 25MG BASE/500ML (EQ 0.05MG N 020913 001 May 14, 1998 Apr CDFR BASE/ML) TIROFIBAN HYDROCHLORIDE AP GLAND PHARMA LTD EQ 12.5MG BASE/250ML (EQ 0.05MG A 206888 001 Apr 08, 2021 Apr NFTG BASE/ML) RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -112

TIVOZANIB HYDROCHLORIDE CAPSULE;ORAL FOTIVDA + AVEO PHARMS EQ 0.89MG BASE N 212904 001 Mar 10, 2021 Mar NEWA +! EQ 1.34MG BASE N 212904 002 Mar 10, 2021 Mar NEWA

TIZANIDINE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE @ PAR PHARM INC EQ 2MG BASE A 207199 001 Mar 14, 2017 Jun DISC @ EQ 4MG BASE A 207199 002 Mar 14, 2017 Jun DISC @ EQ 6MG BASE A 207199 003 Mar 14, 2017 Jun DISC TABLET;ORAL TIZANIDINE HYDROCHLORIDE AB CADILA EQ 2MG BASE A 208187 001 Mar 09, 2018 Feb CAHN AB EQ 4MG BASE A 208187 002 Mar 09, 2018 Feb CAHN @ MYLAN EQ 2MG BASE A 076354 001 Mar 28, 2003 Jan DISC @ EQ 4MG BASE A 076354 002 Mar 28, 2003 Feb DISC

TOBRAMYCIN SOLUTION;INHALATION TOBRAMYCIN AN ALKEM LABS LTD 300MG/5ML A 212848 001 Apr 01, 2021 Mar NEWA >D> @ AUROBINDO PHARMA LTD 300MG/5ML A 210871 001 Jan 22, 2021 Aug CAHN @ 300MG/5ML A 210871 001 Jan 22, 2021 Jul DISC AN 300MG/5ML A 210871 001 Jan 22, 2021 Jan NEWA >A> @ LUOXIN AUROVITAS 300MG/5ML A 210871 001 Jan 22, 2021 Aug CAHN SOLUTION/DROPS;OPHTHALMIC TOBRAMYCIN AT GLAND PHARMA LTD 0.3% A 212628 001 Mar 09, 2021 Feb NEWA

TOBRAMYCIN SULFATE INJECTABLE;INJECTION TOBRAMYCIN SULFATE AP GLAND PHARMA LTD EQ 10MG BASE/ML A 209621 001 Feb 11, 2021 Feb NEWA AP EQ 40MG BASE/ML A 209621 002 Feb 11, 2021 Feb NEWA AP EQ 1.2GM BASE/VIAL A 211189 001 May 18, 2021 May NEWA TOBRAMYCIN SULFATE (PHARMACY BULK) AP ! FRESENIUS KABI USA EQ 40MG BASE/ML A 065120 001 Nov 29, 2002 Jan CTEC AP GLAND PHARMA LTD EQ 40MG BASE/ML A 209346 001 Feb 09, 2021 Jan NEWA

TOFACITINIB CITRATE SOLUTION;ORAL XELJANZ +! PFIZER EQ 1MG/ML BASE N 213082 001 Sep 25, 2020 Feb CMS1 TABLET;ORAL CITRATE AB AJANTA PHARMA LTD EQ 10MG BASE A 212943 001 Jun 01, 2021 May NFTG TABLET, EXTENDED RELEASE;ORAL >A> TOFACITINIB >A> AB ZYDUS PHARMS EQ 11MG BASE A 214264 001 Aug 19, 2021 Aug NFTG >A> AB EQ 22MG BASE A 214264 002 Aug 19, 2021 Aug NFTG

TOLAZAMIDE TABLET;ORAL >A> @ CHARTWELL RX 100MG A 071633 001 Dec 09, 1987 Aug CAHN >A> @ 250MG A 070289 001 Mar 13, 1986 Aug CAHN >A> @ 500MG A 070290 001 Mar 13, 1986 Aug CAHN >D> @ YAOPHARMA CO LTD 100MG A 071633 001 Dec 09, 1987 Aug CAHN >D> @ 250MG A 070289 001 Mar 13, 1986 Aug CAHN >D> @ 500MG A 070290 001 Mar 13, 1986 Aug CAHN

TOLBUTAMIDE TABLET;ORAL >A> @ CHARTWELL RX 500MG A 086574 001 Aug CAHN >D> @ YAOPHARMA CO LTD 500MG A 086574 001 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -113

TOLCAPONE TABLET;ORAL @ ALVOGEN 100MG A 207729 001 Jul 29, 2020 Jan DISC

TOLMETIN SODIUM CAPSULE;ORAL SODIUM >D> AB MYLAN EQ 400MG BASE A 073393 001 May 27, 1993 Aug DISC >A> @ EQ 400MG BASE A 073393 001 May 27, 1993 Aug DISC >D> AB ! TEVA EQ 400MG BASE A 073290 001 Nov 27, 1991 Aug DISC >A> @ EQ 400MG BASE A 073290 001 Nov 27, 1991 Aug DISC TABLET;ORAL TOLMETIN SODIUM >D> ! MYLAN EQ 600MG BASE A 074473 001 Aug 30, 1994 Aug DISC >A> @ EQ 600MG BASE A 074473 001 Aug 30, 1994 Aug DISC

TOLTERODINE TARTRATE CAPSULE, EXTENDED RELEASE;ORAL TARTRATE AB AJANTA PHARMA LTD 2MG A 213397 001 May 19, 2020 Jan CMFD AB 4MG A 213397 002 May 19, 2020 Jan CMFD AB AMTA 2MG A 213858 001 Feb 02, 2021 Jan NEWA AB 4MG A 213858 002 Feb 02, 2021 Jan NEWA @ MYLAN 2MG A 201486 001 Oct 31, 2013 Jul DISC @ 4MG A 201486 002 Oct 31, 2013 Jul DISC TABLET;ORAL TOLTERODINE TARTRATE AB HETERO LABS LTD V 1MG A 204397 001 Aug 02, 2021 Jul NEWA AB 2MG A 204397 002 Aug 02, 2021 Jul NEWA

TOLVAPTAN TABLET;ORAL SAMSCA + OTSUKA 15MG N 022275 001 May 19, 2009 Feb CAHN AB +! 30MG N 022275 002 May 19, 2009 Feb CAHN + @ 60MG N 022275 003 May 19, 2009 Feb CAHN TOLVAPTAN ALKEM LABS LTD 60MG A 211891 002 May 19, 2020 Jul CTEC >D> APOTEX@ 30MG A 207605 001 May 19, 2020 Aug CMFD >A> AB 30MG A 207605 001 May 19, 2020 Aug CMFD AB HETERO LABS LTD V 30MG A 205646 001 Jul 16, 2021 Jul NEWA

TOPIRAMATE CAPSULE, EXTENDED RELEASE;ORAL AB2 GLENMARK PHARMS LTD 25MG A 210278 001 Feb 01, 2021 Jan NFTG AB2 50MG A 210278 002 Feb 01, 2021 Jan NFTG AB2 100MG A 210278 003 Feb 01, 2021 Jan NFTG AB2 150MG A 210278 004 Feb 01, 2021 Jan NFTG AB2 200MG A 210278 005 Feb 01, 2021 Jan NFTG AB1 ZYDUS PHARMS 25MG A 207382 001 Nov 24, 2017 Jan CTEC AB1 50MG A 207382 002 Nov 24, 2017 Jan CTEC AB1 100MG A 207382 003 Nov 24, 2017 Jan CTEC TROKENDI XR AB1 + SUPERNUS PHARMS 25MG N 201635 001 Aug 16, 2013 Jan CTEC AB1 + 50MG N 201635 002 Aug 16, 2013 Jan CTEC AB1 + 100MG N 201635 003 Aug 16, 2013 Jan CTEC TABLET;ORAL TOPIRAMATE >A> AB ASCENT PHARMS INC 25MG A 215414 001 Aug 26, 2021 Aug NEWA >A> AB 50MG A 215414 002 Aug 26, 2021 Aug NEWA >A> AB 100MG A 215414 003 Aug 26, 2021 Aug NEWA >A> AB 200MG A 215414 004 Aug 26, 2021 Aug NEWA

TOPOTECAN HYDROCHLORIDE INJECTABLE;INJECTION HYDROCHLORIDE >D> AP MEITHEAL EQ 4MG BASE/VIAL A 201166 001 Aug 08, 2012 Aug DISC >A> @ EQ 4MG BASE/VIAL A 201166 001 Aug 08, 2012 Aug DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -114

TORSEMIDE TABLET;ORAL SOAANZ +! SARFE PHARMS 20MG N 213218 001 Jun 14, 2021 Jul CHRS + 20MG N 213218 001 Jun 14, 2021 Jun NEWA + 60MG N 213218 002 Jun 14, 2021 Jul CHRS +! 60MG N 213218 002 Jun 14, 2021 Jun NEWA

TRAMADOL HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE >D> @ GRAVITI PHARMS 50MG A 075968 001 Jun 25, 2002 Aug CAHN @ 50MG A 075968 001 Jun 25, 2002 Apr CAHN AB POLYGEN PHARMS 50MG A 206706 001 Jul 02, 2019 Feb CMFD >A> @ RISING 50MG A 075968 001 Jun 25, 2002 Aug CAHN TABLET, EXTENDED RELEASE;ORAL TRAMADOL HYDROCHLORIDE @ ANCHEN PHARMS 100MG A 200491 001 Jun 27, 2012 Apr DISC @ 200MG A 200491 002 Jun 27, 2012 Apr DISC @ 300MG A 200491 003 Jun 27, 2012 Apr DISC

TRANDOLAPRIL; HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL TARKA >D> AB + ABBVIE 2MG;180MG N 020591 001 Oct 22, 1996 Aug DISC >A> + @ 2MG;180MG N 020591 001 Oct 22, 1996 Aug DISC >D> AB + 2MG;240MG N 020591 004 Oct 22, 1996 Aug DISC >A> + @ 2MG;240MG N 020591 004 Oct 22, 1996 Aug DISC >D> AB +! 4MG;240MG N 020591 002 Oct 22, 1996 Aug DISC >A> + @ 4MG;240MG N 020591 002 Oct 22, 1996 Aug DISC TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE >D> AB GLENMARK GENERICS 2MG;180MG A 079135 001 May 26, 2010 Aug CTEC >A> 2MG;180MG A 079135 001 May 26, 2010 Aug CTEC >D> AB 2MG;240MG A 079135 002 May 26, 2010 Aug CTEC >A> 2MG;240MG A 079135 002 May 26, 2010 Aug CTEC >D> AB 4MG;240MG A 079135 003 May 05, 2010 Aug CTEC >A> ! 4MG;240MG A 079135 003 May 05, 2010 Aug CTEC

TRANEXAMIC ACID INJECTABLE;INJECTION CYKLOKAPRON AP +! PFIZER 100MG/ML N 019281 001 Dec 30, 1986 Mar CAHN AP CAPLIN 100MG/ML A 212360 001 Jul 17, 2019 Jun CMFD AP PROVEPHARM SAS 100MG/ML A 212676 001 Jul 17, 2019 Jan CAHN @ ZYDUS PHARMS 100MG/ML A 205228 001 Jul 17, 2017 Apr DISC TABLET;ORAL TRANEXAMIC ACID AB ANI PHARMS 650MG A 203256 001 Jul 25, 2016 Jun CMFD @ APOTEX INC 650MG A 202286 001 Jan 27, 2014 Mar DISC

TRANYLCYPROMINE SULFATE TABLET;ORAL SULFATE AB NOVITIUM PHARMA EQ 10MG BASE A 206856 001 Apr 17, 2018 Apr CAHN

TRAVOPROST SOLUTION/DROPS;OPHTHALMIC AT MICRO LABS 0.004% A 203767 001 Mar 19, 2021 Mar NEWA

TRAZODONE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE @ ALVOGEN 50MG A 071636 001 Apr 18, 1988 Jun DISC @ 100MG A 071514 001 Apr 18, 1988 Jun DISC AB AUROLIFE PHARMA LLC 50MG A 204852 001 Feb 05, 2020 Feb CMFD AB 100MG A 204852 002 Feb 05, 2020 Feb CMFD AB 150MG A 204852 003 Feb 05, 2020 Feb CMFD AB 300MG A 204852 004 Feb 05, 2020 Feb CMFD @ RISING 50MG A 072484 001 Apr 30, 1990 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -115

TREPROSTINIL INJECTABLE;IV (INFUSION), SUBCUTANEOUS REMODULIN >A> +! UNITED THERAP 20MG/ML N 021272 005 Jul 30, 2021 Aug NEWA AP ALEMBIC GLOBAL 1MG/ML A 211574 001 Feb 11, 2021 Feb NEWA AP 2.5MG/ML A 211574 002 Feb 11, 2021 Feb NEWA AP 5MG/ML A 211574 003 Feb 11, 2021 Feb NEWA AP 10MG/ML A 211574 004 Feb 11, 2021 Feb NEWA SOLUTION;INTRAVENOUS, SUBCUTANEOUS REMODULIN @ UNITED THERAP 20MG/20ML (1MG/ML) N 208276 001 Jul 30, 2018 Jun DISC @ 50MG/20ML (2.5MG/ML) N 208276 002 Jul 30, 2018 Jun DISC @ 100MG/20ML (5MG/ML) N 208276 003 Jul 30, 2018 Jun DISC @ 200MG/20ML (10MG/ML) N 208276 004 Jul 30, 2018 Jun DISC

TRIAMCINOLONE ACETONIDE CREAM;TOPICAL ARISTOCORT >D> @ ASTELLAS 0.5% A 083015 002 Aug CRLD >A> + @ 0.5% A 083015 002 Aug CRLD KENALOG >D> @ DELCOR ASSET CORP 0.5% A 083943 001 Aug CRLD >A> + @ 0.5% A 083943 001 Aug CRLD TRIAMCINOLONE ACETONIDE >D> AT ! FOUGERA PHARMS 0.025% A 085692 001 Aug CRLD >A> AT +! 0.025% A 085692 001 Aug CRLD >D> AT ! 0.1% A 085692 003 Aug CRLD >A> AT +! 0.1% A 085692 003 Aug CRLD >D> AT ! 0.5% A 085692 002 Aug CRLD >A> AT +! 0.5% A 085692 002 Aug CRLD >A> AT MICRO LABS 0.025% A 040671 001 Jun 09, 2006 Aug CAHN >A> AT 0.1% A 040671 002 Jun 09, 2006 Aug CAHN >D> AT SAPTALIS PHARMS 0.025% A 040671 001 Jun 09, 2006 Aug CAHN AT 0.025% A 040671 001 Jun 09, 2006 Jan CAHN >D> AT 0.1% A 040671 002 Jun 09, 2006 Aug CAHN AT 0.1% A 040671 002 Jun 09, 2006 Jan CAHN LOTION;TOPICAL TRIAMCINOLONE ACETONIDE >A> AT MICRO LABS 0.1% A 040672 002 Dec 13, 2006 Aug CAHN >D> AT SAPTALIS PHARMS 0.1% A 040672 002 Dec 13, 2006 Aug CAHN OINTMENT;TOPICAL ARISTOCORT >D> @ ASTELLAS 0.5% A 080745 002 Aug CRLD >A> + @ 0.5% A 080745 002 Aug CRLD ARISTOCORT A >D> @ ASTELLAS 0.5% A 080745 003 Aug CRLD >A> + @ 0.5% A 080745 003 Aug CRLD KENALOG >D> @ DELCOR ASSET CORP 0.5% A 083944 001 Aug CRLD >A> + @ 0.5% A 083944 001 Aug CRLD TRIAMCINOLONE ACETONIDE >D> AT ! PADAGIS US 0.025% A 087385 002 Aug CRLD >A> AT +! 0.025% A 087385 002 Aug CRLD >D> AT ! 0.1% A 087385 003 Aug CRLD >A> AT +! 0.1% A 087385 003 Aug CRLD >D> AT ! 0.5% A 087385 001 Aug CRLD >A> AT +! 0.5% A 087385 001 Aug CRLD SPRAY, METERED;NASAL TRIAMCINOLONE ACETONIDE @ PERRIGO 0.055MG/SPRAY A 078104 001 Jul 30, 2009 Jul CAHN

TRIAZOLAM TABLET;ORAL HALCION AB + PFIZER 0.125MG N 017892 003 Apr 26, 1985 Feb CAHN AB +! 0.25MG N 017892 001 Nov 15, 1982 Feb CAHN @ 0.5MG N 017892 002 Nov 15, 1982 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -116

TRIENTINE HYDROCHLORIDE CAPSULE;ORAL CLOVIQUE @ CHARTWELL RX 250MG A 209731 001 Oct 21, 2019 Jun DISC AB 250MG A 209731 001 Oct 21, 2019 Mar CAHN TRIENTINE HYDROCHLORIDE >A> AB ACCORD HLTHCARE 250MG A 212929 001 Aug 30, 2021 Aug NEWA @ CHARTWELL RX 250MG A 209415 001 Sep 16, 2019 Jun DISC AB 250MG A 209415 001 Sep 16, 2019 Mar CAHN >A> AB ECI PHARMS LLC 250MG A 209945 001 Aug 13, 2021 Aug NEWA

TRILACICLIB DIHYDROCHLORIDE POWDER;INTRAVENOUS COSELA +! G1 THERAP EQ 300MG BASE/VIAL N 214200 001 Feb 12, 2021 Feb NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE CAPSULE;ORAL TIGAN + @ KING PHARMS LLC 300MG N 017531 006 Dec 13, 2001 Apr DISC HYDROCHLORIDE AB ! SUN PHARM INDUSTRIES 300MG A 076570 001 Aug 28, 2003 Apr CHRS

TROPICAMIDE SOLUTION/DROPS;OPHTHALMIC MYDRIACYL >D> AT ! ALCON LABS INC 1% A 084306 001 Aug CRLD >A> AT +! 1% A 084306 001 Aug CRLD >D> AT ! SANDOZ INC 0.5% A 084305 001 Aug CRLD >A> AT +! 0.5% A 084305 001 Aug CRLD

TROSPIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL AB AMTA 60MG A 214760 001 Apr 30, 2021 Apr NEWA

UMBRALISIB TOSYLATE TABLET;ORAL UKONIQ +! TG THERAPS EQ 200MG BASE N 213176 001 Feb 05, 2021 Feb NEWA

URSODIOL CAPSULE;ORAL URSODIOL AB STRIDES PHARMA 300MG A 210344 001 Jan 22, 2021 Jan NEWA AB VGYAAN 300MG A 214329 001 Jul 28, 2021 Jul NEWA

VALACYCLOVIR HYDROCHLORIDE TABLET;ORAL VALACYCLOVIR HYDROCHLORIDE >A> AB CADILA EQ 500MG BASE A 079137 001 Dec 29, 2017 Aug CAHN >A> AB EQ 1GM BASE A 079137 002 Dec 29, 2017 Aug CAHN >D> AB ZYDUS PHARMS EQ 500MG BASE A 079137 001 Dec 29, 2017 Aug CAHN >D> AB EQ 1GM BASE A 079137 002 Dec 29, 2017 Aug CAHN

VALBENAZINE TOSYLATE CAPSULE;ORAL INGREZZA + NEUROCRINE EQ 60MG BASE N 209241 003 Apr 23, 2021 May NEWA

VALGANCICLOVIR HYDROCHLORIDE TABLET;ORAL VALGANCICLOVIR HYDROCHLORIDE AB MYLAN EQ 450MG BASE A 205151 001 Mar 03, 2021 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -117

VALPROIC ACID SYRUP;ORAL VALPROIC ACID AA CHARTWELL RX 250MG/5ML A 075782 001 Dec 22, 2000 Mar CMFD

VANCOMYCIN SOLUTION;INTRAVENOUS, ORAL VANCOMYCIN >A> +! XELLIA PHARMS APS 5GM/100ML (50MG/ML) N 213895 001 Aug 26, 2021 Aug NEWA

VANCOMYCIN HYDROCHLORIDE INJECTABLE;INJECTION VANCOMYCIN HYDROCHLORIDE @ HIKMA EQ 500MG BASE/VIAL A 203300 001 Aug 11, 2020 Feb DISC @ EQ 1GM BASE/VIAL A 203300 002 Aug 11, 2020 Feb DISC ! HOSPIRA EQ 1.5GM BASE/VIAL A 062912 003 Jul 10, 2020 May CMFD

VARDENAFIL HYDROCHLORIDE TABLET;ORAL LEVITRA + @ BAYER HLTHCARE EQ 5MG BASE N 021400 001 Aug 19, 2003 Apr DISC + @ EQ 10MG BASE N 021400 002 Aug 19, 2003 Apr DISC

VARENICLINE TABLET;ORAL AB PAR PHARM INC EQ 0.5MG BASE A 201785 001 Aug 11, 2021 Jul NFTG AB EQ 1MG BASE A 201785 002 Aug 11, 2021 Jul NFTG

VASOPRESSIN SOLUTION;INTRAVENOUS VASOSTRICT +! PAR STERILE PRODUCTS 20UNITS/100ML (0.2UNITS/ML) N 204485 005 Apr 21, 2021 Apr NEWA

VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE >A> AB TORRENT EQ 37.5MG BASE A 090899 001 Jun 01, 2011 Aug CAHN >A> AB EQ 75MG BASE A 090899 002 Jun 01, 2011 Aug CAHN >A> AB EQ 150MG BASE A 090899 003 Jun 01, 2011 Aug CAHN >D> AB TORRENT PHARMS LLC EQ 37.5MG BASE A 090899 001 Jun 01, 2011 Aug CAHN >D> AB EQ 75MG BASE A 090899 002 Jun 01, 2011 Aug CAHN >D> AB EQ 150MG BASE A 090899 003 Jun 01, 2011 Aug CAHN AB YICHANG HUMANWELL EQ 37.5MG BASE A 214654 001 Aug 06, 2021 Jul NEWA AB EQ 75MG BASE A 214654 002 Aug 06, 2021 Jul NEWA AB EQ 150MG BASE A 214654 003 Aug 06, 2021 Jul NEWA TABLET;ORAL VENLAFAXINE HYDROCHLORIDE @ MYLAN EQ 25MG BASE A 077166 001 Jun 13, 2008 Jan DISC @ EQ 37.5MG BASE A 077166 002 Jun 13, 2008 Jan DISC @ EQ 50MG BASE A 077166 003 Jun 13, 2008 Jan DISC @ EQ 75MG BASE A 077166 004 Jun 13, 2008 Jan DISC @ EQ 100MG BASE A 077166 005 Jun 13, 2008 Jan DISC TABLET, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE AB ALKEM LABS LTD EQ 37.5MG BASE A 214127 001 Jun 10, 2021 Jun NEWA AB EQ 75MG BASE A 214127 002 Jun 10, 2021 Jun NEWA AB EQ 150MG BASE A 214127 003 Jun 10, 2021 Jun NEWA AB EQ 225MG BASE A 214127 004 Jun 10, 2021 Jun NEWA AB APPCO EQ 150MG BASE A 214609 001 Jun 30, 2021 Jun NEWA AB EQ 225MG BASE A 214609 002 Jun 30, 2021 Jun NEWA AB DEXCEL PHARMA EQ 75MG BASE A 213927 001 Jan 21, 2021 Jan NEWA

VERICIGUAT TABLET;ORAL VERQUVO + MERCK SHARP DOHME 2.5MG N 214377 001 Jan 19, 2021 Jan NEWA + 5MG N 214377 002 Jan 19, 2021 Jan NEWA +! 10MG N 214377 003 Jan 19, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -118

VIGABATRIN FOR SOLUTION;ORAL AA ANNORA PHARMA 500MG/PACKET A 213519 001 Jan 26, 2021 Jan NEWA AA DEXCEL PHARMA 500MG/PACKET A 214992 001 May 13, 2021 May NEWA AA NAVISCI 500MG/PACKET A 213390 001 Jul 29, 2021 Jul NEWA AA SPECGX LLC 500MG/PACKET A 212626 001 Jul 28, 2021 Jul NEWA TABLET;ORAL VIGABATRIN AB DR REDDYS 500MG A 211539 001 Jan 29, 2021 Jan NEWA

VILAZODONE HYDROCHLORIDE TABLET;ORAL HYDROCHLORIDE AB ACCORD HLTHCARE 10MG A 208209 001 Apr 27, 2021 Apr NEWA AB 20MG A 208209 002 Apr 27, 2021 Apr NEWA AB 40MG A 208209 003 Apr 27, 2021 Apr NEWA AB INVAGEN PHARMS 10MG A 208200 001 Apr 07, 2021 Mar NEWA AB 40MG A 208200 002 Apr 07, 2021 Mar NEWA

VILOXAZINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL QELBREE + SUPERNUS PHARMS EQ 100MG BASE N 211964 001 Apr 02, 2021 Apr NEWA + EQ 150MG BASE N 211964 002 Apr 02, 2021 Apr NEWA +! EQ 200MG BASE N 211964 003 Apr 02, 2021 Apr NEWA

VINBLASTINE SULFATE INJECTABLE;INJECTION SULFATE ! HIKMA PHARMS 10MG/VIAL A 089395 001 Apr 09, 1987 Jul CAHN

VINORELBINE TARTRATE INJECTABLE;INJECTION TARTRATE @ FRESENIUS KABI USA EQ 10MG BASE/ML A 076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN CAPSULE;ORAL LUPKYNIS +! AURINIA 7.9MG N 213716 001 Jan 22, 2021 Jan NEWA

VORICONAZOLE INJECTABLE;INTRAVENOUS AP ALMAJECT 200MG/VIAL A 206398 001 Mar 23, 2016 Feb CAHN

ZINC CHLORIDE INJECTABLE;INJECTION ZINC CHLORIDE AP EXELA PHARMA EQ 1MG ZINC/ML A 212007 001 May 21, 2021 May NFTG

ZIPRASIDONE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE AB CHARTWELL RX EQ 20MG BASE A 090348 001 Sep 05, 2012 Jul CAHN AB EQ 40MG BASE A 090348 002 Sep 05, 2012 Jul CAHN AB EQ 60MG BASE A 090348 003 Sep 05, 2012 Jul CAHN AB EQ 80MG BASE A 090348 004 Sep 05, 2012 Jul CAHN

ZOLEDRONIC ACID INJECTABLE;INTRAVENOUS ZOLEDRONIC ACID >D> AP EMCURE PHARMS LTD EQ 4MG BASE/5ML A 201783 001 Mar 12, 2013 Aug DISC >A> @ EQ 4MG BASE/5ML A 201783 001 Mar 12, 2013 Aug DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 1 -119

ZOLPIDEM TARTRATE TABLET, ORALLY DISINTEGRATING;ORAL TOVALT ODT + @ BIOVAIL LABS INTL 5MG N 021412 001 Apr 25, 2007 Apr CRLD + @ 10MG N 021412 002 Apr 25, 2007 Apr CRLD

ZONISAMIDE CAPSULE;ORAL ZONEGRAN AB + CONCORDIA 25MG N 020789 003 Aug 22, 2003 Mar CAHN + @ 50MG N 020789 002 Aug 22, 2003 Mar CAHN AB +! 100MG N 020789 001 Mar 27, 2000 Mar CAHN AB CADILA 25MG A 077625 001 Oct 16, 2006 Jul CAHN AB 50MG A 077625 002 Oct 16, 2006 Jul CAHN AB 100MG A 077625 003 Oct 16, 2006 Jul CAHN AB GRANULES 25MG A 077636 003 Jul 27, 2006 Jun CAHN AB 50MG A 077636 002 Jul 27, 2006 Jun CAHN AB 100MG A 077636 001 Dec 22, 2005 Jun CAHN AB UNICHEM 25MG A 214492 001 Jan 26, 2021 Jan NEWA AB 50MG A 214492 002 Jan 26, 2021 Jan NEWA AB 100MG A 214492 003 Jan 26, 2021 Jan NEWA OTC DRUG PRODUCT LIST - 41ST EDITION OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 2 -1

ACETAMINOPHEN TABLET, EXTENDED RELEASE;ORAL ACETAMINOPHEN >A> MARKSANS PHARMA 650MG A 215486 001 Aug 25, 2021 Aug NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE TABLET;ORAL ACETAMINOPHEN, ASPIRIN AND CAFFEINE GRANULES 250MG;250MG;65MG A 214039 001 Feb 23, 2021 Feb NEWA

ASPIRIN CAPSULE;ORAL VAZALORE + PLX PHARMA 81MG N 203697 002 Feb 26, 2021 Jun NEWA

AZELASTINE HYDROCHLORIDE SPRAY, METERED;NASAL ASTEPRO ALLERGY +! BAYER HLTHCARE 0.2055MG/SPRAY N 213872 001 Jun 17, 2021 Jun NEWA CHILDREN'S ASTEPRO ALLERGY +! BAYER HLTHCARE 0.2055MG/SPRAY N 213872 002 Jun 17, 2021 Jun NEWA

BUDESONIDE SPRAY, METERED;NASAL RHINOCORT ALLERGY +! J AND J CONSUMER INC 0.032MG/SPRAY N 020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE CAPSULE;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY APOTEX 10MG A 207235 001 Aug 12, 2016 Mar CMFD @ 10MG A 207235 001 Aug 12, 2016 Jan DISC TABLET;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY @ CIPLA LTD 5MG A 077318 001 Jul 25, 2013 May DISC @ 10MG A 077318 002 Jul 25, 2013 May DISC TABLET, CHEWABLE;ORAL CHILDREN'S ZYRTEC ALLERGY + @ J AND J CONSUMER INC 2.5MG N 021621 007 Nov 30, 2020 Apr DISC

DEXTROMETHORPHAN HYDROBROMIDE; TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN AND HYDROBROMIDE SUN PHARM 30MG;600MG A 214781 001 Jul 01, 2021 Jun NEWA 60MG;1.2GM A 214781 002 Jul 01, 2021 Jun NEWA

DICLOFENAC SODIUM GEL;TOPICAL DICLOFENAC SODIUM AUROLIFE PHARMA LLC 1% A 204306 001 May 06, 2019 May CAHN PERRIGO 1% A 211253 001 May 16, 2019 Jun CAHN PERRIGO PHARMA INTL 1% A 211253 001 May 16, 2019 Jul CAHN

FEXOFENADINE HYDROCHLORIDE SUSPENSION;ORAL CHILDREN'S HYDROCHLORIDE ALLERGY TARO 30MG/5ML A 208123 001 Nov 09, 2017 Jun CMFD CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES TARO 30MG/5ML A 208123 002 Nov 09, 2017 Jun CMFD TABLET;ORAL FEXOFENADINE HYDROCHLORIDE L PERRIGO CO 60MG A 212971 001 Feb 24, 2020 Jun CMFD 180MG A 212971 002 Feb 24, 2020 Jun CMFD OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 2 -2

FLUTICASONE PROPIONATE SPRAY, METERED;NASAL FLONASE ALLERGY RELIEF + GLAXOSMITHKLINE CONS 0.05MG/SPRAY N 205434 001 Jul 23, 2014 Apr CHRS FLUTICASONE PROPIONATE ! HIKMA PHARMS 0.05MG/SPRAY A 207957 001 May 26, 2016 Apr CHRS

GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN >D> @ OHM LABS INC 600MG A 209254 001 Jul 16, 2018 Aug CMFD >A> 600MG A 209254 001 Jul 16, 2018 Aug CMFD >D> @ 1.2GM A 209254 002 Jul 16, 2018 Aug CMFD >A> 1.2GM A 209254 002 Jul 16, 2018 Aug CMFD

IBUPROFEN SUSPENSION;ORAL IBUPROFEN GUARDIAN DRUG 100MG/5ML A 210149 001 Aug 17, 2018 Jan CMFD >D> STRIDES PHARMA 100MG/5ML A 211666 001 Feb 22, 2021 Aug DISC >A> @ 100MG/5ML A 211666 001 Feb 22, 2021 Aug DISC 100MG/5ML A 211666 001 Feb 22, 2021 Feb NEWA TABLET;ORAL IBUPROFEN @ YICHANG HUMANWELL 200MG A 214003 001 Oct 19, 2020 Apr DISC

ISOPROPYL SOLUTION;TOPICAL ZURAGARD + @ ZUREX PHARMA 70% N 210872 001 Apr 26, 2019 Jul CPOT

IVERMECTIN LOTION;TOPICAL TARO 0.5% A 210720 001 May 06, 2020 May CMKT

KETOCONAZOLE SHAMPOO;TOPICAL NIZORAL ANTI-DANDRUFF +! KRAMER 1% N 020310 001 Oct 10, 1997 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE TABLET;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE APOTEX 5MG A 211443 001 Apr 21, 2021 Apr NEWA

LOPERAMIDE HYDROCHLORIDE CAPSULE;ORAL HYDROCHLORIDE STRIDES PHARMA 2MG A 213070 001 Aug 11, 2021 Jul NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE TABLET;ORAL LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE GUARDIAN DRUG 2MG;125MG A 214541 001 May 27, 2021 May NEWA HETERO LABS LTD V 2MG;125MG A 211438 001 Jun 17, 2021 Jun NEWA

LORATADINE SYRUP;ORAL HETERO LABS LTD III 1MG/ML A 210409 001 May 07, 2021 Apr NEWA TABLET;ORAL LORATADINE UNIQUE PHARM 10MG A 214684 001 Jan 07, 2021 Jan NEWA TABLET, ORALLY DISINTEGRATING;ORAL LORATADINE @ GLAXOSMITHKLINE 10MG A 075822 001 Feb 10, 2003 Jan DISC TENSHI 5MG A 212795 001 Sep 18, 2020 Jun CMFD @ 5MG A 212795 001 Sep 18, 2020 Mar DISC 10MG A 213294 001 Oct 30, 2020 Jun CMFD OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021 2 -3

TABLET, ORALLY DISINTEGRATING;ORAL LORATADINE @ 10MG A 213294 001 Oct 30, 2020 Mar DISC

MICONAZOLE NITRATE CREAM, INSERT;TOPICAL, VAGINAL NITRATE PERRIGO R AND D 2%,1.2GM A 079114 001 Jun 02, 2010 Jul CDFR MONISTAT 1 COMBINATION PACK +! MEDTECH PRODUCTS 2%,1.2GM N 021308 001 Jun 29, 2001 Jul CDFR

MINOXIDIL AEROSOL, FOAM;TOPICAL MINOXIDIL PERRIGO 5% A 091344 001 Apr 28, 2011 Jul CAHN

NICOTINE POLACRILEX TROCHE/LOZENGE;ORAL + GLAXOSMITHKLINE EQ 2MG BASE N 022360 001 May 18, 2009 Mar CAHN +! EQ 4MG BASE N 022360 002 May 18, 2009 Mar CAHN POLACRILEX AUROBINDO PHARMA LTD EQ 2MG BASE A 213266 001 Aug 03, 2021 Jul NEWA EQ 4MG BASE A 213266 002 Aug 03, 2021 Jul NEWA

OLOPATADINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OLOPATADINE HYDROCHLORIDE AKORN EQ 0.1% BASE A 204532 001 Jan 10, 2017 Jun CMKT EQ 0.2% BASE A 204723 001 Dec 05, 2017 Jun CMKT ALEMBIC PHARMS LTD EQ 0.1% BASE A 209919 001 Dec 07, 2018 Feb CMKT EQ 0.2% BASE A 209420 001 Apr 29, 2019 Jan CMKT APOTEX INC EQ 0.2% BASE A 090918 001 Dec 05, 2017 Jan CMKT BARR LABS INC EQ 0.2% BASE A 090848 001 Jul 13, 2015 Feb CMKT @ BAUSCH EQ 0.1% BASE A 206046 001 Jul 26, 2017 Jun CAHN @ CIPLA EQ 0.2% BASE A 206087 001 Dec 05, 2017 Mar CMKT FDC LTD EQ 0.1% BASE A 209282 001 Sep 26, 2019 Feb CMKT MYLAN EQ 0.1% BASE A 204392 001 Mar 21, 2018 Feb CMKT EQ 0.2% BASE A 204620 001 Jun 16, 2020 Jun CAHN USV EQ 0.1% BASE A 203152 001 Dec 07, 2015 Apr CMKT >A> @ WOCKHARDT LTD EQ 0.1% BASE A 200810 001 Jun 28, 2017 Aug CMKT

OMEPRAZOLE TABLET, DELAYED RELEASE;ORAL OMEPRAZOLE APOTEX 20MG A 210070 001 Feb 11, 2019 May CMFD

POLYETHYLENE GLYCOL 3350 FOR SOLUTION;ORAL POLYETHYLENE GLYCOL 3350 ANNORA PHARMA 17GM/SCOOPFUL A 214990 001 Apr 14, 2021 Apr NEWA

RANITIDINE HYDROCHLORIDE TABLET;ORAL RANITIDINE HYDROCHLORIDE @ AUROBINDO PHARMA LTD EQ 75MG BASE A 207579 001 Nov 13, 2017 Jun DISC @ EQ 150MG BASE A 207578 001 Nov 13, 2017 Jun DISC @ WOCKHARDT EQ 75MG BASE A 076760 001 Feb 24, 2006 Jan DISC ZANTAC 150 + @ SANOFI US EQ 150MG BASE N 021698 001 Aug 31, 2004 Apr DISC + @ EQ 150MG BASE N 021698 002 Mar 13, 2007 Apr DISC ZANTAC 75 + @ SANOFI US EQ 75MG BASE N 020520 001 Dec 19, 1995 Apr DISC

TRIAMCINOLONE ACETONIDE SPRAY, METERED;NASAL TRIAMCINOLONE ACETONIDE PERRIGO 0.055MG/SPRAY A 078104 002 Nov 14, 2014 Jul CAHN

3-1

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2021

NO AUGUST 2021 APPROVALS

4-1

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at: https://www.fda.gov/industry/developing-products-rare-diseases- conditions/designating-orphan-product-drugs-and-biological-products.

5-1

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 2021 ADDITIONS PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 41ST EDITION A - 1 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

ABALOPARATIDE - TYMLOS N 208743 001 10996208 Apr 30, 2038 DP

ACLIDINIUM BROMIDE - TUDORZA PRESSAIR N 202450 001 11000517 Mar 13, 2029 DP U-2513

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR N 210595 001 11000517 Mar 13, 2029 DP U-2513

ALBUTEROL SULFATE - PROAIR DIGIHALER N 205636 002 10918816 Dec 14, 2035 DP 11000653 Dec 18, 2038 DP

ALENDRONATE SODIUM - BINOSTO N 202344 001 9592195 Dec 05, 2031 DP

AMANTADINE HYDROCHLORIDE - GOCOVRI N 208944 001 11065213 Aug 23, 2038 DP 11077073 Aug 23, 2038 U-2106 11077073 Aug 23, 2038 U-2224 11077073 Aug 23, 2038 U-3180

AMANTADINE HYDROCHLORIDE - GOCOVRI N 208944 002 11065213 Aug 23, 2038 DP 11077073 Aug 23, 2038 U-2106 11077073 Aug 23, 2038 U-2224 11077073 Aug 23, 2038 U-3180

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 001 8389578 Jan 22, 2028 U-219 8389578 Jan 22, 2028 U-3054 8796337 Nov 23, 2025 U-219 8796337 Nov 23, 2025 U-2497 8796337 Nov 23, 2025 U-3054 8889740 Nov 23, 2025 DP 8895614 Nov 23, 2025 DP 8895615 Nov 23, 2025 U-219 8895615 Nov 23, 2025 U-3054 8895616 Nov 23, 2025 U-219 8895616 Nov 23, 2025 U-3054 8895617 Nov 23, 2025 U-219 8895617 Nov 23, 2025 U-3054 8895618 Nov 23, 2025 DP 8987333 Nov 23, 2025 DP 9072697 Nov 23, 2025 U-219 9072697 Nov 23, 2025 U-3054

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 002 8389578 Jan 22, 2028 U-219 8389578 Jan 22, 2028 U-3054 8796337 Nov 23, 2025 U-219 8796337 Nov 23, 2025 U-2497 8796337 Nov 23, 2025 U-3054 8889740 Nov 23, 2025 DP 8895614 Nov 23, 2025 DP 8895615 Nov 23, 2025 U-219 8895615 Nov 23, 2025 U-3054 8895616 Nov 23, 2025 U-219 8895616 Nov 23, 2025 U-3054 8895617 Nov 23, 2025 U-219 8895617 Nov 23, 2025 U-3054 8895618 Nov 23, 2025 DP 8987333 Nov 23, 2025 DP 9072697 Nov 23, 2025 U-219 9072697 Nov 23, 2025 U-3054 A - 2 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 002 8389578 Jan 22, 2028 U-219 8389578 Jan 22, 2028 U-3054 8796337 Nov 23, 2025 U-219 8796337 Nov 23, 2025 U-2497 8796337 Nov 23, 2025 U-3054 8889740 Nov 23, 2025 DP 8895614 Nov 23, 2025 DP 8895615 Nov 23, 2025 U-219 8895615 Nov 23, 2025 U-3054 8895616 Nov 23, 2025 U-219 8895616 Nov 23, 2025 U-3054 8895617 Nov 23, 2025 U-219 8895617 Nov 23, 2025 U-3054 8895618 Nov 23, 2025 DP 8987333 Nov 23, 2025 DP 9072697 Nov 23, 2025 U-219 9072697 Nov 23, 2025 U-3054

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 003 8389578 Jan 22, 2028 U-219 8389578 Jan 22, 2028 U-3054 8796337 Nov 23, 2025 U-219 8796337 Nov 23, 2025 U-2497 8796337 Nov 23, 2025 U-3054 8889740 Nov 23, 2025 DP 8895614 Nov 23, 2025 DP 8895615 Nov 23, 2025 U-219 8895615 Nov 23, 2025 U-3054 8895616 Nov 23, 2025 U-219 8895616 Nov 23, 2025 U-3054 8895617 Nov 23, 2025 U-219 8895617 Nov 23, 2025 U-3054 8895618 Nov 23, 2025 DP 8987333 Nov 23, 2025 DP 9072697 Nov 23, 2025 U-219 9072697 Nov 23, 2025 U-3054

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 004 8389578 Jan 22, 2028 U-219 8389578 Jan 22, 2028 U-3054 8796337 Nov 23, 2025 U-219 8796337 Nov 23, 2025 U-2497 8796337 Nov 23, 2025 U-3054 8889740 Nov 23, 2025 DP 8895614 Nov 23, 2025 DP 8895615 Nov 23, 2025 U-219 8895615 Nov 23, 2025 U-3054 8895616 Nov 23, 2025 U-219 8895616 Nov 23, 2025 U-3054 8895617 Nov 23, 2025 U-219 8895617 Nov 23, 2025 U-3054 8895618 Nov 23, 2025 DP 8987333 Nov 23, 2025 DP 9072697 Nov 23, 2025 U-219 9072697 Nov 23, 2025 U-3054

AMIFAMPRIDINE PHOSPHATE - FIRDAPSE N 208078 001 11060128 Jun 29, 2032 U-2956

AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN N 020965 001 10357567 Jan 12, 2038 U-3163 11077192 Jan 12, 2038 U-3163

AMLODIPINE BENZOATE - KATERZIA N 211340 001 10894039 Oct 06, 2037 U-185 10894039 Oct 06, 2037 U-3 10952998 Oct 06, 2037 DP A - 3 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

AMLODIPINE BENZOATE - KATERZIA N 211340 001 10959991 Oct 06, 2037 U-158 10959991 Oct 06, 2037 U-39

AMLODIPINE BESYLATE; CELECOXIB - CONSENSI N 210045 001 10925835 Jun 14, 2038 U-2410 10945960 Jun 14, 2038 DP

AMLODIPINE BESYLATE; CELECOXIB - CONSENSI N 210045 002 10925835 Jun 14, 2038 U-2410 10945960 Jun 14, 2038 DP

AMLODIPINE BESYLATE; CELECOXIB - CONSENSI N 210045 003 10925835 Jun 14, 2038 U-2410 10945960 Jun 14, 2038 DP

AMPHETAMINE SULFATE - EVEKEO ODT N 209905 005 10130580 Apr 19, 2024 DP 10441554 Mar 10, 2037 DP

APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 001 10888499 Feb 14, 2022 DP 10959943 Apr 19, 2036 U-2825 11077068 Feb 14, 2022 DP

APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 002 10888499 Feb 14, 2022 DP 10959943 Apr 19, 2036 U-2825 11077068 Feb 14, 2022 DP

APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 003 10888499 Feb 14, 2022 DP 10959943 Apr 19, 2036 U-2825 11077068 Feb 14, 2022 DP

APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 004 10888499 Feb 14, 2022 DP 10959943 Apr 19, 2036 U-2825 11077068 Feb 14, 2022 DP

APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 005 10888499 Feb 14, 2022 DP 10959943 Apr 19, 2036 U-2825 11077068 Feb 14, 2022 DP

APREPITANT - CINVANTI N 209296 001 10953018 Sep 18, 2035 U-2161

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 001 10980803 Sep 24, 2033 U-1632 10980803 Sep 24, 2033 U-543

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 002 10980803 Sep 24, 2033 U-1632 10980803 Sep 24, 2033 U-543

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 003 10980803 Sep 24, 2033 U-1632 10980803 Sep 24, 2033 U-543

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 004 10980803 Sep 24, 2033 U-1632 10980803 Sep 24, 2033 U-543 A - 4 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU N 209381 001 10918723 Sep 10, 2033 U-2310

ASENAPINE MALEATE - ASENAPINE MALEATE A 206098 002 PC Jun 08, 2021

ATROPINE SULFATE - ATROPINE SULFATE A 213424 001 CGT Sep 21, 2021

AVAPRITINIB - AYVAKIT N 212608 001 9200002 Oct 15, 2034 DS DP U-2726 I-863 Jun 16, 2024 9200002 Oct 15, 2034 DS DP U-3168 I-864 Jun 16, 2024 9944651 Oct 15, 2034 DS DP U-2726 ODE-356 Jun 16, 2028 9944651 Oct 15, 2034 DS DP U-3168 9994575 Oct 15, 2034 DS DP U-2726 9994575 Oct 15, 2034 DS DP U-3168

AVAPRITINIB - AYVAKIT N 212608 002 9200002 Oct 15, 2034 DS DP U-2726 I-863 Jun 16, 2024 9200002 Oct 15, 2034 DS DP U-3168 I-864 Jun 16, 2024 9944651 Oct 15, 2034 DS DP U-2726 ODE-356 Jun 16, 2028 9944651 Oct 15, 2034 DS DP U-3168 9994575 Oct 15, 2034 DS DP U-2726 9994575 Oct 15, 2034 DS DP U-3168

AVAPRITINIB - AYVAKIT N 212608 003 ODE-356 Jun 16, 2028

AVAPRITINIB - AYVAKIT N 212608 004 9200002 Oct 15, 2034 DS DP U-3168 I-863 Jun 16, 2024 9944651 Oct 15, 2034 DS DP U-3168 I-864 Jun 16, 2024 9994575 Oct 15, 2034 DS DP U-3168 NCE Jan 09, 2025 ODE-356 Jun 16, 2028

AVAPRITINIB - AYVAKIT N 212608 005 9200002 Oct 15, 2034 DS DP U-3168 I-863 Jun 16, 2024 9944651 Oct 15, 2034 DS DP U-3168 I-864 Jun 16, 2024 9994575 Oct 15, 2034 DS DP U-3168 NCE Jan 09, 2025 ODE-356 Jun 16, 2028

AXITINIB - INLYTA N 202324 001 10869924 Nov 05, 2036 U-3044

AXITINIB - INLYTA N 202324 002 10869924 Nov 05, 2036 U-3044

AZACITIDINE - ONUREG N 214120 001 ODE-320 Sep 01, 2027

AZACITIDINE - ONUREG N 214120 002 ODE-320 Sep 01, 2027

AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY N 213872 001 8071073 Jun 04, 2028 DP 8518919 Nov 22, 2025 U-3166 9919050 Nov 22, 2025 DP

AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY N 213872 002 >A> 8071073 Jun 04, 2028 DP >A> 8518919 Nov 22, 2025 U-3166 >A> 9919050 Nov 22, 2025 DP A - 5 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

BALOXAVIR MARBOXIL - XOFLUZA N 210854 003 10392406 Apr 27, 2036 DS I-811 Oct 16, 2022 10633397 Apr 27, 2036 U-2816 NCE Oct 24, 2023 10633397 Apr 27, 2036 U-3000 10759814 Aug 09, 2037 DS DP 8927710 May 05, 2031 DP 8987441 Sep 21, 2031 DS DP 9815835 Jun 14, 2030 DP

BALOXAVIR MARBOXIL - XOFLUZA N 214410 001 NCE Oct 24, 2023

BELINOSTAT - BELEODAQ N 206256 001 >A> 6888027 Aug 10, 2026 DS DP U-1544

BELUMOSUDIL MESYLATE - REZUROCK N 214783 001 >A> NCE Jul 16, 2026

BEMPEDOIC ACID - NEXLETOL N 211616 001 10941095 Dec 23, 2023 U-2747

BEMPEDOIC ACID; EZETIMIBE - NEXLIZET N 211617 001 10941095 Dec 23, 2023 U-2746

BENDAMUSTINE HYDROCHLORIDE - BELRAPZO N 205580 001 >A> 11103483 Jan 28, 2031 DP U-1971 >A> 11103483 Jan 28, 2031 DP U-1972

BENDAMUSTINE HYDROCHLORIDE - BENDEKA N 208194 001 >A> 11103483 Jan 28, 2031 DP U-1971 >A> 11103483 Jan 28, 2031 DP U-1972

BENZOYL PEROXIDE; TRETINOIN - TWYNEO N 214902 001 >A> 11071878 Dec 30, 2030 DP >A> 9868103 Aug 08, 2028 DP U-3194

BEROTRALSTAT HYDROCHLORIDE - ORLADEYO N 214094 001 >A> 10125102 Apr 07, 2035 DS U-3010 NCE Dec 03, 2025 ODE-333 Dec 03, 2027

BEROTRALSTAT HYDROCHLORIDE - ORLADEYO N 214094 002 >A> 10125102 Apr 07, 2035 DS U-3010 NCE Dec 03, 2025 ODE-333 Dec 03, 2027

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY N 210251 001 M-82 Feb 24, 2024

BOSENTAN - TRACLEER N 021290 001 >A> ODE* Sep 05, 2024

BOSENTAN - TRACLEER N 021290 002 >A> ODE* Sep 05, 2024

BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR) N 210557 001 6794489 Jun 28, 2025 DS DP

BREXANOLONE - ZULRESSO N 211371 001 10940156 Mar 08, 2037 U-2552

BREXPIPRAZOLE - REXULTI N 205422 001 RE48059 Dec 23, 2028 DS A - 6 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BREXPIPRAZOLE - REXULTI N 205422 002 RE48059 Dec 23, 2028 DS

BREXPIPRAZOLE - REXULTI N 205422 003 RE48059 Dec 23, 2028 DS

BREXPIPRAZOLE - REXULTI N 205422 004 RE48059 Dec 23, 2028 DS

BREXPIPRAZOLE - REXULTI N 205422 005 RE48059 Dec 23, 2028 DS

BREXPIPRAZOLE - REXULTI N 205422 006 RE48059 Dec 23, 2028 DS

BRIMONIDINE TARTRATE - LUMIFY N 208144 001 9259425 Jul 14, 2030 U-2222

BRINCIDOFOVIR - TEMBEXA N 214460 001 9303051 Aug 31, 2031 DS DP U-3165 NP Jun 04, 2024 ODE-354 Jun 04, 2028

BRINCIDOFOVIR - TEMBEXA N 214461 001 10112909 Oct 10, 2034 U-3165 NP Jun 04, 2024 10487061 Oct 10, 2034 DP U-3165 ODE-354 Jun 04, 2028 8962829 Oct 10, 2034 DS DP 9303051 Aug 31, 2031 DS DP U-3165 9371344 Oct 10, 2034 DP

BRIVARACETAM - BRIVIACT N 205836 001 NPP May 10, 2021

BRIVARACETAM - BRIVIACT N 205836 002 NPP May 10, 2021

BRIVARACETAM - BRIVIACT N 205836 003 NPP May 10, 2021

BRIVARACETAM - BRIVIACT N 205836 004 NPP May 10, 2021

BRIVARACETAM - BRIVIACT N 205836 005 NPP May 10, 2021

BRIVARACETAM - BRIVIACT N 205838 001 NPP May 10, 2021

BROMOCRIPTINE MESYLATE - CYCLOSET N 020866 001 11000522 Apr 30, 2032 U-3119 11000522 Apr 30, 2032 U-3120 11000522 Apr 30, 2032 U-3121 11000522 Apr 30, 2032 U-3122

BUPIVACAINE - EXPAREL N 022496 001 11033495 Jan 22, 2041 DP U-3182 NPP Mar 22, 2024

BUPIVACAINE - EXPAREL N 022496 002 11033495 Jan 22, 2041 DP U-3182 NPP Mar 22, 2024

BUPIVACAINE - POSIMIR N 204803 001 8153149 Sep 15, 2025 DP NP Feb 01, 2024 8153661 Sep 15, 2025 U-3074 8753665 Sep 15, 2025 DP U-3074 A - 7 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

BUPIVACAINE - POSIMIR N 204803 001 8846072 Sep 15, 2025 DP U-3074

BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 001 10098957 Apr 20, 2035 U-3118 NP May 12, 2024 10213510 Apr 20, 2035 DP U-3118 10398686 Mar 13, 2034 DP 10632199 Apr 20, 2035 DP U-3118 10898575 Apr 20, 2035 DP U-3118 10980886 Apr 20, 2035 DP >A> 11083730 Apr 20, 2035 DP U-3118 >A> 11083797 Apr 20, 2035 DP U-3118 9592227 Mar 13, 2034 DP U-3118 9694079 Apr 20, 2035 DP U-3118 9744163 Mar 13, 2034 DP 9801945 Apr 20, 2035 DP U-3118 9913909 Mar 13, 2034 U-3118

BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 002 10098957 Apr 20, 2035 U-3118 NP May 12, 2024 10213510 Apr 20, 2035 DP U-3118 10398686 Mar 13, 2034 DP 10632199 Apr 20, 2035 DP U-3118 10898575 Apr 20, 2035 DP U-3118 10980886 Apr 20, 2035 DP >A> 11083730 Apr 20, 2035 DP U-3118 >A> 11083797 Apr 20, 2035 DP U-3118 9592227 Mar 13, 2034 DP U-3118 9694079 Apr 20, 2035 DP U-3118 9744163 Mar 13, 2034 DP 9801945 Apr 20, 2035 DP U-3118 9913909 Mar 13, 2034 U-3118

BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 003 10098957 Apr 20, 2035 U-3118 NP May 12, 2024 10213510 Apr 20, 2035 DP U-3118 10398686 Mar 13, 2034 DP 10632199 Apr 20, 2035 DP U-3118 10898575 Apr 20, 2035 DP U-3118 10980886 Apr 20, 2035 DP >A> 11083730 Apr 20, 2035 DP U-3118 >A> 11083797 Apr 20, 2035 DP U-3118 9592227 Mar 13, 2034 DP U-3118 9694079 Apr 20, 2035 DP U-3118 9744163 Mar 13, 2034 DP 9801945 Apr 20, 2035 DP U-3118 9913909 Mar 13, 2034 U-3118

BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 004 10098957 Apr 20, 2035 U-3118 NP May 12, 2024 10213510 Apr 20, 2035 DP U-3118 10398686 Mar 13, 2034 DP 10632199 Apr 20, 2035 DP U-3118 10898575 Apr 20, 2035 DP U-3118 10980886 Apr 20, 2035 DP >A> 11083730 Apr 20, 2035 DP U-3118 >A> 11083797 Apr 20, 2035 DP U-3118 9592227 Mar 13, 2034 DP U-3118 9694079 Apr 20, 2035 DP U-3118 9744163 Mar 13, 2034 DP 9801945 Apr 20, 2035 DP U-3118 9913909 Mar 13, 2034 U-3118

BUPRENORPHINE - SUBLOCADE N 209819 001 11000520 Nov 06, 2035 U-3111 A - 8 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

BUPRENORPHINE - SUBLOCADE N 209819 002 11000520 Nov 06, 2035 U-3111

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 001 10946010 Sep 18, 2032 DP 11020388 Sep 18, 2032 DP U-3131

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 002 10874661 Sep 18, 2032 DP 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 003 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 004 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 005 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 006 10946010 Sep 18, 2032 DP 11020388 Sep 18, 2032 DP U-3131

CABAZITAXEL - JEVTANA KIT N 201023 001 M-128 Dec 18, 2023

CABOTEGRAVIR SODIUM - VOCABRIA N 212887 001 10927129 Apr 28, 2026 DS DP NCE Jan 21, 2026 8410103 Apr 28, 2026 DS DP U-3061

CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT N 212888 001 10927129 Apr 28, 2026 DS DP NCE Jan 21, 2026 6838464 Feb 26, 2021 DS DP 7125879 Apr 21, 2025 DS DP U-3059 8080551 Apr 11, 2023 DS DP 8410103 Apr 28, 2026 DS DP U-3060

CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT N 212888 002 10927129 Apr 28, 2026 DS DP NCE Jan 21, 2026 6838464 Feb 26, 2021 DS DP 7125879 Apr 21, 2025 DS DP U-3059 8080551 Apr 11, 2023 DS DP 8410103 Apr 28, 2026 DS DP U-3060

CABOZANTINIB S-MALATE - COMETRIQ N 203756 001 >A> 11091439 Jan 15, 2030 DS >A> 11091440 Jan 15, 2030 DP >A> 11098015 Jan 15, 2030 U-1617

CABOZANTINIB S-MALATE - COMETRIQ N 203756 002 >A> 11091439 Jan 15, 2030 DS >A> 11091440 Jan 15, 2030 DP >A> 11098015 Jan 15, 2030 U-1617 A - 9 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

CABOZANTINIB S-MALATE - CABOMETYX N 208692 001 >A> 11091439 Jan 15, 2030 DS I-854 Jan 22, 2024 >A> 11091440 Jan 15, 2030 DP >A> 11098015 Jan 15, 2030 U-1220 >A> 11098015 Jan 15, 2030 U-1480 >A> 11098015 Jan 15, 2030 U-2488

CABOZANTINIB S-MALATE - CABOMETYX N 208692 002 >A> 11091439 Jan 15, 2030 DS I-854 Jan 22, 2024 >A> 11091440 Jan 15, 2030 DP >A> 11098015 Jan 15, 2030 U-1220 >A> 11098015 Jan 15, 2030 U-1480 >A> 11098015 Jan 15, 2030 U-2488

CABOZANTINIB S-MALATE - CABOMETYX N 208692 003 >A> 11091439 Jan 15, 2030 DS I-854 Jan 22, 2024 >A> 11091440 Jan 15, 2030 DP >A> 11098015 Jan 15, 2030 U-1220 >A> 11098015 Jan 15, 2030 U-1480 >A> 11098015 Jan 15, 2030 U-2488

CALCITONIN SALMON - CALCITONIN-SALMON A 212416 001 CGT Nov 10, 2021

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; - XYWAV N 212690 001 10864181 Mar 15, 2033 U-3017 >A> ODE-361 Jul 21, 2027 >A> 8772306 Mar 15, 2033 U-1532 >A> 8772306 Mar 15, 2033 U-3198

CANGRELOR - KENGREAL N 204958 001 8680052 Mar 09, 2033 U-2979

CANNABIDIOL - EPIDIOLEX N 210365 001 10918608 Oct 14, 2035 U-3071 ODE-326 Jul 31, 2027 10918608 Oct 14, 2035 U-3072 ODE-332 Jul 31, 2027 10918608 Oct 14, 2035 U-3073 10966939 Jun 17, 2035 DP U-2780 10966939 Jun 17, 2035 DP U-2781 >A> 11065209 Oct 14, 2035 U-3071

CARGLUMIC ACID - CARBAGLU N 022562 001 ODE-345 Jan 22, 2028

CASIMERSEN - AMONDYS 45 N 213026 001 10287586 Nov 12, 2030 DS DP NCE Feb 25, 2026 10533174 May 04, 2021 DP ODE-347 Feb 25, 2028 10781450 Nov 12, 2030 U-3089 8524880 Apr 02, 2026 DS DP U-3087 8524880 Apr 02, 2026 DS DP U-3088 9228187 Nov 12, 2030 DS DP 9416361 May 04, 2021 DS 9447415 Jun 28, 2025 DS DP 9758783 Nov 12, 2030 U-3088 9758783 Nov 12, 2030 U-3089

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA N 206829 001 10933053 Sep 09, 2034 U-3090 10933053 Sep 09, 2034 U-3091

CERITINIB - ZYKADIA N 211225 001 ODE* Apr 29, 2021 ODE* May 26, 2024 A - 10 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 001 CGT Sep 20, 2021

CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 002 CGT Sep 20, 2021

CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 003 CGT Sep 20, 2021

CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 004 CGT Sep 20, 2021

CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 005 CGT Sep 20, 2021

CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 214542 001 CGT Jan 29, 2022

CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 214542 002 CGT Jan 29, 2022

CIPROFLOXACIN - OTIPRIO N 207986 001 11040004 Nov 12, 2037 U-2252

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI N 208352 001 6706276 Mar 06, 2022 DP

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ N 209589 001 NPP Aug 15, 2021

CLEVIDIPINE - CLEVIPREX N 022156 001 >A> 11103490 Oct 10, 2031 DP

CLEVIDIPINE - CLEVIPREX N 022156 002 >A> 11103490 Oct 10, 2031 DP

CLEVIDIPINE - CLEVIPREX N 022156 003 >A> 11103490 Oct 10, 2031 DP

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA N 210455 001 10786518 Jul 19, 2038 U-2978

COBIMETINIB FUMARATE - COTELLIC N 206192 001 >A> 11087354 Jun 22, 2034 U-1776

COCAINE HYDROCHLORIDE - NUMBRINO N 209575 001 NCE Dec 14, 2022 NP Jan 10, 2023

COCAINE HYDROCHLORIDE - GOPRELTO N 209963 001 10894012 Feb 07, 2037 U-3014 10933060 Feb 07, 2037 U-3014 10973811 Feb 07, 2037 U-2226 10987347 Feb 07, 2037 U-2225

CRIZOTINIB - XALKORI N 202570 001 I-852 Jan 14, 2024 ODE-328 Jan 14, 2028

CRIZOTINIB - XALKORI N 202570 002 I-852 Jan 14, 2024 ODE-328 Jan 14, 2028 A - 11 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

CRIZOTINIB - XALKORI N 202570 002 I-852 Jan 14, 2024 ODE-328 Jan 14, 2028

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS N 209376 002 NCE Apr 30, 2024

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS N 209376 003 >A> NCE Apr 30, 2024

CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 210735 001 >A> 9662342 Jun 26, 2035 DP

CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 210735 002 >A> 9662342 Jun 26, 2035 DP

CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 212501 001 10993952 Feb 15, 2036 DP

CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 212501 002 10993952 Feb 15, 2036 DP

CYCLOSPORINE - CEQUA N 210913 001 10918694 Feb 28, 2037 DP

CYCLOSPORINE - VERKAZIA N 214965 001 7973081 Jan 27, 2026 DP ODE-358 Jun 23, 2028 8298568 Nov 03, 2027 DP 8524779 Jan 27, 2026 DP 9132071 Jun 02, 2029 DP 9220694 Jan 27, 2026 DP 9956289 Jan 27, 2026 DP

CYSTEAMINE BITARTRATE - PROCYSBI N 203389 001 10905662 Aug 16, 2036 U-1399

CYSTEAMINE BITARTRATE - PROCYSBI N 203389 002 10905662 Aug 16, 2036 U-1399

CYSTEAMINE BITARTRATE - PROCYSBI N 213491 001 10905662 Aug 16, 2036 U-1399 ODE* Aug 14, 2022 8026284 Sep 22, 2027 U-1399 ODE* Dec 22, 2024 8026284*PED Mar 22, 2028 PED Feb 14, 2023 9173851 Jun 17, 2034 DP 9173851*PED Dec 17, 2034 9192590 Jan 26, 2027 U-1399 9192590*PED Jul 26, 2027 9198882 Jan 26, 2027 U-1399 9198882*PED Jul 26, 2027 9233077 Jun 17, 2034 DP 9233077*PED Dec 17, 2034

CYSTEAMINE BITARTRATE - PROCYSBI N 213491 002 10905662 Aug 16, 2036 U-1399 ODE* Aug 14, 2022 8026284 Sep 22, 2027 U-1399 ODE* Dec 22, 2024 8026284*PED Mar 22, 2028 PED Feb 14, 2023 9173851 Jun 17, 2034 DP 9173851*PED Dec 17, 2034 9192590 Jan 26, 2027 U-1399 9192590*PED Jul 26, 2027 9198882 Jan 26, 2027 U-1399 9198882*PED Jul 26, 2027 9233077 Jun 17, 2034 DP 9233077*PED Dec 17, 2034 A - 12 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

CYSTEAMINE BITARTRATE - PROCYSBI N 213491 002 10905662 Aug 16, 2036 U-1399 ODE* Aug 14, 2022 8026284 Sep 22, 2027 U-1399 ODE* Dec 22, 2024 8026284*PED Mar 22, 2028 PED Feb 14, 2023 9173851 Jun 17, 2034 DP 9173851*PED Dec 17, 2034 9192590 Jan 26, 2027 U-1399 9192590*PED Jul 26, 2027 9198882 Jan 26, 2027 U-1399 9198882*PED Jul 26, 2027 9233077 Jun 17, 2034 DP 9233077*PED Dec 17, 2034

CYSTEINE HYDROCHLORIDE - ELCYS N 210660 001 10905713 Jan 15, 2039 DP 10905714 Jan 15, 2039 DP 10912795 Jan 15, 2039 DP 10918662 Jan 15, 2039 DP 10933089 Jan 15, 2039 DP

CYSTEINE HYDROCHLORIDE - NOURESS N 212535 001 10905713 Jan 15, 2039 DP 10905714 Jan 15, 2039 DP 10912795 Jan 15, 2039 DP 10918662 Jan 15, 2039 DP 10933089 Jan 15, 2039 DP 11045438 Mar 15, 2039 DP

CYTARABINE; DAUNORUBICIN - VYXEOS N 209401 001 10028912 Sep 29, 2034 DP U-3149 NPP Mar 30, 2024 10028912 Sep 29, 2034 DP U-3150 ODE-350 Mar 30, 2028 10166184 Oct 15, 2032 DP U-3149 10835492 Oct 15, 2032 U-3150 7850990 Jan 23, 2027 DP U-3147 8022279 Sep 14, 2027 DP U-3147 8092828 Apr 01, 2029 U-3147 8431806 Apr 22, 2025 DP U-3147

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 022512 001 6087380 Dec 28, 2021 DS DP U-1931 I-862 Jun 21, 2024 6087380*PED Jun 28, 2022 PED Dec 21, 2024 9034822 Jan 20, 2031 U-1759 9034822*PED Jul 20, 2031 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 022512 002 6087380 Dec 28, 2021 DS DP U-1931 I-862 Jun 21, 2024 6087380*PED Jun 28, 2022 PED Dec 21, 2024 9034822 Jan 20, 2031 U-1759 9034822*PED Jul 20, 2031 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 022512 003 6087380 Dec 28, 2021 DS DP U-1931 I-862 Jun 21, 2024 6087380*PED Jun 28, 2022 PED Dec 21, 2024 7866474 Aug 31, 2027 DP Y 7866474*PED Mar 02, 2028 7932273 Sep 07, 2025 DS DP 7932273*PED Mar 07, 2026 9034822 Jan 20, 2031 U-1759 9034822*PED Jul 20, 2031 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023 A - 13 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 001 >A> 6087380 Dec 28, 2021 DS DP U-3177 NP Jun 21, 2024 >A> 6087380 Dec 28, 2021 DS DP U-3178 PED Dec 21, 2024 >A> 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 DS DP 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 002 >A> 6087380 Dec 28, 2021 DS DP U-3177 NP Jun 21, 2024 >A> 6087380 Dec 28, 2021 DS DP U-3178 PED Dec 21, 2024 >A> 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 DS DP 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 003 >A> 6087380 Dec 28, 2021 DS DP U-3177 NP Jun 21, 2024 >A> 6087380 Dec 28, 2021 DS DP U-3178 PED Dec 21, 2024 >A> 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 DS DP 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 004 >A> 6087380 Dec 28, 2021 DS DP U-3177 NP Jun 21, 2024 >A> 6087380 Dec 28, 2021 DS DP U-3178 PED Dec 21, 2024 >A> 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 DS DP 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 005 >A> 6087380 Dec 28, 2021 DS DP U-3177 NP Jun 21, 2024 >A> 6087380 Dec 28, 2021 DS DP U-3178 PED Dec 21, 2024 >A> 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 DS DP 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 006 >A> 6087380 Dec 28, 2021 DS DP U-3177 NP Jun 21, 2024 >A> 6087380 Dec 28, 2021 DS DP U-3178 PED Dec 21, 2024 >A> 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 DS DP 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 DP 9925174*PED Dec 14, 2023

DABRAFENIB MESYLATE - TAFINLAR N 202806 001 >A> 10869869 Aug 30, 2033 U-3185 >A> 8703781 Oct 15, 2030 DS DP U-1713 >A> 8703781 Oct 15, 2030 DS DP U-2032 >A> 8703781 Oct 15, 2030 DS DP U-2296 >A> 8703781 Oct 15, 2030 DS DP U-2298 9233956 May 04, 2029 U-1811 9233956 May 04, 2029 U-2031 9233956 May 04, 2029 U-2032 9233956 May 04, 2029 U-2296 A - 14 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

DABRAFENIB MESYLATE - TAFINLAR N 202806 002 >A> 10869869 Aug 30, 2033 U-3185 >A> 8703781 Oct 15, 2030 DS DP U-1713 >A> 8703781 Oct 15, 2030 DS DP U-2032 >A> 8703781 Oct 15, 2030 DS DP U-2296 >A> 8703781 Oct 15, 2030 DS DP U-2298 9233956 May 04, 2029 U-1811 9233956 May 04, 2029 U-2031 9233956 May 04, 2029 U-2032 9233956 May 04, 2029 U-2296

DALBAVANCIN HYDROCHLORIDE - DALVANCE N 021883 001 >A> NPP Jul 22, 2024

DAPAGLIFLOZIN - FARXIGA N 202293 001 I-857 Apr 30, 2024

DAPAGLIFLOZIN - FARXIGA N 202293 002 10973836 Mar 09, 2040 U-3127 I-857 Apr 30, 2024

DAPTOMYCIN - DAPTOMYCIN N 210282 001 10357535 Sep 11, 2033 DP U-3176 9655946 Sep 11, 2033 DP U-3175

DAPTOMYCIN - DAPTOMYCIN N 210282 002 10357535 Sep 11, 2033 DP U-3176 9655946 Sep 11, 2033 DP U-3175

DAROLUTAMIDE - NUBEQA N 212099 001 11046713 Oct 27, 2030 DS

DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE N 214231 001 10442847 Feb 03, 2035 DS DP NCE Mar 22, 2026

DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR) N 214231 002 10442847 Feb 03, 2035 DS DP NCE Mar 22, 2026

DEFERIPRONE - DEFERIPRONE A 208800 001 PC Mar 27, 2021

DEFERIPRONE - FERRIPROX N 021825 001 7049328 Jun 28, 2021 U-3083 I-859 Apr 30, 2024

DEFERIPRONE - FERRIPROX N 021825 002 7049328 Jun 28, 2021 U-3083 I-859 Apr 30, 2024

DEFERIPRONE - FERRIPROX N 208030 001 7049328 Jun 28, 2021 U-3083 I-859 Apr 30, 2024 8703156 Oct 26, 2029 DP U-3083

DEFERIPRONE - FERRIPROX N 208030 002 7049328 Jun 28, 2021 U-3083 I-859 Apr 30, 2024 8703156 Oct 26, 2029 DP U-3083

DEFERIPRONE - FERRIPROX N 212269 001 10780055 Oct 25, 2038 DP U-3083 I-859 Apr 30, 2024 10940115 Oct 25, 2038 DP U-3083 10940116 Oct 25, 2038 DP 7049328 Jun 28, 2021 U-3083

DEFIBROTIDE SODIUM - DEFITELIO N 208114 001 >A> 11085043 Jun 22, 2032 DP A - 15 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

DEGARELIX ACETATE - FIRMAGON N 022201 001 10973870 Feb 10, 2029 U-1978

DEGARELIX ACETATE - FIRMAGON N 022201 002 10973870 Feb 10, 2029 U-1978

DESMOPRESSIN ACETATE - NOCDURNA N 022517 001 11020448 May 21, 2029 U-2327

DEUTETRABENAZINE - AUSTEDO N 208082 001 10959996 Mar 07, 2036 U-3055 M-54 Jun 24, 2024 10959996*PED Sep 07, 2036 NCE Apr 03, 2022 8524733 Apr 03, 2031 DS DP ODE-134 Apr 03, 2024 8524733*PED Oct 03, 2031 PED Oct 03, 2022 9233959 Sep 18, 2033 DP PED Oct 03, 2024 9233959*PED Mar 18, 2034 PED Dec 24, 2024 9296739 Sep 18, 2033 DP 9296739*PED Mar 18, 2034 9550780 Sep 18, 2033 DS DP U-1995 9550780 Sep 18, 2033 DS DP U-3055 9550780*PED Mar 18, 2034 9814708 Sep 18, 2033 DP 9814708*PED Mar 18, 2034

DEUTETRABENAZINE - AUSTEDO N 208082 002 10959996 Mar 07, 2036 U-3055 M-54 Jun 24, 2024 10959996*PED Sep 07, 2036 NCE Apr 03, 2022 8524733 Apr 03, 2031 DS DP ODE-134 Apr 03, 2024 8524733*PED Oct 03, 2031 PED Oct 03, 2022 9233959 Sep 18, 2033 DP PED Oct 03, 2024 9233959*PED Mar 18, 2034 PED Dec 24, 2024 9296739 Sep 18, 2033 DP 9296739*PED Mar 18, 2034 9550780 Sep 18, 2033 DS DP U-1995 9550780 Sep 18, 2033 DS DP U-3055 9550780*PED Mar 18, 2034 9814708 Sep 18, 2033 DP 9814708*PED Mar 18, 2034

DEUTETRABENAZINE - AUSTEDO N 208082 003 10959996 Mar 07, 2036 U-3055 M-54 Jun 24, 2024 10959996*PED Sep 07, 2036 NCE Apr 03, 2022 8524733 Apr 03, 2031 DS DP ODE-134 Apr 03, 2024 8524733*PED Oct 03, 2031 PED Oct 03, 2022 9233959 Sep 18, 2033 DP PED Oct 03, 2024 9233959*PED Mar 18, 2034 PED Dec 24, 2024 9296739 Sep 18, 2033 DP 9296739*PED Mar 18, 2034 9550780 Sep 18, 2033 DS DP U-1995 9550780 Sep 18, 2033 DS DP U-3055 9550780*PED Mar 18, 2034 9814708 Sep 18, 2033 DP 9814708*PED Mar 18, 2034

DEXAMETHASONE - DEXYCU KIT N 208912 001 10799642 May 11, 2032 DP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS N 212994 001 10584112 Dec 09, 2037 DS DP NCE May 07, 2026 10584113 Dec 09, 2037 DP 10759778 Dec 09, 2037 DP 10858341 Dec 09, 2037 U-3094 10954213 Dec 09, 2037 U-3094 9079928 Jul 27, 2032 DP A - 16 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS N 212994 002 10584112 Dec 09, 2037 DS DP NCE May 07, 2026 10584113 Dec 09, 2037 DP 10759778 Dec 09, 2037 DP 10858341 Dec 09, 2037 U-3094 10954213 Dec 09, 2037 U-3094 9079928 Jul 27, 2032 DP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS N 212994 003 10584112 Dec 09, 2037 DS DP NCE May 07, 2026 10584113 Dec 09, 2037 DP 10759778 Dec 09, 2037 DP 10858341 Dec 09, 2037 U-3094 10954213 Dec 09, 2037 U-3094 9079928 Jul 27, 2032 DP

DICLOFENAC POTASSIUM - ZIPSOR N 022202 001 NPP May 25, 2024

DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE A 212317 001 CGT Sep 26, 2021

DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE A 212317 002 CGT Sep 26, 2021

DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE A 212317 003 CGT Sep 26, 2021

DIMETHYL FUMARATE - TECFIDERA N 204063 001 10391160 Mar 13, 2035 U-3148 10555993 Mar 13, 2035 U-3148 10959972 Nov 16, 2035 U-1384 10994003 Mar 13, 2035 U-3148 11007166 Nov 16, 2035 U-1384 11007167 Nov 16, 2035 U-1384

DIMETHYL FUMARATE - TECFIDERA N 204063 002 10391160 Mar 13, 2035 U-3148 10555993 Mar 13, 2035 U-3148 10959972 Nov 16, 2035 U-1384 10994003 Mar 13, 2035 U-3148 11007166 Nov 16, 2035 U-1384 11007167 Nov 16, 2035 U-1384

DOCETAXEL - DOCETAXEL N 205934 001 10842770 Aug 07, 2031 DP U-2998

DOCETAXEL - DOCETAXEL N 205934 002 10842770 Aug 07, 2031 DP U-2998

DOCETAXEL - DOCETAXEL N 205934 003 10842770 Aug 07, 2031 DP U-2998

DROSPIRENONE - SLYND N 211367 001 >A> 10603281 Jun 28, 2031 U-2553 >A> 10849857 Jun 28, 2031 DP U-2553 10987364 Jun 28, 2031 DP

DROSPIRENONE; ESTETROL - NEXTSTELLIS N 214154 001 7732430 Mar 02, 2025 DP U-3152 NCE Apr 15, 2026

DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 001 10959982 Apr 13, 2037 DP A - 17 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 002 10959982 Apr 13, 2037 DP

DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 003 10959982 Apr 13, 2037 DP

DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 004 10959982 Apr 13, 2037 DP

EDARAVONE - RADICAVA N 209176 002 ODE* May 05, 2024

EDOXABAN TOSYLATE - SAVAYSA N 206316 001 7365205 Apr 18, 2027 DS

EDOXABAN TOSYLATE - SAVAYSA N 206316 002 7365205 Apr 18, 2027 DS

EDOXABAN TOSYLATE - SAVAYSA N 206316 003 7365205 Apr 18, 2027 DS

EFINACONAZOLE - JUBLIA N 203567 001 10864274 Oct 02, 2034 U-2720 7214506 Feb 22, 2026 U-281

ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; SODIUM - ORIAHNN (COPACKAGED) N 213388 001 10881659 Mar 14, 2034 U-2842 11045470 Mar 14, 2034 U-2842

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) N 212273 001 10022352 Apr 09, 2027 DP U-2651 NPP Jun 08, 2024 10022352 Apr 09, 2027 DP U-3156 ODE-323 Dec 21, 2027 10081621 Mar 25, 2031 DP U-2652 ODE-357 Jun 08, 2028 10081621 Mar 25, 2031 DP U-3032 10081621 Mar 25, 2031 DP U-3157 10239867 Apr 09, 2027 DS DP U-2653 10239867 Apr 09, 2027 DS DP U-3033 10239867 Apr 09, 2027 DS DP U-3158 10758534 Oct 06, 2035 DS DP U-2645 10758534 Oct 06, 2035 DS DP U-3028 10758534 Oct 06, 2035 DS DP U-3144 10793547 Dec 08, 2037 DS DP U-2645 10793547 Dec 08, 2037 DS DP U-3028 10793547 Dec 08, 2037 DS DP U-3144 8324242 Aug 05, 2027 U-2645 8324242 Aug 05, 2027 U-3028 8324242 Aug 05, 2027 U-3144 8354427 Jul 06, 2026 U-2646 8354427 Jul 06, 2026 U-3029 8354427 Jul 06, 2026 U-3145 8415387 Nov 12, 2027 U-2645 8415387 Nov 12, 2027 U-3028 8415387 Nov 12, 2027 U-3144 8598181 May 01, 2027 U-2645 8598181 May 01, 2027 U-3028 8598181 May 01, 2027 U-3144 8629162 Jun 24, 2025 U-2648 8629162 Jun 24, 2025 U-3030 8629162 Jun 24, 2025 U-3146 9012496 Jul 15, 2033 U-2649 9012496 Jul 15, 2033 U-3154 9670163 Dec 28, 2026 DP U-2650 9670163 Dec 28, 2026 DP U-3031 9670163 Dec 28, 2026 DP U-3155 9931334 Dec 28, 2026 DP U-2650 9931334 Dec 28, 2026 DP U-3031 A - 18 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) N 212273 001 9931334 Dec 28, 2026 DP U-3155 9974781 Apr 09, 2027 DP U-2645 9974781 Apr 09, 2027 DP U-3028 9974781 Apr 09, 2027 DP U-3144

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) N 212273 002 10022352 Apr 09, 2027 DP U-3156 NCE Feb 12, 2023 10081621 Mar 25, 2031 DP U-3157 NCE Oct 21, 2024 10239867 Apr 09, 2027 DS DP U-3158 NPP Jun 08, 2024 10646481 Aug 13, 2029 DP ODE-357 Jun 08, 2028 10758534 Oct 06, 2035 DS DP U-3144 10793547 Dec 08, 2037 DS DP U-3144 7495103 May 20, 2027 DS DP 7645789 May 01, 2027 DS DP 7776905 Jun 03, 2027 DS DP 8324242 Aug 05, 2027 U-3144 8354427 Jul 06, 2026 U-3145 8410274 Dec 28, 2026 DP 8415387 Nov 12, 2027 U-3144 8598181 May 01, 2027 U-3144 8623905 May 01, 2027 DS DP 8629162 Jun 24, 2025 U-3146 8754224 Dec 28, 2026 DS DP 9012496 Jul 15, 2033 U-3154 9670163 Dec 28, 2026 DP U-3155 9931334 Dec 28, 2026 DP U-3155 9974781 Apr 09, 2027 DP U-3144

ELIGLUSTAT TARTRATE - CERDELGA N 205494 001 10888544 Dec 13, 2038 U-3040 10888544 Dec 13, 2038 U-3041 10888547 Jan 31, 2031 U-3042 10888547 Jan 31, 2031 U-3043

ELTROMBOPAG OLAMINE - PROMACTA KIT N 207027 001 ODE* Nov 16, 2025

ELTROMBOPAG OLAMINE - PROMACTA KIT N 207027 002 ODE* Aug 26, 2021 ODE* Nov 16, 2025 PED Feb 26, 2022

ELUXADOLINE - VIBERZI N 206940 001 11007179 Mar 14, 2033 DP >A> 11090291 Mar 14, 2033 DP

ELUXADOLINE - VIBERZI N 206940 002 11007179 Mar 14, 2033 DP >A> 11090291 Mar 14, 2033 DP

EMPAGLIFLOZIN - JARDIANCE N 204629 001 >A> 11090323 Apr 03, 2034 U-3191 >A> 9949997 May 17, 2034 U-2292 >A> 9949997 May 17, 2034 U-3199

EMPAGLIFLOZIN - JARDIANCE N 204629 002 >A> 11090323 Apr 03, 2034 U-3191

EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 001 11033552 May 04, 2027 DP >A> 11090323 Apr 03, 2034 U-3191 A - 19 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 002 11033552 May 04, 2027 DP >A> 11090323 Apr 03, 2034 U-3191

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 001 >A> 11090323 Apr 03, 2034 U-3192

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 002 >A> 11090323 Apr 03, 2034 U-3192

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 003 >A> 11090323 Apr 03, 2034 U-3192

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 004 >A> 11090323 Apr 03, 2034 U-3192

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 001 >A> 11090323 Apr 03, 2034 U-3193

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 002 >A> 11090323 Apr 03, 2034 U-3193

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 003 >A> 11090323 Apr 03, 2034 U-3193

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 004 >A> 11090323 Apr 03, 2034 U-3193

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 001 >A> 11090323 Apr 03, 2034 U-3193

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 002 >A> 11090323 Apr 03, 2034 U-3193

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 003 >A> 11090323 Apr 03, 2034 U-3193

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 004 >A> 11090323 Apr 03, 2034 U-3193

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE A 209721 001 PC Mar 09, 2021

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE A 209721 002 PC Mar 09, 2021

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE A 209721 003 PC Mar 09, 2021

ENALAPRIL MALEATE - ENALAPRIL MALEATE A 212408 001 >A> PC Feb 13, 2022

ENALAPRIL MALEATE - EPANED N 208686 001 11040023 Mar 25, 2036 DP

EPHEDRINE SULFATE - EMERPHED N 213407 001 >A> 11090278 May 16, 2040 U-3183

EPINEPHRINE - AUVI-Q N 201739 001 10960155 Jun 25, 2026 DP A - 20 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

EPINEPHRINE - AUVI-Q N 201739 002 10842938 Dec 21, 2037 DP U-2980 10960155 Jun 25, 2026 DP

EPINEPHRINE - AUVI-Q N 201739 003 10842938 Dec 21, 2037 DP U-2980 10960155 Jun 25, 2026 DP

ERDAFITINIB - BALVERSA N 212018 001 10898482 Feb 09, 2036 DP U-2518 10898482 Feb 09, 2036 DP U-3065 10898482 Feb 09, 2036 DP U-3066 10898482 Feb 09, 2036 DP U-3067 >A> 11077106 Feb 02, 2038 U-3196

ERDAFITINIB - BALVERSA N 212018 002 10898482 Feb 09, 2036 DP U-2518 10898482 Feb 09, 2036 DP U-3065 10898482 Feb 09, 2036 DP U-3066 10898482 Feb 09, 2036 DP U-3067 >A> 11077106 Feb 02, 2038 U-3196

ERDAFITINIB - BALVERSA N 212018 003 10898482 Feb 09, 2036 DP U-2518 10898482 Feb 09, 2036 DP U-3065 10898482 Feb 09, 2036 DP U-3066 10898482 Feb 09, 2036 DP U-3067 >A> 11077106 Feb 02, 2038 U-3196

ESKETAMINE HYDROCHLORIDE - SPRAVATO N 211243 001 10869844 Sep 10, 2035 U-3034 10869844 Sep 10, 2035 U-3035 10869844 Sep 10, 2035 U-3036

ESLICARBAZEPINE ACETATE - APTIOM N 022416 001 10912781 Oct 23, 2028 DP

ESLICARBAZEPINE ACETATE - APTIOM N 022416 002 10912781 Oct 23, 2028 DP

ESLICARBAZEPINE ACETATE - APTIOM N 022416 003 10912781 Oct 23, 2028 DP

ESLICARBAZEPINE ACETATE - APTIOM N 022416 004 10912781 Oct 23, 2028 DP

ESTRADIOL - IMVEXXY N 208564 001 10888516 Jun 18, 2033 U-2316 10888516 Jun 18, 2033 U-2317 11065197 Jun 18, 2033 DP

ESTRADIOL - IMVEXXY N 208564 002 10888516 Jun 18, 2033 U-2316 10888516 Jun 18, 2033 U-2317 11065197 Jun 18, 2033 DP

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE N 214846 001 11033551 Sep 29, 2037 U-3129 NCE Dec 18, 2025 7300935 Jan 28, 2024 DS NP May 26, 2024 8058280 Jan 28, 2024 DS DP 9346822 Feb 17, 2024 U-3129 A - 21 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

ESTRADIOL; - BIJUVA N 210132 001 11033626 Nov 21, 2032 DP U-2439

ETEPLIRSEN - EXONDYS 51 N 206488 001 RE47769 Feb 02, 2029 DP RE48468 Oct 27, 2028 U-2097

ETEPLIRSEN - EXONDYS 51 N 206488 002 RE47769 Feb 02, 2029 DP RE48468 Oct 27, 2028 U-2097

ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME N 209405 001 NDF Mar 30, 2023

ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN A 213950 001 CGT Aug 25, 2021

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE A 212706 001 CGT Jul 17, 2021

ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA N 209627 001 10918649 Jun 21, 2039 DP 10925882 Jun 21, 2039 DP 10940157 Jun 21, 2039 DP

EXENATIDE SYNTHETIC - BYDUREON N 022200 001 6515117 Oct 04, 2025 DS DP U-2588 M-240 Feb 15, 2022 6515117*PED Apr 04, 2026 >A> NPP Jul 22, 2024 >A> 7456254 Jun 30, 2025 DP U-2588 PED Aug 15, 2023 >A> 7456254 Jun 30, 2025 DP U-2589 >A> PED Jan 22, 2025 >A> 7456254 Jun 30, 2025 DP U-2590 >A> 7456254 Jun 30, 2025 DP U-3188 >A> 7456254 Jun 30, 2025 DP U-3189 >A> 7456254 Jun 30, 2025 DP U-3190 >A> 7456254*PED Dec 30, 2025 >A> 7612176 Apr 13, 2025 DP U-2588 >A> 7612176 Apr 13, 2025 DP U-2589 >A> 7612176 Apr 13, 2025 DP U-2590 >A> 7612176 Apr 13, 2025 DP U-3188 >A> 7612176 Apr 13, 2025 DP U-3189 >A> 7612176 Apr 13, 2025 DP U-3190 >A> 7612176*PED Oct 13, 2025 >A> 8329648 Aug 18, 2026 U-2588 >A> 8329648 Aug 18, 2026 U-2589 >A> 8329648 Aug 18, 2026 U-2590 >A> 8329648 Aug 18, 2026 U-2593 >A> 8329648 Aug 18, 2026 U-2594 >A> 8329648 Aug 18, 2026 U-2595 >A> 8329648 Aug 18, 2026 U-2596 >A> 8329648 Aug 18, 2026 U-3188 >A> 8329648 Aug 18, 2026 U-3189 >A> 8329648 Aug 18, 2026 U-3190 >A> 8329648*PED Feb 18, 2027 8361972 Mar 21, 2028 U-2588 8361972*PED Sep 21, 2028 >A> 8431685 Apr 13, 2025 DP U-2588 >A> 8431685 Apr 13, 2025 DP U-2589 >A> 8431685 Apr 13, 2025 DP U-2590 >A> 8431685 Apr 13, 2025 DP U-3188 >A> 8431685 Apr 13, 2025 DP U-3189 >A> 8431685 Apr 13, 2025 DP U-3190 >A> 8431685*PED Oct 13, 2025 >A> 8461105 Apr 13, 2025 DP U-2588 >A> 8461105 Apr 13, 2025 DP U-2589 >A> 8461105 Apr 13, 2025 DP U-2590 >A> 8461105 Apr 13, 2025 DP U-3188 >A> 8461105 Apr 13, 2025 DP U-3189 A - 22 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

EXENATIDE SYNTHETIC - BYDUREON N 022200 001 >A> 8461105 Apr 13, 2025 DP U-3190 >A> 8461105*PED Oct 13, 2025 8501698 Jun 20, 2027 DP U-2588 8501698*PED Dec 20, 2027 >A> 8906851 Aug 18, 2026 U-2588 >A> 8906851 Aug 18, 2026 U-2589 >A> 8906851 Aug 18, 2026 U-2590 >A> 8906851 Aug 18, 2026 U-2593 >A> 8906851 Aug 18, 2026 U-3188 >A> 8906851 Aug 18, 2026 U-3189 >A> 8906851 Aug 18, 2026 U-3190 >A> 8906851*PED Feb 18, 2027 >A> 9238076 Apr 15, 2024 DP U-2588 >A> 9238076 Apr 15, 2024 DP U-2589 >A> 9238076 Apr 15, 2024 DP U-2590 >A> 9238076 Apr 15, 2024 DP U-2599 >A> 9238076 Apr 15, 2024 DP U-3188 >A> 9238076 Apr 15, 2024 DP U-3189 >A> 9238076 Apr 15, 2024 DP U-3190 >A> 9238076*PED Oct 15, 2024 >A> 9884092 Aug 18, 2026 U-2588 >A> 9884092 Aug 18, 2026 U-2589 >A> 9884092 Aug 18, 2026 U-2590 >A> 9884092 Aug 18, 2026 U-2593 >A> 9884092 Aug 18, 2026 U-2594 >A> 9884092 Aug 18, 2026 U-2595 >A> 9884092 Aug 18, 2026 U-2596 >A> 9884092 Aug 18, 2026 U-3188 >A> 9884092 Aug 18, 2026 U-3189 >A> 9884092 Aug 18, 2026 U-3190 >A> 9884092*PED Feb 18, 2027

EXENATIDE SYNTHETIC - BYDUREON PEN N 022200 002 6515117 Oct 04, 2025 DS DP U-2588 M-240 Feb 15, 2022 6515117*PED Apr 04, 2026 >A> NPP Jul 22, 2024 6824822 Oct 09, 2022 DP PED Aug 15, 2023 6824822*PED Apr 09, 2023 >A> PED Jan 22, 2025 7223440 Aug 31, 2021 DP 7223440*PED Mar 03, 2022 >A> 7456254 Jun 30, 2025 DP U-2588 >A> 7456254 Jun 30, 2025 DP U-2589 >A> 7456254 Jun 30, 2025 DP U-2590 >A> 7456254 Jun 30, 2025 DP U-3188 >A> 7456254 Jun 30, 2025 DP U-3189 >A> 7456254 Jun 30, 2025 DP U-3190 >A> 7456254*PED Dec 30, 2025 7563871 Apr 15, 2024 DP 7563871*PED Oct 15, 2024 >A> 7612176 Apr 13, 2025 DP U-2588 >A> 7612176 Apr 13, 2025 DP U-2589 >A> 7612176 Apr 13, 2025 DP U-2590 >A> 7612176 Apr 13, 2025 DP U-3188 >A> 7612176 Apr 13, 2025 DP U-3189 >A> 7612176 Apr 13, 2025 DP U-3190 >A> 7612176*PED Oct 13, 2025 8216180 Jan 12, 2028 DP 8216180*PED Jul 12, 2028 >A> 8329648 Aug 18, 2026 U-2588 >A> 8329648 Aug 18, 2026 U-2589 >A> 8329648 Aug 18, 2026 U-2590 >A> 8329648 Aug 18, 2026 U-2593 >A> 8329648 Aug 18, 2026 U-2594 >A> 8329648 Aug 18, 2026 U-2595 >A> 8329648 Aug 18, 2026 U-2596 >A> 8329648 Aug 18, 2026 U-3188 >A> 8329648 Aug 18, 2026 U-3189 >A> 8329648 Aug 18, 2026 U-3190 >A> 8329648*PED Feb 18, 2027 A - 23 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

EXENATIDE SYNTHETIC - BYDUREON PEN N 022200 002 8361972 Mar 21, 2028 U-2588 8361972*PED Sep 21, 2028 >A> 8431685 Apr 13, 2025 DP U-2588 >A> 8431685 Apr 13, 2025 DP U-2589 >A> 8431685 Apr 13, 2025 DP U-2590 >A> 8431685 Apr 13, 2025 DP U-3188 >A> 8431685 Apr 13, 2025 DP U-3189 >A> 8431685 Apr 13, 2025 DP U-3190 >A> 8431685*PED Oct 13, 2025 8439864 Mar 25, 2028 DP 8439864*PED Sep 25, 2028 >A> 8461105 Apr 13, 2025 DP U-2588 >A> 8461105 Apr 13, 2025 DP U-2589 >A> 8461105 Apr 13, 2025 DP U-2590 >A> 8461105 Apr 13, 2025 DP U-3188 >A> 8461105 Apr 13, 2025 DP U-3189 >A> 8461105 Apr 13, 2025 DP U-3190 >A> 8461105*PED Oct 13, 2025 8501698 Jun 20, 2027 DP U-2588 8501698*PED Dec 20, 2027 8690837 May 19, 2029 DP 8690837*PED Nov 19, 2029 8721615 Jan 18, 2030 DP 8721615*PED Jul 18, 2030 8758292 Nov 12, 2027 DP 8758292*PED May 12, 2028 8827963 Feb 04, 2029 DP 8827963*PED Aug 04, 2029 >A> 8906851 Aug 18, 2026 U-2588 >A> 8906851 Aug 18, 2026 U-2589 >A> 8906851 Aug 18, 2026 U-2590 >A> 8906851 Aug 18, 2026 U-2593 >A> 8906851 Aug 18, 2026 U-3188 >A> 8906851 Aug 18, 2026 U-3189 >A> 8906851 Aug 18, 2026 U-3190 >A> 8906851*PED Feb 18, 2027 8998876 Jan 07, 2030 DP 8998876*PED Jul 07, 2030 >A> 9238076 Apr 15, 2024 DP U-2588 >A> 9238076 Apr 15, 2024 DP U-2589 >A> 9238076 Apr 15, 2024 DP U-2590 >A> 9238076 Apr 15, 2024 DP U-2599 >A> 9238076 Apr 15, 2024 DP U-3188 >A> 9238076 Apr 15, 2024 DP U-3189 >A> 9238076 Apr 15, 2024 DP U-3190 >A> 9238076*PED Oct 15, 2024 9320853 Mar 25, 2028 DP 9320853*PED Sep 25, 2028 >A> 9884092 Aug 18, 2026 U-2588 >A> 9884092 Aug 18, 2026 U-2589 >A> 9884092 Aug 18, 2026 U-2590 >A> 9884092 Aug 18, 2026 U-2593 >A> 9884092 Aug 18, 2026 U-2594 >A> 9884092 Aug 18, 2026 U-2595 >A> 9884092 Aug 18, 2026 U-2596 >A> 9884092 Aug 18, 2026 U-3188 >A> 9884092 Aug 18, 2026 U-3189 >A> 9884092 Aug 18, 2026 U-3190 >A> 9884092*PED Feb 18, 2027

EXENATIDE SYNTHETIC - BYDUREON BCISE N 209210 001 6515117 Oct 04, 2025 DS DP U-2588 M-240 Feb 15, 2022 6515117*PED Apr 04, 2026 >A> NPP Jul 22, 2024 6824822 Oct 09, 2022 DP PED Aug 15, 2023 6824822*PED Apr 09, 2023 >A> PED Jan 22, 2025 7223440 Aug 31, 2021 DP 7223440*PED Mar 03, 2022 >A> 7456254 Jun 30, 2025 DP U-2588 A - 24 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

EXENATIDE SYNTHETIC - BYDUREON BCISE N 209210 001 >A> 7456254 Jun 30, 2025 DP U-2589 >A> 7456254 Jun 30, 2025 DP U-2590 >A> 7456254 Jun 30, 2025 DP U-3188 >A> 7456254 Jun 30, 2025 DP U-3189 >A> 7456254 Jun 30, 2025 DP U-3190 >A> 7456254*PED Dec 30, 2025 7563871 Apr 15, 2024 DP 7563871*PED Oct 15, 2024 >A> 7612176 Apr 13, 2025 DP U-2589 >A> 7612176 Apr 13, 2025 DP U-2590 >A> 7612176 Apr 13, 2025 DP U-3188 >A> 7612176 Apr 13, 2025 DP U-3189 >A> 7612176 Apr 13, 2025 DP U-3190 >A> 7612176*PED Oct 13, 2025 >A> 8329648 Aug 18, 2026 U-2588 >A> 8329648 Aug 18, 2026 U-2589 >A> 8329648 Aug 18, 2026 U-2590 >A> 8329648 Aug 18, 2026 U-2593 >A> 8329648 Aug 18, 2026 U-2594 >A> 8329648 Aug 18, 2026 U-2595 >A> 8329648 Aug 18, 2026 U-2596 >A> 8329648 Aug 18, 2026 U-3188 >A> 8329648 Aug 18, 2026 U-3189 >A> 8329648 Aug 18, 2026 U-3190 >A> 8329648*PED Feb 18, 2027 8361972 Mar 21, 2028 U-2588 8361972*PED Sep 21, 2028 >A> 8431685 Apr 13, 2025 DP U-2588 >A> 8431685 Apr 13, 2025 DP U-2589 >A> 8431685 Apr 13, 2025 DP U-2590 >A> 8431685 Apr 13, 2025 DP U-2597 >A> 8431685 Apr 13, 2025 DP U-3188 >A> 8431685 Apr 13, 2025 DP U-3189 >A> 8431685 Apr 13, 2025 DP U-3190 >A> 8431685*PED Oct 13, 2025 >A> 8461105 Apr 13, 2025 DP U-2588 >A> 8461105 Apr 13, 2025 DP U-2589 >A> 8461105 Apr 13, 2025 DP U-2590 >A> 8461105 Apr 13, 2025 DP U-2597 >A> 8461105 Apr 13, 2025 DP U-3188 >A> 8461105 Apr 13, 2025 DP U-3189 >A> 8461105 Apr 13, 2025 DP U-3190 >A> 8461105*PED Oct 13, 2025 8501698 Jun 20, 2027 U-2588 8501698*PED Dec 20, 2027 >A> 8895033 Oct 04, 2030 DP U-2589 >A> 8895033 Oct 04, 2030 DP U-2590 >A> 8895033 Oct 04, 2030 DP U-2597 >A> 8895033 Oct 04, 2030 DP U-2601 >A> 8895033 Oct 04, 2030 DP U-2602 >A> 8895033 Oct 04, 2030 DP U-3188 >A> 8895033 Oct 04, 2030 DP U-3189 >A> 8895033 Oct 04, 2030 DP U-3190 >A> 8895033*PED Apr 04, 2031 >A> 8906851 Aug 18, 2026 U-2588 >A> 8906851 Aug 18, 2026 U-2589 >A> 8906851 Aug 18, 2026 U-2590 >A> 8906851 Aug 18, 2026 U-2593 >A> 8906851 Aug 18, 2026 U-2597 >A> 8906851 Aug 18, 2026 U-3188 >A> 8906851 Aug 18, 2026 U-3189 >A> 8906851 Aug 18, 2026 U-3190 >A> 8906851*PED Feb 18, 2027 >A> 9238076 Apr 15, 2024 DP U-2588 >A> 9238076 Apr 15, 2024 DP U-2589 >A> 9238076 Apr 15, 2024 DP U-2590 >A> 9238076 Apr 15, 2024 DP U-2597 >A> 9238076 Apr 15, 2024 DP U-2599 >A> 9238076 Apr 15, 2024 DP U-3188 A - 25 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

EXENATIDE SYNTHETIC - BYDUREON BCISE N 209210 001 >A> 9238076 Apr 15, 2024 DP U-3189 >A> 9238076 Apr 15, 2024 DP U-3190 >A> 9238076*PED Oct 15, 2024 >A> 9884092 Aug 18, 2026 U-2588 >A> 9884092 Aug 18, 2026 U-2589 >A> 9884092 Aug 18, 2026 U-2590 >A> 9884092 Aug 18, 2026 U-2593 >A> 9884092 Aug 18, 2026 U-2594 >A> 9884092 Aug 18, 2026 U-2595 >A> 9884092 Aug 18, 2026 U-2596 >A> 9884092 Aug 18, 2026 U-2597 >A> 9884092 Aug 18, 2026 U-3188 >A> 9884092 Aug 18, 2026 U-3189 >A> 9884092 Aug 18, 2026 U-3190 >A> 9884092*PED Feb 18, 2027

EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 001 10376470 May 01, 2033 DP U-3095 9763885 May 01, 2033 DP U-3095

EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 002 10376470 May 01, 2033 DP U-3095 9763885 May 01, 2033 DP U-3095

EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 003 10376470 May 01, 2033 DP U-3095 9763885 May 01, 2033 DP U-3095

EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 004 10376470 May 01, 2033 DP U-3095 9763885 May 01, 2033 DP U-3095

FENFLURAMINE HYDROCHLORIDE - FINTEPLA N 212102 001 10947183 Dec 20, 2036 DS DP 10950331 Sep 28, 2035 U-3098 11040018 Aug 02, 2037 U-2861

FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 001 7754702 Feb 15, 2028 U-1432 7754702 Feb 15, 2028 U-2555 7754702 Feb 15, 2028 U-2556 7754702 Feb 15, 2028 U-2557 8895612 Jan 08, 2027 U-1620 8895612 Jan 08, 2027 U-3050 8895612 Jan 08, 2027 U-3051 8895612 Jan 08, 2027 U-3115 8895612 Jan 08, 2027 U-3116

FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 002 7612109 Feb 05, 2024 DS DP 7754702 Feb 15, 2028 U-2555 7754702 Feb 15, 2028 U-2556 7754702 Feb 15, 2028 U-2557 8895612 Jan 08, 2027 U-1620 8895612 Jan 08, 2027 U-3050 8895612 Jan 08, 2027 U-3051 8895612 Jan 08, 2027 U-3115 8895612 Jan 08, 2027 U-3116 9376505 Oct 20, 2023 DS DP

FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 003 7612109 Feb 05, 2024 DS DP >A> NS Apr 28, 2024 7754702 Feb 15, 2028 U-2555 7754702 Feb 15, 2028 U-2556 7754702 Feb 15, 2028 U-2557 A - 26 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 003 8895612 Jan 08, 2027 U-1620 8895612 Jan 08, 2027 U-3050 8895612 Jan 08, 2027 U-3051 8895612 Jan 08, 2027 U-3115 8895612 Jan 08, 2027 U-3116 9376505 Oct 20, 2023 DS DP

FERRIC OXYHYDROXIDE - VELPHORO N 205109 001 10624855 Nov 26, 2034 DP 10624855*PED May 26, 2035 10682376 Nov 13, 2028 DP 10682376*PED May 13, 2029 10695367 Nov 13, 2028 DP 10695367*PED May 13, 2029 10925896 Nov 13, 2028 DP 10925896*PED May 13, 2029 10925897 Nov 13, 2028 DP 10925897*PED May 13, 2029 10933090 Nov 13, 2028 DP 10933090*PED May 13, 2029 11013761 Nov 13, 2028 DP 11013761*PED May 13, 2029 11013762 Nov 13, 2028 DP 11013762*PED May 13, 2029 9561251 Jan 23, 2030 DP U-1468 9561251*PED Jul 23, 2030

FESOTERODINE FUMARATE - TOVIAZ N 022030 001 8501723 Jun 07, 2027 DP I-861 Jun 17, 2024 8501723*PED Dec 07, 2027 PED Dec 17, 2024

FESOTERODINE FUMARATE - TOVIAZ N 022030 002 8501723 Jun 07, 2027 DP I-861 Jun 17, 2024 8501723*PED Dec 07, 2027 PED Dec 17, 2024

FEXINIDAZOLE - FEXINIDAZOLE N 214429 001 >A> NCE Jul 16, 2026 ODE-359 Jul 16, 2028

FINERENONE - KERENDIA N 215341 001 8436180 Apr 12, 2029 DS DP NCE Jul 09, 2026

FINERENONE - KERENDIA N 215341 002 8436180 Apr 12, 2029 DS DP NCE Jul 09, 2026

FLUCICLOVINE F-18 - AXUMIN N 208054 001 10933147 Dec 30, 2035 U-2450 10953112 Nov 28, 2026 U-1879 10967077 Dec 30, 2035 U-2450

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 001 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 A - 27 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 001 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 002 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 003 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 A - 28 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 003 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031

FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 004 10022510 May 18, 2031 DP >A> NPP Jul 09, 2024 10022510*PED Nov 18, 2031 >A> PED Jan 09, 2025 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 A - 29 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 005 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036

FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 006 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 A - 30 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 006 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 007 10022510 May 18, 2031 DP >A> NS Jul 09, 2024 10124131 May 18, 2031 DP >A> PED Jan 09, 2025 10195375 Feb 14, 2031 DP 10561808 Jan 01, 2032 DP 10765820 May 19, 2025 DP 7540282 May 06, 2023 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP 9731087 May 18, 2031 DP

FLUTICASONE PROPIONATE - XHANCE N 209022 001 11033696 May 20, 2033 DP

FLUTICASONE PROPIONATE; XINAFOATE - AIRDUO RESPICLICK N 208799 001 10022510 May 18, 2031 DP >A> M-61 Jul 09, 2024 10022510*PED Nov 18, 2031 >A> PED Jan 09, 2025 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9415008 Oct 06, 2034 DP U-645 9415008*PED Apr 06, 2035 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 002 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP A - 31 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 002 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 003 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 004 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP A - 32 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 004 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9415008 Oct 06, 2034 DP U-645 9415008*PED Apr 06, 2035 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 005 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP A - 33 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 005 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 006 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025

FOSCARNET SODIUM - FOSCARNET SODIUM A 213001 001 CGT Dec 28, 2021

FOSDENOPTERIN HYDROBROMIDE - NULIBRY N 214018 001 7504095 Jan 31, 2025 DP U-3092 NCE Feb 26, 2026 ODE-342 Feb 26, 2028

GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11 N 212642 001 NCE Dec 01, 2025 W Dec 01, 2025

GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11 N 212643 001 NCE Dec 01, 2025 W Dec 01, 2025

GLECAPREVIR; PIBRENTASVIR - MAVYRET N 209394 001 10028937 Jun 10, 2030 U-2141 D-175 Sep 26, 2022 10028937 Jun 10, 2030 U-2532 M-259 Apr 10, 2023 A - 34 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

GLECAPREVIR; PIBRENTASVIR - MAVYRET N 209394 001 10028937*PED Dec 10, 2030 NCE Aug 03, 2022 10039754 Jun 10, 2030 U-2141 NPP Apr 30, 2022 10039754 Jun 10, 2030 U-2532 ODE-232 Apr 30, 2026 10039754*PED Dec 10, 2030 ODE-233 Apr 30, 2026 10286029 Mar 14, 2034 U-2532 PED Oct 30, 2022 10286029*PED Sep 14, 2034 PED Feb 03, 2023 8648037 Jan 19, 2032 DS DP U-2141 PED Mar 26, 2023 8648037 Jan 19, 2032 DS DP U-2532 PED Oct 10, 2023 8648037*PED Jul 19, 2032 PED Oct 30, 2026 8937150 May 18, 2032 DS DP PED Oct 30, 2026 8937150*PED Nov 18, 2032 9321807 Jun 05, 2035 DS 9321807*PED Dec 05, 2035 9586978 Jun 10, 2030 U-2141 9586978 Jun 10, 2030 U-2532 9586978*PED Dec 10, 2030

GLECAPREVIR; PIBRENTASVIR - MAVYRET N 215110 001 10028937 Jun 10, 2030 U-3167 10028937*PED Dec 10, 2030 10039754 Jun 10, 2030 U-3167 10039754*PED Dec 10, 2030 10286029 Mar 14, 2034 U-3167 10286029*PED Sep 14, 2034 8648037 Jan 19, 2032 DS DP U-3167 8648037*PED Jul 19, 2032 8937150 May 18, 2032 DS DP 8937150*PED Nov 18, 2032 9321807 Jun 05, 2035 DS DP 9321807*PED Dec 05, 2035 9586978 Jun 10, 2030 U-3167 9586978*PED Dec 10, 2030

GLUCAGON - BAQSIMI N 210134 001 10894133 Jan 03, 2038 DP

GLYCEROL PHENYLBUTYRATE - RAVICTI N 203284 001 NPP Dec 21, 2021

GLYCOPYRROLATE - LONHALA MAGNAIR KIT N 208437 001 10940110 Feb 26, 2029 DP U-1773

GOLODIRSEN - VYONDYS 53 N 211970 001 10968450 Jun 28, 2025 DS DP 10995337 Jun 28, 2025 DP U-2675

HALOBETASOL PROPIONATE - LEXETTE N 210566 001 10857159 Nov 30, 2036 DP 10857159*PED May 30, 2037 11020407 Nov 30, 2036 DP U-3143

HYDROCORTISONE - ALKINDI SPRINKLE N 213876 001 9649280 May 12, 2034 DP U-3075 9675559 Jan 10, 2033 U-3075 9717740 Nov 19, 2032 U-3075

HYDROCORTISONE - ALKINDI SPRINKLE N 213876 002 9649280 May 12, 2034 DP U-3075 9675559 Jan 10, 2033 U-3075 9717740 Nov 19, 2032 U-3075

HYDROCORTISONE - ALKINDI SPRINKLE N 213876 003 9649280 May 12, 2034 DP U-3075 9675559 Jan 10, 2033 U-3075 9717740 Nov 19, 2032 U-3075 A - 35 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

HYDROCORTISONE - ALKINDI SPRINKLE N 213876 003 9649280 May 12, 2034 DP U-3075 9675559 Jan 10, 2033 U-3075 9717740 Nov 19, 2032 U-3075

HYDROCORTISONE - ALKINDI SPRINKLE N 213876 004 9649280 May 12, 2034 DP U-3075 9675559 Jan 10, 2033 U-3075 9717740 Nov 19, 2032 U-3075

IBREXAFUNGERP CITRATE - BREXAFEMME N 214900 001 10174074 Jan 19, 2035 DS DP NCE Jun 01, 2026 10370406 Jan 19, 2035 U-3159 GAIN Jun 01, 2031 10927142 Jan 19, 2035 DS 8188085 Aug 28, 2030 DS DP U-3159

IBRUTINIB - IMBRUVICA N 205552 001 10961251 Jun 03, 2033 DP

IBRUTINIB - IMBRUVICA N 205552 002 10961251 Jun 03, 2033 DP

IBRUTINIB - IMBRUVICA N 210563 001 10961251 Jun 03, 2033 DP

IBRUTINIB - IMBRUVICA N 210563 002 10961251 Jun 03, 2033 DP

IBRUTINIB - IMBRUVICA N 210563 003 10961251 Jun 03, 2033 DP

IBRUTINIB - IMBRUVICA N 210563 004 10961251 Jun 03, 2033 DP

ICOSAPENT ETHYL - VASCEPA N 202057 001 10881632 Apr 29, 2030 U-3052 10894028 Jun 28, 2033 U-3053 11000499 Jun 28, 2033 U-3126

ICOSAPENT ETHYL - VASCEPA N 202057 002 10881632 Apr 29, 2030 U-3052 10894028 Jun 28, 2033 U-3053 11000499 Jun 28, 2033 U-3126

IMIQUIMOD - ZYCLARA N 022483 001 10918635 Apr 30, 2030 U-1455 10918635 Apr 30, 2030 U-172

INFIGRATINIB PHOSPHATE - TRUSELTIQ N 214622 001 10278969 Dec 11, 2034 DP NCE May 28, 2026 8552002 Aug 25, 2029 DS DP ODE-353 May 28, 2028 >A> 9067896 Aug 06, 2028 DS

INFIGRATINIB PHOSPHATE - TRUSELTIQ N 214622 002 10278969 Dec 11, 2034 DP NCE May 28, 2026 8552002 Aug 25, 2029 DS DP ODE-353 May 28, 2028 >A> 9067896 Aug 06, 2028 DS

IRINOTECAN HYDROCHLORIDE - ONIVYDE N 207793 001 10980795 Jun 12, 2033 U-1848 10993914 Oct 15, 2036 DP A - 36 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

ISOPROPYL ALCOHOL - ZURAGARD N 210872 001 10688291 Dec 20, 2034 DP U-1397 >A> M-268 Jun 24, 2024 8226971 May 06, 2025 DP 8389583 Aug 09, 2029 U-1397 8703828 May 23, 2028 DP 9011897 Feb 08, 2025 DP 9629368 May 23, 2028 U-1397 9844654 Apr 24, 2036 DP U-1397

IVACAFTOR - KALYDECO N 203188 001 ODE-338 Dec 21, 2027

IVACAFTOR - KALYDECO N 207925 001 ODE-338 Dec 21, 2027

IVACAFTOR - KALYDECO N 207925 002 ODE-338 Dec 21, 2027

IVACAFTOR - KALYDECO N 207925 003 ODE-338 Dec 21, 2027

IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED) N 210491 001 10058546 Jul 15, 2033 U-2399 ODE-335 Dec 21, 2027 10058546 Jul 15, 2033 U-2572 10058546 Jul 15, 2033 U-3022 10058546 Jul 15, 2033 U-3023 10081621 Mar 25, 2031 DP U-2420 10081621 Mar 25, 2031 DP U-2571 10081621 Mar 25, 2031 DP U-3024 10081621 Mar 25, 2031 DP U-3025 10206877 Apr 14, 2035 DP U-2498 10206877 Apr 14, 2035 DP U-2570 10206877 Apr 14, 2035 DP U-3026 10206877 Apr 14, 2035 DP U-3027 8354427 Jul 06, 2026 U-3021

IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED) N 210491 002 10058546 Jul 15, 2033 U-2399 ODE-335 Dec 21, 2027 10058546 Jul 15, 2033 U-2572 10058546 Jul 15, 2033 U-3022 10058546 Jul 15, 2033 U-3023 10081621 Mar 25, 2031 DP U-2420 10081621 Mar 25, 2031 DP U-2571 10081621 Mar 25, 2031 DP U-3024 10081621 Mar 25, 2031 DP U-3025 10206877 Apr 14, 2035 DP U-2498 10206877 Apr 14, 2035 DP U-2570 10206877 Apr 14, 2035 DP U-3026 10206877 Apr 14, 2035 DP U-3027 8354427 Jul 06, 2026 U-3021

IVACAFTOR; - ORKAMBI N 206038 001 11052075 Dec 04, 2028 DP U-3181

IVACAFTOR; LUMACAFTOR - ORKAMBI N 206038 002 11052075 Dec 04, 2028 DP U-3181

IVERMECTIN - IVERMECTIN A 210720 001 PC May 29, 2021

IVERMECTIN - SOOLANTRA N 206255 001 11033565 Apr 22, 2024 DP A - 37 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

IVOSIDENIB - TIBSOVO N 211192 001 10980788 Jun 07, 2039 U-3112 10980788 Jun 07, 2039 U-3113

LANSOPRAZOLE - LANSOPRAZOLE N 208025 001 11077055 Apr 21, 2036 DP

LAROTRECTINIB SULFATE - VITRAKVI N 210861 001 10799505 Aug 15, 2036 DS DP

LAROTRECTINIB SULFATE - VITRAKVI N 210861 002 10799505 Aug 15, 2036 DS DP

LAROTRECTINIB SULFATE - VITRAKVI N 211710 001 10799505 Aug 15, 2036 DS

LASMIDITAN SUCCINATE - REYVOW N 211280 001 11053214 Dec 05, 2037 DS DP U-1719

LASMIDITAN SUCCINATE - REYVOW N 211280 002 11053214 Dec 05, 2037 DS DP U-1719

LASMIDITAN SUCCINATE - REYVOW N 211280 003 11053214 Dec 05, 2037 DS DP U-1719 NCE Jan 31, 2025 7423050 Apr 06, 2025 DS DP U-1719 8748459 Mar 27, 2023 U-1719

LATANOPROST; DIMESYLATE - ROCKLATAN N 208259 001 10882840 Jul 11, 2026 U-1524 11021456 Jul 11, 2026 U-1524 11028081 Jan 27, 2030 U-1524

LEDIPASVIR; SOFOSBUVIR - HARVONI N 205834 001 ODE* Aug 28, 2026 ODE* Aug 28, 2026 ODE* Aug 28, 2026

LEDIPASVIR; SOFOSBUVIR - HARVONI N 205834 002 ODE* Apr 07, 2024 ODE* Aug 28, 2026 ODE* Aug 28, 2026 ODE* Aug 28, 2026 PED Oct 07, 2024

LENVATINIB MESYLATE - LENVIMA N 206947 001 7253286 Oct 24, 2025 DS DP

LENVATINIB MESYLATE - LENVIMA N 206947 002 7253286 Oct 24, 2025 DS DP

LEUPROLIDE MESYLATE - CAMCEVI KIT N 211488 001 10646572 Jan 16, 2027 DP NP May 25, 2024 9572857 Jan 16, 2027 DP 9744207 Jan 16, 2027 DP

LEVONORGESTREL - MIRENA N 021225 001 10987244 Apr 01, 2031 DP

LEVONORGESTREL - SKYLA N 203159 001 10987244 Apr 01, 2031 DP A - 38 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

LEVONORGESTREL - KYLEENA N 208224 001 10987244 Apr 01, 2031 DP

LIFITEGRAST - XIIDRA N 208073 001 11058677 Dec 18, 2033 DP

LINAGLIPTIN - TRADJENTA N 201280 001 11033552 May 04, 2027 DP

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 001 10973827 Apr 02, 2029 DP

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 002 10973827 Apr 02, 2029 DP

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 003 10973827 Apr 02, 2029 DP

LIRAGLUTIDE RECOMBINANT - SAXENDA N 206321 001 NPP Dec 04, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 001 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-842 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-842 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-842 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-842 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 DP 7700561*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 002 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-842 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-842 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-842 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-842 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 DP 7700561*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 003 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-842 7674774*PED Aug 24, 2023 A - 39 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 003 7678770 Feb 24, 2023 U-842 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-842 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-842 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 DP 7700561*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 004 7105486 Feb 24, 2023 U-727 7105486 Feb 24, 2023 U-842 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-842 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-842 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-842 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-842 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 DP 7700561*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 005 7105486 Feb 24, 2023 U-842 7105486*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-842 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-842 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-842 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-842 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 DP 7700561*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 006 7105486 Feb 24, 2023 U-727 7105486 Feb 24, 2023 U-842 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-842 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-842 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-842 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-842 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 DP 7700561*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 007 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 DS A - 40 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 007 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 DS DP U-727 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 U-1034 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 DS 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 U-727 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 DP U-727 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-842 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-842 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 DP 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-842 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 DP 7700561*PED Aug 24, 2023 7713936 Feb 24, 2023 U-727 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 DP U-842 7718619*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 001 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 DS DP 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 DS DP U-727 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 U-727 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 DS 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 U-727 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 DP U-727 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-727 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-727 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-727 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 DP 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-727 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 U-727 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 DP U-727 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 DP U-727 7723305*PED Aug 24, 2023 A - 41 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 002 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 DS DP 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 DS DP U-727 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 U-727 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 DS 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 U-727 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 DP U-727 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-727 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-727 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-727 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 DP 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-727 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 U-727 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 DP U-727 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 DP U-727 7723305*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 003 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 DS DP 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 DS DP U-727 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 U-727 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 DS 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 U-727 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 DP U-727 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-727 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-727 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-727 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 DP 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-727 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 U-727 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 DP U-727 7718619*PED Aug 24, 2023 A - 42 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 003 7723305 Feb 24, 2023 DP U-727 7723305*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 004 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 DS DP 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 DS DP U-727 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 U-727 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 DS 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 U-727 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 DP U-727 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-727 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-727 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-727 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 DP 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-727 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 U-727 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 DP U-727 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 DP U-727 7723305*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 005 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 DS DP 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 DS DP U-727 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 U-727 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 DS 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 U-727 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 DP U-727 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-727 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-727 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-727 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 DP 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-727 7687467*PED Aug 24, 2023 A - 43 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 005 7713936 Feb 24, 2023 U-727 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 DP U-727 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 DP U-727 7723305*PED Aug 24, 2023

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 006 7105486 Feb 24, 2023 U-727 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 DP 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 DS DP 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 DS DP U-727 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 U-727 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 DS 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 U-727 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 DP U-727 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 U-727 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 DP U-727 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 U-727 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 DP U-727 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 DP 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 DP U-727 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 U-727 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 DP U-727 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 DP U-727 7723305*PED Aug 24, 2023

LISINOPRIL - QBRELIS N 208401 001 10940177 Nov 06, 2035 DP

LONAFARNIB - ZOKINVY N 213969 001 7838531 Jul 26, 2024 U-3070 ODE-324 Nov 20, 2027 8828356 Oct 17, 2023 U-3070

LONAFARNIB - ZOKINVY N 213969 002 7838531 Jul 26, 2024 U-3070 ODE-324 Nov 20, 2027 8828356 Oct 17, 2023 U-3070

LORLATINIB - LORBRENA N 210868 001 10420749 Jul 27, 2036 DS DP U-2633 I-847 Mar 03, 2024 10420749 Jul 27, 2036 DS DP U-3096 ODE-349 Mar 03, 2028 11020376 Jul 27, 2036 DP

LORLATINIB - LORBRENA N 210868 002 10420749 Jul 27, 2036 DS DP U-2633 I-847 Mar 03, 2024 10420749 Jul 27, 2036 DS DP U-3096 ODE-349 Mar 03, 2028 11020376 Jul 27, 2036 DP A - 44 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LOTEPREDNOL ETABONATE - LOTEPREDNOL ETABONATE A 212450 001 CGT Nov 02, 2021

LOTEPREDNOL ETABONATE - EYSUVIS N 210933 001 10940108 May 03, 2033 U-2985 10945948 May 03, 2033 U-2985 10993908 May 03, 2033 U-3117

LUMASIRAN SODIUM - OXLUMO N 214103 001 >A> 11060093 Dec 26, 2034 DS DP U-2995 ODE-339 Nov 23, 2027

LUMATEPERONE TOSYLATE - CAPLYTA N 209500 001 10960009 Dec 03, 2034 U-814

MACITENTAN - OPSUMIT N 204410 001 10946015 Sep 11, 2026 DP U-1445

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED) N 213135 001 11033498 Aug 04, 2037 U-3164

MANNITOL - BRONCHITOL N 202049 001 NP Oct 30, 2023 ODE-327 Oct 30, 2027

MELOXICAM - ANJESO N 210583 001 10881663 Mar 08, 2039 U-3038

MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO N 214383 001 10285946 Apr 25, 2032 DP NCE Feb 26, 2026 10322182 Apr 25, 2032 DP ODE-348 Feb 26, 2028 10543274 Apr 25, 2032 U-3093 10869928 Apr 25, 2032 DP 6992207 Jun 25, 2022 DS DP U-3093

MELPHALAN HYDROCHLORIDE - EVOMELA N 207155 001 10940128 Jun 14, 2030 DP U-3086 11020363 May 28, 2030 DP

MEROPENEM; VABORBACTAM - VABOMERE N 209776 001 11007206 Aug 08, 2031 U-3128 NCE Aug 29, 2022 8680136 Aug 29, 2031 DS DP GAIN Aug 29, 2027

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET N 022044 001 M-187 Dec 04, 2023 PED Jun 04, 2024

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET N 022044 002 M-187 Dec 04, 2023 PED Jun 04, 2024

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 001 M-187 Dec 04, 2023 PED Jun 04, 2024

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 002 M-187 Dec 04, 2023 PED Jun 04, 2024

METHYLENE BLUE - PROVAYBLUE N 204630 002 >A> ODE* Apr 08, 2023 A - 45 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 001 >A> 11103494 Aug 14, 2033 DP >A> 11103495 Aug 14, 2033 DP U-2993

METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 002 >A> 11103494 Aug 14, 2033 DP >A> 11103495 Aug 14, 2033 DP U-2993

METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 003 >A> 11103494 Aug 14, 2033 DP >A> 11103495 Aug 14, 2033 DP U-2993

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 001 10881618 Mar 23, 2032 U-2357 10905652 Mar 23, 2032 DP

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 002 10881618 Mar 23, 2032 U-2357 10905652 Mar 23, 2032 DP

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 003 10881618 Mar 23, 2032 U-2357 10905652 Mar 23, 2032 DP

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 004 10881618 Mar 23, 2032 U-2357 10905652 Mar 23, 2032 DP

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 005 10881618 Mar 23, 2032 U-2357 10905652 Mar 23, 2032 DP

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 001 >A> M-82 Jun 28, 2024

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 002 >A> M-82 Jun 28, 2024

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 003 >A> M-82 Jun 28, 2024

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 004 >A> M-82 Jun 28, 2024

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 005 >A> M-82 Jun 28, 2024

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 006 >A> M-82 Jun 28, 2024

METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI N 209388 001 11020361 Dec 22, 2029 U-2843

MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE N 211844 001 10966990 Jun 20, 2038 DP

MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE N 211844 002 10966990 Jun 20, 2038 DP

MIGALASTAT HYDROCHLORIDE - GALAFOLD N 208623 001 10874655 May 30, 2038 U-2371 10874656 May 30, 2038 U-2371 10874657 May 30, 2038 U-2371 A - 46 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

MIGALASTAT HYDROCHLORIDE - GALAFOLD N 208623 001 10925866 Apr 28, 2028 U-2371 11033538 Apr 28, 2028 U-2371 RE48608 Feb 12, 2029 U-2371

MINOCYCLINE HYDROCHLORIDE - MINOLIRA N 209269 001 >A> 11103517 Apr 07, 2036 DP

MINOCYCLINE HYDROCHLORIDE - MINOLIRA N 209269 002 >A> 11103517 Apr 07, 2036 DP

MINOCYCLINE HYDROCHLORIDE - ZILXI N 213690 001 10946101 Oct 01, 2030 U-1631

MIRABEGRON - MYRBETRIQ N 202611 001 10842780 Sep 28, 2029 DP U-2996 I-777 Apr 27, 2021 10842780*PED Mar 28, 2030 I-855 Mar 25, 2024 6346532 Mar 27, 2022 DS DP PED Sep 25, 2024 6346532*PED Sep 27, 2022 8772315 Oct 30, 2028 U-2300 8772315*PED Apr 30, 2029 8835474 Nov 04, 2023 U-1527 8835474*PED May 04, 2024 RE44872 Nov 04, 2023 U-1527 RE44872*PED May 04, 2024

MIRABEGRON - MYRBETRIQ N 202611 002 10842780 Sep 28, 2029 DP U-2996 I-777 Apr 27, 2021 10842780*PED Mar 28, 2030 I-855 Mar 25, 2024 6346532 Mar 27, 2022 DS DP PED Sep 25, 2024 6346532*PED Sep 27, 2022 8772315 Oct 30, 2028 U-2300 8772315*PED Apr 30, 2029 8835474 Nov 04, 2023 U-1527 8835474*PED May 04, 2024 RE44872 Nov 04, 2023 U-1527 RE44872*PED May 04, 2024

MIRABEGRON - MYRBETRIQ GRANULES N 213801 001 10058536 Mar 31, 2036 DP U-3108 NP Mar 25, 2024 10058536*PED Oct 01, 2036 PED Sep 25, 2024 6346532 Mar 27, 2022 DS 6346532*PED Sep 27, 2022 7342117 Nov 04, 2023 DS 7342117*PED May 04, 2024 7982049 Nov 04, 2023 DP 7982049*PED May 04, 2024

MONOMETHYL FUMARATE - BAFIERTAM N 210296 001 10918615 Aug 12, 2035 DP U-1384 10918616 Jun 03, 2035 U-1384 10918617 Aug 10, 2035 DP 10945985 Aug 14, 2035 DP

MORPHINE SULFATE - MORPHINE SULFATE A 212451 001 CGT Aug 10, 2021

MORPHINE SULFATE - MORPHINE SULFATE A 212451 002 CGT Aug 10, 2021

MORPHINE SULFATE - MORPHINE SULFATE N 022195 001 NPP Jun 02, 2024 A - 47 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

MORPHINE SULFATE - MORPHINE SULFATE N 022195 002 NPP Jun 02, 2024

MORPHINE SULFATE - MORPHINE SULFATE N 022207 001 NPP Jun 02, 2024

MORPHINE SULFATE - MORPHINE SULFATE N 022207 002 NPP Jun 02, 2024

NALDEMEDINE TOSYLATE - SYMPROIC N 208854 001 10952968 May 13, 2033 DS DP

NALOXONE HYDROCHLORIDE - EVZIO N 205787 001 10960155 Jun 25, 2026 DP

NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR) N 209862 001 10960155 Jun 25, 2026 DP

NALOXONE HYDROCHLORIDE - KLOXXADO N 212045 001 10722510 Aug 26, 2034 DP U-3110 10973814 Aug 26, 2034 DP U-3110

NAPROXEN SODIUM - NAPROXEN SODIUM N 021920 001 >A> 11090280 Mar 03, 2026 DP U-1731 >A> 11090280 Mar 03, 2026 DP U-1732 >A> 11090280 Mar 03, 2026 DP U-3195

NERATINIB MALEATE - NERLYNX N 208051 001 10035788 Oct 15, 2028 U-2043 10035788 Oct 15, 2028 U-3047 10035788 Oct 15, 2028 U-3097 7982043 Oct 08, 2025 U-2043 7982043 Oct 08, 2025 U-3047 7982043 Oct 08, 2025 U-3097 8518446 Nov 20, 2030 DP U-2043 8518446 Nov 20, 2030 DP U-3047 8518446 Nov 20, 2030 DP U-3097 8669273 Jul 18, 2031 U-3047 8790708 Nov 05, 2030 DP U-2043 8790708 Nov 05, 2030 DP U-3047 8790708 Nov 05, 2030 DP U-3097 9139558 Oct 15, 2028 U-2043 9139558 Oct 15, 2028 U-3047 9139558 Oct 15, 2028 U-3097 9211291 Mar 24, 2030 U-2043 9211291 Mar 24, 2030 U-3097 9265784 Aug 04, 2029 U-3047 9630946 Oct 15, 2028 U-2043 9630946 Oct 15, 2028 U-3047 9630946 Oct 15, 2028 U-3097

NETARSUDIL MESYLATE - RHOPRESSA N 208254 001 10882840 Jul 11, 2026 U-1524 11021456 Jul 11, 2026 U-1524 11028081 Jan 27, 2030 U-1524

NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO N 205718 001 10961195 Sep 25, 2035 DS DP

NIFURTIMOX - LAMPIT N 213464 001 ODE-319 Aug 06, 2027 A - 48 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

NIFURTIMOX - LAMPIT N 213464 002 ODE-319 Aug 06, 2027

NIRAPARIB TOSYLATE - ZEJULA N 208447 001 >A> 11091459 Mar 27, 2038 DP 8071623 Mar 27, 2031 DS DP

NITAZOXANIDE - NITAZOXANIDE A 213820 001 CGT Jun 05, 2021

NITRIC OXIDE - GENOSYL N 202860 001 10124142 Aug 18, 2025 U-3037 10814092 Oct 17, 2025 U-3037 10926054 Aug 13, 2029 DP 7947227 Oct 17, 2026 U-3037 8057742 Jan 18, 2026 U-3037 8226916 Aug 18, 2025 U-3037 8607785 Jul 14, 2030 DP 8609028 Aug 18, 2025 U-3037 8821801 Aug 18, 2025 DP 8944049 Aug 13, 2029 DP 9522249 Aug 18, 2025 DP 9701538 Jan 28, 2029 DP 9956373 Aug 18, 2025 U-3037

OBETICHOLIC ACID - OCALIVA N 207999 001 RE48286 Nov 16, 2027 DS DP

OBETICHOLIC ACID - OCALIVA N 207999 002 RE48286 Nov 16, 2027 DS DP

OCTREOTIDE ACETATE - MYCAPSSA N 208232 001 11052126 Feb 03, 2036 U-2857

ODEVIXIBAT - BYLVAY N 215498 001 >A> 10011633 Nov 08, 2031 U-3186 >A> NCE Jul 20, 2026 >A> 10093697 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3187 >A> 10975046 Jun 20, 2039 DS >A> 10981952 Nov 08, 2031 U-3186 >A> 10981952 Nov 08, 2031 U-3187 >A> 7132416 Sep 05, 2022 DS DP >A> 9694018 Nov 08, 2031 U-3186

ODEVIXIBAT - BYLVAY N 215498 002 >A> 10011633 Nov 08, 2031 U-3186 >A> NCE Jul 20, 2026 >A> 10093697 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3187 >A> 10975046 Jun 20, 2039 DS >A> 10981952 Nov 08, 2031 U-3186 >A> 10981952 Nov 08, 2031 U-3187 >A> 7132416 Sep 05, 2022 DS DP >A> 9694018 Nov 08, 2031 U-3186

ODEVIXIBAT - BYLVAY N 215498 003 >A> 10011633 Nov 08, 2031 U-3186 >A> NCE Jul 20, 2026 >A> 10093697 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3187 >A> 10975046 Jun 20, 2039 DS >A> 10981952 Nov 08, 2031 U-3186 >A> 10981952 Nov 08, 2031 U-3187 >A> 7132416 Sep 05, 2022 DS DP >A> 9694018 Nov 08, 2031 U-3186 A - 49 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

ODEVIXIBAT - BYLVAY N 215498 003 >A> 10011633 Nov 08, 2031 U-3186 >A> NCE Jul 20, 2026 >A> 10093697 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3187 >A> 10975046 Jun 20, 2039 DS >A> 10981952 Nov 08, 2031 U-3186 >A> 10981952 Nov 08, 2031 U-3187 >A> 7132416 Sep 05, 2022 DS DP >A> 9694018 Nov 08, 2031 U-3186

ODEVIXIBAT - BYLVAY N 215498 004 >A> 10011633 Nov 08, 2031 U-3186 >A> NCE Jul 20, 2026 >A> 10093697 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3186 >A> 10487111 Nov 08, 2031 U-3187 >A> 10975046 Jun 20, 2039 DS >A> 10981952 Nov 08, 2031 U-3186 >A> 10981952 Nov 08, 2031 U-3187 >A> 7132416 Sep 05, 2022 DS DP >A> 9694018 Nov 08, 2031 U-3186

OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 001 10300054 Aug 23, 2031 DP U-3140 NCE May 28, 2026 10300054 Aug 23, 2031 DP U-3141 10716785 Aug 23, 2031 U-3136 10716785 Aug 23, 2031 U-3137 7262298 Nov 23, 2025 DS 7956187 Oct 31, 2021 DS 8252929 Oct 31, 2021 DS 8778960 Feb 13, 2032 U-3136 8778960 Feb 13, 2032 U-3137 9119848 Aug 30, 2031 DS 9126977 Aug 23, 2031 DP U-3136 9126977 Aug 23, 2031 DP U-3137 9517235 Aug 23, 2031 U-3138 9517235 Aug 23, 2031 U-3139

OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 002 10300054 Aug 23, 2031 DP U-3140 NCE May 28, 2026 10300054 Aug 23, 2031 DP U-3141 10716785 Aug 23, 2031 U-3136 10716785 Aug 23, 2031 U-3137 7262298 Nov 23, 2025 DS 7956187 Oct 31, 2021 DS 8252929 Oct 31, 2021 DS 8778960 Feb 13, 2032 U-3136 8778960 Feb 13, 2032 U-3137 9119848 Aug 30, 2031 DS 9126977 Aug 23, 2031 DP U-3136 9126977 Aug 23, 2031 DP U-3137 9517235 Aug 23, 2031 U-3138 9517235 Aug 23, 2031 U-3139

OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 003 10300054 Aug 23, 2031 DP U-3140 NCE May 28, 2026 10300054 Aug 23, 2031 DP U-3141 10716785 Aug 23, 2031 U-3136 10716785 Aug 23, 2031 U-3137 7262298 Nov 23, 2025 DS 7956187 Oct 31, 2021 DS 8252929 Oct 31, 2021 DS 8778960 Feb 13, 2032 U-3136 8778960 Feb 13, 2032 U-3137 9119848 Aug 30, 2031 DS 9126977 Aug 23, 2031 DP U-3136 9126977 Aug 23, 2031 DP U-3137 9517235 Aug 23, 2031 U-3138 A - 50 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 003 9517235 Aug 23, 2031 U-3139

OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 004 10300054 Aug 23, 2031 DP U-3140 NCE May 28, 2026 10300054 Aug 23, 2031 DP U-3141 10716785 Aug 23, 2031 U-3136 10716785 Aug 23, 2031 U-3137 7262298 Nov 23, 2025 DS 7956187 Oct 31, 2021 DS 8252929 Oct 31, 2021 DS 8778960 Feb 13, 2032 U-3136 8778960 Feb 13, 2032 U-3137 9119848 Aug 30, 2031 DS 9126977 Aug 23, 2031 DP U-3136 9126977 Aug 23, 2031 DP U-3137 9517235 Aug 23, 2031 U-3138 9517235 Aug 23, 2031 U-3139

OLAPARIB - LYNPARZA N 208558 001 8071579 Aug 12, 2027 U-2101 8071579 Aug 12, 2027 U-2103 8071579 Aug 12, 2027 U-2480 8071579 Aug 12, 2027 U-2481 8071579 Aug 12, 2027 U-2482 8071579 Aug 12, 2027 U-2483 8071579 Aug 12, 2027 U-2716 8071579 Aug 12, 2027 U-2819 8071579 Aug 12, 2027 U-2820 8071579 Aug 12, 2027 U-2821 8071579 Aug 12, 2027 U-2822 8071579 Aug 12, 2027 U-2823 8071579 Aug 12, 2027 U-2824 8071579 Aug 12, 2027 U-2832 8071579 Aug 12, 2027 U-2833 8859562 Aug 04, 2031 U-2101 8859562 Aug 04, 2031 U-2103 8859562 Aug 04, 2031 U-2480 8859562 Aug 04, 2031 U-2481 8859562 Aug 04, 2031 U-2482 8859562 Aug 04, 2031 U-2483 8859562 Aug 04, 2031 U-2716 8859562 Aug 04, 2031 U-2819 8859562 Aug 04, 2031 U-2820 8859562 Aug 04, 2031 U-2821 8859562 Aug 04, 2031 U-2822 8859562 Aug 04, 2031 U-2823 8859562 Aug 04, 2031 U-2824 8859562 Aug 04, 2031 U-2832 8859562 Aug 04, 2031 U-2833

OLAPARIB - LYNPARZA N 208558 002 8071579 Aug 12, 2027 U-2101 8071579 Aug 12, 2027 U-2103 8071579 Aug 12, 2027 U-2480 8071579 Aug 12, 2027 U-2481 8071579 Aug 12, 2027 U-2482 8071579 Aug 12, 2027 U-2483 8071579 Aug 12, 2027 U-2716 8071579 Aug 12, 2027 U-2819 8071579 Aug 12, 2027 U-2820 8071579 Aug 12, 2027 U-2821 8071579 Aug 12, 2027 U-2822 8071579 Aug 12, 2027 U-2823 8071579 Aug 12, 2027 U-2824 8071579 Aug 12, 2027 U-2832 8071579 Aug 12, 2027 U-2833 8859562 Aug 04, 2031 U-2101 A - 51 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

OLAPARIB - LYNPARZA N 208558 002 8859562 Aug 04, 2031 U-2103 8859562 Aug 04, 2031 U-2480 8859562 Aug 04, 2031 U-2481 8859562 Aug 04, 2031 U-2482 8859562 Aug 04, 2031 U-2483 8859562 Aug 04, 2031 U-2716 8859562 Aug 04, 2031 U-2819 8859562 Aug 04, 2031 U-2820 8859562 Aug 04, 2031 U-2821 8859562 Aug 04, 2031 U-2822 8859562 Aug 04, 2031 U-2823 8859562 Aug 04, 2031 U-2824 8859562 Aug 04, 2031 U-2832 8859562 Aug 04, 2031 U-2833

OLICERIDINE - OLINVYK N 210730 001 >A> 11077098 Mar 23, 2032 DS DP U-2986 NCE Oct 30, 2025

OLICERIDINE - OLINVYK N 210730 002 >A> 11077098 Mar 23, 2032 DS DP U-2986 NCE Oct 30, 2025

OLICERIDINE - OLINVYK N 210730 003 >A> 11077098 Mar 23, 2032 DS DP U-2986 NCE Oct 30, 2025

ORITAVANCIN DIPHOSPHATE - KIMYRSA N 214155 001 8420592 Aug 29, 2029 U-3101 NCE Aug 06, 2019 9649352 Jul 16, 2035 DS DP NP Mar 12, 2024 9682061 Apr 26, 2030 U-3101 GAIN Aug 06, 2024

OSIMERTINIB MESYLATE - TAGRISSO N 208065 001 10183020 Jan 02, 2035 DP U-1777 I-853 Dec 18, 2023 10183020 Jan 02, 2035 DP U-2289 ODE-337 Dec 18, 2027 10183020 Jan 02, 2035 DP U-3016 8946235 Aug 08, 2032 DS DP U-1777 8946235 Aug 08, 2032 DS DP U-2289 8946235 Aug 08, 2032 DS DP U-3016 9732058 Jul 25, 2032 DS DP U-1777 9732058 Jul 25, 2032 DS DP U-2289 9732058 Jul 25, 2032 DS DP U-3016

OSIMERTINIB MESYLATE - TAGRISSO N 208065 002 10183020 Jan 02, 2035 DP U-1777 I-853 Dec 18, 2023 10183020 Jan 02, 2035 DP U-2289 ODE-337 Dec 18, 2027 10183020 Jan 02, 2035 DP U-3016 8946235 Aug 08, 2032 DS DP U-1777 8946235 Aug 08, 2032 DS DP U-2289 8946235 Aug 08, 2032 DS DP U-3016 9732058 Jul 25, 2032 DS DP U-1777 9732058 Jul 25, 2032 DS DP U-2289 9732058 Jul 25, 2032 DS DP U-3016

OSPEMIFENE - OSPHENA N 203505 001 9566252 Nov 02, 2022 U-1370

OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ N 212520 001 10898573 Dec 16, 2039 DP 10912765 Aug 26, 2031 U-2849 10940138 Dec 16, 2039 U-2849

OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 001 8309112 Feb 04, 2023 DP 8329216 Feb 04, 2023 DP 8808737 Jun 21, 2027 U-3085 8871779 Nov 22, 2029 DS A - 52 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 002 8309112 Feb 04, 2023 DP 8329216 Feb 04, 2023 DP 8808737 Jun 21, 2027 U-3085 8871779 Nov 22, 2029 DS

OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 003 8309112 Feb 04, 2023 DP 8329216 Feb 04, 2023 DP 8808737 Jun 21, 2027 U-3085 8871779 Nov 22, 2029 DS

OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 004 8309112 Feb 04, 2023 DP 8329216 Feb 04, 2023 DP 8808737 Jun 21, 2027 U-3085 8871779 Nov 22, 2029 DS

OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 005 8309112 Feb 04, 2023 DP 8329216 Feb 04, 2023 DP 8808737 Jun 21, 2027 U-3085 8871779 Nov 22, 2029 DS

OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 006 8309112 Feb 04, 2023 DP 8329216 Feb 04, 2023 DP 8808737 Jun 21, 2027 U-3085 8871779 Nov 22, 2029 DS

OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 007 8309112 Feb 04, 2023 DP 8329216 Feb 04, 2023 DP 8808737 Jun 21, 2027 U-3085 8871779 Nov 22, 2029 DS

OZANIMOD HYDROCHLORIDE - ZEPOSIA N 209899 001 10239846 Nov 15, 2030 U-3132 I-860 May 27, 2024

OZANIMOD HYDROCHLORIDE - ZEPOSIA N 209899 002 10239846 Nov 15, 2030 U-3132 I-860 May 27, 2024

OZANIMOD HYDROCHLORIDE - ZEPOSIA N 209899 003 10239846 Nov 15, 2030 U-3132 I-860 May 27, 2024

OZENOXACIN - XEPI N 208945 001 6335447 Nov 09, 2023 DS

PALBOCICLIB - IBRANCE N 207103 001 RE47739 Mar 05, 2027 DS DP

PALBOCICLIB - IBRANCE N 207103 002 RE47739 Mar 05, 2027 DS DP

PALBOCICLIB - IBRANCE N 207103 003 RE47739 Mar 05, 2027 DS DP

PALBOCICLIB - IBRANCE N 212436 001 >A> 11065250 May 24, 2036 DP RE47739 Mar 05, 2027 DS DP A - 53 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

PALBOCICLIB - IBRANCE N 212436 002 >A> 11065250 May 24, 2036 DP RE47739 Mar 05, 2027 DS DP

PALBOCICLIB - IBRANCE N 212436 003 >A> 11065250 May 24, 2036 DP RE47739 Mar 05, 2027 DS DP

PARICALCITOL - ZEMPLAR N 020819 001 >A> ODE* Oct 18, 2023

PARICALCITOL - ZEMPLAR N 020819 002 >A> ODE* Oct 18, 2023

PARICALCITOL - ZEMPLAR N 020819 003 >A> ODE* Oct 18, 2023

PATISIRAN SODIUM - ONPATTRO N 210922 001 >A> 10240152 Oct 20, 2029 DS DP U-2378 >A> 11079379 Aug 27, 2035 DS DP U-2378

PEGCETACOPLAN - EMPAVELI N 215014 001 10035822 Nov 15, 2033 DS NCE May 14, 2026 10125171 Aug 02, 2033 DS ODE-351 May 14, 2028 10875893 Nov 15, 2033 DS U-3124 11040107 Apr 09, 2038 DP U-3172 11040107 Apr 09, 2038 DP U-3173 11040107 Apr 09, 2038 DP U-3174 7888323 Dec 04, 2027 DS 7989589 Dec 04, 2027 DS 9169307 Nov 18, 2027 DS U-3123

PERAMIVIR - RAPIVAB N 206426 001 10391075 Feb 12, 2027 U-2622 10391075 Feb 12, 2027 U-3069 8778997 May 07, 2027 U-1627 8778997 May 07, 2027 U-2622 8778997 May 07, 2027 U-3069

PERAMPANEL - FYCOMPA N 202834 001 6949571 Jun 08, 2022 DS DP U-106 6949571 Jun 08, 2022 DS DP U-2088 6949571 Jun 08, 2022 DS DP U-2089 6949571 Jun 08, 2022 DS DP U-2428 6949571 Jun 08, 2022 DS DP U-2429

PERAMPANEL - FYCOMPA N 202834 002 6949571 Jun 08, 2022 DS DP U-106 6949571 Jun 08, 2022 DS DP U-2088 6949571 Jun 08, 2022 DS DP U-2089 6949571 Jun 08, 2022 DS DP U-2428 6949571 Jun 08, 2022 DS DP U-2429

PERAMPANEL - FYCOMPA N 202834 003 6949571 Jun 08, 2022 DS DP U-106 6949571 Jun 08, 2022 DS DP U-2088 6949571 Jun 08, 2022 DS DP U-2089 6949571 Jun 08, 2022 DS DP U-2428 6949571 Jun 08, 2022 DS DP U-2429

PERAMPANEL - FYCOMPA N 202834 004 6949571 Jun 08, 2022 DS DP U-106 6949571 Jun 08, 2022 DS DP U-2088 6949571 Jun 08, 2022 DS DP U-2089 6949571 Jun 08, 2022 DS DP U-2428 A - 54 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

PERAMPANEL - FYCOMPA N 202834 004 6949571 Jun 08, 2022 DS DP U-2429

PERAMPANEL - FYCOMPA N 202834 005 6949571 Jun 08, 2022 DS DP U-106 6949571 Jun 08, 2022 DS DP U-2088 6949571 Jun 08, 2022 DS DP U-2089 6949571 Jun 08, 2022 DS DP U-2428 6949571 Jun 08, 2022 DS DP U-2429

PERAMPANEL - FYCOMPA N 202834 006 6949571 Jun 08, 2022 DS DP U-106 6949571 Jun 08, 2022 DS DP U-2088 6949571 Jun 08, 2022 DS DP U-2089 6949571 Jun 08, 2022 DS DP U-2428 6949571 Jun 08, 2022 DS DP U-2429

PERAMPANEL - FYCOMPA N 208277 001 6949571 Jun 08, 2022 DS DP U-106 6949571 Jun 08, 2022 DS DP U-2088 6949571 Jun 08, 2022 DS DP U-2089 6949571 Jun 08, 2022 DS DP U-2428 6949571 Jun 08, 2022 DS DP U-2429

PEXIDARTINIB HYDROCHLORIDE - TURALIO N 211810 001 10941142 Jul 24, 2038 DP 10961240 Jul 24, 2038 U-2606

PIFLUFOLASTAT F-18 - PYLARIFY N 214793 001 10947197 Jun 09, 2037 DS DP U-3130 NCE May 26, 2026 8487129 Nov 07, 2027 DS DP 8778305 Sep 21, 2030 DS DP U-3130 9861713 Jul 31, 2029 DS DP U-3130

PIMAVANSERIN TARTRATE - NUPLAZID N 207318 002 10953000 Mar 23, 2037 U-1974

PITOLISANT HYDROCHLORIDE - WAKIX N 211150 001 ODE-331 Oct 13, 2027

PITOLISANT HYDROCHLORIDE - WAKIX N 211150 002 ODE-331 Oct 13, 2027

POMALIDOMIDE - POMALYST N 204026 001 M-14 Nov 20, 2023 PED May 20, 2024

POMALIDOMIDE - POMALYST N 204026 002 M-14 Nov 20, 2023 PED May 20, 2024

POMALIDOMIDE - POMALYST N 204026 003 M-14 Nov 20, 2023 PED May 20, 2024

POMALIDOMIDE - POMALYST N 204026 004 M-14 Nov 20, 2023 PED May 20, 2024

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 001 I-849 Dec 18, 2023 A - 55 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 002 I-849 Dec 18, 2023

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 003 8114874 Jan 24, 2027 DS DP I-849 Dec 18, 2023

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 004 8114874 Jan 24, 2027 DS DP I-849 Dec 18, 2023 9029533 Dec 22, 2026 U-1283 9029533 Dec 22, 2026 U-1699 9029533 Dec 22, 2026 U-1700 9029533 Dec 22, 2026 U-1701 9029533 Dec 22, 2026 U-836 9493470 Dec 12, 2033 DS DP U-1700 9493470 Dec 12, 2033 DS DP U-1948

PONESIMOD - PONVORY N 213498 001 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 002 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 003 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 004 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 005 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 006 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 007 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP A - 56 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

PONESIMOD - PONVORY N 213498 008 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 009 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

PONESIMOD - PONVORY N 213498 010 10220023 Dec 10, 2035 U-3103 NCE Mar 18, 2026 8273779 Dec 17, 2025 U-2774 9000018 Nov 16, 2024 U-3102 9062014 May 06, 2032 DS DP U-2774 RE43728 Nov 16, 2024 DS DP

POSACONAZOLE - NOXAFIL N 205053 001 NPP May 31, 2024 ODE-355 Jun 17, 2028

POSACONAZOLE - NOXAFIL N 205596 001 9023790 Jul 04, 2031 DP U-1698 NPP May 31, 2024 9023790 Jul 04, 2031 DP U-3160 ODE-355 Jun 17, 2028 9023790 Jul 04, 2031 DP U-3171 9358297 Jun 24, 2031 DP U-3160 9358297 Jun 24, 2031 DP U-3171

POSACONAZOLE - NOXAFIL POWDERMIX KIT N 214770 001 NP May 31, 2024

PRALSETINIB - GAVRETO N 213721 001 ODE-340 Dec 01, 2027 ODE-341 Dec 01, 2027

RELUGOLIX - ORGOVYX N 214621 001 10350170 Feb 25, 2036 DP NCE Dec 18, 2025 10449191 Sep 29, 2037 U-3020 10786501 Sep 29, 2037 U-3020 7300935 Jan 28, 2024 DS 8058280 Jan 28, 2024 DS DP 8735401 Feb 04, 2024 U-3019

REMDESIVIR - VEKLURY N 214787 001 11007208 Sep 16, 2036 U-2984

REMDESIVIR - VEKLURY N 214787 002 11007208 Sep 16, 2036 U-2984

REMIMAZOLAM BESYLATE - BYFAVO N 212295 001 NCE Oct 06, 2025

REVEFENACIN - YUPELRI N 210598 001 11008289 Jul 14, 2030 U-2440

RIFAXIMIN - XIFAXAN N 021361 002 >A> 10314828 Jul 24, 2029 U-1481 >A> 10335397 Jul 24, 2029 U-2579 >A> 10456384 Feb 26, 2029 U-2643 >A> 10456384 Feb 26, 2029 U-2644 >A> 10703763 Feb 27, 2026 U-1708 A - 57 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

RIFAXIMIN - XIFAXAN N 021361 002 >A> 10703763 Feb 27, 2026 U-2847 >A> 10703763 Feb 27, 2026 U-2848 >A> 10709694 Jul 24, 2029 U-2579 >A> 10765667 Feb 26, 2029 U-2643 >A> 10765667 Feb 26, 2029 U-2644 >A> 7045620 Jun 19, 2024 DS >A> 7612199 Jun 19, 2024 DS DP >A> 7902206 Jun 19, 2024 DS DP >A> 7906542 Jun 01, 2025 DS DP >A> 7915275 Feb 23, 2025 U-1707 >A> 7915275 Feb 23, 2025 U-1708 >A> 8158644 Jun 19, 2024 DP >A> 8158781 Jun 19, 2024 DS >A> 8193196 Sep 02, 2027 DS DP U-1707 >A> 8193196 Sep 02, 2027 DS DP U-1708 >A> 8309569 Jul 18, 2029 U-1707 >A> 8309569 Jul 18, 2029 U-1708 >A> 8518949 Feb 27, 2026 DP >A> 8642573 Oct 02, 2029 U-1481 >A> 8741904 Feb 27, 2026 DS U-1526 >A> 8741904 Feb 27, 2026 DS U-1707 >A> 8741904 Feb 27, 2026 DS U-1708 >A> 8829017 Jul 24, 2029 U-1562 >A> 8835452 Jun 19, 2024 DS DP >A> 8853231 Jun 19, 2024 DP >A> 8946252 Jul 24, 2029 U-1481 >A> 8969398 Oct 02, 2029 U-1481 >A> 9271968 Feb 27, 2026 DP >A> 9421195 Jul 24, 2029 U-1481 >A> 9629828 Jul 24, 2029 U-1994

RILPIVIRINE HYDROCHLORIDE - EDURANT N 202022 001 7125879 Apr 21, 2025 DS DP U-1153 7125879 Apr 21, 2025 DS DP U-1307 7125879 Apr 21, 2025 DS DP U-1740 7125879 Apr 21, 2025 DS DP U-3068

RIMEGEPANT SULFATE - NURTEC ODT N 212728 001 >A> 11083724 Mar 25, 2039 DP U-2718 I-865 May 27, 2024 >A> 11083724 Mar 25, 2039 DP U-3142 8314117 Feb 22, 2031 DS DP U-2718 8314117 Feb 22, 2031 DS DP U-3142

RIPRETINIB - QINLOCK N 213973 001 10966966 Aug 12, 2040 U-3153

RISDIPLAM - EVRYSDI N 213535 001 ODE-334 Aug 07, 2027

RISPERIDONE - PERSERIS KIT N 210655 001 11013809 Feb 13, 2028 DP U-3135 >A> 11110093 Nov 05, 2026 DP U-3135

RISPERIDONE - PERSERIS KIT N 210655 002 11013809 Feb 13, 2028 DP U-3135 >A> 11110093 Nov 05, 2026 DP U-3135

ROLAPITANT HYDROCHLORIDE - VARUBI N 206500 001 7049320 Aug 19, 2028 DS DP U-1741

ROLAPITANT HYDROCHLORIDE - VARUBI N 208399 001 7049320 Aug 19, 2028 DS DP U-1741 A - 58 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

RUFINAMIDE - RUFINAMIDE A 204988 001 PC Nov 28, 2021

RUFINAMIDE - RUFINAMIDE A 204988 002 PC Nov 28, 2021

SACUBITRIL; VALSARTAN - ENTRESTO N 207620 001 11058667 May 09, 2036 U-3170 M-82 Feb 16, 2024 9517226 Aug 22, 2033 U-3084 9937143 Aug 22, 2033 U-3084

SACUBITRIL; VALSARTAN - ENTRESTO N 207620 002 11058667 May 09, 2036 U-3170 M-82 Feb 16, 2024 9517226 Aug 22, 2033 U-3084 9937143 Aug 22, 2033 U-3084

SACUBITRIL; VALSARTAN - ENTRESTO N 207620 003 11058667 May 09, 2036 U-3170 M-82 Feb 16, 2024 9517226 Aug 22, 2033 U-3084 9937143 Aug 22, 2033 U-3084

SAFINAMIDE MESYLATE - XADAGO N 207145 001 8283380 Mar 21, 2031 U-1993

SAFINAMIDE MESYLATE - XADAGO N 207145 002 8283380 Mar 21, 2031 U-1993

SECNIDAZOLE - SOLOSEC N 209363 001 10849884 Sep 04, 2035 DP U-2583 >A> I-866 Jun 30, 2024 10849884 Sep 04, 2035 DP U-3169 11000507 Sep 04, 2035 DP U-2583 11000507 Sep 04, 2035 DP U-3169 11000508 Sep 04, 2035 DP U-2583 11000508 Sep 04, 2035 DP U-3169 11020377 Sep 04, 2035 DP U-2583 11020377 Sep 04, 2035 DP U-3169

SELENIOUS ACID - SELENIOUS ACID N 209379 002 NCE Apr 30, 2024

SELENIOUS ACID - SELENIOUS ACID N 209379 003 >A> NCE Apr 30, 2024

SELEXIPAG - UPTRAVI N 214275 001 >A> 7205302 Apr 04, 2023 DS DP U-1797 >A> 8791122 Aug 01, 2030 DS DP >A> 9173881 Aug 12, 2029 U-1798 >A> 9284280 Jun 25, 2030 U-1831

SELINEXOR - XPOVIO N 212306 001 10519139 Aug 14, 2035 DS DP U-2584 ODE-346 Dec 18, 2027 10519139 Aug 14, 2035 DS DP U-2855 10519139 Aug 14, 2035 DS DP U-3018 10544108 Jul 26, 2032 U-2584 10544108 Jul 26, 2032 U-3018 11034660 Jul 26, 2032 U-2584 11034660 Jul 26, 2032 U-3018 9079865 Jul 26, 2032 U-2584 9079865 Jul 26, 2032 U-2855 9079865 Jul 26, 2032 U-3018

SELINEXOR - XPOVIO N 212306 002 10519139 Aug 14, 2035 DS DP U-2584 ODE-346 Dec 18, 2027 10519139 Aug 14, 2035 DS DP U-2855 10519139 Aug 14, 2035 DS DP U-3018 A - 59 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

SELINEXOR - XPOVIO N 212306 002 10544108 Jul 26, 2032 U-2584 10544108 Jul 26, 2032 U-3018 11034660 Jul 26, 2032 U-2584 11034660 Jul 26, 2032 U-3018 8999996 Sep 15, 2032 DS DP 9079865 Jul 26, 2032 U-2584 9079865 Jul 26, 2032 U-2855 9079865 Jul 26, 2032 U-3018 9714226 Jul 26, 2032 DS DP

SELINEXOR - XPOVIO N 212306 003 10519139 Aug 14, 2035 DS DP U-2584 ODE-346 Dec 18, 2027 10519139 Aug 14, 2035 DS DP U-2855 10519139 Aug 14, 2035 DS DP U-3018 10544108 Jul 26, 2032 U-2584 10544108 Jul 26, 2032 U-3018 11034660 Jul 26, 2032 U-2584 11034660 Jul 26, 2032 U-3018 8999996 Sep 15, 2032 DS DP 9079865 Jul 26, 2032 U-2584 9079865 Jul 26, 2032 U-2855 9079865 Jul 26, 2032 U-3018 9714226 Jul 26, 2032 DS DP

SELINEXOR - XPOVIO N 212306 004 10519139 Aug 14, 2035 DS DP U-2584 ODE-346 Dec 18, 2027 10519139 Aug 14, 2035 DS DP U-2855 10519139 Aug 14, 2035 DS DP U-3018 10544108 Jul 26, 2032 U-2584 10544108 Jul 26, 2032 U-3018 11034660 Jul 26, 2032 U-2584 11034660 Jul 26, 2032 U-3018 8999996 Sep 15, 2032 DS DP 9079865 Jul 26, 2032 U-2584 9079865 Jul 26, 2032 U-2855 9079865 Jul 26, 2032 U-3018 9714226 Jul 26, 2032 DS DP

SEMAGLUTIDE - RYBELSUS N 213051 001 10933120 Mar 15, 2033 DP 10960052 Dec 16, 2031 DP

SEMAGLUTIDE - RYBELSUS N 213051 002 10933120 Mar 15, 2033 DP 10960052 Dec 16, 2031 DP

SEMAGLUTIDE - RYBELSUS N 213051 003 10933120 Mar 15, 2033 DP 10960052 Dec 16, 2031 DP

SEMAGLUTIDE - WEGOVY N 215256 001 10888605 Aug 24, 2038 DP U-3162 NCE Dec 05, 2022 8129343 Jan 29, 2029 DS DP NP Jun 04, 2024 8536122 Mar 20, 2026 DS DP 9764003 Jun 21, 2033 U-3161

SEMAGLUTIDE - WEGOVY N 215256 002 10888605 Aug 24, 2038 DP U-3162 NCE Dec 05, 2022 8129343 Jan 29, 2029 DS DP NP Jun 04, 2024 8536122 Mar 20, 2026 DS DP 9764003 Jun 21, 2033 U-3161

SEMAGLUTIDE - WEGOVY N 215256 003 10888605 Aug 24, 2038 DP U-3162 NCE Dec 05, 2022 8129343 Jan 29, 2029 DS DP NP Jun 04, 2024 A - 60 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

SEMAGLUTIDE - WEGOVY N 215256 003 8536122 Mar 20, 2026 DS DP 9764003 Jun 21, 2033 U-3161

SEMAGLUTIDE - WEGOVY N 215256 004 10888605 Aug 24, 2038 DP U-3162 NCE Dec 05, 2022 8129343 Jan 29, 2029 DS DP NP Jun 04, 2024 8536122 Mar 20, 2026 DS DP 9764003 Jun 21, 2033 U-3161

SEMAGLUTIDE - WEGOVY N 215256 005 10888605 Aug 24, 2038 DP U-3162 NCE Dec 05, 2022 8129343 Jan 29, 2029 DS DP NP Jun 04, 2024 8536122 Mar 20, 2026 DS DP 9764003 Jun 21, 2033 U-3161

SETMELANOTIDE ACETATE - IMCIVREE N 213793 001 ODE-336 Nov 25, 2027

SIPONIMOD FUMARIC ACID - MAYZENT N 209884 003 >A> NCE Mar 26, 2024

SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 001 M-187 Dec 04, 2023 PED Jun 04, 2024

SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 002 M-187 Dec 04, 2023 PED Jun 04, 2024

SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 003 M-187 Dec 04, 2023 PED Jun 04, 2024

SODIUM ACETATE - SODIUM ACETATE A 214805 001 CGT Jan 03, 2022

SODIUM OXYBATE - XYREM N 021196 001 10864181 Mar 15, 2033 U-1532

SOFOSBUVIR - SOVALDI N 204671 001 ODE* Aug 28, 2026

SOFOSBUVIR - SOVALDI N 204671 002 ODE* Apr 07, 2024 ODE* Aug 28, 2026 PED Oct 07, 2024

SOFOSBUVIR; VELPATASVIR - EPCLUSA N 208341 001 10086011 Jan 30, 2034 U-1470 D-177 Nov 15, 2022 10086011*PED Jul 30, 2034 M-264 Jul 14, 2023 8575135 Nov 16, 2032 DS DP U-1470 NPP Mar 19, 2023 8575135*PED May 16, 2033 PED May 15, 2023 8735372 Mar 21, 2028 U-1470 PED Sep 19, 2023 8735372*PED Sep 21, 2028 PED Jan 14, 2024 8921341 Nov 16, 2032 DS DP U-1470 8921341*PED May 16, 2033 8940718 Nov 16, 2032 DS DP U-1470 8940718*PED May 16, 2033 9757406 Jan 30, 2034 DP 9757406*PED Jul 30, 2034 A - 61 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

SOFOSBUVIR; VELPATASVIR - EPCLUSA N 208341 002 10086011 Jan 30, 2034 U-1470 M-264 Jul 14, 2023 10086011*PED Jul 30, 2034 NS Mar 19, 2023 7964580 Mar 26, 2029 DS DP U-1470 PED Sep 19, 2023 7964580*PED Sep 26, 2029 PED Jan 14, 2024 8334270 Mar 21, 2028 DS DP U-1470 8334270*PED Sep 21, 2028 8575135 Nov 16, 2032 DS DP U-1470 8575135*PED May 16, 2033 8580765 Mar 21, 2028 DS DP U-1470 8580765*PED Sep 21, 2028 8618076 Dec 11, 2030 DS DP U-1470 8618076*PED Jun 11, 2031 8633309 Mar 26, 2029 DS DP U-1470 8633309*PED Sep 26, 2029 8735372 Mar 21, 2028 U-1470 8735372*PED Sep 21, 2028 8889159 Mar 26, 2029 DP U-1470 8889159*PED Sep 26, 2029 8921341 Nov 16, 2032 DS DP U-1470 8921341*PED May 16, 2033 8940718 Nov 16, 2032 DS DP U-1470 8940718*PED May 16, 2033 9085573 Mar 21, 2028 DS DP U-1470 9085573*PED Sep 21, 2028 9284342 Sep 13, 2030 DS DP U-1470 9284342*PED Mar 13, 2031 9757406 Jan 30, 2034 DP 9757406*PED Jul 30, 2034

SOFOSBUVIR; VELPATASVIR - EPCLUSA N 214187 001 >A> 7964580 Mar 26, 2029 DS DP U-1470 >A> 7964580*PED Sep 26, 2029 >A> 8334270 Mar 21, 2028 DS DP U-1470 >A> 8334270*PED Sep 21, 2028 >A> 8575135 Nov 16, 2032 DS DP U-1470 >A> 8575135*PED May 16, 2033 >A> 8580765 Mar 21, 2028 DS DP U-1470 >A> 8580765*PED Sep 21, 2028 >A> 8618076 Dec 11, 2030 DS DP U-1470 >A> 8618076*PED Jun 11, 2031 >A> 8633309 Mar 26, 2029 DS DP U-1470 >A> 8633309*PED Sep 26, 2029 >A> 8735372 Mar 21, 2028 U-1470 >A> 8735372*PED Sep 21, 2028 >A> 8889159 Mar 26, 2029 DP U-1470 >A> 8889159*PED Sep 26, 2029 >A> 8921341 Nov 16, 2032 DS DP U-1470 >A> 8921341*PED May 16, 2033 >A> 8940718 Nov 16, 2032 DS DP U-1470 >A> 8940718*PED May 16, 2033 >A> 9085573 Mar 21, 2028 DS DP U-1470 >A> 9085573*PED Sep 21, 2028 >A> 9284342 Sep 13, 2030 DS DP U-1470 >A> 9284342*PED Mar 13, 2031

SOFOSBUVIR; VELPATASVIR - EPCLUSA N 214187 002 >A> 7964580 Mar 26, 2029 DS DP U-1470 >A> 7964580*PED Sep 26, 2029 >A> 8334270 Mar 21, 2028 DS DP U-1470 >A> 8334270*PED Sep 21, 2028 >A> 8575135 Nov 16, 2032 DS DP U-1470 >A> 8575135*PED May 16, 2033 >A> 8580765 Mar 21, 2028 DS DP U-1470 >A> 8580765*PED Sep 21, 2028 >A> 8618076 Dec 11, 2030 DS DP U-1470 >A> 8618076*PED Jun 11, 2031 >A> 8633309 Mar 26, 2029 DS DP U-1470 >A> 8633309*PED Sep 26, 2029 A - 62 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

SOFOSBUVIR; VELPATASVIR - EPCLUSA N 214187 002 >A> 8735372 Mar 21, 2028 U-1470 >A> 8735372*PED Sep 21, 2028 >A> 8889159 Mar 26, 2029 DP U-1470 >A> 8889159*PED Sep 26, 2029 >A> 8921341 Nov 16, 2032 DS DP U-1470 >A> 8921341*PED May 16, 2033 >A> 8940718 Nov 16, 2032 DS DP U-1470 >A> 8940718*PED May 16, 2033 >A> 9085573 Mar 21, 2028 DS DP U-1470 >A> 9085573*PED Sep 21, 2028 >A> 9284342 Sep 13, 2030 DS DP U-1470 >A> 9284342*PED Mar 13, 2031

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI N 209195 001 10912814 Jun 01, 2037 DP 8575135 Nov 16, 2032 DS DP U-2039 8575135 Nov 16, 2032 DS DP U-2040 8575135*PED May 16, 2033 8735372 Mar 21, 2028 DS DP U-2039 8735372 Mar 21, 2028 DS DP U-2040 8735372*PED Sep 21, 2028 8921341 Nov 16, 2032 DS DP U-2039 8921341 Nov 16, 2032 DS DP U-2040 8921341*PED May 16, 2033 8940718 Nov 16, 2032 DS DP U-2039 8940718 Nov 16, 2032 DS DP U-2040 8940718*PED May 16, 2033 8957046 Mar 21, 2028 U-2039 8957046 Mar 21, 2028 U-2040

SOLIFENACIN SUCCINATE - VESICARE LS N 209529 001 9918970 May 18, 2031 DP

SOLRIAMFETOL HYDROCHLORIDE - SUNOSI N 211230 001 10912754 Jun 01, 2038 U-3082 10940133 Mar 19, 2040 U-3099 10959976 Jun 01, 2038 U-3151

SOLRIAMFETOL HYDROCHLORIDE - SUNOSI N 211230 002 10912754 Jun 01, 2038 U-3082 10959976 Jun 01, 2038 U-3151

SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE N 022306 001 10799138 Apr 05, 2039 U-3125

SOTALOL HYDROCHLORIDE - SOTYLIZE N 205108 001 11013703 Apr 01, 2034 DP

SOTORASIB - LUMAKRAS N 214665 001 NCE May 28, 2026 ODE-352 May 28, 2028

SPINOSAD - NATROBA N 022408 001 I-858 Apr 28, 2024

SPIRONOLACTONE - CAROSPIR N 209478 001 10888570 Oct 28, 2036 DP

SUFENTANIL CITRATE - DSUVIA N 209128 001 10896751 Mar 16, 2030 DP

SUGAMMADEX SODIUM - BRIDION N 022225 001 NPP Jun 25, 2024 A - 63 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

SUGAMMADEX SODIUM - BRIDION N 022225 002 NPP Jun 25, 2024

TACROLIMUS - PROGRAF N 050708 001 >A> ODE-360 Jul 16, 2028

TACROLIMUS - PROGRAF N 050708 002 >A> ODE-360 Jul 16, 2028

TACROLIMUS - PROGRAF N 050708 003 >A> ODE-360 Jul 16, 2028

TACROLIMUS - PROGRAF N 050709 001 >A> ODE-360 Jul 16, 2028

TACROLIMUS - ASTAGRAF XL N 204096 001 ODE* May 24, 2025

TACROLIMUS - ASTAGRAF XL N 204096 002 ODE* May 24, 2025

TACROLIMUS - ASTAGRAF XL N 204096 003 ODE* May 24, 2025

TACROLIMUS - PROGRAF N 210115 001 >A> ODE-360 Jul 16, 2028

TACROLIMUS - PROGRAF N 210115 002 >A> ODE-360 Jul 16, 2028

TAFENOQUINE SUCCINATE - ARAKODA N 210607 001 10888558 Dec 02, 2035 U-2582

TAFLUPROST - ZIOPTAN N 202514 001 10864159 May 28, 2029 DP U-778

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 001 11007156 Oct 22, 2022 DP U-1178 11007156 Oct 22, 2022 DP U-1276

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 002 11007156 Oct 22, 2022 DP U-1178 11007156 Oct 22, 2022 DP U-1276

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 003 11007156 Oct 22, 2022 DP U-1178 11007156 Oct 22, 2022 DP U-1276

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 004 11007156 Oct 22, 2022 DP U-1178 11007156 Oct 22, 2022 DP U-1276

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 005 11007156 Oct 22, 2022 DP U-1178 11007156 Oct 22, 2022 DP U-1276

TASIMELTEON - HETLIOZ N 205677 001 10610511 Oct 10, 2034 U-2615 I-850 Dec 01, 2023 10610511 Oct 10, 2034 U-3007 ODE-330 Dec 01, 2027 10945988 Jan 25, 2033 U-2149 10980770 Jan 25, 2033 U-3106 10980770 Jan 25, 2033 U-3107 A - 64 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

TASIMELTEON - HETLIOZ N 205677 001 10610511 Oct 10, 2034 U-2615 I-850 Dec 01, 2023 10610511 Oct 10, 2034 U-3007 ODE-330 Dec 01, 2027 10945988 Jan 25, 2033 U-2149 10980770 Jan 25, 2033 U-3106 10980770 Jan 25, 2033 U-3107

TASIMELTEON - HETLIOZ LQ N 214517 001 10980770 Jan 25, 2033 U-3106 NP Dec 01, 2023 ODE-329 Dec 01, 2027

TAVABOROLE - TAVABOROLE A 211963 001 PC Apr 17, 2021

TAZEMETOSTAT HYDROBROMIDE - TAZVERIK N 211723 001 10786511 Dec 19, 2035 DP 11052093 Apr 13, 2032 DS DP U-2736 11052093 Apr 13, 2032 DS DP U-3179

TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT N 202207 001 NPP May 19, 2024

TEPOTINIB HYDROCHLORIDE - TEPMETKO N 214096 001 8329692 Oct 30, 2029 DS DP NCE Feb 03, 2026 8580781 Mar 19, 2030 DS DP ODE-325 Feb 03, 2028 8658643 Jul 04, 2028 U-3077 8921357 May 30, 2028 DS DP 8927540 Jul 21, 2028 U-3078 9062029 Jul 04, 2028 DP 9284300 Apr 29, 2028 DP 9403799 Jul 04, 2028 U-3077

TERIFLUNOMIDE - AUBAGIO N 202992 001 6794410 Sep 12, 2026 U-1285 M-61 Apr 30, 2024 6794410*PED Mar 12, 2027 PED Oct 30, 2024 8802735 Sep 14, 2030 DP 8802735*PED Mar 14, 2031 9186346 Feb 04, 2034 U-1786 9186346*PED Aug 04, 2034

TERIFLUNOMIDE - AUBAGIO N 202992 002 6794410 Sep 12, 2026 U-1285 M-61 Apr 30, 2024 6794410*PED Mar 12, 2027 PED Oct 30, 2024 8802735 Sep 14, 2030 DP 8802735*PED Mar 14, 2031 9186346 Feb 04, 2034 U-1786 9186346*PED Aug 04, 2034

TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) N 209863 001 10881798 Feb 11, 2034 DP 10905827 Aug 21, 2031 DP 10912782 Feb 19, 2035 DP U-2418

TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) N 209863 002 10881798 Feb 11, 2034 DP 10905827 Aug 21, 2031 DP 10912782 Feb 19, 2035 DP U-2418

TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) N 209863 003 10881798 Feb 11, 2034 DP 10905827 Aug 21, 2031 DP 10912782 Feb 19, 2035 DP U-2418 A - 65 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

THEOPHYLLINE - THEOPHYLLINE A 212184 002 CGT Dec 08, 2021

TICAGRELOR - BRILINTA N 022433 001 I-851 May 28, 2023

TICAGRELOR - BRILINTA N 022433 002 I-851 May 28, 2023

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 001 10960004 Feb 03, 2037 U-2642 RE46284 Sep 22, 2029 U-1751 RE46284 Sep 22, 2029 U-2503

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 002 10960004 Feb 03, 2037 U-2642 RE46284 Sep 22, 2029 U-1751 RE46284 Sep 22, 2029 U-2503

TIRBANIBULIN - KLISYRI N 213189 001 10323001 Dec 28, 2027 DP NCE Dec 14, 2025 10617693 Mar 12, 2038 U-3015 10669236 Sep 07, 2038 DS DP 7300931 Feb 06, 2026 DS DP 7851470 Feb 02, 2029 DS DP U-3015 8236799 Dec 28, 2025 DS DP 8980890 Dec 28, 2025 DS DP

TIVOZANIB HYDROCHLORIDE - FOTIVDA N 212904 001 6821987 Apr 26, 2022 DS DP U-3100 NCE Mar 10, 2026 7166722 Nov 16, 2023 DS

TIVOZANIB HYDROCHLORIDE - FOTIVDA N 212904 002 6821987 Apr 26, 2022 DS DP U-3100 NCE Mar 10, 2026 7166722 Nov 16, 2023 DS

TOLVAPTAN - SAMSCA N 022275 001 10905694 Apr 07, 2030 DP

TOLVAPTAN - SAMSCA N 022275 002 10905694 Apr 07, 2030 DP

TOLVAPTAN - SAMSCA N 022275 003 10905694 Apr 07, 2030 DP

TOLVAPTAN - JYNARQUE N 204441 001 10905694 Apr 07, 2030 DP

TOLVAPTAN - JYNARQUE N 204441 002 10905694 Apr 07, 2030 DP

TOLVAPTAN - JYNARQUE N 204441 003 10905694 Apr 07, 2030 DP

TOLVAPTAN - JYNARQUE N 204441 004 10905694 Apr 07, 2030 DP

TOLVAPTAN - JYNARQUE N 204441 005 10905694 Apr 07, 2030 DP

TORSEMIDE - SOAANZ N 213218 001 >A> 10154963 Oct 06, 2033 DP A - 66 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TORSEMIDE - SOAANZ N 213218 002 >A> 10154963 Oct 06, 2033 DP

TRAMETINIB - MEKINIST N 204114 001 >A> 10869869 Aug 30, 2033 U-3184

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 002 >A> 10869869 Aug 30, 2033 U-3184

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 003 >A> 10869869 Aug 30, 2033 U-3184

TREPROSTINIL - REMODULIN N 021272 005 >A> 10076505 Dec 16, 2024 DP >A> 10695308 Dec 16, 2024 U-2845 >A> 7999007 Mar 29, 2029 DP U-1437 >A> 8653137 Sep 05, 2028 U-1437 >A> 8658694 Sep 05, 2028 U-1437 >A> 9199908 May 24, 2024 U-1771 >A> 9593066 Dec 15, 2028 DS >A> 9604901 Dec 15, 2028 DS >A> 9713599 Dec 16, 2024 U-2036

TREPROSTINIL - TYVASO N 022387 001 I-856 Mar 31, 2024

TRIFAROTENE - AKLIEF N 211527 001 9498465 May 30, 2033 DP U-1033

TRILACICLIB DIHYDROCHLORIDE - COSELA N 214200 001 10085992 Mar 14, 2034 U-3081 NCE Feb 12, 2026 10189849 Oct 25, 2031 DS 10189850 Oct 25, 2031 DP 10927120 Oct 25, 2031 DP 10966984 Mar 14, 2034 U-3079 10966984 Mar 14, 2034 U-3080 11040042 Mar 14, 2034 DP 8598186 Oct 25, 2031 DS DP 8598197 Oct 25, 2031 DS DP 9487530 Mar 14, 2034 U-3079 9487530 Mar 14, 2034 U-3080 9957276 Oct 25, 2031 DS

UMBRALISIB TOSYLATE - UKONIQ N 213176 001 10072013 Jul 02, 2033 U-3063 NCE Feb 05, 2026 10072013 Jul 02, 2033 U-3064 ODE-343 Feb 05, 2028 10414773 May 26, 2035 DS DP U-3063 ODE-344 Feb 05, 2028 10414773 May 26, 2035 DS DP U-3064 10570142 Jul 02, 2033 DS DP U-3063 10570142 Jul 02, 2033 DS DP U-3064 10947244 May 26, 2035 U-3063 10947244 May 26, 2035 U-3064 9150579 Jul 02, 2033 DS DP 9669033 Jul 02, 2033 U-3063 9669033 Jul 02, 2033 U-3064 9969740 May 26, 2035 DS DP U-3063 9969740 May 26, 2035 DS DP U-3064

UPADACITINIB - RINVOQ N 211675 001 10981923 Oct 17, 2036 DS 10981924 Oct 17, 2036 DP

VALBENAZINE TOSYLATE - INGREZZA N 209241 001 10874648 Oct 10, 2037 U-1995 10874648 Oct 10, 2037 U-3046 10906902 Dec 22, 2036 DS DP A - 67 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

VALBENAZINE TOSYLATE - INGREZZA N 209241 001 10906903 Dec 22, 2036 DS DP 10912771 Oct 10, 2037 U-1995 10912771 Oct 10, 2037 U-3076 10919892 Dec 22, 2036 DS DP 10940141 Aug 10, 2040 U-1995 10952997 Oct 10, 2037 U-1995 10993941 Oct 10, 2037 U-1995 11026931 Aug 14, 2039 U-1995 11026939 Sep 18, 2038 DP U-1995 11040029 Oct 10, 2037 U-1995

VALBENAZINE TOSYLATE - INGREZZA N 209241 002 10874648 Oct 10, 2037 U-1995 10874648 Oct 10, 2037 U-3046 10906902 Dec 22, 2036 DS DP 10906903 Dec 22, 2036 DS DP 10912771 Oct 10, 2037 U-1995 10912771 Oct 10, 2037 U-3076 10919892 Dec 22, 2036 DS DP 10940141 Aug 10, 2040 U-1995 10952997 Oct 10, 2037 U-1995 10993941 Oct 10, 2037 U-1995 11026931 Aug 14, 2039 U-1995 11026939 Sep 18, 2038 DP U-1995 11040029 Oct 10, 2037 U-1995

VALBENAZINE TOSYLATE - INGREZZA N 209241 003 10065952 Oct 28, 2036 DS DP U-1995 NCE Apr 11, 2022 10844058 Oct 28, 2036 DS DP U-1995 10851103 Oct 28, 2036 DS DP U-1995 10851104 Oct 28, 2036 DS U-1995 10857137 Oct 10, 2037 U-1995 10857148 Oct 10, 2037 U-1995 10874648 Oct 10, 2037 U-1995 10874648 Oct 10, 2037 U-3046 10906902 Dec 22, 2036 DS DP 10906903 Dec 22, 2036 DS DP 10912771 Oct 10, 2037 U-1995 10912771 Oct 10, 2037 U-3076 10919892 Dec 22, 2036 DS DP 10940141 Aug 10, 2040 U-1995 10952997 Oct 10, 2037 U-1995 10993941 Oct 10, 2037 U-1995 11026931 Aug 14, 2039 U-1995 11026939 Sep 18, 2038 DP U-1995 11040029 Oct 10, 2037 U-1995 8039627 Oct 06, 2029 DS DP 8357697 Nov 08, 2027 U-1995

VALSARTAN - DIOVAN N 021283 001 NPP Apr 19, 2024

VALSARTAN - DIOVAN N 021283 002 NPP Apr 19, 2024

VALSARTAN - DIOVAN N 021283 004 NPP Apr 19, 2024

VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT N 208910 001 10959946 Mar 13, 2035 DP 10959947 Mar 13, 2035 DP U-3104 10959947 Mar 13, 2035 DP U-3105 10959948 Mar 13, 2035 DP U-3104 10959948 Mar 13, 2035 DP U-3105 10959949 Mar 13, 2035 DP U-3104 10959949 Mar 13, 2035 DP U-3105 A - 68 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT N 208910 001 10959946 Mar 13, 2035 DP 10959947 Mar 13, 2035 DP U-3104 10959947 Mar 13, 2035 DP U-3105 10959948 Mar 13, 2035 DP U-3104 10959948 Mar 13, 2035 DP U-3105 10959949 Mar 13, 2035 DP U-3104 10959949 Mar 13, 2035 DP U-3105

VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT N 208910 002 10959946 Mar 13, 2035 DP 10959947 Mar 13, 2035 DP U-3104 10959947 Mar 13, 2035 DP U-3105 10959948 Mar 13, 2035 DP U-3104 10959948 Mar 13, 2035 DP U-3105 10959949 Mar 13, 2035 DP U-3104 10959949 Mar 13, 2035 DP U-3105

VENETOCLAX - VENCLEXTA N 208573 001 10993942 Sep 06, 2033 U-3114

VENETOCLAX - VENCLEXTA N 208573 002 10993942 Sep 06, 2033 U-3114

VENETOCLAX - VENCLEXTA N 208573 003 10993942 Sep 06, 2033 U-3114

VERICIGUAT - VERQUVO N 214377 001 10736896 May 19, 2031 DS DP NCE Jan 19, 2026 8420656 May 19, 2031 DS DP 8921377 May 19, 2031 U-3062 9604948 Nov 26, 2032 DS DP U-3062 9993476 May 19, 2031 U-3062

VERICIGUAT - VERQUVO N 214377 002 10736896 May 19, 2031 DS DP NCE Jan 19, 2026 8420656 May 19, 2031 DS DP 8921377 May 19, 2031 U-3062 9604948 Nov 26, 2032 DS DP U-3062 9993476 May 19, 2031 U-3062

VERICIGUAT - VERQUVO N 214377 003 10736896 May 19, 2031 DS DP NCE Jan 19, 2026 8420656 May 19, 2031 DS DP 8921377 May 19, 2031 U-3062 9604948 Nov 26, 2032 DS DP U-3062 9993476 May 19, 2031 U-3062

VIBEGRON - GEMTESA N 213006 001 8247415 Dec 01, 2030 DS DP U-3045 NCE Dec 23, 2025 8653260 Apr 02, 2029 DS

VIGABATRIN - VIGABATRIN A 211539 001 CGT Jul 31, 2021

VILOXAZINE HYDROCHLORIDE - QELBREE N 211964 001 9358204 Feb 07, 2033 DP NCE Apr 02, 2026 9603853 Feb 07, 2033 U-727 9662338 Feb 07, 2033 DP

VILOXAZINE HYDROCHLORIDE - QELBREE N 211964 002 9358204 Feb 07, 2033 DP NCE Apr 02, 2026 9603853 Feb 07, 2033 U-727 9662338 Feb 07, 2033 DP A - 69 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD PATENT PATENT EXCLUSIVITY

NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION

DATE CODES REQUESTED CODE(S) DATE

VILOXAZINE HYDROCHLORIDE - QELBREE N 211964 003 9358204 Feb 07, 2033 DP NCE Apr 02, 2026 9603853 Feb 07, 2033 U-727 9662338 Feb 07, 2033 DP

VILTOLARSEN - VILTEPSO N 212154 001 10870676 Aug 31, 2031 DS DP U-3039 ODE-280 Aug 12, 2027

VISMODEGIB - ERIVEDGE N 203388 001 9790183 Sep 02, 2025 U-3109

VOCLOSPORIN - LUPKYNIS N 213716 001 10286036 Dec 07, 2037 U-3056 NCE Jan 22, 2026 7332472 Oct 17, 2022 DS DP U-3056

VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 001 M-187 Jan 22, 2024

VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 002 M-187 Jan 22, 2024

VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 003 M-187 Jan 22, 2024

VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 004 M-187 Jan 22, 2024

VOXELOTOR - OXBRYTA N 213137 001 11020382 Dec 02, 2036 U-3133 11020382 Dec 02, 2036 U-3134

ZANUBRUTINIB - BRUKINSA N 213217 001 10570139 Apr 22, 2034 DS DP U-2145 10927117 Aug 15, 2037 DS DP

B-1

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG ST PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41 Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm